

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Sentinel pilot. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand the capabilities of the Sentinel pilot.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentrinelsystem.org.

Overview for Request cder_ahr_wp012

Request ID: cder_ahr_wp012_ndsp_v01

Query Description: The goal of this query was to estimate refill rates associated with initial opioid analgesic prescriptions of varying durations for oral opioid analgesics following 12 surgical procedures in the Sentinel Distributed Database (SDD).

Sentinel Modular Program Tool Used: Cohort Identification and Descriptive Analysis (CIDA) tool, version 5.4.4, with ad hoc programming.

Data Source: Data from October 1, 2009 to September 30, 2015 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed on October 10, 2018. See Appendix A for a list of dates of available data for each Data Partner.

Study Design: This request was designed to identify patients undergoing common surgical procedures and follow them for subsequent dispensings of oral solid dosage forms of opioid analgesics, excluding fentanyl products. The number of eligible members with each procedure and the subsequent number of eligible members with a dispensing were calculated. Patients were followed for a second dispensing (i.e., "re-fill") within 14 days after the last day of supply of the initial dispensing. Descriptive statistics concerning the quantity of opioid analgesics in each initial dispensing were calculated, and logistic models were used to estimate the probability of a "re-fill" among patients with an initial dispensing. Descriptive results were calculated overall and stratified by surgery, year of the initial dispensing, patient age group, and opioid analgesic of interest. Modeling results were calculated overall and stratified by surgery and age group.

Surgical Procedures of Interest: The 12 surgical procedures of interest were selected based on regulatory interest and their frequency in the United States, as defined by the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP).^{1,2} Four of the procedures were divided into specific types (e.g., laparoscopic or non-laparoscopic), forming 17 procedures in total. The surgical procedures were identified using Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology, Fourth Revision (CPT-4), and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes recorded in health services claims of ambulatory visits or inpatient hospital stays (see Appendix B for specific codes).

Cohort Eligibility Criteria: Seventeen surgery-specific cohorts were identified, comprising patients who had one of the surgical procedures of interest during the study period. Patients were required to be continuously enrolled in medical and prescription drug plans for at least 365 days prior to the admission date of their first valid surgery and 111 days after, during which no gaps in coverage were allowed. The 111 days of enrollment after surgery accounted for the 7-day follow-up period after surgery for an initial dispensing, the maximum anticipated prescription duration of 90 days, and the 14-day follow-up period for a "re-fill". For surgeries that occurred during inpatient hospital stays spanning more than one day, patients were required to be enrolled for the 111 days following their discharge date. Only the first valid occurrence of each surgical procedure for each patient was included. Patients were excluded if they had a dispensing of an oral solid formulation of an opioid analgesic, a dispensing of fentanyl, evidence of cancer or substance abuse history, or an admission to inpatient rehabilitation, hospice, or a nursing home in the 365 days prior to the admission date of their first valid surgery. Opioid analgesics were defined using National Drug Codes (NDCs); see Appendix C for a list of generic and brand names. Fentanyl use was defined using NDCs; see Appendix D for a list of generic and brand names. Substance abuse history was defined using ICD-9-CM, HCPCS, Current Procedural Terminology, Category II (CPT-II), CPT-4, and NDC codes; see Appendix D for a list of generic and brand names and Appendix E for ICD-9-CM, HCPCS, and CPT-4 codes. Cancer was defined using ICD-9-CM, CPT-4, and HCPCS codes; see Appendix E for specific codes. For each surgical procedure cohort, patients were excluded if they had a recorded history of any of the other study surgeries in the 365 days prior to the admission date of their surgery of interest. Patients were allowed to contribute to multiple surgery-specific cohorts if they had related procedures on the same day, including: (1) same-day hip fracture treatment and hip replacement, (2) same-day spinal fusions of different levels, or (3) same-day spinal fusion and laminectomy/discectomy. An overall "all surgeries" cohort was created and patients were de-duplicated according to the following hierarchy: (1) those with same-day hip fracture treatment and hip replacement only contributed their hip replacement observation, (2) those with same-day spinal fusions of different levels only contributed their observation corresponding to the highest recorded level, and (3) those with same-day spinal fusions and laminectomy/discectomies only contributed their spinal fusion observation. The following age groups were included in the cohorts: 18-40, 41-64, and 65+ years.

Initial Dispensing of Interest: The dispensings of interest were oral solid formulations of opioid analgesics identified using National Drug Codes (NDCs) recorded in outpatient pharmacy dispensings within 7 days of the admission date of the surgery encounter (for ambulatory surgeries) or the discharge date of the surgery encounter (for inpatient surgeries). The oral solid formulations of opioid analgesics did not include fentanyl products. Please see Appendix C for generic and brand names.

Follow-Up Time: Follow-up time for the “re-fill” analysis was determined by the length of the initial dispensing plus an extension period of 14 days following the end of the last day of supply.³ Follow-up began on the date of initial dispensing of interest and continued until the earliest occurrence of either the end of the extension period or a “re-fill”.

Re-fills: Re-fills were defined as a dispensing of an oral solid formulation of an opioid analgesic occurring during follow-up. The re-fill did not have to be for the same opioid analgesic product or moiety as the initial dispensing. Please see Appendix C for generic and brand names.

Descriptive Statistics: Descriptive statistics concerning the days’ supply of the initial dispensing, number of tablets/capsules dispensed, morphine milligram equivalents (MME), and time to first “re-fill” were generated. The MME was calculated by multiplying the number of tablets/capsules in the initial dispensing, the strength associated with the NDC, and a product-specific conversion factor defined by the Centers for Medicare and Medicaid Services (see Appendix F for conversions used).

Baseline Covariates: The following covariates were assessed during the baseline period: age group, sex, recorded use of benzodiazepines, gabapentinoids, and sedative hypnotics, Charlson/Elixhauser combined comorbidity score, length of hospital stay, hospital discharge status, admission to hospice, inpatient rehabilitation, or nursing home, and days’ supply of the initial opioid analgesic dispensing. Age was evaluated on the admission date of the surgery encounter. Benzodiazepines, gabapentinoids, and sedative hypnotics were evaluated in the 30 days before or on the surgery admission date. Charlson/Elixhauser combined comorbidity score was evaluated in the 365 days before or on the surgery admission date. Length of stay and discharge status were evaluated on the discharge date of the surgery admission. Admission to hospice, inpatient rehabilitation, or nursing home was evaluated in the 7 days following the discharge date of the surgery admission. Days’ supply of the initial opioid analgesic dispensing was evaluated on the dispensing date. Benzodiazepines, gabapentinoids, and sedative hypnotics were defined using NDCs; please see Appendix G for generic and brand names.

Estimating Re-fill Rates Associated with Initial Prescription Amounts: For each surgery of interest and for the overall “all surgeries” cohort, a logistic regression model using Firth’s penalized likelihood was fitted to estimate the probability of “re-fill” among patients dispensed ≤ 90 days of an opioid analgesic following surgery. Separate models were fit using three methods of quantifying the amount of initial opioid dispensed: days’ supply, number of tablets/capsules dispensed, and MMEs. Each model included the following terms: surgery, age group, sex (except in female-only surgeries), year of the initial opioid dispensing, Charlson/Elixhauser combined comorbidity score, Drug Enforcement Agency (DEA) schedule of initial opioid dispensing on the dispensing date, length of stay of the surgery admission, comedication use in the 30 days prior to surgery, and Data Partner. Index-defining surgery was also included as a covariate in models fit to the overall “all surgeries” cohort. The three continuous independent variables of interest were modeled with cubic splines to allow for a nonlinear relationship with the probability of “re-fill”. Observations with days’ supply, number of tablets/capsules dispensed, or MME above the 90th percentile were considered outliers and were excluded from the analysis. After model fitting, population-standardized “re-fill” probabilities⁴ were estimated at each possible value of each independent variable (up to its respective 90th percentile). Refill rates associated with initial prescription amounts of opioid analgesics were estimated in two ways: (1) as the first days’ supply value associated with an estimated probability of “re-fill” < 20%⁵ and (2) as the days’ supply value associated with the lowest probability of “re-fill” (LPR)³. In analysis of the overall “all surgeries” cohort, odds ratios comparing the frequency of “re-fill” across surgeries, after adjustment for age group, sex, Charlson/Elixhauser combined comorbidity score, year of initial opioid analgesic prescription, Data Partner, history of comedication use, and independent variable of interest (days’ supply, number of tablets/capsules dispensed, or MME of the initial dispensing) were estimated.

Assessing Model Fit: For each model, fit was assessed by the Akaike Information Criterion (AIC), C-statistic, and the Hosmer-Lemeshow test. Likelihood ratio tests were used to evaluate the significance for each variable included in the models.

Limitations: Algorithms used to define the exposure (including the associated days' supply), outcomes, exclusions, and covariates are imperfect and were not validated prior to use in this analysis; thus, it is possible that there may be misclassification. Prescriptions paid for with cash or other insurance coverage were not captured in this data source. Opioid dispensings occurring within 7 days of a surgical procedure or subsequent re-fills may be for indications unrelated to post-surgical pain. Estimates of re-fill rates associated with initial prescription amounts of opioid analgesics only included patients who filled an opioid analgesic prescription within 7 days of a surgical procedure. We used a re-fill to indicate that more opioid analgesic was needed to treat the surgical pain, but the lack of re-fill may also reflect healthcare access issues. While we excluded patients with initial fill values above the 90th percentile for days' supply, units, and MMEs, we did not exclude patients at the low end of the distribution. Patients with lower quantities in their initial prescription fill may have had different probability of re-fills. We can only capture prescription fills in the outpatient setting so the proportion with an opioid analgesic fill within 7 days of surgery may appear low for surgeries with high proportions of discharge to places other than home/self care.

Please see Appendix H for the specifications of parameters used in the analyses for this request.

Please contact the Sentinel Operations Center Query Fulfillment Team (qf@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

¹Steiner CA, et al. Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014. Agency for Healthcare Research and Quality, 2017.

²McDermott KW, et al. Trends in Hospital Inpatient Stays in the United States, 2005–2014. Agency for Healthcare Research and Quality, 2017.

³Scully R, et al. Defining Optimal Length of Opioid Pain Medication Prescription After Common Surgical Procedures. *JAMA Surgery*, 2017.

⁴Greenland, S. "Introduction to Regression Modeling." *Modern Epidemiology*, by KJ Rothman, Lippincott Williams & Wilkins, 2008, pp. 418–455.

⁵Hill M, et al. Guideline for Discharge Opioid Prescriptions after Inpatient General Surgical Procedures. *Journal of the American College of Surgeons*, 2017.

Table of Contents

| | |
|-----------------|--|
| Glossary | List of Terms Found in this Report and their Definitions |
| Table 1a | Baseline Characteristics of Patients Undergoing Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery |
| Table 1b | Baseline Characteristics of Patients Initiating Opioid Analgesics within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery |
| Table 2 | Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group |
| Table 3 | Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year |
| Table 4a | Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Days' Supply for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group |
| Table 4b | Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Number of Tablets/Capsules Dispensed of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group |
| Table 4c | Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Morphine Milligram Equivalents of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group |
| Table 5 | Model Diagnostics for the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group |
| Table 6 | Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group |
| Table 7 | Odds Ratios for Re-filling Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery, and Age Group |
| Figure 1 | Re-fill Probability of Initial Dispensings for Patients with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| Figure 2 | Re-fill Probability of Initial Dispensings for Patients with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| Figure 3 | Re-fill Probability of Initial Dispensings for Patients with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| Figure 4 | Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| Figure 5 | Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| Figure 6 | Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Bunionectomy with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |

Table of Contents Continued

- Figure 7** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cesarean Section with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 8** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 9** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 10** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Coronary Artery Bypass Graft with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 11** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Fracture Treatment with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 12** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Replacement with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 13** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 14** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (non-laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 15** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Knee Arthroplasty with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 16** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Laminectomy/Discectomy with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 17** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (1-3 levels) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 18** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (4+ levels) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 19** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (all levels) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 20** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Tooth Extraction with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 21** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015

Table of Contents Continued

- Figure 22** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 23** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Bunionectomy with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 24** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cesarean Section with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 25** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 26** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 27** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Coronary Artery Bypass Graft with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 28** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Fracture Treatment with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 29** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Replacement with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 30** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 31** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (non-laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 32** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Knee Arthroplasty with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 33** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Laminectomy/Discectomy with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 34** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (1-3 levels) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 35** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (4+ levels) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 36** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (all levels) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015

Table of Contents Continued

- Figure 37** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Tooth Extraction with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 38** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 39** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 40** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Bunionectomy with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 41** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cesarean Section with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 42** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 43** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 44** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Coronary Artery Bypass Graft with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 45** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Fracture Treatment with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 46** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Replacement with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 47** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 48** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (non-laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 49** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Knee Arthroplasty with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 50** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Laminectomy/Discectomy with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015
- Figure 51** Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (1-3 levels) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015

Table of Contents Continued

| | |
|--------------------------|--|
| <u>Figure 52</u> | Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (4+ levels) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| <u>Figure 53</u> | Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (all levels) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| <u>Figure 54</u> | Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Tooth Extraction with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015 |
| <u>Appendix A</u> | Dates of Available Data for Each Data Partner (DP) in the Sentinel Distributed Database (SDD) up to Request End Date (September 30, 2015) |
| <u>Appendix B</u> | List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request |
| <u>Appendix C</u> | List of Generic and Brand Names of Products Used to Define Opioid Analgesics in this Request |
| <u>Appendix D</u> | List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request |
| <u>Appendix E</u> | List of Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request |
| <u>Appendix F</u> | List of Morphine Milligram Equivalent (MME) Conversion Factors |
| <u>Appendix G</u> | List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request |
| <u>Appendix H</u> | Specifications for Parameters for this Request |

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Tool***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03:

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '!' = blank. Along with the Care Setting

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

| Table 1a. Baseline Characteristics of Patients Undergoing Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery | | | | | | | |
|---|--------------------|--------------------------------|-------------------------------|-----------------|------------------|-----------------------------------|----------------------------------|
| Number (%) with characteristic | All surgeries* | Appendectomy (laparoscopic) | Appendectomy (nonspecific) | Bunionectomy | Cesarean section | Cholecystectomy (laparoscopic) | Cholecystectomy (nonspecific) |
| Patients undergoing surgery | 1,618,135 (100.0%) | 74,330 (100.0%) | 13,418 (100.0%) | 60,417 (100.0%) | 323,721 (100.0%) | 219,026 (100.0%) | 10,389 (100.0%) |
| Sex | | | | | | | |
| Female | 1,114,034 (68.8%) | 35,307 (47.5%) | 6,296 (46.9%) | 49,088 (81.2%) | 323,721 (100.0%) | 151,633 (69.2%) | 5,419 (52.2%) |
| Age (years) | | | | | | | |
| 18-40 | 637,723 (39.4%) | 38,780 (52.2%) | 4,624 (34.5%) | 9,775 (16.2%) | 310,769 (96.0%) | 50,744 (23.2%) | 742 (7.1%) |
| 41-64 | 408,159 (25.2%) | 24,478 (32.9%) | 4,764 (35.5%) | 31,109 (51.5%) | 12,922 (4.0%) | 82,463 (37.6%) | 2,875 (27.7%) |
| 65+ | 572,253 (35.4%) | 11,072 (14.9%) | 4,030 (30.0%) | 19,533 (32.3%) | 30 (0.0%) | 85,819 (39.2%) | 6,772 (65.2%) |
| Baseline medications | | | | | | | |
| Benzodiazepines | 58,296 (3.6%) | 1,942 (2.6%) | 421 (3.1%) | 2,825 (4.7%) | 681 (0.2%) | 10,031 (4.6%) | 466 (4.5%) |
| Sedative hypnotics | 31,272 (1.9%) | 1,017 (1.4%) | 289 (2.2%) | 2,000 (3.3%) | 3,034 (0.9%) | 5,545 (2.5%) | 240 (2.3%) |
| Gabapentinoids | 36,837 (2.3%) | 728 (1.0%) | 233 (1.7%) | 1,561 (2.6%) | 84 (0.0%) | 5,507 (2.5%) | 384 (3.7%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 0.7 (1.6) | 0.3 (1.1) | 1.0 (1.7) | 0.2 (1.1) | 0.3 (0.6) | 0.8 (1.7) | 2.2 (2.5) |
| Length of stay (days) | | | | | | | |
| 0 | 620,754 (38.4%) | 35,638 (47.9%) | 1,962 (14.6%) | 59,490 (98.5%) | 5,224 (1.6%) | 140,510 (64.2%) | 430 (4.1%) |
| 1 | 14,391 (0.9%) | 3,770 (5.1%) | 287 (2.1%) | 100 (0.2%) | 1,756 (0.5%) | 2,555 (1.2%) | 67 (0.6%) |
| 2-5 | 743,087 (45.9%) | 30,263 (40.7%) | 5,580 (41.6%) | 600 (1.0%) | 280,683 (86.7%) | 51,489 (23.5%) | 2,705 (26.0%) |
| 6+ | 239,903 (14.8%) | 4,659 (6.3%) | 5,589 (41.7%) | 227 (0.4%) | 36,058 (11.1%) | 24,472 (11.2%) | 7,187 (69.2%) |
| Discharge status for inpatient surgeries | | | | | | | |
| Against medical advice | 201 (0.0%) | 15 (0.0%) | ***** | ***** | 39 (0.0%) | 57 (0.0%) | ***** |
| Home health | 143,097 (8.8%) | 813 (1.1%) | 1,189 (8.9%) | 150 (0.2%) | 5,765 (1.8%) | 5,155 (2.4%) | 1,529 (14.7%) |
| Home/self care | 589,932 (36.5%) | 36,006 (48.4%) | 8,889 (66.2%) | 522 (0.9%) | 307,441 (95.0%) | 65,373 (29.8%) | 5,932 (57.1%) |
| Nursing home, includes ICF | 3,810 (0.2%) | 42 (0.1%) | 46 (0.3%) | ***** | ***** | 377 (0.2%) | 93 (0.9%) |
| Other | 12,545 (0.8%) | 818 (1.1%) | 218 (1.6%) | 28 (0.0%) | 3,375 (1.0%) | 1,095 (0.5%) | 241 (2.3%) |
| Other acute inpatient hospital | 9,286 (0.6%) | 119 (0.2%) | 104 (0.8%) | ***** | 601 (0.2%) | 758 (0.3%) | 187 (1.8%) |
| Rehabilitation facility | 51,447 (3.2%) | 66 (0.1%) | 137 (1.0%) | 27 (0.0%) | 21 (0.0%) | 553 (0.3%) | 251 (2.4%) |
| Skilled nursing facility | 175,046 (10.8%) | 517 (0.7%) | 760 (5.7%) | 175 (0.3%) | 15 (0.0%) | 4,310 (2.0%) | 1,563 (15.0%) |
| Still in hospital | 6,008 (0.4%) | 23 (0.0%) | 41 (0.3%) | ***** | 364 (0.1%) | 101 (0.0%) | 66 (0.6%) |
| Unknown | 5,484 (0.3%) | 264 (0.4%) | 58 (0.4%) | ***** | 852 (0.3%) | 707 (0.3%) | 84 (0.8%) |
| Admitted to hospice, inpatient rehab, or nursing home within 7 days | 174,317 (10.8%) | 1,219 (1.6%) | 291 (2.2%) | 217 (0.4%) | 2,041 (0.6%) | 3,697 (1.7%) | 516 (5.0%) |
| Patients initiating oral opioid analgesic within 7 days | 935,443 (57.8%) | 53,428 (71.9%) | 8,035 (59.9%) | 43,163 (71.4%) | 248,281 (76.7%) | 149,026 (68.0%) | 4,873 (46.9%) |

Table 1a. Baseline Characteristics of Patients Undergoing Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

| N (%) with characteristic | Coronary artery bypass graft | Hip fracture treatment | Hip replacement | Hysterectomy (non-laparoscopic) | Hysterectomy (laparoscopic) | Knee arthroplasty | Laminectomy /discectomy |
|--|------------------------------|------------------------|------------------|---------------------------------|-----------------------------|-------------------|-------------------------|
| Patients undergoing surgery | 62,253 (100.0%) | 104,070 (100.0%) | 126,506 (100.0%) | 17,506 (100.0%) | 16,513 (100.0%) | 184,769 (100.0%) | 22,210 (100.0%) |
| Sex | | | | | | | |
| Female | 20,609 (33.1%) | 82,405 (79.2%) | 85,636 (67.7%) | 17,506 (100.0%) | 16,513 (100.0%) | 122,817 (66.5%) | 8,921 (40.2%) |
| Age (years) | | | | | | | |
| 18-40 | 423 (0.7%) | 3,089 (3.0%) | 1,353 (1.1%) | 3,617 (20.7%) | 5,825 (35.3%) | 660 (0.4%) | 4,483 (20.2%) |
| 41-64 | 15,078 (24.2%) | 8,228 (7.9%) | 25,180 (19.9%) | 6,831 (39.0%) | 7,924 (48.0%) | 41,819 (22.6%) | 9,178 (41.3%) |
| 65+ | 46,752 (75.1%) | 92,753 (89.1%) | 99,973 (79.0%) | 7,058 (40.3%) | 2,764 (16.7%) | 142,290 (77.0%) | 8,549 (38.5%) |
| Baseline medications | | | | | | | |
| Benzodiazepines | 2,602 (4.2%) | 6,267 (6.0%) | 5,984 (4.7%) | 833 (4.8%) | 949 (5.7%) | 7,645 (4.1%) | 1,660 (7.5%) |
| Sedative hypnotics | 1,391 (2.2%) | 2,742 (2.6%) | 3,141 (2.5%) | 424 (2.4%) | 436 (2.6%) | 5,300 (2.9%) | 675 (3.0%) |
| Gabapentinoids | 2,116 (3.4%) | 4,030 (3.9%) | 4,328 (3.4%) | 316 (1.8%) | 279 (1.7%) | 7,770 (4.2%) | 2,170 (9.8%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 2.9 (2.5) | 2.6 (2.5) | 1.4 (2.2) | 0.3 (1.2) | 0.3 (0.9) | 0.6 (1.6) | 0.3 (1.2) |
| Length of stay (days) | | | | | | | |
| 0 | 845 (1.4%) | 2,360 (2.3%) | 1,284 (1.0%) | 6,401 (36.6%) | 11,994 (72.6%) | 5,501 (3.0%) | 14,700 (66.2%) |
| 1 | 233 (0.4%) | 338 (0.3%) | 816 (0.6%) | 414 (2.4%) | 452 (2.7%) | 960 (0.5%) | 1,001 (4.5%) |
| 2-5 | 6,336 (10.2%) | 50,997 (49.0%) | 93,265 (73.7%) | 10,210 (58.3%) | 3,963 (24.0%) | 166,039 (89.9%) | 5,705 (25.7%) |
| 6+ | 54,839 (88.1%) | 50,375 (48.4%) | 31,141 (24.6%) | 481 (2.7%) | 104 (0.6%) | 12,269 (6.6%) | 804 (3.6%) |
| Discharge status for inpatient surgeries | | | | | | | |
| Against medical advice | 13 (0.0%) | 17 (0.0%) | 18 (0.0%) | 0 (0.0%) | ***** | 15 (0.0%) | 0 (0.0%) |
| Home health | 20,457 (32.9%) | 7,312 (7.0%) | 31,400 (24.8%) | 234 (1.3%) | 44 (0.3%) | 62,819 (34.0%) | 574 (2.6%) |
| Home/self care | 23,469 (37.7%) | 7,826 (7.5%) | 27,159 (21.5%) | 10,538 (60.2%) | 4,319 (26.2%) | 54,286 (29.4%) | 5,967 (26.9%) |
| Nursing home, includes ICF | 195 (0.3%) | 1,393 (1.3%) | 904 (0.7%) | ***** | ***** | 595 (0.3%) | 11 (0.0%) |
| Other | 1,636 (2.6%) | 1,474 (1.4%) | 999 (0.8%) | 144 (0.8%) | 91 (0.6%) | 1,378 (0.7%) | 204 (0.9%) |
| Other acute inpatient hospital | 659 (1.1%) | 2,107 (2.0%) | 1,594 (1.3%) | 15 (0.1%) | ***** | 2,436 (1.3%) | 40 (0.2%) |
| Rehabilitation facility | 4,622 (7.4%) | 16,649 (16.0%) | 13,230 (10.5%) | ***** | ***** | 11,660 (6.3%) | 284 (1.3%) |
| Skilled nursing facility | 9,223 (14.8%) | 61,655 (59.2%) | 47,776 (37.8%) | 76 (0.4%) | 16 (0.1%) | 44,026 (23.8%) | 353 (1.6%) |
| Still in hospital | 352 (0.6%) | 2,316 (2.2%) | 1,407 (1.1%) | ***** | ***** | 1,100 (0.6%) | 17 (0.1%) |
| Unknown | 763 (1.2%) | 685 (0.7%) | 632 (0.5%) | 73 (0.4%) | 38 (0.2%) | 914 (0.5%) | 59 (0.3%) |
| Admitted to hospice, inpatient rehab, or nursing home within 7 days | 3,468 (5.6%) | 57,469 (55.2%) | 47,174 (37.3%) | 215 (1.2%) | 227 (1.4%) | 53,211 (28.8%) | 452 (2.0%) |
| Patients initiating oral opioid analgesic within 7 days | 33,289 (53.5%) | 11,939 (11.5%) | 42,788 (33.8%) | 11,600 (66.3%) | 11,675 (70.7%) | 92,819 (50.2%) | 13,935 (62.7%) |

Table 1a. Baseline Characteristics of Patients Undergoing Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

| N (%) with characteristic | Spinal fusion (all levels) | Spinal fusion (1-3 levels) | Spinal fusion (4+ levels) | Tooth extraction |
|--|-------------------------------|-------------------------------|------------------------------|------------------|
| Patients undergoing surgery | 52,259 (100.0%) | 35,055 (100.0%) | 14,635 (100.0%) | 330,748 (100.0%) |
| Sex | | | | |
| Female | 27,769 (53.1%) | 18,846 (53.8%) | 7,570 (51.7%) | 160,394 (48.5%) |
| Age (years) | | | | |
| 18-40 | 4,681 (9.0%) | 2,719 (7.8%) | 1,621 (11.1%) | 198,158 (59.9%) |
| 41-64 | 21,136 (40.4%) | 14,310 (40.8%) | 5,693 (38.9%) | 114,174 (34.5%) |
| 65+ | 26,442 (50.6%) | 18,026 (51.4%) | 7,321 (50.0%) | 18,416 (5.6%) |
| Baseline medications | | | | |
| Benzodiazepines | 3,458 (6.6%) | 2,364 (6.7%) | 914 (6.2%) | 12,532 (3.8%) |
| Sedative hypnotics | 1,936 (3.7%) | 1,350 (3.9%) | 506 (3.5%) | 3,102 (0.9%) |
| Gabapentinoids | 5,585 (10.7%) | 3,849 (11.0%) | 1,501 (10.3%) | 1,746 (0.5%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 0.7 (1.6) | 0.6 (1.6) | 0.9 (1.7) | 0.1 (0.7) |
| Length of stay (days) | | | | |
| 0 | 6,234 (11.9%) | 4,264 (12.2%) | 610 (4.2%) | 328,181 (99.2%) |
| 1 | 1,563 (3.0%) | 1,196 (3.4%) | 273 (1.9%) | 79 (0.0%) |
| 2-5 | 33,891 (64.9%) | 24,728 (70.5%) | 8,428 (57.6%) | 1,361 (0.4%) |
| 6+ | 10,571 (20.2%) | 4,867 (13.9%) | 5,324 (36.4%) | 1,127 (0.3%) |
| Discharge status for inpatient surgeries | | | | |
| Against medical advice | ***** | ***** | ***** | ***** |
| Home health | 5,372 (10.3%) | 3,457 (9.9%) | 1,773 (12.1%) | 284 (0.1%) |
| Home/self care | 30,458 (58.3%) | 21,672 (61.8%) | 8,137 (55.6%) | 1,747 (0.5%) |
| Nursing home, includes ICF | 95 (0.2%) | 47 (0.1%) | 43 (0.3%) | 41 (0.0%) |
| Other | 784 (1.5%) | 431 (1.2%) | 277 (1.9%) | 60 (0.0%) |
| Other acute inpatient hospital | 598 (1.1%) | 240 (0.7%) | 327 (2.2%) | 61 (0.0%) |
| Rehabilitation facility | 3,881 (7.4%) | 2,108 (6.0%) | 1,640 (11.2%) | 52 (0.0%) |
| Skilled nursing facility | 4,302 (8.2%) | 2,598 (7.4%) | 1,557 (10.6%) | 279 (0.1%) |
| Still in hospital | 191 (0.4%) | 60 (0.2%) | 125 (0.9%) | 16 (0.0%) |
| Unknown | 329 (0.6%) | 169 (0.5%) | 141 (1.0%) | 20 (0.0%) |
| Admitted to hospice, inpatient rehab, or nursing home within 7 days | 3,990 (7.6%) | 2,449 (7.0%) | 1,423 (9.7%) | 130 (0.0%) |
| Patients initiating oral opioid analgesic within 7 days | 29,292 (56.1%) | 20,908 (59.6%) | 7,193 (49.1%) | 181,300 (54.8%) |

*After exclusion of patients with history of same or other study surgery

Table 1a. Baseline Characteristics of Patients Undergoing Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1b. Baseline Characteristics of Patients Initiating Opioid Analgesics within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

| Number (%) with characteristic | All surgeries* | Appendectomy (laparoscopic) | Appendectomy (nonspecific) | Buniorrhaphy | Cesarean section |
|--|------------------|-----------------------------|----------------------------|-----------------|------------------|
| Patients initiating oral opioid analgesic within 7 days | 935,443 (100.0%) | 53,428 (100.0%) | 8,035 (100.0%) | 43,163 (100.0%) | 248,281 (100.0%) |
| Sex | | | | | |
| Female | 650,447 (69.5%) | 24,916 (46.6%) | 3,604 (44.9%) | 35,351 (81.9%) | 248,281 (100.0%) |
| Age (years) | | | | | |
| 18-40 | 467,619 (50.0%) | 30,177 (56.5%) | 3,319 (41.3%) | 7,354 (17.0%) | 239,047 (96.3%) |
| 41-64 | 241,354 (25.8%) | 17,286 (32.4%) | 3,043 (37.9%) | 22,535 (52.2%) | 9,234 (3.7%) |
| 65+ | 226,470 (24.2%) | 5,965 (11.2%) | 1,673 (20.8%) | 13,274 (30.8%) | 0 (0.0%) |
| Baseline medications | | | | | |
| Benzodiazepines | 33,074 (3.5%) | 1,490 (2.8%) | 247 (3.1%) | 2,254 (5.2%) | 558 (0.2%) |
| Sedative hypnotics | 18,467 (2.0%) | 797 (1.5%) | 175 (2.2%) | 1,567 (3.6%) | 2,649 (1.1%) |
| Gabapentinoids | 17,690 (1.9%) | 473 (0.9%) | 112 (1.4%) | 1,128 (2.6%) | 72 (0.0%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 0.4 (1.2) | 0.3 (0.9) | 0.6 (1.4) | 0.2 (1.0) | 0.3 (0.6) |
| Length of stay (days) | | | | | |
| 0 | 389,609 (41.6%) | 27,183 (50.9%) | 1,365 (17.0%) | 42,768 (99.1%) | 2,609 (1.1%) |
| 1 | 8,966 (1.0%) | 2,772 (5.2%) | 200 (2.5%) | 63 (0.1%) | 968 (0.4%) |
| 2-5 | 449,428 (48.0%) | 21,230 (39.7%) | 3,852 (47.9%) | 282 (0.7%) | 218,748 (88.1%) |
| 6+ | 87,440 (9.3%) | 2,243 (4.2%) | 2,618 (32.6%) | 50 (0.1%) | 25,956 (10.5%) |
| Discharge status for inpatient surgeries | | | | | |
| Against medical advice | 63 (0.0%) | ***** | 0 (0.0%) | 0 (0.0%) | 17 (0.0%) |
| Home health | 99,887 (10.7%) | 424 (0.8%) | 668 (8.3%) | 73 (0.2%) | 4,311 (1.7%) |
| Home/self care | 423,930 (45.3%) | 25,015 (46.8%) | 5,838 (72.7%) | 300 (0.7%) | 237,806 (95.8%) |
| Nursing home, includes ICF | 732 (0.1%) | 12 (0.0%) | ***** | ***** | ***** |
| Other | 5,059 (0.5%) | 546 (1.0%) | 59 (0.7%) | ***** | 2,190 (0.9%) |
| Other acute inpatient hospital | 1,619 (0.2%) | 47 (0.1%) | 12 (0.1%) | ***** | 409 (0.2%) |
| Rehabilitation facility | 3,008 (0.3%) | ***** | ***** | ***** | 12 (0.0%) |
| Skilled nursing facility | 8,269 (0.9%) | 29 (0.1%) | 28 (0.3%) | ***** | ***** |
| Still in hospital | 634 (0.1%) | ***** | ***** | ***** | 252 (0.1%) |
| Unknown | 2,505 (0.3%) | 148 (0.3%) | 36 (0.4%) | ***** | 652 (0.3%) |
| Days' supply of index opioid dispensing | | | | | |
| 1-30 | 935,101 (100.0%) | ***** (>99.9%) | ***** (>99%) | ***** (>99.9%) | 248,258 (100.0%) |
| 31-60 | 293 (0.0%) | ***** (<0.1%) | ***** (<1%) | ***** (<0.1%) | ***** (<0.1%) |
| 61-90 | ***** (<0.1%) | ***** (<0.1%) | ***** (<1%) | ***** (<0.1%) | ***** (<0.1%) |
| 90+ | ***** (<0.1%) | 0 (0.0%) | 0 (0.0%) | ***** (<0.1%) | ***** (<0.1%) |
| Index opioid schedule | | | | | |
| Schedule II | 474,207 (50.7%) | 24,380 (45.6%) | 3,577 (44.5%) | 20,184 (46.8%) | 165,712 (66.7%) |
| Oxymorphone | 12 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Hydrocodone (after rescheduling) | 72,035 (7.7%) | 4,663 (8.7%) | 415 (5.2%) | 3,478 (8.1%) | 11,162 (4.5%) |
| Hydromorphone | 13,361 (1.4%) | 461 (0.9%) | 131 (1.6%) | 458 (1.1%) | 2,990 (1.2%) |
| Oxycodone | 384,566 (41.1%) | 19,175 (35.9%) | 3,017 (37.5%) | 15,313 (35.5%) | 150,885 (60.8%) |
| Morphine | 746 (0.1%) | ***** | ***** | 18 (0.0%) | 181 (0.1%) |
| Other | 3,487 (0.4%) | ***** | ***** | 917 (2.1%) | 494 (0.2%) |
| Other schedule | 461,236 (49.3%) | 29,048 (54.4%) | 4,458 (55.5%) | 22,979 (53.2%) | 82,569 (33.3%) |
| Tramadol | 25,833 (2.8%) | 980 (1.8%) | 173 (2.2%) | 1,030 (2.4%) | 1,454 (0.6%) |
| Codeine | 33,992 (3.6%) | 1,397 (2.6%) | 247 (3.1%) | 2,020 (4.7%) | 8,046 (3.2%) |
| Hydrocodone (before rescheduling) | 394,504 (42.2%) | 26,306 (49.2%) | 3,944 (49.1%) | 19,521 (45.2%) | 70,853 (28.5%) |
| Other | 6,907 (0.7%) | 365 (0.7%) | 94 (1.2%) | 408 (0.9%) | 2,216 (0.9%) |

Table 1b. Baseline Characteristics of Patients Initiating Opioid Analgesics within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

| N (%) with characteristic | Cholecystectomy (laparoscopic) | Cholecystectomy (nonspecific) | Coronary artery bypass graft | Hip fracture treatment | Hip replacement |
|--|-----------------------------------|----------------------------------|---------------------------------|---------------------------|------------------------|
| Patients initiating oral opioid analgesic within 7 days | 149,026 (100.0%) | 4,873 (100.0%) | 33,289 (100.0%) | 11,939 (100.0%) | 42,788 (100.0%) |
| Sex | | | | | |
| Female | 104,455 (70.1%) | 2,486 (51.0%) | 8,810 (26.5%) | 7,590 (63.6%) | 23,747 (55.5%) |
| Age (years) | | | | | |
| 18-40 | 39,432 (26.5%) | 469 (9.6%) | 287 (0.9%) | 1,597 (13.4%) | 776 (1.8%) |
| 41-64 | 60,139 (40.4%) | 1,677 (34.4%) | 10,634 (31.9%) | 2,975 (24.9%) | 15,047 (35.2%) |
| 65+ | 49,455 (33.2%) | 2,727 (56.0%) | 22,368 (67.2%) | 7,367 (61.7%) | 26,965 (63.0%) |
| Baseline medications | | | | | |
| Benzodiazepines | 7,291 (4.9%) | 205 (4.2%) | 1,504 (4.5%) | 722 (6.0%) | 1,629 (3.8%) |
| Sedative hypnotics | 4,056 (2.7%) | 132 (2.7%) | 783 (2.4%) | 332 (2.8%) | 1,090 (2.5%) |
| Gabapentinoids | 3,456 (2.3%) | 155 (3.2%) | 969 (2.9%) | 407 (3.4%) | 1,208 (2.8%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 0.6 (1.4) | 1.5 (2.1) | 2.4 (2.3) | 1.6 (2.2) | 0.5 (1.5) |
| Length of stay (days) | | | | | |
| 0 | 105,100 (70.5%) | 219 (4.5%) | 177 (0.5%) | 569 (4.8%) | 446 (1.0%) |
| 1 | 1,703 (1.1%) | 31 (0.6%) | 46 (0.1%) | 97 (0.8%) | 422 (1.0%) |
| 2-5 | 32,639 (21.9%) | 1,755 (36.0%) | 4,391 (13.2%) | 7,178 (60.1%) | 38,929 (91.0%) |
| 6+ | 9,584 (6.4%) | 2,868 (58.9%) | 28,675 (86.1%) | 4,095 (34.3%) | 2,991 (7.0%) |
| Discharge status for inpatient surgeries | | | | | |
| Against medical advice | ***** | ***** | ***** | ***** | ***** |
| Home health | 2,243 (1.5%) | 807 (16.6%) | 14,607 (43.9%) | 4,624 (38.7%) | 21,778 (50.9%) |
| Home/self care | 40,375 (27.1%) | 3,648 (74.9%) | 16,842 (50.6%) | 3,915 (32.8%) | 17,326 (40.5%) |
| Nursing home, includes ICF | 94 (0.1%) | 32 (0.7%) | 12 (0.0%) | 309 (2.6%) | 143 (0.3%) |
| Other | 471 (0.3%) | 22 (0.5%) | 573 (1.7%) | 121 (1.0%) | 199 (0.5%) |
| Other acute inpatient hospital | 177 (0.1%) | 28 (0.6%) | 94 (0.3%) | 157 (1.3%) | 154 (0.4%) |
| Rehabilitation facility | 11 (0.0%) | ***** | 226 (0.7%) | 393 (3.3%) | 582 (1.4%) |
| Skilled nursing facility | 173 (0.1%) | 68 (1.4%) | 348 (1.0%) | 1,682 (14.1%) | 1,882 (4.4%) |
| Still in hospital | 13 (0.0%) | ***** | 32 (0.1%) | 58 (0.5%) | 70 (0.2%) |
| Unknown | 348 (0.2%) | 28 (0.6%) | 366 (1.1%) | 62 (0.5%) | 182 (0.4%) |
| Days' supply of index opioid dispensing | | | | | |
| 1-30 | 148,996 (100.0%) | ***** ($\geq 99\%$) | 33,265 (99.9%) | 11,922 (99.9%) | 42,737 (99.9%) |
| 31-60 | ***** (<0.1%) | ***** ($\leq 1\%$) | ***** ($\leq 0.1\%$) | 17 (0.1%) | ***** ($\leq 0.1\%$) |
| 61-90 | ***** (<0.1%) | ***** ($\leq 1\%$) | ***** ($\leq 0.1\%$) | 0 (0.0%) | ***** ($\leq 0.1\%$) |
| 90+ | ***** (<0.1%) | 0 (0.0%) | ***** ($\leq 0.1\%$) | 0 (0.0%) | 0 (0.0%) |
| Index opioid schedule | | | | | |
| Schedule II | 63,618 (42.7%) | 2,354 (48.3%) | 14,723 (44.2%) | 5,757 (48.2%) | 23,040 (53.8%) |
| Oxymorphone | ***** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ***** |
| Hydrocodone (after rescheduling) | 13,496 (9.1%) | 332 (6.8%) | 2,191 (6.6%) | 947 (7.9%) | 3,584 (8.4%) |
| Hydromorphone | 1,602 (1.1%) | 151 (3.1%) | 677 (2.0%) | 198 (1.7%) | 1,253 (2.9%) |
| Oxycodone | 48,027 (32.2%) | 1,859 (38.1%) | 11,830 (35.5%) | 4,565 (38.2%) | 18,018 (42.1%) |
| Morphine | ***** | ***** | 14 (0.0%) | 35 (0.3%) | ***** |
| Other | 444 (0.3%) | ***** | 11 (0.0%) | 12 (0.1%) | 109 (0.3%) |
| Other schedule | 85,408 (57.3%) | 2,519 (51.7%) | 18,566 (55.8%) | 6,182 (51.8%) | 19,748 (46.2%) |
| Tramadol | 4,176 (2.8%) | 186 (3.8%) | 3,370 (10.1%) | 883 (7.4%) | 3,522 (8.2%) |
| Codeine | 4,008 (2.7%) | 123 (2.5%) | 1,189 (3.6%) | 284 (2.4%) | 500 (1.2%) |
| Hydrocodone (before rescheduling) | 75,891 (50.9%) | 2,186 (44.9%) | 13,487 (40.5%) | 4,985 (41.8%) | 15,578 (36.4%) |
| Other | 1,333 (0.9%) | 24 (0.5%) | 520 (1.6%) | 30 (0.3%) | 148 (0.3%) |

Table 1b. Baseline Characteristics of Patients Initiating Opioid Analgesics within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

| N (%) with characteristic | Hysterectomy (non-laparoscopic) | Hysterectomy (laparoscopic) | Knee arthroplasty | Laminectomy /discectomy |
|--|---------------------------------|-----------------------------|-------------------|-------------------------|
| Patients initiating oral opioid analgesic within 7 days | 11,600 (100.0%) | 11,675 (100.0%) | 92,819 (100.0%) | 13,935 (100.0%) |
| Sex | | | | |
| Female | 11,600 (100.0%) | 11,675 (100.0%) | 57,807 (62.3%) | 5,358 (38.4%) |
| Age (years) | | | | |
| 18-40 | 2,652 (22.9%) | 4,337 (37.1%) | 331 (0.4%) | 3,194 (22.9%) |
| 41-64 | 4,880 (42.1%) | 5,727 (49.1%) | 24,716 (26.6%) | 5,948 (42.7%) |
| 65+ | 4,068 (35.1%) | 1,611 (13.8%) | 67,772 (73.0%) | 4,793 (34.4%) |
| Baseline medications | | | | |
| Benzodiazepines | 626 (5.4%) | 743 (6.4%) | 3,844 (4.1%) | 1,341 (9.6%) |
| Sedative hypnotics | 317 (2.7%) | 349 (3.0%) | 2,788 (3.0%) | 471 (3.4%) |
| Gabapentinoids | 216 (1.9%) | 201 (1.7%) | 3,485 (3.8%) | 1,577 (11.3%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 0.3 (1.1) | 0.3 (0.9) | 0.4 (1.4) | 0.2 (1.1) |
| Length of stay (days) | | | | |
| 0 | 4,120 (35.5%) | 8,481 (72.6%) | 2,566 (2.8%) | 9,561 (68.6%) |
| 1 | 250 (2.2%) | 310 (2.7%) | 450 (0.5%) | 642 (4.6%) |
| 2-5 | 6,991 (60.3%) | 2,833 (24.3%) | 85,426 (92.0%) | 3,485 (25.0%) |
| 6+ | 239 (2.1%) | 51 (0.4%) | 4,377 (4.7%) | 247 (1.8%) |
| Discharge status for inpatient surgeries | | | | |
| Against medical advice | 0 (0.0%) | ***** | ***** | 0 (0.0%) |
| Home health | 140 (1.2%) | 24 (0.2%) | 45,987 (49.5%) | 372 (2.7%) |
| Home/self care | 7,208 (62.1%) | 3,071 (26.3%) | 37,357 (40.2%) | 3,861 (27.7%) |
| Nursing home, includes ICF | ***** | ***** | 84 (0.1%) | 0 (0.0%) |
| Other | 73 (0.6%) | 62 (0.5%) | 425 (0.5%) | 70 (0.5%) |
| Other acute inpatient hospital | ***** | ***** | 450 (0.5%) | ***** |
| Rehabilitation facility | 0 (0.0%) | ***** | 1,538 (1.7%) | 12 (0.1%) |
| Skilled nursing facility | ***** | ***** | 3,779 (4.1%) | 21 (0.2%) |
| Still in hospital | ***** | 0 (0.0%) | 160 (0.2%) | ***** |
| Unknown | 47 (0.4%) | 29 (0.2%) | 441 (0.5%) | 28 (0.2%) |
| Days' supply of index opioid dispensing | | | | |
| 1-30 | 11,600 (100.0%) | 11,675 (100.0%) | 92,681 (99.9%) | ***** (>99.9%) |
| 31-60 | 0 (0.0%) | 0 (0.0%) | 122 (0.1%) | ***** (<0.1%) |
| 61-90 | 0 (0.0%) | 0 (0.0%) | ***** (<0.1%) | ***** (<0.1%) |
| 90+ | 0 (0.0%) | 0 (0.0%) | ***** (<0.1%) | 0 (0.0%) |
| Index opioid schedule | | | | |
| Schedule II | 6,609 (57.0%) | 7,382 (63.2%) | 52,336 (56.4%) | 7,578 (54.4%) |
| Oxymorphone | 0 (0.0%) | 0 (0.0%) | ***** | 0 (0.0%) |
| Hydrocodone (after rescheduling) | 532 (4.6%) | 605 (5.2%) | 7,236 (7.8%) | 1,150 (8.3%) |
| Hydromorphone | 273 (2.4%) | 303 (2.6%) | 3,548 (3.8%) | 236 (1.7%) |
| Oxycodone | 5,736 (49.4%) | 6,362 (54.5%) | 40,948 (44.1%) | 6,150 (44.1%) |
| Morphine | ***** | ***** | ***** | 19 (0.1%) |
| Other | ***** | ***** | 391 (0.4%) | 23 (0.2%) |
| Other schedule | 4,991 (43.0%) | 4,293 (36.8%) | 40,483 (43.6%) | 6,357 (45.6%) |
| Tramadol | 256 (2.2%) | 226 (1.9%) | 6,203 (6.7%) | 460 (3.3%) |
| Codeine | 532 (4.6%) | 323 (2.8%) | 1,042 (1.1%) | 221 (1.6%) |
| Hydrocodone (before rescheduling) | 4,014 (34.6%) | 3,605 (30.9%) | 32,932 (35.5%) | 5,614 (40.3%) |
| Other | 189 (1.6%) | 139 (1.2%) | 306 (0.3%) | 62 (0.4%) |

Table 1b. Baseline Characteristics of Patients Initiating Opioid Analgesics within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

| N (%) with characteristic | Spinal fusion (all levels) | Spinal fusion (1-3 levels) | Spinal fusion (4+ levels) | Tooth extraction |
|--|-------------------------------|-------------------------------|------------------------------|------------------|
| Patients initiating oral opioid analgesic within 7 days | 29,292 (100.0%) | 20,908 (100.0%) | 7,193 (100.0%) | 181,300 (100.0%) |
| Sex | | | | |
| Female | 15,191 (51.9%) | 10,953 (52.4%) | 3,598 (50.0%) | 89,576 (49.4%) |
| Age (years) | | | | |
| 18-40 | 2,810 (9.6%) | 1,767 (8.5%) | 875 (12.2%) | 131,837 (72.7%) |
| 41-64 | 13,141 (44.9%) | 9,373 (44.8%) | 3,261 (45.3%) | 44,372 (24.5%) |
| 65+ | 13,341 (45.5%) | 9,768 (46.7%) | 3,057 (42.5%) | 5,091 (2.8%) |
| Baseline medications | | | | |
| Benzodiazepines | 2,248 (7.7%) | 1,631 (7.8%) | 516 (7.2%) | 8,372 (4.6%) |
| Sedative hypnotics | 1,277 (4.4%) | 928 (4.4%) | 302 (4.2%) | 1,684 (0.9%) |
| Gabapentinoids | 3,432 (11.7%) | 2,496 (11.9%) | 811 (11.3%) | 799 (0.4%) |
| Charlson/Elixhauser Combined Comorbidity Score (mean, SD) | 0.4 (1.3) | 0.4 (1.3) | 0.6 (1.4) | 0.1 (0.6) |
| Length of stay (days) | | | | |
| 0 | 3,842 (13.1%) | 2,883 (13.8%) | 325 (4.5%) | 180,603 (99.6%) |
| 1 | 983 (3.4%) | 785 (3.8%) | 152 (2.1%) | 29 (0.0%) |
| 2-5 | 21,242 (72.5%) | 15,748 (75.3%) | 5,067 (70.4%) | 447 (0.2%) |
| 6+ | 3,225 (11.0%) | 1,492 (7.1%) | 1,649 (22.9%) | 221 (0.1%) |
| Discharge status for inpatient surgeries | | | | |
| Against medical advice | ***** | ***** | ***** | 0 (0.0%) |
| Home health | 3,739 (12.8%) | 2,443 (11.7%) | 1,200 (16.7%) | 90 (0.0%) |
| Home/self care | 20,799 (71.0%) | 15,042 (71.9%) | 5,335 (74.2%) | 569 (0.3%) |
| Nursing home, includes ICF | 20 (0.1%) | ***** | ***** | ***** |
| Other | 233 (0.8%) | 163 (0.8%) | 60 (0.8%) | ***** |
| Other acute inpatient hospital | 72 (0.2%) | 27 (0.1%) | 40 (0.6%) | ***** |
| Rehabilitation facility | 211 (0.7%) | 118 (0.6%) | 85 (1.2%) | 0 (0.0%) |
| Skilled nursing facility | 230 (0.8%) | 139 (0.7%) | 83 (1.2%) | ***** |
| Still in hospital | 14 (0.0%) | ***** | ***** | 0 (0.0%) |
| Unknown | 128 (0.4%) | 78 (0.4%) | 45 (0.6%) | ***** |
| Days' supply of index opioid dispensing | | | | |
| 1-30 | 29,263 (99.9%) | 20,888 (99.9%) | *****(>99%) | *****(>99.9%) |
| 31-60 | ***** (<0.1%) | ***** (<0.1%) | ***** (<1%) | ***** (<0.1%) |
| 61-90 | ***** (<0.1%) | ***** (<0.1%) | ***** (<1%) | ***** (<0.1%) |
| 90+ | 0 (0.0%) | 0 (0.0%) | ***** (<1%) | 0 (0.0%) |
| Index opioid schedule | | | | |
| Schedule II | 16,939 (57.8%) | 11,949 (57.2%) | 4,360 (60.6%) | 60,018 (33.1%) |
| Oxymorphone | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Hydrocodone (after rescheduling) | 2,319 (7.9%) | 1,708 (8.2%) | 514 (7.1%) | 19,925 (11.0%) |
| Hydromorphone | 977 (3.3%) | 639 (3.1%) | 299 (4.2%) | ***** |
| Oxycodone | 13,432 (45.9%) | 9,460 (45.2%) | 3,489 (48.5%) | 39,249 (21.6%) |
| Morphine | 116 (0.4%) | 74 (0.4%) | 35 (0.5%) | ***** |
| Other | 95 (0.3%) | 68 (0.3%) | 23 (0.3%) | 736 (0.4%) |
| Other schedule | 12,353 (42.2%) | 8,959 (42.8%) | 2,833 (39.4%) | 121,282 (66.9%) |
| Tramadol | 1,295 (4.4%) | 933 (4.5%) | 301 (4.2%) | 1,619 (0.9%) |
| Codeine | 434 (1.5%) | 320 (1.5%) | 90 (1.3%) | 13,626 (7.5%) |
| Hydrocodone (before rescheduling) | 10,500 (35.8%) | 7,618 (36.4%) | 2,417 (33.6%) | 105,088 (58.0%) |
| Other | 124 (0.4%) | 88 (0.4%) | 25 (0.3%) | 949 (0.5%) |

*After exclusion of patients with history of same or other study surgery

Table 1b. Baseline Characteristics of Patients Initiating Opioid Analgesics within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| All surgeries* | | | | | | | | | | |
| All ages | 935,443 | 5.3 (3.6) | 5 (3, 6) | 36.8 (21.5) | 30 (24, 40) | 264.2 (203.6) | 225 (150, 300) | 167,423 (17.9%) | 9.7 (5.3) | 9 (6, 13) |
| Schedule II | 474,207 | 5.4 (3.7) | 5 (3, 6) | 39.9 (23.3) | 30 (30, 45) | 312.6 (222.7) | 225 (200, 375) | 84,378 (17.8%) | 9.9 (5.2) | 9 (6, 13) |
| Oxymorphone | 12 | 14.7 (8.6) | 11 (9, 20) | 34.4 (20.7) | 25 (20, 50) | 858.8 (775.1) | 435 (300, 1,200) | ***** | 9.0 (4.2) | 8 (6, 12) |
| Hydromorphone | 13,361 | 6.3 (4.2) | 5 (4, 8) | 51.2 (29.3) | 40 (30, 60) | 444.0 (289.0) | 352 (240, 600) | 4,169 (31.2%) | 10.1 (5.3) | 9 (6, 13) |
| Hydrocodone (after rescheduling) | 72,035 | 5.7 (3.9) | 5 (3, 7) | 38.3 (25.3) | 30 (20, 42) | 247.3 (217.3) | 150 (125, 300) | 10,040 (13.9%) | 11.0 (5.7) | 10 (7, 14) |
| Oxycodone | 384,566 | 5.4 (3.5) | 5 (3, 6) | 39.9 (22.6) | 30 (30, 45) | 318.6 (210.3) | 225 (225, 375) | 69,165 (18.0%) | 9.7 (5.1) | 9 (6, 13) |
| Morphine | 746 | 10.5 (7.5) | 8 (5, 14) | 44.8 (29.1) | 30 (30, 60) | 745.6 (719.2) | 510 (450, 900) | ***** | 9.6 (6.7) | 8 (5, 13) |
| Other | 3,487 | 5.5 (3.8) | 5 (3, 6) | 34.1 (19.3) | 30 (20, 40) | 394.5 (502.7) | 150 (100, 500) | 757 (21.7%) | 8.8 (5.3) | 7 (5, 12) |
| Other Schedule | 461,236 | 5.2 (3.5) | 5 (3, 6) | 33.6 (18.9) | 30 (20, 40) | 214.5 (167.9) | 150 (120, 250) | 83,045 (18.0%) | 9.5 (5.3) | 8 (6, 13) |
| Tramadol | 25,833 | 8.8 (5.8) | 7 (5, 10) | 45.6 (25.0) | 40 (30, 60) | 225.2 (125.9) | 200 (150, 300) | 6,340 (24.5%) | 11.1 (6.6) | 10 (6, 15) |
| Codeine | 33,992 | 4.4 (2.9) | 4 (3, 5) | 27.5 (15.1) | 25 (20, 30) | 126.2 (75.3) | 113 (90, 135) | 3,587 (10.6%) | 8.5 (5.2) | 7 (5, 11) |
| Hydrocodone (before rescheduling) | 394,504 | 5.0 (3.2) | 5 (3, 6) | 33.3 (18.5) | 30 (20, 40) | 212.7 (156.5) | 150 (125, 250) | 72,053 (18.3%) | 9.4 (5.1) | 8 (6, 13) |
| Other | 6,907 | 5.6 (3.5) | 5 (4, 7) | 31.4 (14.4) | 30 (20, 40) | 713.3 (331.2) | 690 (460, 805) | 1,065 (15.4%) | 8.9 (5.1) | 8 (5, 12) |
| 18-40 | 467,619 | 4.5 (2.5) | 4 (3, 5) | 29.6 (12.4) | 30 (20, 30) | 209.4 (122.6) | 200 (150, 225) | 53,371 (11.4%) | 7.8 (4.3) | 7 (5, 10) |
| Schedule II | 254,954 | 4.5 (2.6) | 4 (3, 5) | 31.5 (12.8) | 30 (25, 40) | 239.5 (120.1) | 225 (180, 300) | 26,521 (10.4%) | 7.9 (4.3) | 7 (5, 10) |
| Oxymorphone | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0.0%) | - | - |
| Hydromorphone | 4,069 | 5.0 (3.2) | 5 (3, 5) | 35.6 (18.0) | 30 (30, 40) | 308.9 (202.0) | 240 (240, 320) | 626 (15.4%) | 8.0 (4.7) | 7 (5, 11) |
| Hydrocodone (after rescheduling) | 32,840 | 4.5 (2.6) | 4 (3, 5) | 28.6 (13.1) | 30 (20, 30) | 172.3 (105.8) | 150 (100, 200) | 2,444 (7.4%) | 8.3 (4.5) | 7 (5, 11) |
| Oxycodone | 216,306 | 4.5 (2.6) | 4 (3, 5) | 31.9 (12.6) | 30 (25, 40) | 248.2 (114.4) | 225 (225, 300) | 23,208 (10.7%) | 7.9 (4.2) | 7 (5, 10) |
| Morphine | ***** | 6.9 (4.5) | 5 (5, 8) | 35.6 (16.3) | 30 (30, 40) | 547.8 (247.9) | 450 (450, 600) | 27 (*****) | 8.7 (6.9) | 6 (4, 12) |
| Other | 1,514 | 4.5 (2.6) | 4 (3, 5) | 27.1 (11.9) | 25 (20, 30) | 208.0 (242.8) | 150 (100, 200) | 216 (14.3%) | 6.7 (4.1) | 6 (4, 8) |
| Other Schedule | 212,665 | 4.3 (2.4) | 4 (3, 5) | 27.4 (11.4) | 30 (20, 30) | 173.4 (115.7) | 150 (100, 200) | 26,850 (12.6%) | 7.6 (4.3) | 6 (5, 9) |
| Tramadol | 3,778 | 6.2 (4.1) | 5 (4, 7) | 32.1 (15.6) | 30 (20, 36) | 158.0 (80.4) | 150 (100, 160) | 485 (12.8%) | 7.7 (4.8) | 7 (4, 10) |
| Codeine | 16,892 | 4.1 (2.4) | 4 (3, 5) | 25.8 (10.8) | 26 (20, 30) | 117.9 (53.6) | 126 (90, 135) | 1,518 (9.0%) | 7.1 (4.3) | 6 (4, 9) |
| Hydrocodone (before rescheduling) | 188,557 | 4.3 (2.4) | 4 (3, 5) | 27.5 (11.4) | 30 (20, 30) | 169.7 (94.8) | 150 (100, 200) | 24,435 (13.0%) | 7.6 (4.3) | 7 (5, 9) |
| Other | 3,438 | 5.1 (2.8) | 5 (3, 5) | 29.1 (10.3) | 30 (20, 30) | 662.6 (241.3) | 690 (460, 690) | 412 (12.0%) | 7.6 (4.4) | 6 (4, 10) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|--------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| All surgeries*, continued | | | | | | | | | | |
| 41-64 | 241,354 | 5.5 (3.7) | 5 (3, 7) | 39.6 (24.4) | 30 (24, 50) | 293.0 (245.0) | 225 (150, 375) | 48,767 (20.2%) | 10.0 (5.3) | 9 (6, 13) |
| Schedule II | 113,106 | 5.9 (4.0) | 5 (3, 7) | 45.8 (27.1) | 40 (30, 60) | 369.5 (275.6) | 300 (225, 450) | 25,922 (22.9%) | 10.2 (5.3) | 9 (6, 13) |
| Oxymorphone | ***** | 21.8 (10.9) | 25 (14, 30) | 43.5 (21.8) | 50 (27, 60) | 1,530.0 (963.1) | 1,500 (810, 2,250) | ***** (50.0%) | 5.5 (0.7) | 6 (5, 6) |
| Hydromorphone | 4,653 | 6.4 (4.1) | 5 (4, 8) | 57.0 (31.4) | 50 (30, 80) | 499.3 (314.1) | 480 (240, 640) | 1,684 (36.2%) | 9.9 (5.2) | 9 (6, 13) |
| Hydrocodone (after rescheduling) | 17,827 | 5.8 (4.1) | 5 (3, 7) | 39.3 (27.3) | 30 (20, 50) | 260.2 (242.1) | 175 (125, 300) | 2,489 (14.0%) | 11.0 (5.8) | 10 (7, 15) |
| Oxycodone | 89,000 | 5.9 (3.9) | 5 (3, 7) | 46.6 (26.5) | 40 (30, 60) | 381.3 (260.2) | 300 (225, 450) | 21,284 (23.9%) | 10.1 (5.2) | 9 (6, 13) |
| Morphine | ***** | 12.2 (8.1) | 10 (6, 15) | 52.5 (34.9) | 40 (30, 60) | 913.6 (958.5) | 720 (450, 1,125) | ***** (42.9%) | 10.3 (7.1) | 9 (5, 15) |
| Other | 1,389 | 6.0 (4.2) | 5 (3, 7) | 37.7 (21.1) | 30 (24, 45) | 485.4 (568.8) | 200 (140, 600) | 363 (26.1%) | 9.3 (5.4) | 8 (5, 13) |
| Other Schedule | 128,248 | 5.2 (3.5) | 5 (3, 6) | 34.2 (20.4) | 30 (20, 40) | 225.6 (190.4) | 150 (113, 263) | 22,845 (17.8%) | 9.7 (5.4) | 9 (6, 13) |
| Tramadol | 6,142 | 8.3 (5.7) | 7 (5, 10) | 43.7 (25.6) | 40 (30, 60) | 215.5 (129.6) | 188 (150, 300) | 1,371 (22.3%) | 10.6 (6.8) | 9 (5, 15) |
| Codeine | 10,382 | 4.1 (2.7) | 3 (2, 5) | 25.1 (15.2) | 20 (16, 30) | 115.9 (76.5) | 90 (72, 135) | 984 (9.5%) | 8.7 (5.3) | 8 (5, 12) |
| Hydrocodone (before rescheduling) | 109,213 | 5.1 (3.3) | 5 (3, 6) | 34.6 (20.2) | 30 (20, 40) | 225.1 (176.7) | 150 (120, 263) | 20,047 (18.4%) | 9.7 (5.3) | 9 (6, 13) |
| Other | 2,511 | 5.6 (3.7) | 5 (3, 7) | 31.8 (15.8) | 30 (20, 40) | 723.1 (361.3) | 690 (460, 920) | 443 (17.6%) | 9.3 (5.3) | 8 (6, 13) |
| 65+ | 226,470 | 6.9 (4.5) | 5 (4, 8) | 48.5 (26.5) | 40 (30, 60) | 346.8 (249.6) | 300 (160, 450) | 65,285 (28.8%) | 11.1 (5.4) | 11 (7, 14) |
| Schedule II | 106,147 | 7.1 (4.6) | 6 (5, 9) | 54.0 (29.0) | 50 (30, 60) | 427.5 (276.5) | 375 (225, 576) | 31,935 (30.1%) | 11.3 (5.3) | 11 (7, 14) |
| Oxymorphone | ***** | 12.0 (4.3) | 10 (10, 15) | 31.3 (21.1) | 20 (20, 40) | 555.0 (421.5) | 300 (300, 1,125) | ***** (57.1%) | 10.8 (4.1) | 10 (8, 14) |
| Hydromorphone | 4,639 | 7.4 (4.8) | 6 (5, 10) | 59.2 (29.9) | 60 (40, 80) | 507.0 (287.7) | 480 (320, 640) | 1,859 (40.1%) | 10.9 (5.3) | 10 (7, 14) |
| Hydrocodone (after rescheduling) | 21,368 | 7.4 (4.8) | 6 (5, 10) | 52.4 (30.4) | 41 (30, 60) | 351.9 (270.7) | 300 (150, 450) | 5,107 (23.9%) | 12.3 (5.6) | 12 (8, 15) |
| Oxycodone | 79,260 | 7.0 (4.5) | 6 (5, 8) | 54.2 (28.5) | 50 (30, 60) | 440.3 (264.8) | 375 (225, 600) | 24,673 (31.1%) | 11.2 (5.3) | 11 (7, 14) |
| Morphine | ***** | 12.0 (7.9) | 10 (6, 15) | 45.7 (29.9) | 36 (24, 60) | 763.4 (704.6) | 600 (420, 900) | ***** (39.4%) | 9.2 (6.3) | 8 (4, 12) |
| Other | 584 | 7.2 (4.7) | 5 (4, 10) | 43.7 (23.4) | 40 (30, 60) | 661.7 (637.4) | 400 (150, 1,000) | 178 (30.5%) | 10.2 (5.8) | 9 (6, 13) |
| Other Schedule | 120,323 | 6.8 (4.5) | 5 (4, 8) | 43.7 (23.0) | 40 (30, 60) | 275.6 (197.5) | 225 (150, 300) | 33,350 (27.7%) | 10.9 (5.5) | 10 (7, 14) |
| Tramadol | 15,913 | 9.6 (6.0) | 8 (5, 12) | 49.5 (25.4) | 45 (30, 60) | 244.9 (127.3) | 200 (150, 300) | 4,484 (28.2%) | 11.6 (6.6) | 11 (7, 15) |
| Codeine | 6,718 | 5.6 (3.9) | 5 (3, 7) | 35.3 (20.8) | 30 (20, 40) | 163.1 (103.7) | 135 (90, 180) | 1,085 (16.2%) | 10.1 (5.8) | 9 (6, 14) |
| Hydrocodone (before rescheduling) | 96,734 | 6.4 (4.0) | 5 (4, 8) | 43.3 (22.5) | 40 (30, 60) | 282.5 (196.1) | 225 (150, 338) | 27,571 (28.5%) | 10.8 (5.3) | 10 (7, 14) |
| Other | 958 | 7.2 (4.6) | 6 (5, 9) | 38.7 (19.8) | 30 (30, 45) | 869.9 (454.2) | 690 (575, 1,035) | 210 (21.9%) | 10.6 (5.5) | 10 (7, 14) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|------------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Appendectomy (laparoscopic) | | | | | | | | | | |
| All ages | 53,428 | 4.5 (2.5) | 4 (3, 5) | 31.7 (10.7) | 30 (30, 40) | 208.6 (103.6) | 200 (150, 225) | 3,939 (7.4%) | 8.1 (4.9) | 7 (5, 11) |
| Schedule II | 24,380 | 4.5 (2.5) | 4 (3, 5) | 32.4 (11.1) | 30 (30, 40) | 238.8 (101.7) | 225 (180, 300) | 1,501 (6.2%) | 8.2 (5.0) | 7 (5, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 461 | 4.4 (2.7) | 4 (3, 5) | 31.3 (13.7) | 30 (20, 40) | 260.9 (127.9) | 240 (160, 320) | ***** | 7.7 (4.9) | 7 (4, 9) |
| Hydrocodone (after rescheduling) | 4,663 | 4.7 (2.5) | 4 (3, 5) | 32.5 (11.2) | 30 (30, 40) | 185.8 (90.1) | 150 (150, 200) | 228 (4.9%) | 8.8 (5.1) | 8 (5, 12) |
| Oxycodone | 19,175 | 4.4 (2.5) | 4 (3, 5) | 32.4 (11.1) | 30 (30, 40) | 250.4 (96.2) | 225 (225, 300) | 1,213 (6.3%) | 8.1 (5.0) | 7 (5, 11) |
| Morphine | ***** | 8.3 (10.0) | 5 (2, 10) | 31.4 (14.9) | 30 (20, 40) | 600.0 (542.6) | 450 (300, 600) | ***** (14.3%) | ***** | ***** |
| Other | ***** | 4.6 (1.8) | 5 (3, 5) | 28.9 (9.1) | 30 (24, 30) | 406.5 (349.7) | 228 (150, 600) | ***** (8.1%) | 10.8 (7.4) | 13 (2, 15) |
| Other Schedule | 29,048 | 4.5 (2.5) | 4 (3, 5) | 31.2 (10.2) | 30 (30, 35) | 183.3 (98.2) | 150 (150, 200) | 2,438 (8.4%) | 8.1 (4.8) | 7 (5, 11) |
| Tramadol | 980 | 6.4 (4.6) | 5 (4, 7) | 30.8 (12.8) | 30 (23, 30) | 151.6 (64.7) | 150 (103, 150) | 89 (9.1%) | 7.7 (5.1) | 7 (3, 11) |
| Codeine | 1,397 | 4.5 (2.4) | 4 (3, 5) | 30.2 (10.2) | 30 (25, 30) | 140.2 (53.2) | 135 (113, 135) | 85 (6.1%) | 7.4 (5.3) | 6 (3, 10) |
| Hydrocodone (before rescheduling) | 26,306 | 4.5 (2.4) | 4 (3, 5) | 31.3 (10.1) | 30 (30, 35) | 180.2 (79.3) | 150 (150, 200) | 2,239 (8.5%) | 8.1 (4.7) | 7 (5, 11) |
| Other | 365 | 5.4 (3.7) | 5 (3, 6) | 28.7 (10.3) | 30 (20, 30) | 656.7 (240.7) | 690 (460, 690) | 25 (6.8%) | 7.2 (5.7) | 6 (3, 8) |
| 18-40 | 30,177 | 4.5 (2.4) | 4 (3, 5) | 31.8 (10.6) | 30 (30, 40) | 209.9 (103.5) | 200 (150, 225) | 2,283 (7.6%) | 7.6 (4.6) | 6 (4, 10) |
| Schedule II | 14,071 | 4.4 (2.5) | 4 (3, 5) | 32.4 (11.1) | 30 (30, 40) | 239.7 (101.2) | 225 (180, 300) | 878 (6.2%) | 7.7 (4.6) | 7 (4, 10) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 229 | 4.2 (2.1) | 4 (3, 5) | 31.4 (13.7) | 30 (20, 40) | 256.9 (113.8) | 240 (160, 320) | ***** | 6.6 (4.3) | 6 (3, 8) |
| Hydrocodone (after rescheduling) | 2,555 | 4.7 (2.5) | 4 (3, 5) | 32.4 (11.4) | 30 (30, 40) | 185.9 (91.9) | 150 (150, 200) | 129 (5.0%) | 7.8 (5.1) | 7 (4, 10) |
| Oxycodone | 11,237 | 4.4 (2.4) | 4 (3, 5) | 32.5 (11.0) | 30 (30, 40) | 250.7 (95.0) | 225 (225, 300) | 715 (6.4%) | 7.7 (4.6) | 6 (4, 10) |
| Morphine | ***** | 8.0 (2.8) | 8 (6, 10) | 35.0 (7.1) | 35 (30, 40) | 525.0 (106.1) | 525 (450, 600) | 0 (0.0%) | - | - |
| Other | ***** | 4.5 (1.8) | 5 (3, 5) | 29.1 (10.0) | 30 (24, 30) | 448.3 (384.7) | 400 (150, 600) | ***** (10.4%) | 9.0 (6.6) | 11 (2, 15) |
| Other Schedule | 16,106 | 4.5 (2.4) | 4 (3, 5) | 31.2 (10.0) | 30 (30, 32) | 183.8 (98.3) | 150 (150, 200) | 1,405 (8.7%) | 7.5 (4.6) | 6 (4, 10) |
| Tramadol | 415 | 6.0 (3.1) | 5 (4, 7) | 30.0 (11.1) | 30 (20, 30) | 147.3 (56.2) | 150 (100, 150) | 36 (8.7%) | 6.3 (4.8) | 5 (2, 9) |
| Codeine | 778 | 4.5 (2.3) | 4 (3, 5) | 30.4 (9.8) | 30 (25, 30) | 141.4 (53.7) | 135 (113, 135) | 46 (5.9%) | 7.3 (5.7) | 6 (3, 10) |
| Hydrocodone (before rescheduling) | 14,705 | 4.4 (2.3) | 4 (3, 5) | 31.3 (10.0) | 30 (30, 35) | 180.3 (77.4) | 150 (150, 200) | 1,307 (8.9%) | 7.6 (4.5) | 6 (4, 10) |
| Other | 208 | 5.5 (3.5) | 5 (4, 6) | 28.8 (11.4) | 30 (20, 30) | 661.2 (264.2) | 690 (460, 690) | 16 (7.7%) | 6.8 (5.5) | 6 (3, 8) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | | |
|---|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|------------------|-------------------------|------------|--------------|--|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) | |
| Appendectomy (laparoscopic), continued | | | | | | | | | | | |
| 41-64 | | | | | | | | | | | |
| Schedule II | 17,286 | 4.5 (2.6) | 4 (3, 5) | 32.1 (10.7) | 30 (30, 40) | 212.5 (106.2) | 200 (150, 225) | 1,316 (7.6%) | 8.7 (5.1) | 7 (5, 12) | |
| Oxymorphone | 7,837 | 4.5 (2.6) | 4 (3, 5) | 32.8 (11.2) | 30 (30, 40) | 242.4 (104.5) | 225 (188, 300) | 513 (6.5%) | 8.8 (5.3) | 8 (5, 12) | |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - | |
| Hydrocodone (after rescheduling) | ***** | 4.5 (3.3) | 4 (3, 5) | 30.9 (14.5) | 30 (20, 40) | 264.9 (151.6) | 240 (160, 320) | ***** (12.0%) | 9.5 (5.2) | 9 (5, 14) | |
| Oxycodone | 1,410 | 4.7 (2.3) | 4 (3, 5) | 32.7 (10.4) | 30 (30, 40) | 187.1 (87.5) | 150 (150, 200) | ***** | 9.4 (4.6) | 10 (6, 13) | |
| Morphine | 6,217 | 4.5 (2.6) | 4 (3, 5) | 32.8 (11.3) | 30 (30, 40) | 253.6 (99.2) | 225 (225, 300) | 414 (6.7%) | 8.6 (5.4) | 7 (5, 12) | |
| Other | ***** | 9.3 (13.8) | 3 (2, 17) | 33.8 (18.0) | 28 (23, 45) | 731.3 (715.1) | 413 (338, 1,125) | ***** (25.0%) | ***** | ***** | |
| Other Schedule | 9,449 | 4.5 (2.6) | 4 (3, 5) | 31.5 (10.1) | 30 (30, 35) | 187.6 (101.1) | 150 (150, 210) | 803 (8.5%) | 8.6 (5.0) | 7 (5, 12) | |
| Tramadol | 345 | 6.9 (6.1) | 5 (4, 8) | 31.9 (14.9) | 30 (25, 30) | 156.9 (75.1) | 150 (113, 150) | ***** | 8.2 (5.6) | 8 (2, 11) | |
| Codeine | 422 | 4.4 (2.4) | 4 (3, 5) | 30.9 (10.3) | 30 (30, 30) | 143.0 (52.1) | 135 (135, 135) | ***** | 7.6 (5.0) | 7 (3, 10) | |
| Hydrocodone (before rescheduling) | 8,543 | 4.5 (2.3) | 4 (3, 5) | 31.5 (9.9) | 30 (30, 36) | 183.6 (82.1) | 150 (150, 210) | 729 (8.5%) | 8.7 (4.9) | 7 (5, 12) | |
| Other | 139 | 5.1 (4.1) | 5 (3, 5) | 28.4 (8.3) | 30 (20, 30) | 646.0 (197.8) | 690 (460, 690) | ***** | 8.4 (6.7) | 7 (4, 11) | |
| 65+ | | | | | | | | | | | |
| Schedule II | 5,965 | 4.8 (2.9) | 4 (3, 5) | 30.6 (11.2) | 30 (25, 30) | 191.3 (94.2) | 150 (150, 225) | 340 (5.7%) | 9.8 (5.0) | 9 (6, 14) | |
| Oxymorphone | 2,472 | 4.8 (2.8) | 4 (3, 5) | 31.0 (11.0) | 30 (25, 35) | 221.9 (94.0) | 225 (150, 240) | 110 (4.4%) | 10.0 (5.4) | 9 (6, 14) | |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - | |
| Hydrocodone (after rescheduling) | ***** | 5.0 (2.1) | 5 (3, 6) | 32.5 (10.4) | 30 (30, 40) | 264.8 (89.0) | 240 (240, 320) | ***** (4.1%) | 3.0 (1.4) | 3 (2, 4) | |
| Oxycodone | 698 | 5.1 (2.9) | 5 (3, 6) | 32.2 (11.9) | 30 (30, 40) | 182.9 (88.4) | 150 (150, 210) | ***** | 11.8 (5.2) | 12 (8, 16) | |
| Morphine | 1,721 | 4.6 (2.8) | 4 (3, 5) | 30.6 (10.6) | 30 (25, 35) | 236.4 (91.2) | 225 (188, 300) | 84 (4.9%) | 9.6 (5.4) | 8 (6, 14) | |
| Other | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0.0%) | - | - | |
| Other Schedule | 3,493 | 4.8 (3.0) | 4 (3, 5) | 30.3 (11.3) | 30 (24, 30) | 169.7 (88.2) | 150 (125, 200) | 230 (6.6%) | 9.6 (4.8) | 9 (6, 13) | |
| Tramadol | 220 | 6.5 (4.1) | 5 (4, 7) | 30.7 (12.2) | 30 (20, 30) | 151.3 (61.8) | 150 (100, 150) | ***** | 9.3 (4.0) | 9 (7, 11) | |
| Codeine | 197 | 4.7 (2.7) | 5 (3, 5) | 28.3 (10.9) | 30 (20, 30) | 129.5 (52.2) | 135 (90, 135) | ***** | 7.3 (4.7) | 5 (4, 12) | |
| Hydrocodone (before rescheduling) | 3,058 | 4.7 (2.8) | 4 (3, 5) | 30.4 (11.2) | 30 (25, 30) | 170.6 (79.6) | 150 (150, 200) | 203 (6.6%) | 9.8 (4.9) | 9 (6, 14) | |
| Other | 18 | 6.1 (2.6) | 5 (5, 7) | 29.9 (11.6) | 30 (20, 40) | 687.4 (266.6) | 690 (460, 920) | ***** | ***** | ***** | |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Appendectomy (nonspecific) | | | | | | | | | | |
| All ages | 8,035 | 4.8 (2.8) | 4 (3, 5) | 32.2 (12.2) | 30 (25, 40) | 219.5 (124.9) | 200 (150, 250) | 1,186 (14.8%) | 8.4 (4.4) | 7 (5, 11) |
| Schedule II | 3,577 | 4.8 (3.0) | 4 (3, 5) | 33.4 (13.0) | 30 (30, 40) | 255.3 (129.1) | 225 (188, 300) | 514 (14.4%) | 8.3 (4.1) | 8 (5, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 131 | 5.0 (3.2) | 5 (3, 5) | 36.6 (14.6) | 30 (30, 48) | 314.8 (158.2) | 240 (240, 400) | 27 (20.6%) | 7.1 (3.5) | 6 (4, 10) |
| Hydrocodone (after rescheduling) | 415 | 5.2 (3.2) | 5 (3, 6) | 32.9 (13.0) | 30 (28, 40) | 188.3 (90.2) | 150 (150, 225) | 40 (9.6%) | 9.3 (3.6) | 9 (7, 12) |
| Oxycodone | 3,017 | 4.8 (3.0) | 4 (3, 5) | 33.4 (12.9) | 30 (30, 40) | 261.1 (127.7) | 225 (225, 300) | 444 (14.7%) | 8.3 (4.2) | 7 (5, 11) |
| Morphine | ***** | 7.3 (4.8) | 5 (4, 13) | 34.7 (16.4) | 36 (30, 50) | 520.0 (246.4) | 540 (450, 750) | ***** (16.7%) | ***** | ***** |
| Other | ***** | 5.0 (2.4) | 5 (3, 6) | 36.3 (13.0) | 30 (30, 45) | 368.8 (261.8) | 275 (150, 600) | ***** (25.0%) | 7.5 (4.9) | 8 (4, 11) |
| Other Schedule | 4,458 | 4.9 (2.7) | 5 (3, 5) | 31.3 (11.4) | 30 (25, 35) | 190.8 (113.6) | 150 (150, 225) | 672 (15.1%) | 8.4 (4.7) | 7 (5, 11) |
| Tramadol | 173 | 6.9 (4.3) | 6 (4, 8) | 32.2 (15.3) | 30 (24, 30) | 155.2 (75.9) | 150 (113, 150) | 25 (14.5%) | 10.6 (8.5) | 7 (4, 14) |
| Codeine | 247 | 5.1 (3.3) | 5 (3, 6) | 28.7 (9.3) | 30 (20, 30) | 133.1 (53.4) | 135 (90, 135) | 32 (13.0%) | 8.9 (5.5) | 8 (4, 12) |
| Hydrocodone (before rescheduling) | 3,944 | 4.8 (2.5) | 4 (3, 5) | 31.4 (11.4) | 30 (25, 35) | 184.9 (88.4) | 150 (150, 225) | 604 (15.3%) | 8.3 (4.4) | 7 (5, 11) |
| Other | 94 | 5.3 (2.6) | 5 (4, 6) | 28.6 (8.6) | 30 (20, 30) | 655.4 (196.7) | 690 (460, 690) | 11 (11.7%) | 7.1 (4.4) | 7 (3, 8) |
| 18-40 | 3,319 | 4.7 (2.5) | 4 (3, 5) | 32.2 (11.7) | 30 (28, 40) | 221.1 (130.3) | 200 (150, 250) | 474 (14.3%) | 7.5 (4.0) | 7 (4, 9) |
| Schedule II | 1,495 | 4.7 (2.7) | 4 (3, 5) | 33.5 (12.9) | 30 (30, 40) | 257.2 (142.1) | 225 (200, 300) | 213 (14.2%) | 7.4 (3.9) | 7 (5, 10) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 4.6 (1.9) | 4 (3, 5) | 34.6 (11.7) | 30 (28, 40) | 289.5 (105.3) | 240 (224, 320) | ***** (19.1%) | 5.8 (2.8) | 6 (4, 7) |
| Hydrocodone (after rescheduling) | 139 | 5.4 (2.5) | 5 (4, 7) | 35.2 (13.3) | 30 (30, 40) | 201.3 (92.1) | 180 (150, 225) | 12 (8.6%) | 7.9 (2.6) | 9 (6, 10) |
| Oxycodone | 1,305 | 4.7 (2.7) | 4 (3, 5) | 33.3 (12.9) | 30 (30, 40) | 261.9 (146.2) | 225 (225, 300) | 191 (14.6%) | 7.4 (4.0) | 7 (4, 10) |
| Morphine | ***** | 4.0 (1.4) | 4 (3, 5) | 19.0 (18.4) | 19 (6, 32) | 285.0 (275.8) | 285 (90, 480) | ***** (50.0%) | ***** | ***** |
| Other | ***** | 7.0 (4.2) | 7 (4, 10) | 55.0 (7.1) | 55 (50, 60) | 275.0 (35.4) | 275 (250, 300) | 0 (0.0%) | - | - |
| Other Schedule | 1,824 | 4.6 (2.3) | 4 (3, 5) | 31.0 (10.5) | 30 (25, 30) | 191.4 (111.4) | 150 (150, 225) | 261 (14.3%) | 7.6 (4.1) | 7 (4, 9) |
| Tramadol | 39 | 5.5 (2.6) | 5 (3, 7) | 28.9 (13.1) | 30 (20, 36) | 139.8 (66.7) | 150 (100, 150) | ***** | 6.7 (6.2) | 5 (3, 6) |
| Codeine | 104 | 4.9 (3.4) | 4 (3, 6) | 29.7 (10.3) | 30 (20, 30) | 140.0 (64.7) | 135 (90, 158) | ***** | 6.5 (2.9) | 7 (4, 8) |
| Hydrocodone (before rescheduling) | 1,635 | 4.6 (2.2) | 4 (3, 5) | 31.3 (10.5) | 30 (28, 35) | 183.6 (84.4) | 150 (150, 210) | 241 (14.7%) | 7.7 (4.1) | 7 (5, 9) |
| Other | 46 | 4.8 (2.2) | 5 (3, 5) | 27.4 (6.7) | 30 (20, 30) | 629.5 (154.7) | 690 (460, 690) | ***** | 6.2 (3.5) | 6 (3, 8) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|-------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Appendectomy (nonspecific), continued | | | | | | | | | | |
| 41-64 | 3,043 | 4.8 (2.9) | 4 (3, 5) | 32.6 (12.2) | 30 (30, 40) | 227.0 (127.0) | 200 (150, 300) | 505 (16.6%) | 8.6 (4.4) | 8 (5, 11) |
| Schedule II | 1,395 | 4.8 (3.1) | 4 (3, 5) | 34.1 (13.0) | 30 (30, 40) | 262.6 (120.2) | 225 (210, 300) | 219 (15.7%) | 8.9 (4.1) | 8 (6, 12) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.0 (2.7) | 5 (3, 5) | 38.7 (17.2) | 35 (30, 50) | 344.3 (200.9) | 320 (240, 400) | ***** (21.1%) | 7.5 (3.7) | 8 (5, 10) |
| Hydrocodone (after rescheduling) | 135 | 5.2 (4.2) | 5 (3, 5) | 31.9 (13.3) | 30 (26, 35) | 185.5 (90.6) | 150 (150, 225) | 11 (8.1%) | 10.5 (4.1) | 11 (8, 15) |
| Oxycodone | 1,200 | 4.7 (2.9) | 4 (3, 5) | 34.1 (12.7) | 30 (30, 40) | 266.9 (112.6) | 225 (225, 300) | 196 (16.3%) | 8.9 (4.1) | 8 (6, 12) |
| Morphine | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | - | - |
| Other | ***** | 6.0 (1.4) | 6 (5, 7) | 25.0 (7.1) | 25 (20, 30) | 350.0 (353.6) | 350 (100, 600) | 0 (0.0%) | - | - |
| Other Schedule | 1,648 | 4.9 (2.7) | 5 (3, 5) | 31.4 (11.3) | 30 (25, 35) | 196.9 (124.7) | 150 (150, 225) | 286 (17.4%) | 8.3 (4.7) | 7 (5, 10) |
| Tramadol | 63 | 7.5 (5.5) | 6 (4, 10) | 34.0 (19.0) | 30 (25, 30) | 163.3 (92.9) | 150 (113, 150) | ***** | 11.3 (11.7) | 7 (4, 14) |
| Codeine | ***** | 5.2 (3.7) | 5 (3, 5) | 27.6 (8.8) | 30 (20, 30) | 127.8 (46.8) | 135 (90, 135) | ***** (23.5%) | 10.1 (6.3) | 9 (5, 16) |
| Hydrocodone (before rescheduling) | 1,458 | 4.7 (2.3) | 4 (3, 5) | 31.6 (11.0) | 30 (25, 36) | 188.3 (90.5) | 150 (150, 225) | 251 (17.2%) | 8.0 (4.0) | 7 (5, 10) |
| Other | ***** | 6.0 (3.0) | 5 (4, 8) | 30.2 (10.2) | 30 (20, 35) | 687.1 (236.4) | 690 (460, 736) | ***** (11.9%) | 8.2 (5.4) | 7 (7, 8) |
| 65+ | 1,673 | 5.2 (3.3) | 5 (3, 6) | 31.6 (13.0) | 30 (25, 36) | 202.8 (107.6) | 175 (150, 225) | 207 (12.4%) | 9.9 (4.9) | 9 (6, 13) |
| Schedule II | 687 | 5.1 (3.6) | 4 (3, 5) | 31.8 (13.0) | 30 (24, 40) | 236.3 (114.1) | 225 (150, 300) | 82 (11.9%) | 9.1 (4.4) | 9 (6, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.7 (5.4) | 4 (3, 7) | 35.6 (12.8) | 30 (30, 50) | 296.6 (123.4) | 240 (240, 400) | ***** (22.2%) | 8.3 (3.9) | 8 (5, 11) |
| Hydrocodone (after rescheduling) | 141 | 5.0 (2.6) | 5 (3, 6) | 31.6 (12.4) | 30 (24, 40) | 178.2 (87.0) | 150 (140, 210) | 17 (12.1%) | 9.5 (3.7) | 9 (7, 12) |
| Oxycodone | 512 | 5.1 (3.7) | 4 (3, 5) | 31.7 (13.2) | 30 (24, 40) | 245.5 (107.9) | 225 (180, 300) | 57 (11.1%) | 9.2 (4.7) | 7 (6, 11) |
| Morphine | ***** | 7.7 (5.5) | 5 (4, 14) | 40.0 (10.0) | 40 (30, 50) | 600.0 (150.0) | 600 (450, 750) | 0 (0.0%) | - | - |
| Other | ***** | 3.5 (1.0) | 3 (3, 4) | 32.5 (5.0) | 30 (30, 35) | 425.0 (327.9) | 375 (150, 700) | ***** (50.0%) | 7.5 (4.9) | 8 (4, 11) |
| Other Schedule | 986 | 5.3 (3.1) | 5 (3, 6) | 31.4 (13.0) | 30 (25, 35) | 179.5 (96.3) | 150 (135, 200) | 125 (12.7%) | 10.4 (5.1) | 10 (6, 13) |
| Tramadol | 71 | 7.1 (3.6) | 6 (5, 10) | 32.3 (12.5) | 30 (30, 40) | 156.4 (62.3) | 150 (113, 200) | ***** | 12.4 (4.9) | 13 (9, 15) |
| Codeine | ***** | 5.1 (2.2) | 5 (4, 7) | 28.6 (8.2) | 30 (25, 30) | 128.7 (37.0) | 135 (113, 135) | ***** (6.9%) | 8.0 (4.1) | 8 (5, 12) |
| Hydrocodone (before rescheduling) | 851 | 5.2 (3.1) | 5 (3, 6) | 31.5 (13.3) | 30 (25, 35) | 181.7 (92.1) | 150 (150, 200) | 112 (13.2%) | 10.3 (5.1) | 9 (6, 13) |
| Other | ***** | 5.0 (1.1) | 5 (4, 5) | 27.5 (7.6) | 28 (20, 30) | 632.5 (174.4) | 633 (460, 690) | 0 (0.0%) | - | - |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|-----------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|------------------|-----------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Bunionectomy | | | | | | | | | | |
| All ages | 43,163 | 5.6 (3.1) | 5 (4, 7) | 37.8 (15.2) | 30 (30, 40) | 280.9 (174.2) | 225 (150, 338) | 9,554 (22.1%) | 8.1 (5.0) | 7 (4, 11) |
| Schedule II | 20,184 | 5.6 (3.0) | 5 (4, 7) | 40.8 (16.3) | 40 (30, 50) | 337.0 (186.8) | 300 (225, 450) | 4,733 (23.4%) | 8.0 (4.9) | 7 (4, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 458 | 5.5 (3.8) | 5 (3, 6) | 42.6 (19.1) | 40 (30, 50) | 400.8 (238.9) | 320 (240, 480) | ***** | 8.4 (6.2) | 7 (4, 11) |
| Hydrocodone (after rescheduling) | 3,478 | 5.9 (3.1) | 5 (4, 7) | 39.4 (15.6) | 40 (30, 50) | 265.5 (160.1) | 225 (150, 300) | 580 (16.7%) | 8.9 (5.2) | 8 (5, 13) |
| Oxycodone | 15,313 | 5.5 (3.0) | 5 (4, 6) | 41.5 (16.3) | 40 (30, 50) | 350.7 (169.3) | 300 (225, 450) | 3,798 (24.8%) | 7.8 (4.8) | 7 (4, 11) |
| Morphine | 18 | 9.7 (5.5) | 10 (5, 15) | 39.2 (22.7) | 30 (21, 60) | 587.5 (339.8) | 450 (315, 900) | ***** | 7.7 (6.7) | 6 (2, 15) |
| Other | 917 | 5.3 (3.3) | 5 (3, 6) | 33.2 (14.0) | 30 (24, 40) | 342.1 (369.2) | 150 (125, 400) | 225 (24.5%) | 8.1 (4.9) | 7 (4, 11) |
| Other Schedule | 22,979 | 5.6 (3.1) | 5 (4, 7) | 35.1 (13.7) | 30 (30, 40) | 231.7 (145.6) | 200 (150, 300) | 4,821 (21.0%) | 8.2 (5.1) | 7 (4, 11) |
| Tramadol | 1,030 | 7.4 (4.9) | 6 (5, 10) | 36.2 (16.6) | 30 (30, 40) | 179.0 (88.4) | 150 (125, 200) | 167 (16.2%) | 8.7 (5.8) | 7 (4, 13) |
| Codeine | 2,020 | 4.9 (3.3) | 5 (3, 5) | 30.6 (13.1) | 30 (20, 30) | 141.9 (67.7) | 135 (90, 162) | 302 (15.0%) | 7.2 (4.8) | 6 (3, 10) |
| Hydrocodone (before rescheduling) | 19,521 | 5.5 (3.0) | 5 (4, 7) | 35.6 (13.5) | 30 (30, 40) | 233.7 (128.1) | 200 (150, 300) | 4,269 (21.9%) | 8.3 (5.1) | 7 (4, 12) |
| Other | 408 | 5.7 (3.1) | 5 (4, 7) | 31.6 (12.8) | 30 (24, 40) | 714.1 (293.4) | 690 (460, 920) | 83 (20.3%) | 7.0 (4.6) | 7 (3, 9) |
| 18-40 | 7,354 | 5.5 (3.0) | 5 (4, 7) | 38.0 (15.5) | 30 (30, 42) | 289.8 (178.3) | 225 (150, 350) | 2,260 (30.7%) | 7.2 (4.6) | 6 (4, 9) |
| Schedule II | 3,538 | 5.6 (3.0) | 5 (4, 7) | 41.2 (16.8) | 40 (30, 50) | 345.7 (189.9) | 300 (225, 450) | 1,153 (32.6%) | 7.2 (4.4) | 6 (4, 9) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 65 | 5.2 (2.8) | 5 (4, 6) | 44.5 (21.2) | 40 (30, 60) | 403.1 (266.8) | 320 (240, 480) | 32 (49.2%) | 7.4 (5.4) | 6 (4, 10) |
| Hydrocodone (after rescheduling) | 525 | 5.9 (3.2) | 5 (4, 7) | 39.7 (15.8) | 40 (30, 50) | 276.4 (163.4) | 225 (150, 300) | 124 (23.6%) | 8.6 (5.2) | 8 (5, 12) |
| Oxycodone | 2,793 | 5.5 (3.0) | 5 (4, 6) | 41.9 (17.0) | 40 (30, 50) | 357.3 (173.3) | 300 (225, 450) | 941 (33.7%) | 7.0 (4.3) | 6 (4, 9) |
| Morphine | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Other | ***** | 5.3 (3.0) | 5 (3, 6) | 32.2 (12.1) | 30 (25, 40) | 341.9 (374.3) | 150 (125, 400) | ***** (36.4%) | 7.1 (4.3) | 6 (4, 9) |
| Other Schedule | 3,816 | 5.4 (3.0) | 5 (4, 6) | 35.0 (13.5) | 30 (30, 40) | 238.0 (149.1) | 200 (150, 300) | 1,107 (29.0%) | 7.2 (4.9) | 6 (4, 9) |
| Tramadol | 107 | 7.8 (5.7) | 5 (4, 10) | 37.8 (17.8) | 30 (30, 50) | 186.4 (86.7) | 150 (125, 225) | 21 (19.6%) | 7.6 (5.6) | 4 (4, 11) |
| Codeine | 293 | 4.7 (2.8) | 5 (3, 5) | 29.0 (10.3) | 30 (20, 30) | 136.5 (60.4) | 135 (90, 135) | 59 (20.1%) | 5.8 (3.7) | 5 (3, 9) |
| Hydrocodone (before rescheduling) | 3,339 | 5.4 (2.9) | 5 (4, 7) | 35.6 (13.5) | 30 (30, 40) | 238.3 (134.0) | 200 (150, 300) | 1,008 (30.2%) | 7.3 (4.9) | 6 (4, 9) |
| Other | 77 | 5.2 (2.4) | 5 (4, 6) | 30.4 (10.3) | 30 (20, 40) | 686.6 (235.8) | 690 (460, 920) | 19 (24.7%) | 7.7 (5.8) | 7 (3, 13) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|-----------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Buniorrhaphy, continued | | | | | | | | | | |
| 41-64 | 22,535 | 5.5 (2.9) | 5 (4, 6) | 38.2 (14.9) | 35 (30, 45) | 289.6 (180.3) | 225 (150, 338) | 5,057 (22.4%) | 8.1 (5.0) | 7 (4, 11) |
| Schedule II | 11,029 | 5.5 (2.9) | 5 (4, 6) | 41.0 (15.9) | 40 (30, 50) | 341.5 (191.3) | 300 (225, 450) | 2,593 (23.5%) | 8.0 (5.0) | 7 (4, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.4 (3.4) | 5 (3, 6) | 43.6 (19.4) | 40 (30, 50) | 410.2 (250.6) | 320 (240, 480) | ***** (26.4%) | 9.1 (7.0) | 7 (4, 14) |
| Hydrocodone (after rescheduling) | 1,601 | 5.8 (3.2) | 5 (4, 7) | 40.4 (15.8) | 40 (30, 50) | 277.3 (172.3) | 225 (150, 300) | 281 (17.6%) | 8.7 (5.2) | 8 (5, 12) |
| Oxycodone | 8,552 | 5.4 (2.8) | 5 (4, 6) | 41.6 (15.7) | 40 (30, 50) | 350.1 (168.0) | 300 (225, 450) | 2,093 (24.5%) | 7.9 (4.8) | 7 (4, 11) |
| Morphine | 11 | 8.0 (5.1) | 8 (4, 10) | 27.8 (16.0) | 21 (20, 40) | 417.3 (239.3) | 315 (300, 600) | ***** | 7.7 (6.7) | 6 (2, 15) |
| Other | 592 | 5.2 (3.2) | 5 (3, 6) | 33.3 (13.8) | 30 (24, 40) | 357.8 (386.6) | 175 (125, 433) | 144 (24.3%) | 8.2 (5.0) | 7 (4, 12) |
| Other Schedule | 11,506 | 5.5 (3.0) | 5 (4, 7) | 35.5 (13.5) | 30 (30, 40) | 239.8 (153.5) | 200 (150, 300) | 2,464 (21.4%) | 8.2 (5.1) | 7 (4, 11) |
| Tramadol | 414 | 7.5 (5.0) | 6 (5, 10) | 36.3 (15.4) | 30 (30, 40) | 182.1 (87.9) | 150 (150, 200) | 82 (19.8%) | 8.4 (6.0) | 7 (3, 13) |
| Codeine | 903 | 4.7 (3.0) | 4 (3, 5) | 30.9 (13.1) | 30 (20, 30) | 143.8 (69.4) | 135 (90, 180) | 151 (16.7%) | 7.4 (5.0) | 6 (3, 11) |
| Hydrocodone (before rescheduling) | 9,925 | 5.5 (2.8) | 5 (4, 7) | 36.0 (13.3) | 30 (30, 40) | 238.2 (130.8) | 200 (150, 300) | 2,178 (21.9%) | 8.3 (5.1) | 7 (4, 12) |
| Other | 264 | 5.6 (2.8) | 5 (4, 7) | 31.9 (12.8) | 30 (25, 40) | 722.1 (292.4) | 690 (552, 920) | 53 (20.1%) | 6.5 (3.9) | 6 (3, 8) |
| 65+ | 13,274 | 5.7 (3.4) | 5 (4, 7) | 37.0 (15.4) | 30 (30, 40) | 261.3 (159.3) | 225 (150, 300) | 2,237 (16.9%) | 9.0 (5.2) | 8 (5, 13) |
| Schedule II | 5,617 | 5.8 (3.3) | 5 (4, 7) | 40.2 (16.7) | 40 (30, 50) | 322.6 (174.8) | 300 (225, 408) | 987 (17.6%) | 8.8 (5.1) | 8 (5, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.8 (4.9) | 5 (3, 7) | 39.4 (16.8) | 40 (30, 50) | 378.1 (191.3) | 320 (240, 480) | ***** (19.2%) | 7.7 (4.1) | 7 (5, 9) |
| Hydrocodone (after rescheduling) | 1,352 | 5.9 (3.0) | 5 (4, 7) | 38.2 (15.2) | 30 (30, 45) | 247.3 (141.2) | 200 (150, 300) | 175 (12.9%) | 9.4 (5.3) | 8 (5, 14) |
| Oxycodone | 3,968 | 5.8 (3.3) | 5 (4, 7) | 41.2 (17.0) | 40 (30, 50) | 347.3 (168.9) | 300 (225, 450) | 764 (19.3%) | 8.7 (5.0) | 8 (5, 12) |
| Morphine | ***** | 13.2 (5.3) | 15 (9, 15) | 54.0 (20.8) | 60 (30, 60) | 810.0 (311.8) | 900 (450, 900) | ***** | - | - |
| Other | ***** | 5.6 (4.2) | 5 (3, 6) | 33.8 (16.3) | 30 (24, 40) | 288.2 (291.5) | 150 (125, 300) | ***** (14.6%) | 9.8 (4.9) | 9 (6, 13) |
| Other Schedule | 7,657 | 5.7 (3.4) | 5 (4, 7) | 34.7 (14.0) | 30 (30, 40) | 216.4 (129.6) | 188 (150, 250) | 1,250 (16.3%) | 9.1 (5.2) | 8 (5, 13) |
| Tramadol | 509 | 7.3 (4.7) | 6 (5, 8) | 35.7 (17.4) | 30 (30, 40) | 175.0 (89.0) | 150 (125, 200) | 64 (12.6%) | 9.4 (5.6) | 8 (5, 13) |
| Codeine | 824 | 5.2 (3.8) | 5 (3, 5) | 30.9 (13.9) | 30 (20, 36) | 141.7 (68.3) | 135 (90, 171) | 92 (11.2%) | 7.7 (5.0) | 7 (4, 11) |
| Hydrocodone (before rescheduling) | 6,257 | 5.6 (3.2) | 5 (4, 7) | 35.1 (13.7) | 30 (30, 40) | 224.3 (119.9) | 200 (150, 300) | 1,083 (17.3%) | 9.2 (5.2) | 8 (5, 13) |
| Other | 67 | 6.4 (4.5) | 5 (4, 7) | 32.2 (15.5) | 30 (20, 40) | 714.5 (353.8) | 690 (460, 920) | 11 (16.4%) | 8.5 (5.5) | 8 (4, 14) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-------------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|------------------|-------------------------|-------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Coronary artery bypass graft | | | | | | | | | | |
| All ages | 33,289 | 7.2 (4.4) | 6 (5, 8) | 46.3 (20.3) | 40 (30, 60) | 306.4 (191.8) | 250 (200, 375) | 7,101 (21.3%) | 11.7 (5.6) | 11 (8, 15) |
| Schedule II | 14,723 | 7.1 (4.2) | 6 (5, 8) | 48.8 (21.9) | 45 (30, 60) | 363.0 (189.4) | 300 (225, 450) | 2,804 (19.0%) | 11.7 (5.3) | 11 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 677 | 7.0 (4.5) | 6 (5, 8) | 46.5 (20.7) | 40 (30, 60) | 384.8 (178.1) | 360 (240, 480) | ***** | 12.1 (5.9) | 11 (8, 16) |
| Hydrocodone (after rescheduling) | 2,191 | 7.9 (4.3) | 7 (5, 10) | 51.1 (22.6) | 50 (30, 60) | 294.5 (165.5) | 250 (200, 350) | 370 (16.9%) | 13.1 (5.7) | 12 (9, 17) |
| Oxycodone | 11,830 | 6.9 (4.2) | 6 (5, 8) | 48.5 (21.8) | 45 (30, 60) | 373.9 (190.6) | 338 (225, 450) | 2,292 (19.4%) | 11.4 (5.2) | 11 (8, 15) |
| Morphine | 14 | 10.1 (4.6) | 10 (5, 15) | 39.4 (12.6) | 35 (30, 50) | 590.4 (188.6) | 525 (450, 750) | ***** | 6.0 (4.6) | 5 (2, 11) |
| Other | 11 | 6.2 (3.1) | 6 (3, 10) | 40.0 (14.1) | 40 (30, 50) | 550.0 (585.2) | 200 (200, 800) | ***** | 10.3 (4.2) | 9 (7, 15) |
| Other Schedule | 18,566 | 7.2 (4.5) | 6 (5, 8) | 44.3 (18.7) | 40 (30, 50) | 261.6 (181.5) | 225 (150, 300) | 4,297 (23.1%) | 11.8 (5.8) | 11 (8, 15) |
| Tramadol | 3,370 | 9.5 (5.7) | 8 (6, 11) | 45.3 (20.1) | 40 (30, 50) | 222.5 (101.3) | 200 (150, 250) | 615 (18.2%) | 12.5 (6.9) | 12 (8, 17) |
| Codeine | 1,189 | 6.5 (4.1) | 5 (4, 8) | 42.6 (19.0) | 40 (30, 50) | 193.7 (91.8) | 180 (135, 225) | 198 (16.7%) | 11.1 (6.3) | 10 (6, 15) |
| Hydrocodone (before rescheduling) | 13,487 | 6.7 (4.0) | 5 (5, 8) | 44.3 (18.4) | 40 (30, 50) | 250.0 (128.7) | 225 (150, 300) | 3,348 (24.8%) | 11.7 (5.5) | 11 (8, 15) |
| Other | 520 | 7.7 (4.2) | 7 (5, 10) | 42.3 (15.7) | 40 (30, 50) | 971.5 (364.4) | 920 (690, 1,150) | 136 (26.2%) | 11.4 (5.1) | 11 (8, 15) |
| 18-40 | 287 | 7.1 (4.6) | 6 (5, 8) | 48.4 (20.0) | 48 (30, 60) | 346.6 (208.1) | 300 (225, 450) | 122 (42.5%) | 10.9 (5.6) | 10 (7, 14) |
| Schedule II | 148 | 7.2 (4.4) | 6 (5, 8) | 51.0 (20.6) | 50 (30, 60) | 416.9 (228.9) | 375 (300, 450) | 58 (39.2%) | 11.0 (5.7) | 10 (7, 14) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 10.8 (8.8) | 6 (5, 15) | 63.8 (29.3) | 60 (40, 90) | 529.2 (220.4) | 480 (400, 720) | ***** (46.2%) | 13.7 (10.8) | 11 (5, 17) |
| Hydrocodone (after rescheduling) | ***** | 7.5 (3.0) | 8 (5, 8) | 44.5 (13.6) | 45 (30, 58) | 238.1 (86.9) | 240 (150, 300) | ***** (25.0%) | 14.0 (2.8) | 14 (12, 16) |
| Oxycodone | 125 | 6.8 (3.7) | 6 (5, 8) | 50.0 (19.7) | 50 (30, 60) | 400.1 (176.7) | 375 (300, 450) | 50 (40.0%) | 10.6 (5.0) | 10 (8, 14) |
| Morphine | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0%) | - | - |
| Other | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0%) | - | - |
| Other Schedule | 139 | 7.0 (4.9) | 5 (4, 8) | 45.6 (19.1) | 40 (30, 50) | 271.9 (151.7) | 250 (175, 300) | 64 (46.0%) | 10.8 (5.5) | 11 (7, 14) |
| Tramadol | 15 | 10.1 (6.0) | 10 (7, 10) | 53.7 (29.1) | 50 (40, 60) | 258.3 (124.5) | 250 (200, 300) | ***** | 8.3 (4.7) | 10 (3, 12) |
| Codeine | ***** | 7.0 (6.4) | 5 (3, 8) | 42.3 (22.0) | 30 (30, 50) | 190.4 (99.2) | 135 (135, 225) | ***** (30.8%) | 14.8 (15.0) | 11 (4, 26) |
| Hydrocodone (before rescheduling) | 108 | 6.5 (4.4) | 5 (4, 7) | 45.0 (17.1) | 40 (30, 50) | 265.6 (117.8) | 250 (200, 300) | 57 (52.8%) | 10.7 (4.5) | 11 (7, 13) |
| Other | ***** | 8.0 (2.6) | 9 (5, 10) | 40.0 (0.0) | 40 (40, 40) | 920.0 (0.0) | 920 (920, 920) | ***** | ***** | ***** |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Coronary artery bypass graft, continued | | | | | | | | | | |
| 41-64 | 10,634 | 7.0 (4.2) | 6 (5, 8) | 47.8 (20.2) | 45 (30, 60) | 335.1 (212.8) | 300 (200, 375) | 3,086 (29.0%) | 11.4 (5.4) | 10 (7, 15) |
| Schedule II | 5,075 | 7.1 (4.2) | 6 (5, 8) | 50.2 (21.5) | 50 (40, 60) | 383.6 (204.3) | 360 (250, 450) | 1,326 (26.1%) | 11.5 (5.3) | 11 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 254 | 7.1 (4.9) | 6 (4, 8) | 49.6 (22.7) | 45 (30, 60) | 417.8 (197.9) | 400 (288, 480) | ***** | 11.6 (5.5) | 10 (8, 16) |
| Hydrocodone (after rescheduling) | ***** | 8.2 (4.6) | 7 (5, 10) | 52.5 (21.8) | 50 (40, 60) | 313.3 (171.9) | 300 (200, 400) | ***** (21.7%) | 12.7 (5.8) | 12 (8, 16) |
| Oxycodone | 4,240 | 6.9 (4.1) | 6 (5, 8) | 50.0 (21.4) | 50 (40, 60) | 390.6 (206.6) | 375 (300, 450) | 1,132 (26.7%) | 11.4 (5.2) | 11 (7, 15) |
| Morphine | ***** | 9.6 (4.8) | 7 (5, 15) | 37.8 (10.9) | 30 (30, 40) | 566.7 (163.9) | 450 (450, 600) | ***** (22.2%) | 8.0 (4.2) | 8 (5, 11) |
| Other | ***** | 5.8 (3.3) | 6 (4, 8) | 42.5 (12.6) | 40 (35, 50) | 362.5 (298.3) | 250 (175, 550) | ***** (50.0%) | 8.0 (1.4) | 8 (7, 9) |
| Other Schedule | 5,559 | 7.0 (4.1) | 6 (5, 8) | 45.7 (18.7) | 40 (30, 50) | 290.8 (210.7) | 250 (175, 300) | 1,760 (31.7%) | 11.3 (5.5) | 10 (7, 15) |
| Tramadol | 720 | 9.4 (5.5) | 8 (6, 10) | 45.5 (21.5) | 40 (30, 50) | 223.6 (107.9) | 200 (150, 250) | ***** | 12.4 (7.0) | 12 (7, 17) |
| Codeine | ***** | 6.4 (4.2) | 5 (4, 8) | 44.6 (19.2) | 40 (30, 60) | 201.8 (88.7) | 180 (135, 270) | ***** (20.0%) | 10.2 (5.7) | 9 (6, 14) |
| Hydrocodone (before rescheduling) | 4,216 | 6.7 (3.7) | 5 (5, 8) | 46.1 (18.4) | 40 (30, 50) | 266.5 (131.7) | 250 (200, 300) | 1,423 (33.8%) | 11.2 (5.3) | 10 (7, 15) |
| Other | ***** | 7.2 (3.7) | 7 (5, 9) | 41.6 (15.1) | 40 (30, 45) | 956.6 (348.1) | 920 (690, 1,035) | ***** (34.8%) | 10.7 (4.5) | 10 (7, 13) |
| 65+ | 22,368 | 7.2 (4.5) | 6 (5, 8) | 45.5 (20.2) | 40 (30, 50) | 292.3 (179.0) | 250 (200, 375) | 3,893 (17.4%) | 12.0 (5.8) | 11 (8, 16) |
| Schedule II | 9,500 | 7.1 (4.3) | 6 (5, 8) | 48.0 (22.0) | 45 (30, 60) | 351.1 (179.2) | 300 (225, 450) | 1,420 (14.9%) | 11.8 (5.3) | 11 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 6.8 (3.9) | 6 (5, 8) | 44.1 (18.5) | 40 (30, 60) | 359.7 (157.5) | 320 (240, 480) | ***** (15.4%) | 12.5 (5.8) | 12 (8, 17) |
| Hydrocodone (after rescheduling) | 1,615 | 7.7 (4.3) | 7 (5, 10) | 50.6 (23.0) | 50 (30, 60) | 288.2 (163.0) | 250 (200, 300) | 245 (15.2%) | 13.3 (5.7) | 12 (9, 17) |
| Oxycodone | 7,465 | 6.9 (4.3) | 6 (5, 8) | 47.6 (22.0) | 40 (30, 60) | 364.0 (180.4) | 338 (225, 450) | 1,110 (14.9%) | 11.5 (5.2) | 11 (8, 15) |
| Morphine | ***** | 11.5 (5.2) | 12 (8, 16) | 37.8 (14.6) | 40 (26, 50) | 566.3 (219.2) | 600 (383, 750) | ***** (25.0%) | ***** | ***** |
| Other | ***** | 6.2 (3.4) | 6 (3, 10) | 36.7 (16.3) | 40 (30, 40) | 433.3 (408.2) | 200 (200, 600) | ***** (16.7%) | ***** | ***** |
| Other Schedule | 12,868 | 7.3 (4.6) | 6 (5, 8) | 43.7 (18.6) | 40 (30, 50) | 248.9 (166.0) | 200 (150, 300) | 2,473 (19.2%) | 12.2 (6.0) | 11 (8, 16) |
| Tramadol | 2,635 | 9.5 (5.8) | 8 (6, 11) | 45.1 (19.6) | 40 (30, 50) | 222.0 (99.2) | 200 (150, 250) | 440 (16.7%) | 12.6 (6.9) | 12 (8, 17) |
| Codeine | 826 | 6.5 (4.0) | 5 (4, 8) | 41.8 (18.8) | 40 (30, 50) | 190.4 (92.9) | 180 (135, 225) | 124 (15.0%) | 11.5 (6.3) | 11 (7, 15) |
| Hydrocodone (before rescheduling) | 9,163 | 6.8 (4.1) | 5 (5, 8) | 43.5 (18.3) | 40 (30, 50) | 242.2 (126.6) | 200 (150, 300) | 1,868 (20.4%) | 12.1 (5.7) | 11 (8, 16) |
| Other | 244 | 8.3 (4.7) | 7 (5, 10) | 43.2 (16.5) | 40 (30, 50) | 988.8 (383.9) | 920 (690, 1,150) | 41 (16.8%) | 13.2 (5.9) | 13 (9, 17) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|-----------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|------------------|------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Cesarean section | | | | | | | | | | |
| All ages | 248,281 | 4.7 (2.6) | 5 (3, 5) | 32.5 (9.6) | 30 (30, 40) | 234.5 (103.4) | 225 (150, 300) | 29,512 (11.9%) | 8.0 (4.1) | 7 (5, 10) |
| Schedule II | 165,712 | 4.7 (2.6) | 4 (3, 5) | 32.8 (9.7) | 30 (30, 40) | 247.9 (86.5) | 225 (225, 300) | 17,578 (10.6%) | 7.9 (4.0) | 7 (5, 10) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 2,990 | 4.7 (2.7) | 4 (3, 5) | 32.5 (11.1) | 30 (30, 40) | 277.9 (119.9) | 240 (240, 320) | 355 (11.9%) | 7.6 (4.1) | 6 (5, 10) |
| Hydrocodone (after rescheduling) | 11,162 | 5.2 (2.7) | 5 (3, 6) | 34.5 (10.1) | 30 (30, 40) | 206.9 (95.3) | 200 (150, 225) | 997 (8.9%) | 9.1 (4.5) | 8 (6, 12) |
| Oxycodone | 150,885 | 4.6 (2.6) | 4 (3, 5) | 32.6 (9.7) | 30 (30, 40) | 250.3 (83.0) | 225 (225, 300) | 16,165 (10.7%) | 7.8 (4.0) | 7 (5, 10) |
| Morphine | 181 | 6.0 (3.6) | 5 (5, 7) | 33.1 (8.7) | 30 (30, 40) | 507.8 (146.2) | 450 (450, 600) | 13 (7.2%) | 7.5 (4.7) | 6 (5, 7) |
| Other | 494 | 5.2 (2.9) | 5 (3, 6) | 31.7 (11.3) | 30 (25, 36) | 191.1 (182.8) | 150 (140, 200) | 48 (9.7%) | 8.2 (4.8) | 6 (5, 10) |
| Other Schedule | 82,569 | 4.9 (2.6) | 5 (3, 5) | 32.0 (9.3) | 30 (30, 30) | 207.7 (126.6) | 150 (150, 225) | 11,934 (14.5%) | 8.3 (4.3) | 7 (5, 11) |
| Tramadol | 1,454 | 6.5 (3.9) | 5 (5, 7) | 34.2 (13.3) | 30 (30, 40) | 170.9 (72.6) | 150 (150, 200) | 198 (13.6%) | 7.9 (4.2) | 7 (5, 10) |
| Codeine | 8,046 | 4.6 (2.6) | 4 (3, 5) | 30.8 (9.9) | 30 (30, 30) | 140.4 (50.4) | 135 (135, 135) | 834 (10.4%) | 7.4 (4.2) | 6 (5, 10) |
| Hydrocodone (before rescheduling) | 70,853 | 4.9 (2.5) | 5 (3, 5) | 32.1 (9.2) | 30 (30, 30) | 200.6 (92.2) | 150 (150, 225) | 10,614 (15.0%) | 8.3 (4.3) | 7 (5, 11) |
| Other | 2,216 | 5.3 (2.8) | 5 (4, 6) | 30.9 (9.5) | 30 (30, 30) | 701.6 (224.6) | 690 (575, 690) | 288 (13.0%) | 7.8 (4.2) | 7 (5, 10) |
| 18-40 | 239,047 | 4.7 (2.6) | 5 (3, 5) | 32.5 (9.6) | 30 (30, 40) | 234.5 (103.4) | 225 (150, 300) | 28,371 (11.9%) | 8.0 (4.1) | 7 (5, 10) |
| Schedule II | 159,619 | 4.7 (2.6) | 4 (3, 5) | 32.8 (9.7) | 30 (30, 40) | 247.9 (86.6) | 225 (225, 300) | 16,883 (10.6%) | 7.9 (4.0) | 7 (5, 10) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 2,843 | 4.7 (2.8) | 4 (3, 5) | 32.5 (11.0) | 30 (30, 40) | 278.4 (120.6) | 240 (240, 320) | ***** | 7.6 (4.0) | 6 (5, 10) |
| Hydrocodone (after rescheduling) | 10,741 | 5.2 (2.7) | 5 (3, 6) | 34.5 (10.2) | 30 (30, 40) | 207.0 (95.6) | 200 (150, 225) | 957 (8.9%) | 9.1 (4.5) | 8 (6, 12) |
| Oxycodone | 145,382 | 4.6 (2.6) | 4 (3, 5) | 32.6 (9.7) | 30 (30, 40) | 250.2 (83.1) | 225 (225, 300) | 15,532 (10.7%) | 7.8 (4.0) | 7 (5, 10) |
| Morphine | ***** | 6.0 (3.6) | 5 (5, 7) | 33.1 (8.8) | 30 (30, 40) | 507.7 (147.7) | 450 (450, 600) | ***** (7.4%) | 7.5 (4.7) | 6 (5, 7) |
| Other | ***** | 5.2 (2.9) | 5 (3, 6) | 31.6 (11.4) | 30 (25, 35) | 188.0 (179.0) | 150 (140, 200) | ***** (9.4%) | 8.1 (4.6) | 6 (5, 9) |
| Other Schedule | 79,428 | 4.9 (2.6) | 5 (3, 5) | 31.9 (9.4) | 30 (30, 30) | 207.4 (126.4) | 150 (150, 225) | 11,488 (14.5%) | 8.2 (4.3) | 7 (5, 11) |
| Tramadol | 1,378 | 6.6 (3.9) | 5 (5, 7) | 34.2 (13.4) | 30 (30, 40) | 170.8 (73.3) | 150 (150, 200) | 184 (13.4%) | 7.9 (4.3) | 7 (5, 10) |
| Codeine | 7,706 | 4.6 (2.6) | 4 (3, 5) | 30.8 (9.9) | 30 (30, 30) | 140.4 (50.6) | 135 (135, 135) | 801 (10.4%) | 7.4 (4.2) | 6 (5, 10) |
| Hydrocodone (before rescheduling) | 68,221 | 4.9 (2.5) | 5 (3, 5) | 32.1 (9.2) | 30 (30, 30) | 200.3 (92.0) | 150 (150, 225) | 10,230 (15.0%) | 8.3 (4.3) | 7 (5, 11) |
| Other | 2,123 | 5.3 (2.8) | 5 (4, 6) | 30.9 (9.5) | 30 (30, 30) | 701.3 (225.7) | 690 (575, 690) | 273 (12.9%) | 7.9 (4.3) | 7 (5, 10) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|------------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Cesarean section, continued | | | | | | | | | | |
| 41-64 | 9,234 | 4.8 (2.7) | 5 (3, 5) | 32.8 (9.4) | 30 (30, 40) | 237.0 (103.4) | 225 (150, 300) | 1,141 (12.4%) | 8.1 (4.1) | 7 (5, 11) |
| Schedule II | 6,093 | 4.7 (2.7) | 4 (3, 5) | 32.9 (9.7) | 30 (30, 40) | 248.4 (83.2) | 225 (225, 300) | 695 (11.4%) | 7.9 (4.0) | 7 (5, 10) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 147 | 4.4 (1.8) | 4 (3, 5) | 31.4 (11.1) | 30 (25, 40) | 269.7 (106.7) | 240 (240, 320) | ***** | 6.9 (4.6) | 6 (4, 7) |
| Hydrocodone (after rescheduling) | 421 | 5.4 (3.0) | 5 (4, 6) | 35.0 (9.8) | 30 (30, 40) | 205.8 (85.0) | 200 (150, 225) | 40 (9.5%) | 8.9 (4.1) | 8 (7, 11) |
| Oxycodone | 5,503 | 4.7 (2.7) | 4 (3, 5) | 32.8 (9.6) | 30 (30, 40) | 250.7 (79.9) | 225 (225, 300) | 633 (11.5%) | 7.9 (4.0) | 7 (5, 10) |
| Morphine | ***** | 5.2 (0.4) | 5 (5, 5) | 34.0 (5.5) | 30 (30, 40) | 510.0 (82.2) | 450 (450, 600) | ***** | ***** | ***** |
| Other | ***** | 4.9 (3.3) | 4 (3, 5) | 34.4 (7.5) | 30 (30, 40) | 277.9 (260.7) | 150 (150, 200) | ***** (17.6%) | 10.7 (7.6) | 9 (4, 19) |
| Other Schedule | 3,141 | 5.1 (2.5) | 5 (4, 5) | 32.4 (9.0) | 30 (30, 30) | 214.8 (131.3) | 150 (150, 263) | 446 (14.2%) | 8.5 (4.3) | 7 (5, 11) |
| Tramadol | 76 | 6.4 (2.8) | 5 (5, 7) | 34.7 (11.7) | 30 (30, 40) | 173.2 (58.9) | 150 (150, 200) | 14 (18.4%) | 7.6 (2.3) | 8 (6, 9) |
| Codeine | 340 | 4.7 (2.7) | 4 (3, 5) | 31.3 (9.3) | 30 (30, 30) | 141.5 (46.2) | 135 (135, 135) | 33 (9.7%) | 8.1 (4.4) | 6 (5, 12) |
| Hydrocodone (before rescheduling) | 2,632 | 5.1 (2.5) | 5 (4, 5) | 32.6 (8.9) | 30 (30, 30) | 208.1 (97.3) | 150 (150, 300) | 384 (14.6%) | 8.6 (4.4) | 8 (5, 12) |
| Other | 93 | 5.3 (3.2) | 5 (4, 6) | 30.8 (8.6) | 30 (30, 30) | 707.3 (198.6) | 690 (690, 690) | 15 (16.1%) | 6.7 (2.8) | 7 (4, 8) |
| 65+ | 0 | - | - | - | - | - | - | - | - | - |
| Schedule II | 0 | - | - | - | - | - | - | - | - | - |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydrocodone (after rescheduling) | 0 | - | - | - | - | - | - | - | - | - |
| Oxycodone | 0 | - | - | - | - | - | - | - | - | - |
| Morphine | 0 | - | - | - | - | - | - | - | - | - |
| Other | 0 | - | - | - | - | - | - | - | - | - |
| Other Schedule | 0 | - | - | - | - | - | - | - | - | - |
| Tramadol | 0 | - | - | - | - | - | - | - | - | - |
| Codeine | 0 | - | - | - | - | - | - | - | - | - |
| Hydrocodone (before rescheduling) | 0 | - | - | - | - | - | - | - | - | - |
| Other | 0 | - | - | - | - | - | - | - | - | - |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|---------------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|-----------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Cholecystectomy (laparoscopic) | | | | | | | | | | |
| All ages | 149,026 | 4.7 (2.7) | 4 (3, 5) | 31.6 (10.8) | 30 (30, 40) | 210.3 (112.9) | 200 (150, 225) | 10,691 (7.2%) | 8.4 (5.0) | 7 (5, 11) |
| Schedule II | 63,618 | 4.7 (2.7) | 4 (3, 5) | 32.6 (11.4) | 30 (30, 40) | 243.9 (119.2) | 225 (180, 300) | 3,701 (5.8%) | 8.3 (5.1) | 7 (4, 11) |
| Oxymorphone | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Hydromorphone | 1,602 | 4.9 (3.1) | 5 (3, 5) | 32.2 (13.2) | 30 (25, 40) | 277.1 (154.3) | 240 (200, 320) | 142 (8.9%) | 8.1 (5.4) | 7 (3, 12) |
| Hydrocodone (after rescheduling) | 13,496 | 4.9 (2.7) | 5 (3, 5) | 32.4 (11.3) | 30 (30, 40) | 190.8 (89.7) | 150 (150, 225) | 684 (5.1%) | 9.0 (5.2) | 8 (5, 12) |
| Oxycodone | 48,027 | 4.6 (2.7) | 4 (3, 5) | 32.7 (11.3) | 30 (30, 40) | 256.7 (118.0) | 225 (225, 300) | 2,833 (5.9%) | 8.2 (5.0) | 7 (4, 11) |
| Morphine | ***** | 6.7 (4.7) | 5 (4, 8) | 28.3 (11.1) | 30 (20, 30) | 454.7 (214.2) | 450 (300, 450) | ***** (10.4%) | 8.0 (5.1) | 8 (6, 8) |
| Other | 444 | 5.0 (2.8) | 5 (3, 5) | 29.0 (9.5) | 30 (20, 30) | 325.3 (277.2) | 150 (125, 600) | 37 (8.3%) | 7.4 (4.9) | 6 (3, 11) |
| Other Schedule | 85,408 | 4.8 (2.7) | 4 (3, 5) | 30.8 (10.3) | 30 (25, 31) | 185.2 (100.9) | 150 (150, 205) | 6,990 (8.2%) | 8.4 (5.0) | 7 (5, 12) |
| Tramadol | 4,176 | 6.4 (4.0) | 5 (4, 7) | 30.8 (13.5) | 30 (20, 30) | 151.0 (68.9) | 150 (100, 150) | 358 (8.6%) | 9.3 (6.0) | 8 (4, 13) |
| Codeine | 4,008 | 4.7 (2.8) | 4 (3, 5) | 29.9 (10.6) | 30 (24, 30) | 137.4 (54.0) | 135 (95, 135) | 294 (7.3%) | 7.7 (5.7) | 7 (3, 11) |
| Hydrocodone (before rescheduling) | 75,891 | 4.7 (2.6) | 4 (3, 5) | 30.9 (10.1) | 30 (25, 35) | 181.4 (79.5) | 150 (150, 225) | 6,239 (8.2%) | 8.4 (4.9) | 7 (5, 11) |
| Other | 1,333 | 5.1 (2.7) | 5 (4, 5) | 28.6 (8.6) | 30 (20, 30) | 652.4 (198.8) | 690 (460, 690) | 99 (7.4%) | 8.0 (5.0) | 7 (4, 11) |
| <u>18-40</u> | 39,432 | 4.6 (2.6) | 4 (3, 5) | 32.2 (10.3) | 30 (30, 40) | 218.2 (109.7) | 200 (150, 250) | 3,584 (9.1%) | 7.3 (4.5) | 6 (4, 9) |
| Schedule II | 17,284 | 4.6 (2.6) | 4 (3, 5) | 33.3 (11.0) | 30 (30, 40) | 251.3 (108.8) | 225 (200, 300) | 1,229 (7.1%) | 7.3 (4.6) | 6 (4, 10) |
| Oxymorphone | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Hydromorphone | 371 | 5.1 (3.6) | 5 (3, 6) | 34.2 (13.2) | 30 (30, 40) | 299.7 (169.3) | 240 (240, 320) | 38 (10.2%) | 7.8 (5.9) | 5 (3, 12) |
| Hydrocodone (after rescheduling) | 3,182 | 4.9 (2.6) | 5 (3, 5) | 33.1 (11.0) | 30 (30, 40) | 197.1 (91.9) | 150 (150, 225) | 193 (6.1%) | 7.9 (4.8) | 7 (4, 11) |
| Oxycodone | 13,603 | 4.6 (2.6) | 4 (3, 5) | 33.4 (10.9) | 30 (30, 40) | 261.4 (101.8) | 225 (225, 300) | 983 (7.2%) | 7.2 (4.5) | 6 (4, 9) |
| Morphine | ***** | 6.3 (3.2) | 5 (4, 10) | 23.3 (5.8) | 20 (20, 30) | 350.0 (86.6) | 300 (300, 450) | 0 (0.0%) | - | - |
| Other | ***** | 5.0 (3.0) | 5 (3, 6) | 30.4 (10.2) | 30 (20, 36) | 379.8 (316.5) | 200 (150, 600) | ***** (12.1%) | 5.4 (3.7) | 5 (2, 7) |
| Other Schedule | 22,148 | 4.6 (2.5) | 4 (3, 5) | 31.4 (9.6) | 30 (30, 36) | 192.4 (103.4) | 150 (150, 225) | 2,355 (10.6%) | 7.3 (4.4) | 6 (4, 9) |
| Tramadol | 697 | 6.1 (3.7) | 5 (4, 7) | 31.4 (12.9) | 30 (25, 30) | 153.9 (65.8) | 150 (113, 150) | 81 (11.6%) | 6.6 (4.2) | 6 (4, 9) |
| Codeine | 932 | 4.5 (2.7) | 4 (3, 5) | 30.1 (9.5) | 30 (25, 30) | 138.9 (49.9) | 135 (113, 135) | 81 (8.7%) | 6.3 (4.7) | 5 (2, 9) |
| Hydrocodone (before rescheduling) | 20,093 | 4.6 (2.5) | 4 (3, 5) | 31.5 (9.5) | 30 (30, 40) | 186.6 (78.1) | 150 (150, 225) | 2,161 (10.8%) | 7.4 (4.4) | 6 (4, 9) |
| Other | 426 | 4.9 (2.3) | 5 (3, 5) | 28.4 (8.3) | 30 (20, 30) | 648.0 (194.2) | 690 (460, 690) | 32 (7.5%) | 7.1 (5.0) | 5 (3, 11) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Cholecystectomy (laparoscopic), continued | | | | | | | | | | |
| 41-64 | 60,139 | 4.7 (2.6) | 4 (3, 5) | 32.1 (10.7) | 30 (30, 40) | 218.2 (124.1) | 200 (150, 250) | 4,406 (7.3%) | 8.4 (5.0) | 7 (5, 12) |
| Schedule II | 26,567 | 4.7 (2.7) | 4 (3, 5) | 33.2 (11.4) | 30 (30, 40) | 251.0 (134.7) | 225 (188, 300) | 1,581 (6.0%) | 8.3 (5.1) | 7 (4, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 772 | 4.7 (3.0) | 4 (3, 5) | 32.2 (13.4) | 30 (25, 40) | 278.8 (158.2) | 240 (200, 320) | ***** | 7.8 (5.4) | 6 (3, 12) |
| Hydrocodone (after rescheduling) | 4,859 | 4.9 (2.7) | 5 (3, 5) | 32.8 (10.9) | 30 (30, 40) | 194.0 (89.0) | 150 (150, 225) | 255 (5.2%) | 8.6 (5.1) | 7 (5, 12) |
| Oxycodone | 20,675 | 4.6 (2.7) | 4 (3, 5) | 33.3 (11.5) | 30 (30, 40) | 262.2 (136.2) | 225 (225, 300) | 1,235 (6.0%) | 8.2 (5.1) | 7 (4, 11) |
| Morphine | 13 | 5.2 (2.4) | 5 (4, 5) | 33.5 (13.4) | 30 (30, 30) | 565.4 (230.4) | 450 (450, 750) | ***** | 12.0 (5.7) | 12 (8, 16) |
| Other | 248 | 5.0 (3.0) | 5 (3, 5) | 29.4 (9.6) | 30 (22, 30) | 330.9 (269.8) | 180 (150, 600) | ***** | 9.0 (5.2) | 7 (6, 14) |
| Other Schedule | 33,572 | 4.7 (2.6) | 4 (3, 5) | 31.3 (10.0) | 30 (30, 35) | 192.2 (108.2) | 150 (150, 225) | 2,825 (8.4%) | 8.5 (5.0) | 7 (5, 12) |
| Tramadol | 1,326 | 6.3 (3.9) | 5 (4, 7) | 31.7 (14.0) | 30 (25, 40) | 155.1 (72.0) | 150 (113, 150) | 115 (8.7%) | 9.0 (5.9) | 8 (4, 13) |
| Codeine | 1,464 | 4.6 (2.4) | 4 (3, 5) | 30.3 (10.1) | 30 (25, 30) | 139.6 (52.4) | 135 (113, 135) | 127 (8.7%) | 7.4 (4.9) | 7 (3, 10) |
| Hydrocodone (before rescheduling) | 30,073 | 4.6 (2.5) | 4 (3, 5) | 31.4 (9.8) | 30 (30, 35) | 185.5 (80.5) | 150 (150, 225) | 2,527 (8.4%) | 8.5 (4.9) | 7 (5, 12) |
| Other | 709 | 5.1 (3.0) | 5 (3, 5) | 28.8 (8.8) | 30 (20, 30) | 654.6 (200.7) | 690 (460, 690) | 56 (7.9%) | 8.0 (5.0) | 7 (4, 11) |
| 65+ | 49,455 | 4.9 (2.9) | 5 (3, 5) | 30.5 (11.2) | 30 (24, 30) | 194.3 (98.5) | 150 (150, 225) | 2,701 (5.5%) | 9.7 (5.4) | 9 (6, 13) |
| Schedule II | 19,767 | 4.8 (2.8) | 5 (3, 5) | 31.3 (11.6) | 30 (25, 40) | 227.8 (103.2) | 225 (150, 278) | 891 (4.5%) | 9.7 (5.5) | 9 (6, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 459 | 4.9 (3.0) | 5 (3, 5) | 30.6 (12.7) | 30 (20, 40) | 256.0 (130.5) | 240 (160, 320) | ***** | 9.1 (4.9) | 8 (6, 13) |
| Hydrocodone (after rescheduling) | 5,455 | 5.0 (2.9) | 5 (3, 5) | 31.5 (11.8) | 30 (25, 40) | 184.2 (88.7) | 150 (150, 225) | 236 (4.3%) | 10.2 (5.5) | 9 (7, 13) |
| Oxycodone | 13,749 | 4.8 (2.8) | 4 (3, 5) | 31.2 (11.4) | 30 (25, 40) | 243.7 (101.2) | 225 (188, 300) | 615 (4.5%) | 9.6 (5.5) | 9 (6, 13) |
| Morphine | ***** | 7.4 (5.4) | 6 (5, 9) | 26.7 (9.9) | 30 (20, 30) | 419.5 (202.6) | 450 (300, 450) | ***** (9.4%) | 5.3 (3.1) | 6 (2, 8) |
| Other | ***** | 4.9 (1.4) | 5 (5, 5) | 25.5 (6.6) | 30 (20, 30) | 212.2 (185.8) | 150 (100, 150) | ***** (1.4%) | ***** | ***** |
| Other Schedule | 29,688 | 5.0 (3.0) | 5 (3, 5) | 29.9 (10.9) | 30 (24, 30) | 172.0 (88.4) | 150 (125, 200) | 1,810 (6.1%) | 9.7 (5.4) | 9 (6, 13) |
| Tramadol | 2,153 | 6.6 (4.2) | 5 (4, 8) | 30.2 (13.4) | 30 (20, 30) | 147.6 (67.7) | 150 (100, 150) | 162 (7.5%) | 10.9 (6.3) | 10 (6, 15) |
| Codeine | 1,612 | 5.0 (3.2) | 5 (3, 5) | 29.3 (11.5) | 30 (20, 30) | 134.5 (57.6) | 135 (90, 135) | 86 (5.3%) | 9.4 (7.1) | 8 (5, 13) |
| Hydrocodone (before rescheduling) | 25,725 | 4.8 (2.8) | 5 (3, 5) | 29.9 (10.7) | 30 (24, 30) | 172.7 (78.7) | 150 (140, 200) | 1,551 (6.0%) | 9.6 (5.2) | 9 (6, 13) |
| Other | 198 | 5.3 (2.2) | 5 (4, 6) | 28.7 (8.7) | 30 (20, 30) | 653.8 (202.2) | 690 (460, 690) | 11 (5.6%) | 10.8 (4.2) | 10 (8, 13) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--------------------------------------|--------------------|------------------|-----------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|------------------|------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Cholecystectomy (nonspecific) | | | | | | | | | | |
| All ages | 4,873 | 5.4 (3.3) | 5 (3, 6) | 33.7 (15.4) | 30 (25, 40) | 232.3 (143.7) | 210 (150, 300) | 840 (17.2%) | 9.8 (5.0) | 9 (6, 13) |
| Schedule II | 2,354 | 5.3 (3.3) | 5 (3, 6) | 35.4 (16.8) | 30 (30, 40) | 275.9 (160.5) | 225 (188, 300) | 382 (16.2%) | 9.7 (4.8) | 9 (6, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 151 | 5.5 (3.9) | 5 (3, 7) | 36.4 (16.4) | 30 (30, 40) | 326.3 (208.8) | 240 (240, 360) | 31 (20.5%) | 10.1 (5.5) | 10 (6, 15) |
| Hydrocodone (after rescheduling) | 332 | 5.5 (2.9) | 5 (4, 6) | 33.9 (15.5) | 30 (29, 40) | 204.0 (106.1) | 150 (150, 250) | 41 (12.3%) | 9.5 (4.7) | 8 (7, 12) |
| Oxycodone | 1,859 | 5.3 (3.4) | 5 (3, 6) | 35.7 (17.1) | 30 (30, 40) | 284.4 (159.5) | 225 (225, 300) | 310 (16.7%) | 9.7 (4.8) | 9 (6, 13) |
| Morphine | ***** | 5.0 (1.7) | 4 (4, 5) | 30.0 (12.2) | 30 (20, 30) | 450.0 (183.7) | 450 (300, 450) | ***** | - | - |
| Other | ***** | 6.3 (2.6) | 6 (4, 8) | 25.6 (10.5) | 24 (16, 30) | 224.3 (299.5) | 120 (80, 150) | ***** | - | - |
| Other Schedule | 2,519 | 5.5 (3.3) | 5 (3, 7) | 32.0 (13.8) | 30 (24, 40) | 191.5 (111.5) | 150 (135, 225) | 458 (18.2%) | 9.8 (5.2) | 9 (6, 13) |
| Tramadol | 186 | 7.7 (5.3) | 7 (5, 10) | 32.8 (21.2) | 30 (20, 35) | 159.5 (105.0) | 150 (100, 175) | 33 (17.7%) | 12.5 (8.6) | 11 (7, 16) |
| Codeine | 123 | 5.3 (3.1) | 5 (3, 7) | 29.1 (13.4) | 30 (20, 30) | 130.9 (61.6) | 135 (90, 135) | ***** (8.9%) | 9.6 (5.3) | 10 (5, 15) |
| Hydrocodone (before rescheduling) | 2,186 | 5.3 (3.0) | 5 (3, 6) | 32.2 (13.0) | 30 (25, 40) | 192.4 (99.5) | 150 (150, 225) | 409 (18.7%) | 9.7 (4.8) | 9 (6, 13) |
| Other | 24 | 5.9 (2.0) | 5 (5, 8) | 30.3 (11.3) | 30 (22, 30) | 668.9 (214.6) | 690 (506, 690) | ***** | 7.6 (3.0) | 7 (6, 9) |
| 18-40 | 469 | 5.3 (3.4) | 5 (3, 6) | 35.5 (21.4) | 30 (30, 40) | 255.3 (201.2) | 225 (150, 300) | 126 (26.9%) | 9.3 (5.3) | 8 (6, 12) |
| Schedule II | 252 | 5.3 (3.7) | 5 (3, 6) | 38.0 (26.2) | 30 (30, 40) | 301.0 (236.5) | 225 (225, 329) | 68 (27.0%) | 9.0 (4.5) | 8 (6, 12) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.6 (2.6) | 5 (3, 7) | 44.3 (19.6) | 40 (30, 50) | 354.4 (156.9) | 320 (240, 400) | ***** (41.2%) | 8.3 (3.1) | 8 (7, 11) |
| Hydrocodone (after rescheduling) | 26 | 5.1 (2.0) | 5 (4, 6) | 34.0 (12.3) | 30 (28, 40) | 205.3 (99.8) | 150 (140, 278) | ***** | 10.1 (4.5) | 9 (7, 13) |
| Oxycodone | 207 | 5.3 (3.9) | 5 (3, 6) | 38.0 (28.0) | 30 (30, 40) | 307.2 (250.1) | 225 (225, 338) | 53 (25.6%) | 8.9 (4.7) | 7 (6, 12) |
| Morphine | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0%) | - | - |
| Other | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0%) | - | - |
| Other Schedule | 217 | 5.2 (3.0) | 5 (3, 6) | 32.5 (13.4) | 30 (25, 40) | 202.2 (132.1) | 150 (135, 225) | 58 (26.7%) | 9.7 (6.2) | 9 (5, 12) |
| Tramadol | ***** | 7.6 (3.4) | 7 (5, 10) | 29.0 (13.4) | 30 (20, 30) | 145.0 (67.1) | 150 (100, 150) | 0 (0%) | - | - |
| Codeine | ***** | 5.0 (2.3) | 5 (4, 7) | 27.1 (12.8) | 30 (20, 36) | 110.3 (51.4) | 115 (90, 135) | ***** (12.5%) | ***** | ***** |
| Hydrocodone (before rescheduling) | 202 | 5.2 (3.0) | 5 (3, 6) | 32.8 (13.5) | 30 (25, 40) | 201.3 (115.6) | 150 (150, 225) | ***** | 9.9 (6.2) | 9 (5, 13) |
| Other | ***** | 6.5 (0.7) | 7 (6, 7) | 35.0 (21.2) | 35 (20, 50) | 805.0 (487.9) | 805 (460,1,150) | ***** (50.0%) | ***** | ***** |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | | |
|---|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|--|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) | |
| Cholecystectomy (nonspecific), continued | | | | | | | | | | | |
| 41-64 | | | | | | | | | | | |
| Schedule II | 1,677 | 5.3 (3.4) | 5 (3, 6) | 35.0 (14.8) | 30 (30, 40) | 250.4 (154.5) | 225 (150, 300) | 364 (21.7%) | 9.9 (5.0) | 9 (6, 14) | |
| Oxymorphone | 881 | 5.4 (3.5) | 5 (3, 6) | 37.2 (16.3) | 30 (30, 40) | 296.0 (170.2) | 240 (225, 338) | 171 (19.4%) | 10.1 (5.0) | 9 (6, 14) | |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - | |
| Hydrocodone (after rescheduling) | ***** | 5.5 (4.3) | 5 (3, 7) | 37.6 (17.3) | 30 (30, 45) | 354.3 (258.2) | 300 (240, 400) | ***** (23.4%) | 9.4 (5.6) | 7 (5, 15) | |
| Oxycodone | 110 | 5.6 (2.2) | 5 (4, 7) | 34.2 (14.0) | 30 (30, 40) | 216.6 (98.4) | 200 (150, 300) | 12 (10.9%) | 8.2 (3.8) | 8 (6, 11) | |
| Morphine | 701 | 5.4 (3.6) | 5 (3, 6) | 37.7 (16.5) | 30 (30, 42) | 303.0 (163.7) | 270 (225, 375) | 144 (20.5%) | 10.4 (5.0) | 10 (7, 14) | |
| Other | ***** | 4.5 (0.7) | 5 (4, 5) | 25.0 (7.1) | 25 (20, 30) | 375.0 (106.1) | 375 (300, 450) | ***** | - | - | |
| Other Schedule | 796 | 5.2 (3.2) | 5 (3, 6) | 32.6 (12.5) | 30 (25, 40) | 199.9 (115.8) | 150 (150, 225) | 193 (24.2%) | 9.8 (5.0) | 9 (6, 13) | |
| Tramadol | ***** | 7.7 (5.2) | 6 (5, 10) | 35.1 (18.2) | 30 (23, 40) | 170.6 (91.0) | 150 (106, 200) | ***** (22.7%) | 12.8 (6.9) | 11 (9, 16) | |
| Codeine | ***** | 4.6 (2.0) | 5 (3, 5) | 26.7 (8.3) | 30 (20, 30) | 122.8 (46.3) | 135 (90, 135) | ***** (10.8%) | 8.5 (6.0) | 8 (4, 13) | |
| Hydrocodone (before rescheduling) | 705 | 5.1 (3.0) | 5 (3, 6) | 32.8 (12.2) | 30 (30, 40) | 198.7 (98.6) | 158 (150, 225) | 179 (25.4%) | 9.6 (4.8) | 9 (6, 13) | |
| Other | ***** | 5.6 (2.1) | 5 (4, 6) | 30.4 (11.5) | 30 (24, 30) | 699.2 (263.8) | 690 (552, 690) | 0 (0.0%) | - | - | |
| 65+ | | | | | | | | | | | |
| Schedule II | 2,727 | 5.5 (3.3) | 5 (4, 7) | 32.5 (14.5) | 30 (25, 40) | 217.2 (121.5) | 200 (150, 250) | 350 (12.8%) | 9.7 (5.0) | 9 (6, 13) | |
| Oxymorphone | 1,221 | 5.3 (3.1) | 5 (3, 6) | 33.6 (14.4) | 30 (25, 40) | 256.3 (128.3) | 225 (175, 300) | 143 (11.7%) | 9.5 (4.8) | 9 (6, 12) | |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - | |
| Hydrocodone (after rescheduling) | ***** | 5.4 (3.8) | 5 (3, 6) | 33.3 (13.9) | 30 (22, 40) | 293.9 (161.9) | 240 (192, 320) | ***** (12.9%) | 12.8 (6.2) | 12 (11, 16) | |
| Oxycodone | 196 | 5.6 (3.4) | 5 (4, 6) | 33.8 (16.7) | 30 (27, 40) | 196.8 (110.8) | 150 (150, 225) | ***** | 10.0 (5.2) | 9 (7, 12) | |
| Morphine | 951 | 5.2 (3.0) | 5 (3, 6) | 33.7 (13.9) | 30 (28, 40) | 265.8 (125.3) | 225 (225, 300) | 113 (11.9%) | 9.1 (4.5) | 9 (5, 12) | |
| Other | ***** | 6.0 (2.8) | 6 (4, 8) | 25.0 (7.1) | 25 (20, 30) | 375.0 (106.1) | 375 (300, 450) | ***** | - | - | |
| Other Schedule | ***** | 6.0 (2.8) | 6 (4, 8) | 24.0 (8.5) | 24 (18, 30) | 120.0 (42.4) | 120 (90, 150) | ***** | - | - | |
| Tramadol | 1,506 | 5.6 (3.4) | 5 (4, 7) | 31.6 (14.5) | 30 (24, 40) | 185.6 (105.5) | 150 (125, 225) | 207 (13.7%) | 9.9 (5.2) | 9 (6, 13) | |
| Codeine | 137 | 7.7 (5.4) | 7 (4, 8) | 32.2 (22.4) | 30 (20, 30) | 156.5 (110.4) | 150 (100, 150) | ***** | 12.4 (9.3) | 11 (5, 20) | |
| Hydrocodone (before rescheduling) | 78 | 5.7 (3.6) | 5 (3, 7) | 30.4 (15.2) | 30 (20, 30) | 136.8 (68.3) | 135 (90, 135) | ***** | 11.2 (5.1) | 13 (8, 15) | |
| Other | 1,279 | 5.4 (3.0) | 5 (4, 6) | 31.7 (13.4) | 30 (24, 40) | 187.6 (97.0) | 150 (150, 225) | ***** | 9.6 (4.3) | 9 (6, 13) | |
| Other | 12 | 6.0 (2.1) | 5 (5, 8) | 29.5 (10.6) | 30 (22, 30) | 621.0 (104.7) | 690 (506, 690) | ***** | 8.5 (2.6) | 8 (7, 11) | |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|------------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|-------------------|------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hip fracture treatment | | | | | | | | | | |
| All ages | 11,939 | 7.8 (5.4) | 6 (5, 10) | 49.7 (28.4) | 40 (30, 60) | 355.3 (258.1) | 300 (175, 450) | 4,481 (37.5%) | 10.8 (6.0) | 10 (7, 14) |
| Schedule II | 5,757 | 7.6 (5.1) | 6 (5, 10) | 53.3 (30.3) | 50 (30, 60) | 427.3 (285.0) | 375 (225, 560) | 2,294 (39.8%) | 10.6 (5.5) | 10 (7, 14) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 198 | 7.4 (4.8) | 6 (5, 10) | 55.2 (30.2) | 50 (30, 70) | 505.1 (314.7) | 480 (240, 720) | 100 (50.5%) | 10.7 (5.2) | 11 (7, 14) |
| Hydrocodone (after rescheduling) | 947 | 7.7 (4.9) | 6 (5, 10) | 47.5 (27.6) | 40 (30, 60) | 297.9 (217.5) | 225 (150, 400) | 325 (34.3%) | 11.3 (5.6) | 11 (7, 15) |
| Oxycodone | 4,565 | 7.5 (5.1) | 6 (5, 10) | 54.5 (30.8) | 50 (30, 60) | 449.0 (287.1) | 375 (225, 600) | 1,845 (40.4%) | 10.5 (5.5) | 10 (7, 14) |
| Morphine | 35 | 9.4 (5.3) | 9 (5, 15) | 41.0 (26.7) | 30 (30, 50) | 615.0 (399.8) | 450 (450, 750) | ***** | 8.6 (7.2) | 7 (4, 9) |
| Other | 12 | 9.8 (7.8) | 8 (5, 13) | 41.1 (21.7) | 35 (23, 55) | 571.7 (291.2) | 475 (380, 700) | ***** | 11.3 (4.8) | 12 (6, 15) |
| Other Schedule | 6,182 | 8.1 (5.7) | 7 (5, 10) | 46.3 (26.1) | 40 (30, 60) | 288.2 (209.0) | 225 (150, 360) | 2,187 (35.4%) | 11.0 (6.4) | 10 (6, 15) |
| Tramadol | 883 | 10.7 (7.2) | 8 (5, 13) | 46.8 (29.5) | 40 (30, 60) | 231.6 (148.0) | 200 (150, 300) | 250 (28.3%) | 12.5 (8.4) | 11 (6, 17) |
| Codeine | 284 | 7.7 (5.5) | 6 (5, 10) | 44.0 (28.6) | 30 (30, 60) | 204.0 (145.7) | 135 (135, 270) | ***** | 10.4 (6.1) | 9 (6, 15) |
| Hydrocodone (before rescheduling) | 4,985 | 7.6 (5.3) | 6 (5, 10) | 46.3 (25.2) | 40 (30, 60) | 298.5 (205.1) | 250 (150, 400) | 1,854 (37.2%) | 10.8 (6.1) | 10 (6, 14) |
| Other | 30 | 8.7 (6.2) | 7 (6, 10) | 46.4 (27.9) | 40 (30, 50) | 1,042.9 (655.7) | 920 (690,1,150) | ***** | 11.6 (3.3) | 10 (9, 15) |
| 18-40 | 1,597 | 7.9 (4.9) | 7 (5, 10) | 63.1 (32.4) | 60 (40, 80) | 520.0 (325.7) | 450 (300, 675) | 820 (51.3%) | 10.2 (5.4) | 9 (6, 14) |
| Schedule II | 1,056 | 8.1 (5.0) | 7 (5, 10) | 68.3 (35.1) | 60 (45, 90) | 587.7 (348.3) | 450 (375, 720) | 534 (50.6%) | 10.3 (5.1) | 9 (7, 14) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 53 | 7.5 (5.2) | 6 (5, 8) | 65.4 (35.2) | 56 (40, 90) | 589.9 (362.6) | 480 (320, 800) | 36 (67.9%) | 9.9 (5.1) | 9 (7, 13) |
| Hydrocodone (after rescheduling) | 78 | 8.6 (5.4) | 7 (5, 10) | 67.2 (41.9) | 60 (40, 90) | 478.8 (309.3) | 450 (225, 600) | 39 (50.0%) | 9.8 (4.7) | 10 (6, 14) |
| Oxycodone | 914 | 8.0 (5.0) | 7 (5, 10) | 68.8 (34.5) | 60 (50, 90) | 595.7 (348.9) | 450 (375, 743) | 454 (49.7%) | 10.4 (5.1) | 9 (7, 14) |
| Morphine | ***** | 13.6 (3.1) | 14 (10, 15) | 47.3 (27.4) | 30 (30, 60) | 709.5 (410.4) | 450 (450, 900) | ***** (50.0%) | 13.2 (11.4) | 7 (4, 23) |
| Other | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** |
| Other Schedule | 541 | 7.6 (4.6) | 7 (5, 10) | 53.0 (23.2) | 50 (40, 60) | 387.9 (223.9) | 338 (225, 500) | 286 (52.9%) | 10.0 (5.8) | 9 (6, 13) |
| Tramadol | 33 | 11.0 (7.7) | 9 (5, 12) | 55.9 (28.5) | 50 (30, 60) | 278.0 (143.5) | 250 (150, 300) | ***** | 10.5 (8.2) | 8 (5, 14) |
| Codeine | ***** | 6.3 (3.7) | 5 (3, 8) | 45.2 (26.4) | 40 (30, 60) | 222.6 (173.4) | 180 (135, 270) | ***** (38.1%) | 10.1 (5.2) | 11 (6, 15) |
| Hydrocodone (before rescheduling) | 487 | 7.4 (4.3) | 6 (5, 9) | 53.2 (22.6) | 50 (40, 60) | 402.4 (225.6) | 375 (225, 500) | 267 (54.8%) | 10.0 (5.8) | 9 (6, 13) |
| Other | 0 | - | - | - | - | - | - | - | - | - |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hip fracture treatment, continued | | | | | | | | | | |
| 41-64 | 2,975 | 7.5 (4.9) | 6 (5, 10) | 54.0 (28.5) | 50 (30, 60) | 412.8 (265.3) | 375 (225, 500) | 1,304 (43.8%) | 10.5 (5.6) | 9 (7, 14) |
| Schedule II | 1,690 | 7.4 (4.8) | 6 (5, 9) | 56.8 (29.1) | 50 (40, 70) | 465.7 (277.0) | 450 (300, 600) | 757 (44.8%) | 10.3 (5.2) | 9 (7, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 72 | 7.3 (4.0) | 7 (5, 10) | 57.6 (26.7) | 60 (40, 65) | 558.4 (304.7) | 480 (360, 720) | ***** | 11.9 (5.2) | 12 (9, 15) |
| Hydrocodone (after rescheduling) | 205 | 7.8 (4.6) | 7 (5, 10) | 51.3 (26.1) | 45 (30, 60) | 344.1 (226.9) | 300 (150, 450) | 83 (40.5%) | 10.8 (5.2) | 10 (7, 13) |
| Oxycodone | 1,400 | 7.3 (4.8) | 6 (5, 8) | 57.7 (29.6) | 50 (40, 75) | 477.8 (276.5) | 450 (300, 600) | 632 (45.1%) | 10.1 (5.2) | 9 (7, 13) |
| Morphine | ***** | 9.1 (6.1) | 8 (5, 13) | 37.9 (23.1) | 30 (30, 50) | 568.3 (347.0) | 450 (450, 750) | ***** (33.3%) | 8.3 (6.0) | 9 (2, 14) |
| Other | ***** | 16.5 (9.4) | 13 (10, 23) | 65.0 (17.3) | 60 (55, 75) | 550.0 (441.6) | 375 (275, 825) | ***** (50.0%) | 16.0 (2.8) | 16 (14, 18) |
| Other Schedule | 1,285 | 7.7 (5.0) | 6 (5, 10) | 50.4 (27.2) | 45 (30, 60) | 343.2 (231.5) | 300 (200, 450) | 547 (42.6%) | 10.9 (6.2) | 10 (7, 14) |
| Tramadol | 109 | 10.7 (6.6) | 10 (5, 15) | 54.3 (34.7) | 45 (30, 60) | 270.4 (174.3) | 225 (150, 300) | ***** | 14.0 (9.1) | 12 (8, 19) |
| Codeine | ***** | 7.3 (5.6) | 6 (4, 8) | 48.9 (35.9) | 40 (30, 60) | 231.0 (176.3) | 203 (135, 270) | ***** (28.0%) | 10.7 (5.5) | 8 (6, 16) |
| Hydrocodone (before rescheduling) | 1,117 | 7.4 (4.7) | 6 (5, 10) | 50.1 (26.0) | 45 (30, 60) | 350.4 (228.8) | 300 (200, 450) | 493 (44.1%) | 10.6 (5.9) | 9 (6, 13) |
| Other | ***** | 6.4 (2.9) | 5 (5, 7) | 41.9 (14.3) | 40 (30, 40) | 963.4 (329.0) | 920 (690, 920) | ***** (33.3%) | 11.0 (3.6) | 10 (8, 15) |
| 65+ | 7,367 | 7.9 (5.7) | 6 (5, 10) | 45.0 (26.2) | 40 (30, 60) | 296.4 (214.1) | 225 (150, 375) | 2,357 (32.0%) | 11.1 (6.3) | 10 (6, 15) |
| Schedule II | 3,011 | 7.5 (5.2) | 6 (5, 10) | 46.0 (26.7) | 40 (30, 60) | 349.5 (232.0) | 300 (210, 450) | 1,003 (33.3%) | 10.9 (5.9) | 10 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 7.3 (5.2) | 6 (4, 8) | 45.3 (26.9) | 40 (30, 60) | 390.9 (251.1) | 320 (240, 480) | ***** (37.0%) | 9.9 (5.1) | 9 (6, 14) |
| Hydrocodone (after rescheduling) | 664 | 7.5 (5.0) | 6 (5, 10) | 44.0 (24.7) | 40 (30, 60) | 262.4 (186.4) | 200 (150, 300) | 203 (30.6%) | 11.7 (5.9) | 11 (7, 16) |
| Oxycodone | 2,251 | 7.5 (5.3) | 6 (5, 10) | 46.8 (27.2) | 40 (30, 60) | 371.5 (234.5) | 300 (225, 450) | 759 (33.7%) | 10.8 (6.0) | 10 (7, 14) |
| Morphine | ***** | 6.9 (4.4) | 6 (5, 8) | 38.8 (28.9) | 30 (28, 33) | 582.2 (434.2) | 450 (420, 495) | ***** (56.3%) | 6.2 (3.1) | 7 (4, 7) |
| Other | ***** | 6.7 (4.4) | 5 (3, 12) | 29.7 (11.9) | 30 (20, 40) | 594.3 (237.1) | 600 (400, 800) | ***** (71.4%) | 9.4 (4.2) | 9 (6, 12) |
| Other Schedule | 4,356 | 8.2 (6.0) | 7 (5, 10) | 44.2 (25.8) | 40 (30, 60) | 259.6 (192.4) | 200 (150, 300) | 1,354 (31.1%) | 11.2 (6.6) | 10 (6, 15) |
| Tramadol | 741 | 10.6 (7.3) | 8 (5, 13) | 45.3 (28.5) | 35 (30, 60) | 223.8 (142.9) | 165 (150, 300) | 202 (27.3%) | 12.3 (8.3) | 11 (6, 16) |
| Codeine | 213 | 7.9 (5.7) | 6 (5, 10) | 42.7 (26.9) | 30 (30, 60) | 195.8 (134.3) | 135 (135, 270) | ***** | 10.3 (6.5) | 9 (5, 14) |
| Hydrocodone (before rescheduling) | 3,381 | 7.7 (5.6) | 6 (5, 10) | 44.1 (25.0) | 40 (30, 60) | 266.4 (184.2) | 200 (150, 300) | 1,094 (32.4%) | 11.0 (6.2) | 10 (6, 15) |
| Other | ***** | 9.7 (7.0) | 7 (6, 10) | 48.3 (32.1) | 40 (30, 50) | 1,076.9 (759.0) | 920 (690, 1,150) | ***** (19.0%) | 12.0 (3.6) | 11 (10, 15) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|---------------|--------------------------------|-------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hip replacement | | | | | | | | | | |
| All ages | 42,788 | 8.1 (4.8) | 7 (5, 10) | 64.0 (27.3) | 60 (40, 80) | 473.5 (265.8) | 450 (300, 600) | 13,142 (30.7%) | 11.2 (5.4) | 11 (7, 14) |
| Schedule II | 23,040 | 8.1 (4.8) | 7 (5, 10) | 68.4 (28.6) | 60 (50, 90) | 542.5 (269.8) | 450 (375, 675) | 6,593 (28.6%) | 11.3 (5.3) | 11 (7, 14) |
| Oxymorphone | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0.0%) | - | - |
| Hydromorphone | 1,253 | 7.4 (5.0) | 7 (5, 9) | 68.1 (26.0) | 60 (50, 90) | 576.7 (259.7) | 480 (400, 720) | 381 (30.4%) | 10.4 (5.0) | 10 (7, 13) |
| Hydrocodone (after rescheduling) | 3,584 | 9.4 (5.2) | 8 (5, 10) | 72.5 (33.1) | 60 (50, 90) | 507.5 (317.1) | 450 (300, 600) | 854 (23.8%) | 12.8 (5.6) | 13 (9, 16) |
| Oxycodone | 18,018 | 7.8 (4.6) | 7 (5, 10) | 67.7 (27.6) | 60 (50, 90) | 541.7 (246.2) | 450 (375, 675) | 5,297 (29.4%) | 11.1 (5.2) | 11 (7, 14) |
| Morphine | ***** | 11.7 (7.8) | 9 (7, 15) | 55.2 (35.8) | 50 (21, 90) | 894.0 (623.0) | 840 (360,1,350) | 24 (*****) | 9.2 (7.0) | 7 (3, 14) |
| Other | 109 | 9.4 (5.1) | 8 (6, 10) | 62.1 (23.3) | 60 (45, 80) | 1,188.4 (684.5) | 1,200 (800,1,600) | 37 (33.9%) | 10.6 (5.5) | 10 (7, 13) |
| Other Schedule | 19,748 | 8.2 (4.7) | 7 (5, 10) | 58.8 (24.7) | 60 (40, 75) | 392.9 (236.9) | 300 (240, 500) | 6,549 (33.2%) | 11.1 (5.4) | 10 (7, 14) |
| Tramadol | 3,522 | 10.7 (5.9) | 10 (7, 13) | 58.8 (24.6) | 60 (40, 70) | 290.9 (121.8) | 300 (200, 315) | 888 (25.2%) | 11.2 (6.5) | 10 (6, 15) |
| Codeine | 500 | 7.2 (4.3) | 6 (5, 9) | 54.7 (25.5) | 50 (40, 60) | 254.9 (134.6) | 225 (180, 270) | 134 (26.8%) | 10.1 (5.8) | 9 (6, 14) |
| Hydrocodone (before rescheduling) | 15,578 | 7.6 (4.2) | 7 (5, 10) | 59.0 (24.7) | 60 (40, 75) | 412.9 (236.1) | 375 (250, 500) | 5,482 (35.2%) | 11.1 (5.2) | 10 (7, 14) |
| Other | 148 | 9.1 (4.5) | 8 (6, 10) | 52.6 (21.4) | 50 (40, 60) | 1,183.9 (475.1) | 1,150 (920,1,380) | 45 (30.4%) | 10.1 (5.1) | 9 (7, 13) |
| 18-40 | 776 | 8.3 (4.6) | 7 (5, 10) | 70.3 (30.3) | 60 (50, 90) | 547.2 (295.2) | 450 (338, 675) | 304 (39.2%) | 10.9 (5.9) | 10 (7, 14) |
| Schedule II | 471 | 8.2 (4.4) | 7 (5, 10) | 74.7 (31.3) | 75 (60, 90) | 610.8 (302.7) | 600 (450, 675) | 170 (36.1%) | 10.5 (5.9) | 9 (7, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 7.5 (3.4) | 7 (5, 10) | 73.0 (31.3) | 80 (50, 90) | 631.6 (319.7) | 640 (480, 720) | ***** (36.4%) | 8.6 (3.7) | 8 (6, 11) |
| Hydrocodone (after rescheduling) | 37 | 10.0 (4.6) | 9 (7, 15) | 83.4 (43.7) | 80 (50, 100) | 613.6 (438.6) | 450 (300, 900) | ***** | 11.6 (7.1) | 10 (7, 13) |
| Oxycodone | 406 | 8.0 (4.4) | 7 (5, 10) | 73.8 (29.9) | 75 (60, 90) | 606.0 (282.8) | 600 (450, 675) | 151 (37.2%) | 10.5 (5.9) | 9 (7, 13) |
| Morphine | ***** | 12.3 (7.5) | 12 (5, 20) | 83.3 (20.8) | 90 (60, 100) | 1,250.0 (312.2) | 1,350 (900,1,500) | ***** (33.3%) | ***** | ***** |
| Other | ***** | 11.3 (7.6) | 8 (6, 20) | 86.7 (41.6) | 100 (40, 120) | 433.3 (208.2) | 500 (200, 600) | ***** (33.3%) | ***** | ***** |
| Other Schedule | 305 | 8.4 (4.8) | 7 (5, 10) | 63.7 (27.4) | 60 (40, 80) | 448.9 (253.9) | 400 (300, 600) | 134 (43.9%) | 11.4 (5.9) | 11 (7, 15) |
| Tramadol | 39 | 10.4 (5.2) | 10 (7, 12) | 59.3 (21.1) | 60 (40, 80) | 282.6 (91.6) | 300 (200, 338) | ***** | 11.9 (7.8) | 11 (7, 20) |
| Codeine | ***** | 4.9 (2.0) | 5 (3, 6) | 37.9 (11.5) | 40 (30, 40) | 170.4 (51.7) | 180 (135, 180) | ***** (28.6%) | 11.5 (4.9) | 12 (8, 15) |
| Hydrocodone (before rescheduling) | 255 | 8.2 (4.7) | 7 (5, 10) | 65.4 (28.2) | 60 (45, 80) | 474.6 (253.1) | 450 (300, 600) | 115 (45.1%) | 11.4 (5.7) | 11 (7, 15) |
| Other | ***** | 7.3 (2.1) | 7 (6, 9) | 40.0 (14.1) | 35 (30, 50) | 920.0 (325.3) | 805 (690,1,150) | ***** (75.0%) | 9.0 (6.1) | 12 (2, 13) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|--------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hip replacement, continued | | | | | | | | | | |
| 41-64 | 15,047 | 8.0 (4.5) | 7 (5, 10) | 68.7 (27.5) | 60 (50, 90) | 531.2 (282.9) | 450 (315, 675) | 5,124 (34.1%) | 10.8 (5.3) | 10 (7, 14) |
| Schedule II | 9,072 | 7.9 (4.5) | 7 (5, 10) | 71.9 (28.6) | 60 (50, 90) | 581.6 (284.7) | 525 (450, 675) | 2,903 (32.0%) | 10.8 (5.2) | 10 (7, 14) |
| Oxymorphone | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0.0%) | - | - |
| Hydromorphone | ***** | 6.9 (3.9) | 6 (5, 8) | 72.0 (25.9) | 65 (60, 90) | 612.4 (268.0) | 560 (480, 800) | ***** (31.0%) | 9.8 (4.8) | 9 (6, 13) |
| Hydrocodone (after rescheduling) | 893 | 10.1 (5.5) | 9 (7, 12) | 80.0 (36.4) | 80 (60, 100) | 582.4 (360.8) | 450 (300, 750) | ***** | 12.8 (6.1) | 12 (8, 16) |
| Oxycodone | 7,508 | 7.6 (4.3) | 7 (5, 9) | 71.0 (27.5) | 60 (50, 90) | 570.3 (252.3) | 563 (450, 675) | 2,472 (32.9%) | 10.7 (5.1) | 10 (7, 14) |
| Morphine | ***** | 13.8 (9.4) | 10 (7, 20) | 68.4 (39.6) | 60 (30, 100) | 1,166.1 (739.3) | 900 (450, 1,800) | ***** (29.0%) | 10.3 (8.8) | 6 (3, 16) |
| Other | 62 | 9.1 (4.4) | 8 (6, 10) | 65.7 (22.6) | 60 (50, 80) | 1,361.8 (742.4) | 1,200 (800, 1,800) | ***** | 11.3 (5.9) | 11 (8, 16) |
| Other Schedule | 5,975 | 8.2 (4.4) | 7 (5, 10) | 63.7 (24.9) | 60 (45, 80) | 454.8 (262.4) | 400 (300, 600) | 2,221 (37.2%) | 10.8 (5.4) | 10 (7, 14) |
| Tramadol | 764 | 10.6 (5.4) | 10 (7, 13) | 61.9 (22.6) | 60 (50, 80) | 304.9 (111.5) | 300 (225, 375) | ***** | 10.1 (5.9) | 9 (6, 14) |
| Codeine | ***** | 7.6 (4.5) | 6 (5, 10) | 60.4 (28.7) | 60 (40, 80) | 291.3 (164.4) | 270 (180, 405) | ***** (32.0%) | 9.2 (5.3) | 8 (5, 13) |
| Hydrocodone (before rescheduling) | 5,012 | 7.9 (4.1) | 7 (5, 10) | 64.2 (25.2) | 60 (48, 80) | 471.3 (254.2) | 450 (300, 600) | 1,948 (38.9%) | 10.9 (5.3) | 10 (7, 14) |
| Other | ***** | 8.8 (4.2) | 8 (6, 10) | 53.7 (20.3) | 50 (40, 60) | 1,200.5 (430.2) | 1,150 (920, 1,380) | ***** (33.8%) | 9.7 (5.5) | 9 (6, 13) |
| 65+ | 26,965 | 8.2 (4.9) | 7 (5, 10) | 61.2 (26.7) | 60 (40, 80) | 439.1 (248.4) | 400 (270, 600) | 7,714 (28.6%) | 11.4 (5.4) | 11 (7, 15) |
| Schedule II | 13,497 | 8.2 (5.0) | 7 (5, 10) | 65.8 (28.1) | 60 (50, 90) | 513.8 (254.1) | 450 (338, 675) | 3,520 (26.1%) | 11.7 (5.3) | 12 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 654 | 7.7 (5.9) | 7 (5, 10) | 64.5 (25.3) | 60 (50, 80) | 543.3 (245.6) | 480 (400, 720) | 194 (29.7%) | 11.0 (5.2) | 11 (7, 14) |
| Hydrocodone (after rescheduling) | 2,654 | 9.2 (5.2) | 8 (5, 10) | 69.8 (31.4) | 60 (50, 90) | 480.8 (294.4) | 450 (300, 600) | 628 (23.7%) | 12.9 (5.3) | 13 (9, 16) |
| Oxycodone | 10,104 | 7.9 (4.8) | 7 (5, 10) | 65.0 (27.3) | 60 (50, 80) | 517.9 (237.2) | 450 (375, 675) | 2,674 (26.5%) | 11.5 (5.3) | 11 (8, 14) |
| Morphine | 41 | 10.1 (6.0) | 8 (7, 12) | 43.2 (28.9) | 30 (20, 60) | 662.2 (425.8) | 600 (315, 900) | ***** | 8.3 (6.2) | 7 (3, 11) |
| Other | ***** | 9.6 (6.0) | 10 (5, 10) | 55.3 (21.1) | 60 (40, 60) | 995.7 (521.2) | 1,110 (600, 1,380) | ***** (22.7%) | 8.9 (4.0) | 10 (5, 11) |
| Other Schedule | 13,468 | 8.2 (4.8) | 7 (5, 10) | 56.5 (24.2) | 50 (40, 60) | 364.2 (218.4) | 300 (200, 450) | 4,194 (31.1%) | 11.2 (5.4) | 11 (7, 14) |
| Tramadol | 2,719 | 10.8 (6.0) | 10 (7, 13) | 57.9 (25.1) | 60 (40, 60) | 287.1 (124.7) | 300 (200, 300) | 666 (24.5%) | 11.5 (6.6) | 11 (7, 15) |
| Codeine | 365 | 7.1 (4.2) | 6 (5, 9) | 53.1 (24.2) | 50 (32, 60) | 243.7 (121.0) | 225 (144, 270) | 91 (24.9%) | 10.4 (6.0) | 9 (6, 14) |
| Hydrocodone (before rescheduling) | 10,311 | 7.5 (4.2) | 7 (5, 10) | 56.3 (24.0) | 50 (40, 60) | 383.0 (220.4) | 300 (225, 500) | 3,419 (33.2%) | 11.2 (5.1) | 11 (7, 14) |
| Other | 73 | 9.5 (4.9) | 9 (6, 10) | 52.3 (22.6) | 45 (40, 60) | 1,182.3 (522.0) | 966 (740, 1,380) | 18 (24.7%) | 10.8 (4.8) | 11 (7, 12) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hysterectomy (non-laparoscopic) | | | | | | | | | | |
| All ages | 11,600 | 4.9 (2.7) | 5 (3, 5) | 32.1 (11.6) | 30 (30, 40) | 227.6 (130.2) | 225 (150, 263) | 1,488 (12.8%) | 8.7 (4.9) | 7 (5, 12) |
| Schedule II | 6,609 | 4.7 (2.7) | 4 (3, 5) | 32.6 (12.1) | 30 (30, 40) | 250.4 (123.0) | 225 (192, 300) | 769 (11.6%) | 8.5 (4.8) | 7 (5, 12) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 273 | 5.2 (3.5) | 5 (3, 6) | 36.5 (21.0) | 30 (30, 40) | 331.6 (311.8) | 240 (240, 400) | 46 (16.8%) | 9.1 (5.0) | 8 (6, 11) |
| Hydrocodone (after rescheduling) | 532 | 5.0 (2.4) | 5 (3, 6) | 32.0 (10.1) | 30 (30, 40) | 185.6 (88.5) | 150 (150, 200) | **** | 8.9 (5.1) | 8 (5, 12) |
| Oxycodone | 5,736 | 4.7 (2.6) | 4 (3, 5) | 32.5 (11.7) | 30 (30, 40) | 251.9 (101.1) | 225 (225, 300) | 675 (11.8%) | 8.5 (4.8) | 7 (5, 12) |
| Morphine | ***** | 5.2 (1.8) | 5 (5, 5) | 28.0 (4.5) | 30 (30, 30) | 420.0 (67.1) | 450 (450, 450) | ***** (40.0%) | ***** | ***** |
| Other | ***** | 5.4 (3.0) | 5 (3, 7) | 31.5 (10.5) | 30 (30, 30) | 291.1 (322.6) | 150 (150, 225) | ***** (12.7%) | 5.0 (2.7) | 5 (3, 7) |
| Other Schedule | 4,991 | 5.0 (2.7) | 5 (3, 5) | 31.3 (10.8) | 30 (30, 30) | 197.4 (133.3) | 150 (140, 225) | 719 (14.4%) | 8.9 (4.9) | 8 (5, 12) |
| Tramadol | 256 | 6.8 (3.9) | 6 (5, 8) | 34.1 (17.9) | 30 (28, 40) | 167.8 (91.1) | 150 (120, 200) | 27 (10.5%) | 11.0 (6.1) | 11 (5, 15) |
| Codeine | 532 | 4.9 (2.9) | 5 (3, 5) | 30.8 (11.2) | 30 (24, 30) | 139.9 (54.0) | 135 (108, 135) | 52 (9.8%) | 8.5 (5.5) | 8 (5, 11) |
| Hydrocodone (before rescheduling) | 4,014 | 4.9 (2.5) | 5 (3, 5) | 31.3 (10.1) | 30 (30, 30) | 183.8 (83.7) | 150 (150, 225) | 619 (15.4%) | 8.8 (4.8) | 8 (5, 12) |
| Other | 189 | 5.4 (2.8) | 5 (4, 5) | 30.4 (9.1) | 30 (25, 30) | 688.0 (213.7) | 690 (552, 690) | 21 (11.1%) | 9.9 (6.5) | 8 (5, 12) |
| 18-40 | 2,652 | 4.7 (2.5) | 4 (3, 5) | 32.8 (12.2) | 30 (30, 40) | 244.2 (155.2) | 225 (150, 300) | 524 (19.8%) | 8.4 (4.5) | 7 (5, 11) |
| Schedule II | 1,591 | 4.6 (2.5) | 4 (3, 5) | 33.4 (13.5) | 30 (30, 40) | 264.2 (159.1) | 225 (225, 300) | 292 (18.4%) | 8.2 (4.4) | 7 (5, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.0 (4.1) | 4 (3, 5) | 40.5 (34.7) | 30 (30, 40) | 400.9 (564.8) | 304 (240, 400) | ***** (20.6%) | 7.4 (2.3) | 8 (6, 9) |
| Hydrocodone (after rescheduling) | 82 | 4.7 (1.7) | 5 (3, 6) | 31.6 (8.2) | 30 (30, 40) | 194.5 (94.6) | 150 (150, 225) | **** | 8.1 (5.1) | 6 (5, 13) |
| Oxycodone | 1,414 | 4.6 (2.4) | 4 (3, 5) | 33.2 (11.8) | 30 (30, 40) | 261.6 (103.1) | 225 (225, 300) | 261 (18.5%) | 8.3 (4.4) | 7 (5, 11) |
| Morphine | ***** | 5.3 (2.1) | 5 (4, 7) | 27.5 (5.0) | 30 (25, 30) | 412.5 (75.0) | 450 (375, 450) | ***** (25.0%) | ***** | ***** |
| Other | ***** | 4.9 (2.7) | 4 (3, 6) | 32.8 (10.8) | 30 (30, 40) | 244.3 (246.9) | 150 (150, 200) | ***** (8.7%) | ***** | ***** |
| Other Schedule | 1,061 | 4.8 (2.5) | 5 (3, 5) | 31.8 (9.7) | 30 (30, 35) | 214.1 (144.2) | 150 (150, 225) | 232 (21.9%) | 8.7 (4.6) | 8 (5, 12) |
| Tramadol | 31 | 6.3 (2.9) | 6 (4, 8) | 36.0 (14.3) | 30 (25, 50) | 184.2 (82.9) | 150 (125, 250) | **** | 10.0 (4.7) | 10 (5, 14) |
| Codeine | 70 | 4.9 (3.1) | 5 (3, 5) | 33.0 (12.4) | 30 (30, 35) | 153.2 (64.7) | 135 (135, 162) | **** | 7.1 (5.1) | 6 (2, 13) |
| Hydrocodone (before rescheduling) | 905 | 4.8 (2.4) | 5 (3, 5) | 31.6 (9.4) | 30 (30, 35) | 190.7 (84.3) | 150 (150, 225) | 206 (22.8%) | 8.7 (4.6) | 8 (5, 11) |
| Other | 55 | 5.1 (2.3) | 5 (4, 5) | 31.1 (7.9) | 30 (30, 30) | 694.6 (173.9) | 690 (644, 690) | **** | 9.3 (5.7) | 8 (5, 12) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | | |
|---|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|--|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) | |
| Hysterectomy (non-laparoscopic), continued | | | | | | | | | | | |
| 41-64 | | | | | | | | | | | |
| Schedule II | 4,880 | 4.8 (2.7) | 5 (3, 5) | 32.8 (11.2) | 30 (30, 40) | 238.6 (131.1) | 225 (150, 300) | 671 (13.8%) | 8.8 (4.9) | 7 (5, 12) | |
| Oxymorphone | 2,824 | 4.7 (2.7) | 4 (3, 5) | 33.2 (11.5) | 30 (30, 40) | 257.0 (111.9) | 225 (225, 300) | 344 (12.2%) | 8.8 (4.9) | 7 (5, 12) | |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - | |
| Hydrocodone (after rescheduling) | 120 | 5.0 (3.1) | 5 (3, 6) | 36.1 (14.7) | 30 (30, 46) | 323.1 (163.0) | 300 (240, 400) | 23 (19.2%) | 9.2 (6.1) | 7 (5, 12) | |
| Oxycodone | 172 | 5.1 (2.5) | 5 (3, 7) | 32.8 (10.8) | 30 (30, 40) | 199.1 (98.8) | 150 (150, 225) | ***** | 8.2 (3.6) | 8 (6, 9) | |
| Morphine | 2,497 | 4.7 (2.7) | 4 (3, 5) | 33.1 (11.3) | 30 (30, 40) | 257.2 (100.8) | 225 (225, 300) | 300 (12.0%) | 8.9 (4.8) | 7 (5, 12) | |
| Other | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** (100.0%) | ***** | ***** | |
| Other Schedule | 2,056 | 5.0 (2.6) | 5 (3, 6) | 32.2 (10.8) | 30 (30, 36) | 213.3 (150.0) | 150 (150, 225) | 327 (15.9%) | 8.9 (4.9) | 8 (5, 12) | |
| Tramadol | 67 | 7.3 (4.8) | 6 (4, 9) | 36.3 (15.7) | 30 (30, 40) | 176.6 (79.8) | 150 (150, 200) | ***** | 11.2 (4.9) | 12 (9, 15) | |
| Codeine | 179 | 4.7 (3.0) | 4 (3, 5) | 31.2 (11.6) | 30 (25, 30) | 141.8 (54.2) | 135 (113, 135) | 26 (14.5%) | 7.8 (4.3) | 8 (5, 10) | |
| Hydrocodone (before rescheduling) | 1,700 | 4.9 (2.4) | 5 (3, 5) | 32.3 (10.4) | 30 (30, 40) | 192.0 (89.1) | 150 (150, 225) | 286 (16.8%) | 8.8 (4.8) | 8 (5, 12) | |
| Other | 110 | 5.4 (3.2) | 5 (4, 5) | 29.9 (9.9) | 30 (20, 30) | 681.3 (233.6) | 690 (460, 690) | ***** | 10.8 (7.8) | 8 (5, 18) | |
| 65+ | | | | | | | | | | | |
| Schedule II | 4,068 | 5.0 (2.8) | 5 (3, 5) | 30.7 (11.5) | 30 (24, 30) | 203.6 (105.4) | 188 (150, 225) | 293 (7.2%) | 9.0 (5.5) | 8 (5, 12) | |
| Oxymorphone | 2,194 | 4.9 (2.8) | 5 (3, 5) | 31.2 (11.8) | 30 (25, 35) | 231.8 (102.9) | 225 (150, 263) | 133 (6.1%) | 8.6 (5.4) | 7 (5, 11) | |
| Hydromorphone | 0 | - | - | - | - | - | - | - | - | - | |
| Hydrocodone (after rescheduling) | ***** | 5.8 (3.5) | 5 (4, 7) | 33.8 (11.8) | 30 (30, 40) | 288.0 (129.6) | 240 (240, 320) | ***** (10.6%) | 11.3 (4.4) | 11 (8, 14) | |
| Oxycodone | 278 | 5.1 (2.5) | 5 (3, 6) | 31.7 (10.2) | 30 (30, 30) | 174.6 (78.3) | 150 (150, 200) | ***** | 10.9 (6.7) | 9 (6, 13) | |
| Morphine | 1,825 | 4.8 (2.8) | 4 (3, 5) | 31.0 (12.0) | 30 (25, 35) | 237.2 (98.4) | 225 (188, 300) | 114 (6.2%) | 8.1 (5.3) | 7 (5, 11) | |
| Other | 0 | - | - | - | - | - | - | - | - | - | |
| Other Schedule | ***** | 5.5 (2.5) | 6 (5, 7) | 23.8 (9.0) | 29 (15, 30) | 464.2 (421.7) | 380 (150, 600) | 0 (0.0%) | - | - | |
| Tramadol | 1,874 | 5.1 (2.9) | 5 (3, 6) | 30.2 (11.2) | 30 (24, 30) | 170.5 (98.5) | 150 (125, 200) | 160 (8.5%) | 9.4 (5.5) | 8 (5, 12) | |
| Codeine | 158 | 6.7 (3.6) | 5 (5, 8) | 32.7 (19.3) | 30 (24, 40) | 160.8 (96.7) | 150 (113, 169) | ***** | 11.5 (7.2) | 11 (5, 18) | |
| Hydrocodone (before rescheduling) | 283 | 4.9 (2.9) | 5 (3, 5) | 30.0 (10.5) | 30 (24, 30) | 135.4 (50.4) | 135 (90, 135) | ***** | 10.5 (7.0) | 8 (7, 14) | |
| Other | 1,409 | 4.9 (2.7) | 5 (3, 5) | 29.9 (10.1) | 30 (24, 30) | 169.6 (74.4) | 150 (140, 200) | 127 (9.0%) | 9.1 (5.0) | 8 (5, 12) | |
| Other | 24 | 5.8 (2.0) | 5 (5, 7) | 31.2 (8.4) | 30 (30, 30) | 703.4 (207.8) | 690 (633, 690) | ***** | 8.0 (4.2) | 8 (5, 11) | |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|------------------------------------|--------------------|------------------|-----------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|------------------|------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hysterectomy (laparoscopic) | | | | | | | | | | |
| All ages | 11,675 | 4.8 (2.6) | 4 (3, 5) | 32.0 (10.2) | 30 (30, 40) | 229.8 (114.1) | 225 (150, 263) | 1,397 (12.0%) | 8.8 (4.9) | 8 (5, 12) |
| Schedule II | 7,382 | 4.6 (2.4) | 4 (3, 5) | 32.6 (10.5) | 30 (30, 40) | 251.7 (104.8) | 225 (225, 300) | 806 (10.9%) | 8.7 (4.8) | 8 (5, 12) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 303 | 5.0 (2.6) | 5 (3, 6) | 35.3 (13.6) | 30 (30, 40) | 310.5 (158.3) | 240 (240, 360) | 46 (15.2%) | 7.5 (3.9) | 7 (5, 10) |
| Hydrocodone (after rescheduling) | 605 | 5.1 (2.5) | 5 (3, 6) | 33.4 (10.4) | 30 (30, 40) | 192.5 (84.0) | 150 (150, 225) | 54 (8.9%) | 10.4 (5.3) | 10 (6, 14) |
| Oxycodone | 6,362 | 4.6 (2.4) | 4 (3, 5) | 32.5 (10.3) | 30 (30, 40) | 252.8 (92.5) | 225 (225, 300) | 690 (10.8%) | 8.7 (4.8) | 8 (5, 12) |
| Morphine | ***** | 8.2 (3.0) | 7 (6, 10) | 45.6 (40.0) | 40 (30, 40) | 716.7 (584.7) | 600 (450, 600) | ***** (11.1%) | ***** | ***** |
| Other | ***** | 4.6 (2.1) | 4 (3, 5) | 28.2 (9.4) | 30 (20, 30) | 315.9 (252.7) | 200 (150, 400) | ***** (14.6%) | 6.7 (4.4) | 5 (3, 11) |
| Other Schedule | 4,293 | 5.0 (2.7) | 5 (3, 5) | 30.9 (9.4) | 30 (30, 30) | 192.2 (119.7) | 150 (150, 210) | 591 (13.8%) | 8.9 (5.1) | 8 (5, 12) |
| Tramadol | 226 | 6.8 (4.5) | 5 (4, 8) | 32.2 (11.4) | 30 (30, 30) | 159.6 (57.4) | 150 (150, 150) | 24 (10.6%) | 10.9 (5.4) | 11 (6, 16) |
| Codeine | 323 | 4.6 (2.6) | 4 (3, 5) | 30.8 (10.7) | 30 (25, 30) | 139.6 (50.7) | 135 (113, 135) | 31 (9.6%) | 7.3 (4.8) | 5 (4, 10) |
| Hydrocodone (before rescheduling) | 3,605 | 4.9 (2.6) | 5 (3, 5) | 30.8 (9.1) | 30 (30, 30) | 180.4 (74.5) | 150 (150, 200) | 514 (14.3%) | 8.9 (5.1) | 8 (5, 12) |
| Other | 139 | 5.0 (2.9) | 5 (3, 5) | 29.8 (8.6) | 30 (25, 30) | 674.7 (207.1) | 690 (555, 690) | 22 (15.8%) | 8.8 (4.8) | 9 (5, 13) |
| 18-40 | 4,337 | 4.7 (2.5) | 4 (3, 5) | 32.0 (10.4) | 30 (30, 40) | 233.6 (118.2) | 225 (150, 270) | 668 (15.4%) | 8.5 (4.8) | 8 (5, 12) |
| Schedule II | 2,787 | 4.6 (2.4) | 4 (3, 5) | 32.6 (11.0) | 30 (30, 40) | 255.6 (113.2) | 225 (225, 300) | 401 (14.4%) | 8.3 (4.4) | 7 (5, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 4.8 (2.2) | 5 (3, 5) | 35.0 (12.2) | 30 (30, 40) | 302.7 (139.1) | 248 (240, 320) | ***** (25.0%) | 7.8 (3.3) | 7 (6, 10) |
| Hydrocodone (after rescheduling) | 195 | 5.0 (2.4) | 5 (3, 6) | 32.6 (8.9) | 30 (30, 40) | 189.4 (79.8) | 150 (150, 225) | ***** | 9.2 (4.5) | 10 (5, 13) |
| Oxycodone | 2,439 | 4.6 (2.4) | 4 (3, 5) | 32.7 (11.1) | 30 (30, 40) | 257.0 (103.7) | 225 (225, 300) | 349 (14.3%) | 8.4 (4.4) | 7 (5, 11) |
| Morphine | ***** | 9.0 (3.9) | 9 (6, 12) | 32.5 (9.6) | 35 (25, 40) | 562.5 (75.0) | 600 (525, 600) | 0 (0.0%) | - | - |
| Other | ***** | 4.6 (2.0) | 4 (3, 5) | 28.3 (9.7) | 30 (20, 30) | 328.3 (291.8) | 200 (150, 400) | ***** (17.5%) | 5.7 (4.3) | 4 (3, 8) |
| Other Schedule | 1,550 | 4.9 (2.7) | 5 (3, 5) | 30.8 (9.2) | 30 (30, 30) | 194.0 (116.7) | 150 (150, 225) | 267 (17.2%) | 8.9 (5.3) | 8 (5, 13) |
| Tramadol | ***** | 6.8 (4.5) | 5 (4, 8) | 32.5 (11.1) | 30 (30, 30) | 161.6 (54.6) | 150 (150, 150) | ***** (12.3%) | 10.4 (5.4) | 10 (6, 15) |
| Codeine | 105 | 4.2 (1.9) | 4 (3, 5) | 30.0 (9.3) | 30 (24, 30) | 137.8 (44.5) | 135 (113, 158) | 14 (13.3%) | 6.9 (4.9) | 5 (3, 10) |
| Hydrocodone (before rescheduling) | 1,321 | 4.8 (2.6) | 5 (3, 5) | 30.9 (9.2) | 30 (30, 30) | 182.1 (74.6) | 150 (150, 225) | 234 (17.7%) | 9.1 (5.3) | 8 (5, 13) |
| Other | ***** | 4.8 (1.7) | 5 (3, 5) | 29.1 (7.5) | 30 (25, 30) | 663.1 (174.4) | 690 (555, 690) | ***** (19.6%) | 5.2 (3.2) | 5 (2, 8) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|---|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Hysterectomy (laparoscopic), continued | | | | | | | | | | |
| 41-64 | 5,727 | 4.7 (2.6) | 4 (3, 5) | 32.2 (9.9) | 30 (30, 40) | 232.1 (114.6) | 225 (150, 280) | 629 (11.0%) | 9.0 (5.1) | 8 (5, 12) |
| Schedule II | 3,640 | 4.6 (2.4) | 4 (3, 5) | 32.8 (10.2) | 30 (30, 40) | 251.9 (100.3) | 225 (225, 300) | 356 (9.8%) | 9.1 (5.1) | 8 (5, 12) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 172 | 5.0 (2.8) | 5 (3, 6) | 35.4 (13.7) | 30 (30, 40) | 307.3 (158.1) | 240 (240, 360) | 21 (12.2%) | 7.1 (4.7) | 6 (4, 10) |
| Hydrocodone (after rescheduling) | 295 | 5.1 (2.7) | 5 (3, 6) | 34.1 (11.2) | 30 (30, 40) | 199.8 (87.1) | 150 (150, 225) | 27 (9.2%) | 10.2 (4.7) | 10 (7, 13) |
| Oxycodone | 3,128 | 4.5 (2.4) | 4 (3, 5) | 32.5 (9.6) | 30 (30, 40) | 252.3 (85.7) | 225 (225, 300) | 303 (9.7%) | 9.1 (5.2) | 8 (5, 13) |
| Morphine | ***** | 7.6 (2.3) | 7 (6, 10) | 56.0 (53.2) | 40 (30, 40) | 840.0 (798.0) | 600 (450, 600) | ***** (20.0%) | ***** | ***** |
| Other | ***** | 4.7 (2.3) | 4 (3, 5) | 28.4 (9.6) | 30 (20, 30) | 288.9 (193.8) | 200 (150, 400) | ***** (10.0%) | 9.8 (4.3) | 10 (7, 13) |
| Other Schedule | 2,087 | 5.0 (2.7) | 5 (3, 5) | 31.1 (9.4) | 30 (30, 30) | 197.6 (129.0) | 150 (150, 225) | 273 (13.1%) | 9.0 (5.0) | 8 (5, 12) |
| Tramadol | 102 | 6.9 (4.7) | 5 (4, 8) | 33.6 (12.3) | 30 (30, 40) | 166.3 (62.6) | 150 (150, 200) | 12 (11.8%) | 10.5 (5.3) | 10 (7, 16) |
| Codeine | ***** | 4.6 (2.6) | 4 (3, 5) | 30.4 (10.3) | 30 (24, 30) | 137.5 (50.0) | 135 (108, 135) | ***** (5.9%) | 7.3 (5.8) | 6 (4, 8) |
| Hydrocodone (before rescheduling) | 1,751 | 4.9 (2.5) | 5 (3, 5) | 31.1 (9.0) | 30 (30, 30) | 182.3 (73.8) | 150 (150, 225) | 240 (13.7%) | 8.8 (5.0) | 8 (5, 12) |
| Other | ***** | 5.2 (3.5) | 5 (3, 5) | 30.4 (9.4) | 30 (25, 30) | 683.3 (230.2) | 690 (552, 690) | ***** (14.8%) | 11.8 (3.8) | 13 (10, 14) |
| 65+ | 1,611 | 4.9 (2.6) | 5 (3, 5) | 31.1 (10.3) | 30 (30, 30) | 211.5 (98.5) | 200 (150, 225) | 100 (6.2%) | 9.3 (5.0) | 9 (5, 14) |
| Schedule II | 955 | 4.8 (2.4) | 5 (3, 5) | 31.9 (10.6) | 30 (30, 40) | 239.4 (94.4) | 225 (188, 300) | 49 (5.1%) | 9.8 (5.5) | 9 (5, 14) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 5.1 (2.5) | 5 (3, 7) | 35.3 (16.6) | 30 (30, 47) | 343.0 (197.4) | 240 (240, 480) | ***** (5.1%) | 7.0 (2.8) | 7 (5, 9) |
| Hydrocodone (after rescheduling) | 115 | 5.0 (2.0) | 5 (3, 6) | 32.7 (10.8) | 30 (30, 40) | 179.3 (81.6) | 150 (150, 200) | ***** | 14.0 (7.5) | 19 (8, 19) |
| Oxycodone | 795 | 4.7 (2.4) | 5 (3, 5) | 31.7 (10.2) | 30 (28, 40) | 241.9 (80.1) | 225 (225, 300) | 38 (4.8%) | 9.2 (4.7) | 9 (5, 14) |
| Morphine | 0 | - | - | - | - | - | - | - | - | - |
| Other | ***** | 3.8 (1.2) | 4 (3, 5) | 25.7 (5.0) | 27 (20, 30) | 378.3 (208.8) | 400 (150, 600) | ***** (16.7%) | ***** | ***** |
| Other Schedule | 656 | 5.1 (2.8) | 5 (3, 6) | 30.0 (9.7) | 30 (30, 30) | 170.8 (89.9) | 150 (135, 200) | 51 (7.8%) | 8.7 (4.6) | 8 (5, 11) |
| Tramadol | ***** | 6.5 (4.1) | 6 (4, 8) | 29.1 (9.3) | 30 (30, 30) | 143.5 (47.1) | 150 (113, 150) | ***** (5.9%) | 13.7 (7.5) | 18 (5, 18) |
| Codeine | 65 | 5.5 (3.1) | 5 (3, 7) | 33.0 (13.3) | 30 (30, 30) | 147.3 (60.8) | 135 (135, 135) | ***** | 8.0 (3.7) | 8 (5, 11) |
| Hydrocodone (before rescheduling) | 533 | 5.0 (2.6) | 5 (3, 6) | 29.8 (9.2) | 30 (30, 30) | 169.9 (75.7) | 150 (150, 200) | 40 (7.5%) | 8.5 (4.5) | 8 (5, 11) |
| Other | ***** | 4.7 (1.7) | 5 (3, 6) | 28.7 (6.7) | 30 (21, 30) | 660.4 (154.1) | 690 (483, 690) | ***** | - | - |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|--------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Knee arthroplasty | | | | | | | | | | |
| All ages | 92,819 | 8.1 (4.7) | 7 (5, 10) | 63.6 (27.6) | 60 (40, 80) | 493.5 (281.0) | 450 (300, 600) | 56,986 (61.4%) | 10.9 (5.2) | 10 (7, 14) |
| Schedule II | 52,336 | 8.2 (4.8) | 7 (5, 10) | 69.0 (29.3) | 60 (50, 90) | 570.8 (294.1) | 450 (375, 675) | 31,647 (60.5%) | 11.1 (5.2) | 11 (7, 14) |
| Oxymorphone | ***** | 16.4 (8.4) | 14 (10, 20) | 37.9 (21.0) | 35 (20, 60) | 958.5 (816.8) | 788 (300, 1,200) | ***** (60.0%) | 9.0 (4.2) | 8 (6, 12) |
| Hydromorphone | 3,548 | 7.7 (4.4) | 7 (5, 10) | 71.6 (30.3) | 60 (50, 90) | 617.4 (301.6) | 568 (400, 720) | 2,258 (63.6%) | 10.4 (5.0) | 10 (7, 13) |
| Hydrocodone (after rescheduling) | 7,236 | 9.3 (5.1) | 8 (5, 10) | 72.6 (32.2) | 60 (50, 90) | 535.1 (318.9) | 450 (300, 630) | 3,936 (54.4%) | 12.4 (5.4) | 12 (8, 15) |
| Oxycodone | 40,948 | 8.0 (4.7) | 7 (5, 10) | 68.3 (28.5) | 60 (50, 90) | 567.4 (275.0) | 450 (375, 675) | 25,096 (61.3%) | 11.0 (5.1) | 10 (7, 14) |
| Morphine | ***** | 12.6 (7.5) | 10 (7, 15) | 48.6 (33.4) | 40 (20, 70) | 765.8 (521.3) | 600 (360, 1,050) | ***** (53.2%) | 9.5 (5.9) | 9 (5, 13) |
| Other | 391 | 8.7 (4.9) | 8 (5, 10) | 58.6 (24.8) | 60 (40, 80) | 1,053.4 (702.2) | 1,000 (450, 1,600) | 243 (62.1%) | 10.0 (5.5) | 9 (6, 13) |
| Other Schedule | 40,483 | 7.9 (4.6) | 7 (5, 10) | 56.7 (23.6) | 50 (40, 60) | 393.6 (227.0) | 300 (250, 500) | 25,339 (62.6%) | 10.7 (5.2) | 10 (7, 14) |
| Tramadol | 6,203 | 10.6 (6.1) | 9 (7, 13) | 58.8 (25.4) | 60 (40, 60) | 291.8 (127.6) | 300 (200, 300) | 3,065 (49.4%) | 11.3 (6.3) | 10 (7, 15) |
| Codeine | 1,042 | 7.0 (4.3) | 5 (5, 8) | 53.0 (26.0) | 50 (40, 60) | 251.7 (136.3) | 225 (180, 270) | 589 (56.5%) | 10.3 (5.2) | 9 (6, 13) |
| Hydrocodone (before rescheduling) | 32,932 | 7.4 (4.0) | 7 (5, 9) | 56.5 (23.1) | 50 (40, 60) | 410.6 (223.3) | 375 (250, 500) | 21,486 (65.2%) | 10.6 (5.0) | 10 (7, 13) |
| Other | 306 | 8.5 (4.9) | 7 (5, 10) | 50.2 (20.3) | 43 (40, 60) | 1,117.4 (476.3) | 920 (740, 1,380) | 199 (65.0%) | 9.9 (5.5) | 9 (6, 13) |
| 18-40 | 331 | 7.8 (4.4) | 7 (5, 10) | 61.3 (29.7) | 60 (40, 80) | 508.0 (320.6) | 450 (300, 600) | 187 (56.5%) | 9.7 (4.7) | 9 (6, 13) |
| Schedule II | 206 | 8.1 (4.4) | 7 (5, 10) | 66.8 (30.4) | 60 (50, 80) | 592.7 (344.4) | 450 (375, 675) | 125 (60.7%) | 9.7 (4.5) | 9 (6, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 6.9 (3.6) | 6 (4, 8) | 77.2 (25.2) | 80 (60, 100) | 706.7 (379.5) | 640 (480, 800) | ***** (66.7%) | 8.2 (3.1) | 7 (6, 11) |
| Hydrocodone (after rescheduling) | 20 | 10.0 (5.8) | 10 (7, 12) | 67.4 (33.7) | 60 (40, 90) | 494.5 (366.9) | 450 (250, 563) | ***** | 11.4 (4.6) | 11 (9, 13) |
| Oxycodone | 164 | 8.1 (4.3) | 7 (5, 10) | 66.1 (29.2) | 60 (50, 80) | 586.6 (311.9) | 450 (375, 675) | 102 (62.2%) | 9.7 (4.4) | 9 (7, 13) |
| Morphine | ***** | 6.5 (2.4) | 6 (5, 8) | 47.5 (68.4) | 15 (13, 83) | 825.0 (966.3) | 413 (225, 1,425) | ***** (75.0%) | 10.7 (9.0) | 6 (5, 21) |
| Other | 0 | - | - | - | - | - | - | - | - | - |
| Other Schedule | 125 | 7.2 (4.4) | 7 (5, 9) | 52.2 (26.1) | 50 (40, 60) | 368.4 (214.1) | 338 (200, 500) | 62 (49.6%) | 9.8 (5.2) | 9 (6, 13) |
| Tramadol | ***** | 11.6 (7.9) | 10 (7, 15) | 61.8 (46.1) | 50 (30, 80) | 308.8 (230.6) | 250 (150, 400) | ***** (47.1%) | 8.0 (6.3) | 6 (3, 12) |
| Codeine | ***** | 4.0 (1.8) | 4 (3, 6) | 35.0 (10.0) | 40 (30, 40) | 157.5 (45.0) | 180 (135, 180) | ***** (50.0%) | 6.0 (2.8) | 6 (4, 8) |
| Hydrocodone (before rescheduling) | 104 | 6.6 (3.0) | 6 (5, 8) | 51.2 (21.4) | 50 (40, 60) | 386.3 (210.3) | 375 (213, 500) | ***** | 10.2 (5.1) | 9 (6, 14) |
| Other | 0 | - | - | - | - | - | - | - | - | - |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-------------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Knee arthroplasty, continued | | | | | | | | | | |
| 41-64 | 24,716 | 7.9 (4.6) | 7 (5, 10) | 66.8 (28.8) | 60 (50, 90) | 546.0 (305.0) | 450 (320, 675) | 17,127 (69.3%) | 10.4 (5.1) | 9 (7, 13) |
| Schedule II | 15,712 | 8.0 (4.6) | 7 (5, 10) | 71.2 (30.3) | 60 (50, 90) | 605.3 (314.9) | 563 (400, 750) | 10,708 (68.2%) | 10.5 (5.1) | 10 (7, 13) |
| Oxymorphone | ***** | 26.7 (5.8) | 30 (20, 30) | 53.3 (11.5) | 60 (40, 60) | 1,900.0 (755.0) | 1,800 (1,200, 2,700) | ***** (66.7%) | 5.5 (0.7) | 6 (5, 6) |
| Hydromorphone | ***** | 7.2 (4.0) | 6 (5, 9) | 75.3 (31.0) | 70 (60, 90) | 654.2 (308.0) | 640 (480, 800) | ***** (69.8%) | 9.9 (4.9) | 9 (6, 12) |
| Hydrocodone (after rescheduling) | 1,318 | 9.9 (5.7) | 9 (6, 12) | 78.2 (37.2) | 70 (50, 100) | 610.4 (380.0) | 500 (300, 800) | ***** | 12.0 (5.8) | 11 (8, 15) |
| Oxycodone | 12,799 | 7.8 (4.5) | 7 (5, 10) | 70.3 (29.2) | 60 (50, 90) | 591.9 (288.7) | 525 (450, 750) | 8,769 (68.5%) | 10.5 (5.0) | 10 (7, 13) |
| Morphine | ***** | 12.7 (7.5) | 10 (7, 15) | 53.2 (39.2) | 31 (22, 80) | 850.4 (624.6) | 600 (420, 1,200) | ***** (62.7%) | 9.8 (5.7) | 10 (5, 13) |
| Other | 174 | 9.0 (5.2) | 8 (5, 10) | 61.5 (25.7) | 60 (40, 80) | 1,050.6 (737.7) | 1,000 (300, 1,600) | 126 (72.4%) | 10.0 (5.6) | 9 (6, 13) |
| Other Schedule | 9,004 | 7.8 (4.4) | 7 (5, 10) | 59.1 (24.3) | 60 (40, 70) | 442.6 (255.8) | 400 (270, 600) | 6,419 (71.3%) | 10.1 (5.1) | 9 (6, 13) |
| Tramadol | ***** | 11.0 (6.3) | 10 (7, 14) | 62.9 (27.8) | 60 (40, 80) | 312.7 (140.5) | 300 (200, 400) | ***** (57.4%) | 10.9 (6.5) | 10 (6, 15) |
| Codeine | ***** | 6.9 (4.3) | 5 (4, 8) | 54.7 (27.5) | 50 (40, 60) | 274.3 (171.0) | 225 (180, 324) | ***** (65.0%) | 10.0 (5.4) | 9 (6, 12) |
| Hydrocodone (before rescheduling) | 7,852 | 7.5 (4.0) | 7 (5, 9) | 59.0 (23.9) | 60 (40, 70) | 448.1 (240.4) | 400 (300, 600) | ***** | 10.1 (5.0) | 9 (6, 13) |
| Other | 135 | 8.6 (5.3) | 7 (5, 10) | 50.7 (19.2) | 45 (40, 60) | 1,147.5 (450.6) | 1,035 (920, 1,380) | 99 (73.3%) | 10.1 (5.8) | 9 (6, 13) |
| 65+ | 67,772 | 8.1 (4.7) | 7 (5, 10) | 62.5 (27.1) | 60 (40, 80) | 474.3 (269.0) | 450 (300, 600) | 39,672 (58.5%) | 11.2 (5.2) | 11 (7, 14) |
| Schedule II | 36,418 | 8.2 (4.8) | 7 (5, 10) | 68.0 (28.8) | 60 (50, 90) | 555.8 (283.0) | 450 (375, 675) | 20,814 (57.2%) | 11.4 (5.2) | 11 (8, 14) |
| Oxymorphone | ***** | 12.0 (4.3) | 10 (10, 15) | 31.3 (21.1) | 20 (20, 40) | 555.0 (421.5) | 300 (300, 1,125) | ***** (57.1%) | 10.8 (4.1) | 10 (8, 14) |
| Hydromorphone | 2,187 | 8.0 (4.6) | 7 (5, 10) | 69.2 (29.7) | 60 (50, 90) | 594.1 (294.5) | 480 (400, 720) | 1,309 (59.9%) | 10.9 (5.1) | 10 (7, 14) |
| Hydrocodone (after rescheduling) | 5,898 | 9.2 (5.0) | 8 (5, 10) | 71.4 (30.9) | 60 (50, 90) | 518.3 (300.9) | 450 (300, 600) | 3,101 (52.6%) | 12.5 (5.3) | 12 (8, 15) |
| Oxycodone | 27,985 | 8.0 (4.7) | 7 (5, 10) | 67.4 (28.2) | 60 (50, 90) | 556.1 (267.5) | 450 (375, 675) | 16,225 (58.0%) | 11.3 (5.1) | 11 (8, 14) |
| Morphine | ***** | 12.7 (7.6) | 10 (7, 15) | 45.8 (27.8) | 40 (21, 60) | 712.7 (426.0) | 600 (338, 900) | ***** (46.8%) | 9.2 (5.9) | 9 (4, 12) |
| Other | 217 | 8.5 (4.6) | 8 (5, 10) | 56.3 (23.8) | 50 (40, 60) | 1,055.7 (674.1) | 1,000 (600, 1,460) | 117 (53.9%) | 10.0 (5.5) | 9 (6, 13) |
| Other Schedule | 31,354 | 8.0 (4.6) | 7 (5, 10) | 56.1 (23.3) | 50 (40, 60) | 379.7 (216.1) | 300 (225, 450) | 18,858 (60.1%) | 10.9 (5.2) | 10 (7, 14) |
| Tramadol | 5,346 | 10.5 (6.0) | 9 (7, 13) | 58.1 (24.9) | 60 (40, 60) | 288.5 (124.7) | 300 (200, 300) | 2,575 (48.2%) | 11.4 (6.3) | 11 (7, 15) |
| Codeine | 861 | 7.1 (4.3) | 5 (5, 8) | 52.7 (25.7) | 50 (40, 60) | 247.5 (127.8) | 225 (180, 270) | 472 (54.8%) | 10.4 (5.2) | 10 (6, 14) |
| Hydrocodone (before rescheduling) | 24,976 | 7.4 (4.1) | 7 (5, 9) | 55.8 (22.9) | 50 (40, 60) | 398.9 (216.4) | 300 (250, 500) | 15,711 (62.9%) | 10.8 (5.0) | 10 (7, 14) |
| Other | 171 | 8.4 (4.6) | 7 (5, 10) | 49.9 (21.2) | 40 (35, 60) | 1,093.6 (495.6) | 920 (690, 1,380) | 100 (58.5%) | 9.7 (5.2) | 8 (6, 13) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|--------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Laminectomy/discectomy | | | | | | | | | | |
| All ages | 13,935 | 8.2 (4.7) | 7 (5, 10) | 60.2 (25.5) | 60 (40, 75) | 459.2 (264.2) | 450 (300, 600) | 2,396 (17.2%) | 10.9 (6.0) | 10 (6, 15) |
| Schedule II | 7,578 | 8.1 (4.6) | 7 (5, 10) | 63.4 (25.9) | 60 (45, 80) | 516.3 (269.2) | 450 (338, 675) | 1,223 (16.1%) | 10.9 (5.8) | 10 (6, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 236 | 7.7 (4.7) | 7 (5, 10) | 61.5 (28.3) | 60 (40, 84) | 572.3 (381.5) | 480 (320, 720) | 60 (25.4%) | 9.5 (6.0) | 8 (5, 13) |
| Hydrocodone (after rescheduling) | 1,150 | 9.8 (5.6) | 8 (5, 12) | 65.9 (28.5) | 60 (45, 90) | 466.9 (262.8) | 400 (300, 600) | 185 (16.1%) | 11.6 (6.2) | 11 (7, 16) |
| Oxycodone | 6,150 | 7.7 (4.3) | 7 (5, 10) | 63.0 (25.3) | 60 (45, 80) | 521.8 (260.7) | 450 (375, 675) | 966 (15.7%) | 10.9 (5.6) | 10 (6, 15) |
| Morphine | 19 | 13.7 (8.0) | 14 (7, 20) | 57.5 (21.1) | 60 (40, 60) | 910.3 (383.0) | 900 (600, 1,200) | **** | 12.4 (6.8) | 16 (3, 18) |
| Other | 23 | 9.7 (5.1) | 10 (5, 14) | 51.1 (25.4) | 50 (30, 60) | 643.0 (588.9) | 450 (175, 1,000) | **** | 17.0 (7.6) | 19 (10, 24) |
| Other Schedule | 6,357 | 8.3 (4.8) | 7 (5, 10) | 56.4 (24.4) | 60 (40, 60) | 391.0 (241.1) | 300 (225, 500) | 1,173 (18.5%) | 10.9 (6.3) | 10 (6, 15) |
| Tramadol | 460 | 10.4 (6.5) | 8 (6, 12) | 53.3 (24.6) | 50 (30, 60) | 264.5 (126.6) | 250 (150, 300) | 95 (20.7%) | 10.2 (6.1) | 10 (5, 14) |
| Codeine | 221 | 7.4 (4.4) | 7 (5, 10) | 53.1 (26.2) | 50 (30, 60) | 251.6 (139.6) | 225 (135, 270) | 39 (17.6%) | 10.6 (6.3) | 8 (6, 15) |
| Hydrocodone (before rescheduling) | 5,614 | 8.2 (4.7) | 7 (5, 10) | 56.8 (24.3) | 60 (40, 60) | 398.8 (230.3) | 300 (240, 500) | 1,026 (18.3%) | 11.0 (6.3) | 10 (6, 15) |
| Other | 62 | 8.9 (5.5) | 7 (5, 10) | 49.3 (21.3) | 45 (30, 60) | 1,119.5 (498.6) | 980 (690, 1,380) | 13 (21.0%) | 10.7 (6.1) | 9 (7, 14) |
| 18-40 | 3,194 | 8.1 (4.6) | 7 (5, 10) | 61.3 (25.6) | 60 (40, 80) | 477.2 (279.4) | 450 (300, 600) | 537 (16.8%) | 10.6 (5.6) | 10 (6, 14) |
| Schedule II | 1,828 | 8.0 (4.6) | 7 (5, 10) | 64.3 (25.9) | 60 (50, 80) | 531.2 (283.4) | 450 (375, 675) | 294 (16.1%) | 10.7 (5.3) | 10 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 7.5 (4.4) | 5 (5, 8) | 65.6 (23.7) | 60 (50, 90) | 621.6 (498.6) | 480 (400, 720) | ***** (21.4%) | 8.5 (5.8) | 7 (5, 12) |
| Hydrocodone (after rescheduling) | 244 | 10.2 (6.0) | 9 (6, 14) | 66.2 (28.5) | 60 (48, 90) | 490.0 (286.3) | 450 (300, 600) | 38 (15.6%) | 9.3 (5.2) | 8 (5, 14) |
| Oxycodone | 1,522 | 7.7 (4.3) | 7 (5, 10) | 64.0 (25.6) | 60 (50, 80) | 534.2 (270.7) | 450 (375, 675) | 243 (16.0%) | 11.1 (5.3) | 11 (7, 15) |
| Morphine | ***** | 6.0 (1.4) | 6 (5, 7) | 54.0 (36.8) | 54 (28, 80) | 810.0 (551.5) | 810 (420, 1,200) | 0 (0.0%) | - | - |
| Other | ***** | 8.0 (2.4) | 9 (6, 10) | 40.0 (14.1) | 35 (30, 50) | 462.5 (292.6) | 450 (225, 700) | ***** (25.0%) | ***** | ***** |
| Other Schedule | 1,366 | 8.2 (4.6) | 7 (5, 10) | 57.2 (24.6) | 60 (40, 60) | 405.1 (256.9) | 300 (225, 500) | 243 (17.8%) | 10.4 (6.0) | 9 (6, 14) |
| Tramadol | 64 | 10.2 (5.6) | 8 (7, 12) | 51.7 (21.6) | 50 (30, 60) | 255.3 (108.4) | 245 (150, 300) | 13 (20.3%) | 7.5 (4.6) | 6 (3, 11) |
| Codeine | ***** | 6.2 (3.7) | 5 (3, 8) | 47.6 (24.8) | 40 (30, 60) | 221.4 (110.8) | 180 (135, 270) | ***** (21.1%) | 8.4 (4.9) | 9 (4, 12) |
| Hydrocodone (before rescheduling) | 1,251 | 8.1 (4.4) | 7 (5, 10) | 57.7 (24.6) | 60 (40, 60) | 407.6 (228.5) | 300 (250, 500) | 220 (17.6%) | 10.6 (6.0) | 9 (6, 15) |
| Other | ***** | 11.8 (7.8) | 10 (6, 13) | 62.7 (33.1) | 60 (30, 75) | 1,441.9 (760.8) | 1,380 (690, 1,725) | ***** (15.4%) | 13.0 (0.0) | 13 (13, 13) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|---|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|-------------------|-------------------------|-------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Laminectomy/ discectomy, continued | | | | | | | | | | |
| 41-64 | 5,948 | 8.1 (4.7) | 7 (5, 10) | 61.3 (25.6) | 60 (40, 80) | 476.9 (270.0) | 450 (300, 600) | 1,013 (17.0%) | 10.9 (6.0) | 10 (6, 15) |
| Schedule II | 3,364 | 8.0 (4.5) | 7 (5, 10) | 64.5 (25.7) | 60 (50, 80) | 529.7 (270.5) | 450 (375, 675) | 548 (16.3%) | 11.1 (6.0) | 10 (6, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 106 | 7.9 (4.9) | 7 (5, 10) | 65.7 (29.5) | 60 (40, 90) | 618.6 (370.6) | 480 (320, 720) | ***** | 10.4 (6.3) | 10 (5, 16) |
| Hydrocodone (after rescheduling) | 408 | 9.8 (5.3) | 8 (6, 12) | 68.4 (28.1) | 60 (50, 90) | 480.9 (255.2) | 450 (300, 600) | 66 (16.2%) | 12.9 (6.6) | 13 (7, 18) |
| Oxycodone | 2,832 | 7.7 (4.3) | 7 (5, 10) | 64.0 (25.1) | 60 (50, 80) | 532.8 (266.2) | 450 (375, 675) | 453 (16.0%) | 10.8 (5.8) | 10 (6, 15) |
| Morphine | ***** | 12.9 (6.0) | 15 (9, 16) | 50.8 (21.5) | 53 (35, 60) | 761.3 (322.3) | 795 (525, 900) | ***** (37.5%) | 12.7 (8.4) | 17 (3, 18) |
| Other | ***** | 8.6 (4.5) | 7 (5, 12) | 54.5 (23.6) | 60 (35, 60) | 527.5 (418.1) | 375 (200, 900) | ***** (20.0%) | 16.0 (11.3) | 16 (8, 24) |
| Other Schedule | 2,584 | 8.3 (5.0) | 7 (5, 10) | 57.1 (24.9) | 60 (40, 60) | 408.2 (253.3) | 300 (225, 500) | 465 (18.0%) | 10.8 (6.0) | 10 (6, 15) |
| Tramadol | 151 | 10.4 (6.8) | 8 (5, 13) | 53.6 (25.8) | 50 (30, 60) | 269.1 (144.1) | 250 (150, 300) | 28 (18.5%) | 9.5 (5.3) | 10 (5, 13) |
| Codeine | 82 | 7.4 (3.7) | 7 (5, 10) | 56.1 (30.3) | 50 (40, 60) | 260.6 (140.1) | 248 (180, 270) | ***** | 11.5 (6.4) | 8 (6, 18) |
| Hydrocodone (before rescheduling) | 2,311 | 8.3 (4.9) | 7 (5, 10) | 57.5 (24.7) | 60 (40, 60) | 411.4 (241.0) | 300 (250, 500) | 416 (18.0%) | 10.9 (6.0) | 10 (6, 15) |
| Other | 40 | 7.8 (3.6) | 7 (5, 10) | 46.5 (16.4) | 43 (30, 50) | 1,045.3 (387.9) | 920 (690,1,150) | ***** | 10.0 (7.2) | 8 (4, 15) |
| 65+ | 4,793 | 8.3 (4.8) | 7 (5, 10) | 58.0 (25.0) | 60 (40, 65) | 425.1 (242.5) | 375 (250, 525) | 846 (17.7%) | 11.1 (6.3) | 10 (6, 15) |
| Schedule II | 2,386 | 8.2 (4.8) | 7 (5, 10) | 61.0 (26.1) | 60 (40, 80) | 486.1 (253.3) | 450 (300, 600) | 381 (16.0%) | 11.0 (5.8) | 10 (6, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 7.6 (4.7) | 7 (4, 10) | 52.6 (27.9) | 50 (30, 60) | 468.8 (260.3) | 480 (320, 640) | ***** (32.4%) | 9.2 (6.1) | 8 (5, 12) |
| Hydrocodone (after rescheduling) | 498 | 9.7 (5.6) | 8 (5, 12) | 63.7 (28.8) | 60 (40, 80) | 444.1 (255.7) | 400 (250, 600) | 81 (16.3%) | 11.7 (6.1) | 12 (7, 16) |
| Oxycodone | 1,796 | 7.8 (4.3) | 7 (5, 10) | 60.6 (25.1) | 60 (40, 80) | 493.8 (240.7) | 450 (338, 600) | 270 (15.0%) | 10.8 (5.6) | 10 (6, 15) |
| Morphine | ***** | 16.2 (9.4) | 15 (9, 20) | 64.3 (18.1) | 60 (60, 60) | 1,065.0 (386.5) | 900 (900,1,260) | ***** (44.4%) | 12.3 (6.7) | 14 (8, 17) |
| Other | ***** | 11.6 (6.4) | 13 (7, 14) | 52.3 (31.5) | 50 (30, 50) | 851.7 (802.0) | 1,000 (150,1,000) | ***** (22.2%) | 21.5 (3.5) | 22 (19, 24) |
| Other Schedule | 2,407 | 8.4 (4.9) | 7 (5, 10) | 55.1 (23.6) | 50 (40, 60) | 364.5 (214.8) | 300 (225, 450) | 465 (19.3%) | 11.3 (6.7) | 11 (6, 15) |
| Tramadol | 245 | 10.4 (6.5) | 8 (6, 13) | 53.5 (24.7) | 50 (30, 60) | 264.1 (119.8) | 250 (150, 300) | 54 (22.0%) | 11.2 (6.6) | 11 (5, 16) |
| Codeine | ***** | 8.0 (4.9) | 7 (5, 10) | 52.7 (22.9) | 50 (30, 60) | 255.7 (148.4) | 225 (144, 270) | ***** (18.8%) | 10.9 (6.9) | 8 (7, 14) |
| Hydrocodone (before rescheduling) | 2,052 | 8.2 (4.6) | 7 (5, 10) | 55.4 (23.5) | 50 (40, 60) | 379.1 (217.6) | 300 (225, 450) | 390 (19.0%) | 11.3 (6.7) | 11 (6, 15) |
| Other | ***** | 10.1 (7.8) | 8 (5, 10) | 42.8 (12.0) | 40 (30, 50) | 983.9 (276.4) | 920 (690,1,150) | ***** (22.2%) | 11.5 (3.5) | 12 (9, 14) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|------------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|-------------------|-------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Spinal fusion (all levels) | | | | | | | | | | |
| All ages | 29,292 | 9.1 (5.4) | 8 (5, 10) | 66.9 (29.7) | 60 (50, 90) | 539.0 (360.6) | 450 (300, 675) | 9,734 (33.2%) | 11.9 (6.1) | 11 (7, 15) |
| Schedule II | 16,939 | 9.2 (5.5) | 8 (5, 10) | 71.4 (30.8) | 60 (50, 90) | 619.6 (395.5) | 525 (400, 750) | 5,632 (33.2%) | 12.0 (6.1) | 11 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 977 | 8.9 (5.1) | 8 (5, 10) | 73.7 (33.4) | 60 (50, 90) | 657.7 (363.9) | 600 (400, 800) | 391 (40.0%) | 11.4 (5.9) | 11 (7, 15) |
| Hydrocodone (after rescheduling) | 2,319 | 10.5 (5.9) | 10 (7, 14) | 71.7 (31.2) | 60 (50, 90) | 532.3 (303.2) | 450 (300, 675) | 630 (27.2%) | 13.3 (6.9) | 13 (8, 16) |
| Oxycodone | 13,432 | 8.9 (5.3) | 8 (5, 10) | 71.4 (30.5) | 60 (50, 90) | 624.5 (379.2) | 563 (450, 750) | 4,521 (33.7%) | 11.9 (5.9) | 11 (8, 15) |
| Morphine | 116 | 16.0 (8.9) | 15 (10, 24) | 60.9 (34.9) | 60 (30, 80) | 1,233.1 (1,420.1) | 900 (600, 1,350) | 54 (46.6%) | 11.1 (8.5) | 9 (5, 15) |
| Other | 95 | 10.8 (6.1) | 10 (6, 15) | 61.9 (27.1) | 60 (40, 80) | 908.2 (877.7) | 450 (300, 1,200) | 36 (37.9%) | 11.8 (6.5) | 12 (7, 15) |
| Other Schedule | 12,353 | 9.0 (5.4) | 8 (5, 10) | 60.7 (27.1) | 60 (40, 80) | 428.5 (269.8) | 375 (250, 500) | 4,102 (33.2%) | 11.7 (6.3) | 11 (7, 15) |
| Tramadol | 1,295 | 11.6 (6.7) | 10 (7, 15) | 61.0 (31.0) | 60 (40, 80) | 302.4 (156.8) | 300 (200, 400) | 387 (29.9%) | 12.2 (8.2) | 11 (6, 17) |
| Codeine | 434 | 8.0 (4.7) | 7 (5, 10) | 56.3 (25.2) | 55 (40, 60) | 273.6 (138.5) | 270 (180, 360) | 129 (29.7%) | 11.0 (6.5) | 10 (6, 15) |
| Hydrocodone (before rescheduling) | 10,500 | 8.7 (5.1) | 8 (5, 10) | 60.9 (26.6) | 60 (40, 80) | 441.1 (258.4) | 400 (296, 600) | 3,545 (33.8%) | 11.7 (6.0) | 11 (7, 15) |
| Other | 124 | 9.7 (6.0) | 8 (5, 11) | 54.7 (26.8) | 50 (40, 60) | 1,222.1 (619.4) | 1,110 (740, 1,380) | 41 (33.1%) | 11.8 (6.4) | 12 (7, 15) |
| 18-40 | 2,810 | 8.9 (5.3) | 8 (5, 10) | 67.8 (32.7) | 60 (45, 90) | 561.5 (364.4) | 450 (300, 675) | 1,088 (38.7%) | 11.5 (6.2) | 11 (7, 15) |
| Schedule II | 1,750 | 9.0 (5.3) | 8 (5, 10) | 73.0 (34.8) | 60 (50, 90) | 642.8 (387.9) | 600 (450, 750) | 695 (39.7%) | 11.7 (6.2) | 11 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 104 | 9.7 (5.6) | 8 (6, 12) | 78.1 (39.8) | 70 (50, 90) | 716.8 (376.7) | 640 (480, 844) | 54 (51.9%) | 10.7 (6.3) | 11 (7, 13) |
| Hydrocodone (after rescheduling) | 146 | 10.7 (5.7) | 10 (7, 12) | 72.1 (33.4) | 60 (50, 90) | 513.4 (288.2) | 450 (300, 675) | ***** | 12.2 (6.9) | 11 (8, 15) |
| Oxycodone | 1,479 | 8.7 (5.2) | 7 (5, 10) | 73.0 (34.7) | 60 (50, 90) | 649.4 (394.5) | 600 (450, 750) | 582 (39.4%) | 11.8 (6.2) | 11 (7, 15) |
| Morphine | ***** | 15.7 (6.8) | 15 (10, 20) | 51.7 (22.7) | 55 (30, 60) | 805.5 (305.5) | 825 (600, 900) | ***** (30.0%) | 4.3 (4.0) | 2 (2, 9) |
| Other | ***** | 8.5 (4.3) | 7 (5, 10) | 57.3 (28.7) | 60 (30, 60) | 613.6 (486.4) | 450 (150, 1,200) | ***** (54.5%) | 11.3 (5.7) | 13 (7, 15) |
| Other Schedule | 1,060 | 8.7 (5.2) | 7 (5, 10) | 59.3 (26.8) | 60 (40, 75) | 427.4 (273.4) | 308 (225, 533) | 393 (37.1%) | 11.1 (6.3) | 10 (6, 15) |
| Tramadol | 69 | 11.5 (6.1) | 10 (7, 15) | 58.5 (25.1) | 60 (40, 60) | 289.1 (127.6) | 250 (200, 300) | 20 (29.0%) | 11.6 (5.3) | 11 (9, 13) |
| Codeine | 35 | 6.6 (3.8) | 5 (4, 9) | 50.9 (24.7) | 50 (30, 60) | 229.0 (111.0) | 225 (135, 270) | ***** | 8.4 (6.4) | 6 (5, 11) |
| Hydrocodone (before rescheduling) | 944 | 8.5 (5.1) | 7 (5, 10) | 59.8 (27.0) | 60 (40, 80) | 435.6 (263.7) | 375 (250, 600) | 359 (38.0%) | 11.2 (6.3) | 10 (6, 15) |
| Other | 12 | 7.7 (2.9) | 8 (6, 9) | 52.1 (22.3) | 50 (35, 60) | 1,156.7 (515.4) | 1,130 (805, 1,380) | ***** | 11.0 (5.7) | 11 (7, 15) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|-------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Spinal fusion (all levels), continued | | | | | | | | | | |
| 41-64 | 13,141 | 8.9 (5.3) | 8 (5, 10) | 67.4 (29.7) | 60 (50, 90) | 556.2 (383.2) | 450 (300, 675) | 4,322 (32.9%) | 11.9 (6.2) | 11 (7, 15) |
| Schedule II | 7,808 | 9.0 (5.4) | 8 (5, 10) | 71.7 (30.2) | 60 (50, 90) | 631.9 (418.7) | 525 (450, 750) | 2,576 (33.0%) | 11.9 (5.9) | 11 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 486 | 8.5 (5.1) | 7 (5, 10) | 74.5 (33.1) | 60 (50, 90) | 668.5 (388.5) | 640 (400, 800) | 184 (37.9%) | 11.1 (5.3) | 10 (7, 15) |
| Hydrocodone (after rescheduling) | 909 | 10.5 (5.6) | 10 (7, 14) | 72.3 (30.7) | 60 (50, 90) | 542.4 (302.5) | 450 (300, 675) | **** | 13.2 (6.3) | 13 (8, 17) |
| Oxycodone | 6,304 | 8.7 (5.2) | 7 (5, 10) | 71.5 (29.9) | 60 (50, 90) | 633.0 (394.9) | 563 (450, 750) | 2,106 (33.4%) | 11.9 (5.9) | 11 (7, 15) |
| Morphine | 55 | 16.0 (8.9) | 15 (10, 25) | 63.7 (32.0) | 60 (40, 90) | 1,311.2 (1,606.8) | 900 (675,1,350) | 26 (47.3%) | 12.3 (9.3) | 10 (5, 17) |
| Other | 54 | 11.6 (6.5) | 10 (7, 15) | 66.9 (26.9) | 60 (50, 90) | 991.4 (966.7) | 510 (300,1,600) | **** | 10.4 (4.3) | 11 (7, 13) |
| Other Schedule | 5,333 | 8.8 (5.3) | 8 (5, 10) | 61.0 (27.8) | 60 (40, 80) | 445.4 (290.7) | 375 (250, 600) | 1,746 (32.7%) | 11.8 (6.5) | 11 (7, 15) |
| Tramadol | 440 | 11.0 (6.3) | 10 (7, 15) | 61.1 (32.3) | 60 (40, 80) | 303.0 (164.9) | 300 (200, 400) | 123 (28.0%) | 11.8 (8.8) | 9 (5, 17) |
| Codeine | 167 | 7.9 (5.0) | 7 (5, 10) | 56.1 (26.9) | 50 (40, 60) | 269.3 (138.9) | 270 (180, 360) | 49 (29.3%) | 11.0 (6.5) | 11 (7, 16) |
| Hydrocodone (before rescheduling) | 4,642 | 8.6 (5.1) | 7 (5, 10) | 61.3 (27.4) | 60 (40, 80) | 451.0 (269.6) | 400 (300, 600) | 1,544 (33.3%) | 11.9 (6.3) | 11 (7, 15) |
| Other | 84 | 9.6 (5.9) | 8 (6, 12) | 54.6 (27.1) | 48 (40, 60) | 1,232.1 (620.6) | 1,073 (851,1,380) | 30 (35.7%) | 11.1 (5.7) | 12 (7, 15) |
| 65+ | 13,341 | 9.3 (5.6) | 8 (5, 10) | 66.2 (29.1) | 60 (48, 90) | 517.3 (334.7) | 450 (300, 675) | 4,324 (32.4%) | 12.0 (6.1) | 11 (8, 15) |
| Schedule II | 7,381 | 9.4 (5.6) | 8 (5, 11) | 70.7 (30.3) | 60 (50, 90) | 601.0 (370.4) | 480 (375, 675) | 2,361 (32.0%) | 12.1 (6.1) | 12 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 387 | 9.2 (5.1) | 8 (5, 10) | 71.5 (31.7) | 60 (50, 90) | 628.4 (324.6) | 560 (400, 800) | 153 (39.5%) | 12.0 (6.3) | 11 (8, 15) |
| Hydrocodone (after rescheduling) | 1,264 | 10.5 (6.2) | 9 (6, 14) | 71.3 (31.3) | 60 (50, 90) | 527.3 (305.4) | 450 (300, 675) | 336 (26.6%) | 13.5 (7.3) | 13 (9, 16) |
| Oxycodone | 5,649 | 9.2 (5.4) | 8 (5, 10) | 70.8 (29.9) | 60 (50, 90) | 608.5 (355.9) | 525 (450, 675) | 1,833 (32.4%) | 11.9 (5.8) | 11 (8, 15) |
| Morphine | ***** | 16.1 (9.4) | 15 (8, 30) | 59.7 (39.8) | 60 (30, 84) | 1,232.6 (1,338.0) | 900 (450,1,350) | ***** (49.0%) | 10.8 (7.9) | 9 (6, 11) |
| Other | ***** | 10.0 (5.8) | 10 (5, 15) | 54.7 (25.8) | 60 (30, 80) | 866.3 (812.2) | 465 (250,1,200) | ***** (46.7%) | 13.7 (8.6) | 13 (8, 15) |
| Other Schedule | 5,960 | 9.2 (5.5) | 8 (5, 10) | 60.6 (26.4) | 60 (40, 75) | 413.6 (247.9) | 325 (250, 500) | 1,963 (32.9%) | 11.7 (6.1) | 11 (7, 15) |
| Tramadol | 786 | 11.9 (7.0) | 10 (8, 15) | 61.2 (30.8) | 60 (40, 80) | 303.3 (154.6) | 300 (200, 400) | 244 (31.0%) | 12.4 (8.1) | 11 (6, 17) |
| Codeine | 232 | 8.3 (4.7) | 7 (5, 10) | 57.2 (24.1) | 60 (40, 60) | 283.5 (140.9) | 270 (180, 369) | ***** | 11.5 (6.6) | 10 (7, 15) |
| Hydrocodone (before rescheduling) | 4,914 | 8.8 (5.1) | 8 (5, 10) | 60.7 (25.7) | 60 (40, 75) | 432.8 (245.9) | 400 (300, 600) | 1,642 (33.4%) | 11.6 (5.7) | 11 (7, 15) |
| Other | 28 | 10.8 (7.2) | 10 (5, 14) | 56.1 (28.2) | 50 (35, 80) | 1,220.1 (673.2) | 1,015 (715,1,725) | ***** | 14.0 (8.7) | 13 (9, 14) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|------------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|-------------------|-------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Spinal fusion (1-3 levels) | | | | | | | | | | |
| All ages | 20,908 | 9.0 (5.3) | 8 (5, 10) | 66.2 (28.9) | 60 (46, 90) | 526.6 (349.3) | 450 (300, 675) | 6,349 (30.4%) | 11.9 (6.2) | 11 (7, 15) |
| Schedule II | 11,949 | 9.1 (5.4) | 8 (5, 10) | 70.7 (30.0) | 60 (50, 90) | 605.9 (384.5) | 488 (375, 675) | 3,592 (30.1%) | 12.1 (6.2) | 12 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 639 | 8.7 (5.0) | 8 (5, 10) | 72.6 (32.1) | 60 (50, 90) | 638.1 (334.8) | 576 (400, 800) | 230 (36.0%) | 11.4 (6.1) | 11 (7, 15) |
| Hydrocodone (after rescheduling) | 1,708 | 10.4 (5.9) | 9 (6, 13) | 71.2 (30.5) | 60 (50, 90) | 527.1 (294.1) | 450 (300, 675) | 442 (25.9%) | 13.2 (7.2) | 13 (8, 16) |
| Oxycodone | 9,460 | 8.8 (5.2) | 8 (5, 10) | 70.7 (29.7) | 60 (50, 90) | 611.0 (371.5) | 506 (450, 675) | 2,864 (30.3%) | 12.0 (6.0) | 11 (8, 15) |
| Morphine | 74 | 15.9 (8.5) | 15 (10, 20) | 59.2 (30.8) | 60 (30, 90) | 1,234.0 (1,449.5) | 900 (450, 1,350) | 32 (43.2%) | 10.8 (7.8) | 9 (6, 15) |
| Other | 68 | 10.8 (6.1) | 10 (6, 15) | 62.6 (28.0) | 60 (40, 89) | 883.9 (795.5) | 450 (250, 1,200) | 24 (35.3%) | 11.2 (7.1) | 11 (7, 15) |
| Other Schedule | 8,959 | 8.9 (5.3) | 8 (5, 10) | 60.2 (26.1) | 60 (40, 75) | 420.9 (260.7) | 338 (250, 500) | 2,757 (30.8%) | 11.7 (6.2) | 11 (7, 15) |
| Tramadol | 933 | 11.3 (6.2) | 10 (7, 15) | 60.3 (26.4) | 60 (40, 75) | 297.8 (133.3) | 300 (200, 375) | 260 (27.9%) | 12.4 (8.3) | 11 (6, 17) |
| Codeine | 320 | 8.0 (4.5) | 7 (5, 10) | 56.8 (24.7) | 60 (40, 60) | 276.7 (139.8) | 270 (180, 360) | 94 (29.4%) | 11.4 (6.6) | 10 (7, 15) |
| Hydrocodone (before rescheduling) | 7,618 | 8.6 (5.1) | 8 (5, 10) | 60.3 (26.1) | 60 (40, 75) | 432.7 (249.9) | 400 (263, 563) | 2,380 (31.2%) | 11.6 (5.9) | 11 (7, 15) |
| Other | 88 | 9.9 (5.6) | 9 (6, 12) | 55.3 (25.9) | 50 (37, 63) | 1,227.7 (599.4) | 1,110 (740, 1,380) | 23 (26.1%) | 10.2 (5.8) | 10 (6, 14) |
| 18-40 | 1,767 | 8.9 (5.2) | 8 (5, 10) | 68.0 (31.9) | 60 (45, 90) | 554.1 (349.4) | 450 (300, 675) | 599 (33.9%) | 12.2 (6.7) | 11 (7, 16) |
| Schedule II | 1,071 | 9.0 (5.3) | 8 (5, 10) | 73.5 (34.5) | 60 (50, 90) | 632.4 (373.2) | 600 (450, 750) | 365 (34.1%) | 12.5 (6.7) | 12 (8, 16) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 60 | 9.1 (5.6) | 8 (5, 11) | 76.8 (38.0) | 73 (50, 90) | 692.8 (332.9) | 640 (480, 800) | ***** | 10.4 (7.8) | 10 (4, 13) |
| Hydrocodone (after rescheduling) | 102 | 10.7 (5.9) | 9 (7, 12) | 72.9 (35.8) | 60 (50, 90) | 519.8 (298.8) | 450 (300, 675) | 30 (29.4%) | 11.2 (6.0) | 10 (7, 14) |
| Oxycodone | 897 | 8.8 (5.2) | 8 (5, 10) | 73.5 (34.2) | 60 (50, 90) | 641.3 (381.7) | 600 (450, 750) | 303 (33.8%) | 12.9 (6.5) | 13 (8, 17) |
| Morphine | ***** | 16.8 (8.2) | 15 (13, 15) | 41.4 (16.6) | 45 (30, 50) | 681.0 (178.0) | 675 (600, 750) | ***** (40.0%) | ***** | ***** |
| Other | ***** | 9.6 (4.9) | 8 (7, 10) | 65.7 (30.5) | 60 (40, 90) | 585.7 (446.0) | 450 (200, 1,200) | ***** (42.9%) | 9.3 (6.0) | 10 (3, 15) |
| Other Schedule | 696 | 8.7 (5.1) | 8 (5, 10) | 59.7 (25.2) | 60 (40, 80) | 433.7 (267.8) | 375 (250, 544) | 234 (33.6%) | 11.7 (6.6) | 11 (7, 16) |
| Tramadol | ***** | 10.3 (5.6) | 9 (6, 13) | 55.0 (21.2) | 50 (40, 60) | 272.4 (108.7) | 250 (200, 300) | ***** (21.1%) | 11.9 (5.6) | 12 (10, 15) |
| Codeine | ***** | 7.4 (4.6) | 5 (5, 10) | 51.6 (14.3) | 50 (40, 60) | 232.0 (64.5) | 225 (180, 270) | ***** (31.3%) | 5.0 (2.8) | 6 (2, 7) |
| Hydrocodone (before rescheduling) | 633 | 8.7 (5.1) | 8 (5, 10) | 60.2 (25.7) | 60 (40, 80) | 435.8 (247.6) | 400 (270, 600) | 220 (34.8%) | 11.8 (6.7) | 11 (7, 16) |
| Other | ***** | 8.6 (2.5) | 8 (7, 9) | 58.9 (20.3) | 60 (50, 60) | 1,324.4 (473.1) | 1,150 (1,110, 1,380) | ***** (11.1%) | ***** | ***** |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|--------------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Spinal fusion (1-3 levels), continued | | | | | | | | | | |
| 41-64 | 9,373 | 8.8 (5.2) | 8 (5, 10) | 66.8 (28.9) | 60 (50, 90) | 543.8 (376.7) | 450 (300, 675) | 2,765 (29.5%) | 11.9 (6.1) | 11 (7, 15) |
| Schedule II | 5,531 | 8.8 (5.2) | 8 (5, 10) | 71.1 (29.4) | 60 (50, 90) | 618.7 (414.2) | 500 (400, 720) | 1,629 (29.5%) | 12.0 (6.0) | 12 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 316 | 8.1 (4.5) | 7 (5, 10) | 73.5 (31.7) | 60 (50, 90) | 642.9 (341.8) | 600 (400, 720) | ***** | 11.3 (5.3) | 11 (7, 15) |
| Hydrocodone (after rescheduling) | 667 | 10.4 (5.5) | 10 (7, 13) | 72.5 (29.8) | 60 (50, 90) | 539.4 (295.1) | 450 (300, 675) | 168 (25.2%) | 13.2 (6.4) | 14 (8, 17) |
| Oxycodone | 4,476 | 8.6 (5.1) | 7 (5, 10) | 70.8 (29.2) | 60 (50, 90) | 618.8 (383.3) | 506 (450, 675) | 1,328 (29.7%) | 12.0 (6.0) | 11 (8, 15) |
| Morphine | ***** | 16.5 (8.8) | 15 (10, 25) | 63.2 (29.4) | 60 (45, 90) | 1,511.8 (1,985.6) | 900 (720, 1,350) | ***** (50.0%) | 11.7 (7.4) | 9 (6, 17) |
| Other | ***** | 11.5 (6.7) | 10 (6, 15) | 67.1 (28.3) | 60 (40, 90) | 995.9 (890.2) | 585 (300, 1,600) | ***** (26.3%) | 9.3 (4.2) | 9 (7, 12) |
| Other Schedule | 3,842 | 8.7 (5.2) | 8 (5, 10) | 60.7 (27.1) | 60 (40, 80) | 436.0 (282.1) | 375 (250, 525) | 1,136 (29.6%) | 11.7 (6.3) | 11 (7, 15) |
| Tramadol | 313 | 10.8 (5.9) | 10 (7, 15) | 60.2 (27.4) | 60 (40, 70) | 296.2 (139.9) | 300 (200, 350) | 82 (26.2%) | 10.9 (8.0) | 9 (5, 15) |
| Codeine | 123 | 8.2 (5.2) | 7 (5, 10) | 58.4 (27.2) | 60 (40, 80) | 280.1 (142.9) | 270 (180, 360) | 33 (26.8%) | 11.7 (6.4) | 11 (7, 16) |
| Hydrocodone (before rescheduling) | 3,349 | 8.5 (5.0) | 7 (5, 10) | 60.9 (27.1) | 60 (40, 80) | 440.8 (260.7) | 400 (270, 600) | 1,004 (30.0%) | 11.8 (6.1) | 11 (7, 15) |
| Other | 57 | 10.1 (5.7) | 9 (6, 12) | 56.0 (27.3) | 50 (34, 65) | 1,258.4 (622.0) | 1,110 (740, 1,380) | 17 (29.8%) | 10.2 (6.3) | 10 (5, 14) |
| 65+ | 9,768 | 9.2 (5.5) | 8 (5, 10) | 65.3 (28.2) | 60 (45, 90) | 505.2 (319.4) | 450 (300, 675) | 2,985 (30.6%) | 12.0 (6.2) | 11 (8, 15) |
| Schedule II | 5,347 | 9.4 (5.6) | 8 (5, 11) | 69.8 (29.5) | 60 (50, 90) | 587.3 (352.7) | 450 (375, 675) | 1,598 (29.9%) | 12.2 (6.3) | 11 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 263 | 9.3 (5.2) | 8 (5, 10) | 70.5 (31.1) | 60 (50, 90) | 619.9 (326.4) | 480 (400, 800) | 97 (36.9%) | 11.9 (6.3) | 11 (7, 16) |
| Hydrocodone (after rescheduling) | 939 | 10.4 (6.2) | 9 (5, 14) | 70.1 (30.4) | 60 (50, 90) | 519.1 (292.9) | 450 (300, 675) | 244 (26.0%) | 13.4 (7.7) | 13 (8, 16) |
| Oxycodone | 4,087 | 9.1 (5.4) | 8 (5, 10) | 69.9 (29.2) | 60 (50, 90) | 595.8 (355.1) | 450 (450, 675) | 1,233 (30.2%) | 11.9 (5.8) | 11 (8, 15) |
| Morphine | 35 | 15.1 (8.5) | 15 (8, 20) | 57.8 (33.2) | 60 (30, 90) | 1,043.1 (721.7) | 900 (450, 1,350) | 13 (37.1%) | 10.8 (8.3) | 9 (6, 11) |
| Other | 23 | 10.1 (5.5) | 10 (5, 15) | 54.3 (26.1) | 60 (30, 80) | 789.6 (693.6) | 400 (200, 1,200) | 11 (47.8%) | 13.4 (9.2) | 13 (6, 15) |
| Other Schedule | 4,421 | 9.0 (5.4) | 8 (5, 10) | 59.8 (25.3) | 60 (40, 75) | 405.8 (238.6) | 300 (250, 500) | 1,387 (31.4%) | 11.7 (6.0) | 11 (7, 15) |
| Tramadol | ***** | 11.7 (6.4) | 10 (8, 15) | 60.7 (26.1) | 60 (40, 80) | 300.4 (131.0) | 300 (200, 400) | ***** (29.2%) | 13.1 (8.5) | 11 (6, 19) |
| Codeine | ***** | 7.8 (3.9) | 7 (5, 10) | 56.2 (23.5) | 60 (40, 60) | 278.3 (142.4) | 270 (180, 360) | ***** (30.9%) | 11.8 (6.8) | 10 (7, 16) |
| Hydrocodone (before rescheduling) | 3,636 | 8.7 (5.1) | 8 (5, 10) | 59.8 (25.3) | 60 (40, 75) | 424.8 (239.8) | 375 (250, 500) | 1,156 (31.8%) | 11.5 (5.5) | 11 (7, 15) |
| Other | ***** | 9.7 (6.2) | 10 (5, 10) | 52.1 (24.9) | 40 (30, 60) | 1,108.6 (591.6) | 920 (690, 1,380) | ***** (22.7%) | 11.0 (4.8) | 11 (7, 13) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|------------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|-------------------|-------------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Spinal fusion (4+ levels) | | | | | | | | | | |
| All ages | 7,193 | 9.5 (5.7) | 8 (5, 11) | 70.1 (32.1) | 60 (50, 90) | 583.0 (376.8) | 450 (300, 675) | 3,036 (42.2%) | 11.7 (6.1) | 11 (7, 15) |
| Schedule II | 4,360 | 9.5 (5.6) | 8 (5, 11) | 74.2 (32.8) | 60 (60, 90) | 661.6 (403.7) | 600 (450, 750) | 1,852 (42.5%) | 11.7 (5.8) | 11 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 299 | 9.6 (5.5) | 8 (6, 12) | 77.8 (36.0) | 75 (50, 90) | 714.6 (419.9) | 640 (480, 800) | 146 (48.8%) | 11.2 (5.7) | 10 (7, 14) |
| Hydrocodone (after rescheduling) | 514 | 11.2 (6.2) | 10 (7, 15) | 75.2 (33.8) | 60 (60, 90) | 563.3 (335.3) | 450 (300, 683) | 174 (33.9%) | 13.4 (6.4) | 13 (9, 17) |
| Oxycodone | 3,489 | 9.2 (5.4) | 8 (5, 10) | 73.9 (32.3) | 60 (60, 90) | 666.0 (395.5) | 600 (450, 750) | 1,502 (43.0%) | 11.6 (5.7) | 11 (7, 15) |
| Morphine | 35 | 16.0 (9.3) | 15 (8, 30) | 61.3 (41.9) | 60 (30, 60) | 991.3 (648.4) | 900 (480, 900) | 19 (54.3%) | 12.7 (9.9) | 10 (5, 18) |
| Other | 23 | 11.0 (6.1) | 10 (7, 15) | 61.4 (23.9) | 60 (42, 80) | 990.9 (1,127.5) | 450 (300, 1,200) | 11 (47.8%) | 13.5 (5.0) | 13 (9, 18) |
| Other Schedule | 2,833 | 9.5 (5.8) | 8 (5, 11) | 63.8 (29.8) | 60 (40, 80) | 462.1 (292.7) | 400 (300, 600) | 1,184 (41.8%) | 11.7 (6.4) | 11 (7, 15) |
| Tramadol | 301 | 12.6 (8.0) | 10 (7, 15) | 64.7 (42.5) | 60 (40, 80) | 323.9 (214.4) | 300 (200, 400) | 106 (35.2%) | 11.3 (7.8) | 10 (5, 15) |
| Codeine | 90 | 8.3 (5.1) | 7 (5, 10) | 55.5 (26.5) | 50 (30, 75) | 263.2 (125.1) | 270 (180, 360) | 29 (32.2%) | 9.6 (5.9) | 10 (6, 13) |
| Hydrocodone (before rescheduling) | 2,417 | 9.2 (5.4) | 8 (5, 10) | 64.1 (27.9) | 60 (40, 80) | 478.7 (281.3) | 450 (300, 600) | 1,034 (42.8%) | 11.8 (6.3) | 11 (7, 15) |
| Other | 25 | 9.1 (6.2) | 8 (5, 10) | 54.7 (29.2) | 50 (40, 60) | 1,243.2 (677.4) | 1,110 (920, 1,380) | 15 (60.0%) | 12.0 (4.4) | 13 (10, 14) |
| 18-40 | 875 | 9.0 (5.3) | 8 (5, 10) | 70.3 (34.8) | 60 (50, 90) | 605.5 (396.4) | 500 (300, 750) | 447 (51.1%) | 10.6 (5.5) | 10 (7, 13) |
| Schedule II | 598 | 9.1 (5.4) | 8 (5, 10) | 73.9 (36.4) | 60 (50, 90) | 678.3 (419.1) | 600 (450, 900) | 303 (50.7%) | 10.8 (5.4) | 10 (7, 14) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 39 | 10.8 (6.0) | 10 (8, 12) | 82.8 (44.3) | 78 (60, 90) | 787.1 (444.4) | 672 (480, 960) | 25 (64.1%) | 10.4 (3.9) | 11 (8, 13) |
| Hydrocodone (after rescheduling) | ***** | 11.2 (5.4) | 10 (7, 14) | 72.1 (27.4) | 60 (60, 90) | 526.7 (266.0) | 450 (300, 600) | ***** (48.7%) | 13.5 (8.2) | 11 (8, 19) |
| Oxycodone | 511 | 8.8 (5.2) | 8 (5, 10) | 73.7 (36.4) | 60 (50, 90) | 679.2 (423.0) | 600 (450, 900) | 255 (49.9%) | 10.6 (5.3) | 10 (7, 13) |
| Morphine | ***** | 14.6 (5.9) | 16 (10, 20) | 62.0 (24.9) | 60 (60, 60) | 930.0 (373.5) | 900 (900, 900) | ***** (20.0%) | ***** | ***** |
| Other | ***** | 6.8 (2.4) | 6 (5, 9) | 42.5 (20.6) | 45 (25, 60) | 662.5 (621.0) | 675 (125, 1,200) | ***** (75.0%) | 13.3 (5.7) | 15 (7, 18) |
| Other Schedule | 277 | 8.9 (5.3) | 8 (5, 10) | 62.6 (29.4) | 60 (40, 80) | 448.3 (285.6) | 338 (250, 600) | 144 (52.0%) | 10.1 (5.6) | 9 (6, 13) |
| Tramadol | 24 | 13.2 (6.2) | 13 (10, 15) | 65.0 (29.6) | 60 (45, 75) | 319.8 (151.6) | 275 (213, 375) | ***** | 11.5 (5.9) | 11 (9, 12) |
| Codeine | 14 | 6.4 (3.0) | 6 (5, 7) | 52.6 (27.4) | 50 (30, 72) | 236.6 (123.4) | 225 (135, 324) | ***** | 11.7 (7.7) | 10 (6, 18) |
| Hydrocodone (before rescheduling) | 238 | 8.7 (5.1) | 8 (5, 10) | 63.1 (29.5) | 60 (40, 80) | 473.2 (294.8) | 400 (250, 600) | 127 (53.4%) | 9.9 (5.5) | 9 (6, 13) |
| Other | ***** | ***** | ***** | ***** | ***** | ***** | ***** | ***** (100.0%) | ***** | ***** |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|---|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|--------------------|-------------------------|-------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Spinal fusion (4+ levels), continued | | | | | | | | | | |
| 41-64 | 3,261 | 9.4 (5.6) | 8 (5, 11) | 70.4 (31.8) | 60 (50, 90) | 602.5 (397.5) | 500 (360, 750) | 1,413 (43.3%) | 11.9 (6.3) | 11 (7, 15) |
| Schedule II | 2,004 | 9.5 (5.7) | 8 (5, 11) | 74.5 (32.2) | 60 (60, 90) | 674.6 (424.9) | 600 (450, 800) | 868 (43.3%) | 11.8 (5.9) | 11 (7, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 149 | 9.5 (5.9) | 8 (5, 10) | 78.5 (36.0) | 80 (50, 100) | 733.0 (470.9) | 640 (480, 800) | 70 (47.0%) | 10.7 (5.4) | 9 (7, 13) |
| Hydrocodone (after rescheduling) | 200 | 11.4 (6.1) | 10 (7, 15) | 74.7 (34.1) | 70 (50, 90) | 576.4 (334.8) | 500 (300, 775) | 70 (35.0%) | 13.4 (6.2) | 13 (10, 16) |
| Oxycodone | 1,624 | 9.2 (5.4) | 8 (5, 10) | 74.3 (31.6) | 60 (60, 90) | 676.3 (414.8) | 600 (450, 750) | 715 (44.0%) | 11.7 (5.8) | 11 (7, 15) |
| Morphine | ***** | 15.8 (8.7) | 15 (10, 15) | 60.4 (33.8) | 60 (30, 60) | 931.8 (493.8) | 900 (600, 900) | ***** (41.2%) | 16.4 (12.6) | 14 (8, 21) |
| Other | ***** | 11.8 (6.6) | 10 (7, 15) | 64.4 (24.3) | 60 (50, 80) | 956.4 (1,199.2) | 425 (300, 1,200) | ***** (42.9%) | 12.2 (4.2) | 12 (9, 14) |
| Other Schedule | 1,257 | 9.3 (5.6) | 8 (5, 10) | 63.9 (29.9) | 60 (40, 80) | 487.6 (317.0) | 405 (300, 600) | 545 (43.4%) | 12.0 (6.9) | 11 (7, 15) |
| Tramadol | 103 | 11.8 (7.0) | 10 (7, 15) | 66.3 (42.5) | 60 (40, 90) | 335.6 (216.5) | 300 (200, 450) | 34 (33.0%) | 13.1 (9.9) | 11 (6, 21) |
| Codeine | 34 | 7.2 (4.2) | 5 (5, 8) | 52.1 (26.0) | 40 (30, 60) | 248.6 (127.7) | 225 (135, 270) | 14 (41.2%) | 9.1 (6.2) | 10 (2, 14) |
| Hydrocodone (before rescheduling) | 1,100 | 9.1 (5.4) | 8 (5, 10) | 64.1 (28.5) | 60 (41, 80) | 494.8 (294.1) | 450 (300, 600) | 486 (44.2%) | 12.0 (6.7) | 11 (7, 15) |
| Other | 20 | 9.3 (6.5) | 8 (6, 10) | 56.4 (29.7) | 48 (40, 70) | 1,278.1 (689.2) | 1,073 (920, 1,610) | 11 (55.0%) | 11.7 (5.0) | 12 (10, 14) |
| 65+ | 3,057 | 9.7 (5.9) | 8 (5, 12) | 69.8 (31.6) | 60 (50, 90) | 555.8 (345.6) | 450 (300, 675) | 1,176 (38.5%) | 12.0 (6.0) | 11 (8, 15) |
| Schedule II | 1,758 | 9.7 (5.7) | 8 (5, 12) | 74.0 (32.3) | 60 (60, 90) | 641.0 (371.5) | 600 (450, 750) | 681 (38.7%) | 12.1 (5.9) | 12 (8, 15) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | 111 | 9.3 (4.8) | 8 (5, 13) | 75.2 (32.8) | 75 (50, 90) | 664.6 (325.9) | 600 (480, 800) | 51 (45.9%) | 12.3 (6.7) | 11 (8, 15) |
| Hydrocodone (after rescheduling) | ***** | 11.0 (6.5) | 10 (7, 14) | 76.0 (34.6) | 68 (60, 90) | 558.9 (344.8) | 450 (300, 675) | ***** (30.9%) | 13.4 (6.2) | 12 (9, 17) |
| Oxycodone | 1,354 | 9.4 (5.5) | 8 (5, 11) | 73.6 (31.5) | 60 (60, 90) | 648.8 (359.1) | 600 (450, 750) | 532 (39.3%) | 11.8 (5.7) | 11 (8, 15) |
| Morphine | 13 | 16.7 (11.4) | 14 (6, 30) | 62.4 (56.8) | 60 (30, 60) | 1,092.7 (895.4) | 900 (480, 1,200) | 11 (84.6%) | 10.6 (8.2) | 9 (4, 18) |
| Other | ***** | 12.4 (6.4) | 10 (10, 15) | 68.0 (21.7) | 60 (60, 90) | 1,350.0 (1,324.8) | 1,200 (450, 1,200) | ***** (40.0%) | 18.0 (7.1) | 18 (13, 23) |
| Other Schedule | 1,299 | 9.8 (6.0) | 8 (5, 12) | 64.0 (29.8) | 60 (40, 80) | 440.4 (266.7) | 400 (270, 600) | 495 (38.1%) | 11.8 (6.1) | 11 (7, 15) |
| Tramadol | 174 | 12.9 (8.8) | 10 (8, 15) | 63.8 (44.1) | 60 (40, 80) | 317.6 (221.2) | 300 (200, 400) | ***** (35.6%) | 10.3 (6.6) | 9 (5, 14) |
| Codeine | 42 | 9.8 (6.0) | 8 (5, 11) | 59.3 (26.7) | 55 (40, 90) | 283.9 (123.0) | 270 (180, 405) | ***** | 9.0 (4.2) | 10 (6, 11) |
| Hydrocodone (before rescheduling) | 1,079 | 9.3 (5.3) | 8 (5, 10) | 64.3 (26.9) | 60 (40, 80) | 463.4 (263.7) | 400 (300, 600) | 421 (39.0%) | 12.1 (6.1) | 11 (8, 15) |
| Other | ***** | 9.5 (4.9) | 10 (7, 13) | 53.8 (30.9) | 55 (33, 75) | 1,236.3 (711.2) | 1,265 (748, 1,725) | ***** (75.0%) | 12.0 (2.6) | 13 (9, 14) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|-----------------------------------|--------------------|------------------|-----------------|----------------------------|--------------------|--------------------------------|-----------------------|-------------------------|------------------|-----------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Tooth extraction | | | | | | | | | | |
| All ages | 181,300 | 3.5 (1.7) | 3 (2, 4) | 19.7 (6.5) | 20 (15, 20) | 129.1 (65.0) | 113 (90, 150) | 14,976 (8.3%) | 6.9 (3.7) | 6 (4, 8) |
| Schedule II | 60,018 | 3.6 (1.7) | 3 (3, 4) | 21.0 (6.8) | 20 (16, 24) | 155.5 (70.6) | 150 (113, 188) | 4,201 (7.0%) | 7.0 (3.7) | 6 (5, 8) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 3.9 (2.0) | 4 (2, 5) | 25.9 (17.3) | 20 (18, 30) | 261.6 (229.9) | 240 (160, 256) | ***** (15.5%) | 8.0 (3.8) | 7 (5, 11) |
| Hydrocodone (after rescheduling) | 19,925 | 3.6 (1.7) | 3 (3, 4) | 20.1 (6.7) | 20 (15, 24) | 120.0 (51.5) | 100 (85, 150) | 1,078 (5.4%) | 7.5 (3.8) | 7 (5, 9) |
| Oxycodone | 39,249 | 3.6 (1.7) | 3 (3, 4) | 21.4 (6.8) | 20 (18, 25) | 174.0 (70.5) | 150 (150, 225) | 3,020 (7.7%) | 6.9 (3.6) | 6 (4, 8) |
| Morphine | ***** | 4.4 (3.4) | 3 (2, 5) | 16.4 (5.0) | 20 (12, 20) | 226.0 (69.9) | 200 (180, 300) | ***** (40.0%) | 10.5 (3.5) | 11 (8, 13) |
| Other | 736 | 3.4 (1.6) | 3 (2, 4) | 20.1 (6.2) | 20 (16, 20) | 111.6 (76.6) | 100 (80, 120) | 85 (11.5%) | 5.7 (3.4) | 5 (4, 7) |
| Other Schedule | 121,282 | 3.4 (1.6) | 3 (2, 4) | 19.0 (6.2) | 20 (15, 20) | 116.1 (57.8) | 100 (80, 150) | 10,775 (8.9%) | 6.8 (3.7) | 6 (4, 8) |
| Tramadol | 1,619 | 4.2 (3.0) | 3 (3, 5) | 21.8 (10.2) | 20 (16, 25) | 103.7 (50.7) | 100 (75, 120) | 119 (7.4%) | 6.8 (4.3) | 6 (4, 9) |
| Codeine | 13,626 | 3.3 (1.8) | 3 (2, 4) | 17.9 (5.9) | 18 (15, 20) | 81.2 (29.0) | 81 (68, 90) | 781 (5.7%) | 7.4 (4.4) | 6 (4, 10) |
| Hydrocodone (before rescheduling) | 105,088 | 3.4 (1.6) | 3 (2, 4) | 19.1 (6.1) | 20 (15, 20) | 118.1 (50.5) | 100 (85, 150) | 9,805 (9.3%) | 6.7 (3.6) | 6 (4, 8) |
| Other | 949 | 3.4 (2.0) | 3 (2, 4) | 18.3 (6.1) | 20 (15, 20) | 416.7 (139.0) | 460 (345, 460) | 70 (7.4%) | 7.1 (3.8) | 6 (4, 9) |
| 18-40 | 131,837 | 3.5 (1.6) | 3 (3, 4) | 20.2 (6.2) | 20 (16, 21) | 134.0 (63.0) | 120 (100, 150) | 12,023 (9.1%) | 6.5 (3.4) | 6 (4, 8) |
| Schedule II | 48,858 | 3.6 (1.7) | 3 (3, 4) | 21.3 (6.6) | 20 (18, 25) | 158.7 (68.7) | 150 (113, 188) | 3,528 (7.2%) | 6.7 (3.4) | 6 (4, 8) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 3.9 (1.9) | 4 (3, 5) | 27.7 (19.1) | 22 (20, 30) | 285.4 (263.6) | 240 (160, 288) | ***** (14.1%) | 6.4 (2.3) | 7 (5, 8) |
| Hydrocodone (after rescheduling) | 14,862 | 3.6 (1.7) | 3 (3, 4) | 20.7 (6.6) | 20 (16, 24) | 123.5 (51.7) | 100 (90, 150) | 842 (5.7%) | 7.1 (3.5) | 6 (5, 8) |
| Oxycodone | 33,316 | 3.7 (1.7) | 3 (3, 4) | 21.6 (6.5) | 20 (20, 25) | 175.1 (67.8) | 150 (150, 225) | 2,601 (7.8%) | 6.7 (3.4) | 6 (4, 8) |
| Morphine | ***** | ***** | ***** | ***** | ***** | ***** | ***** | 0 (0.0%) | - | - |
| Other | 608 | 3.4 (1.4) | 3 (2, 4) | 20.1 (6.0) | 20 (16, 20) | 109.5 (66.8) | 100 (80, 100) | ***** | 5.4 (2.8) | 5 (4, 7) |
| Other Schedule | 82,979 | 3.5 (1.6) | 3 (2, 4) | 19.5 (5.9) | 20 (16, 20) | 119.4 (54.5) | 100 (90, 150) | 8,495 (10.2%) | 6.4 (3.4) | 6 (4, 8) |
| Tramadol | 796 | 4.3 (2.8) | 4 (3, 5) | 22.0 (8.0) | 20 (16, 30) | 105.4 (41.9) | 100 (75, 125) | ***** | 6.1 (3.3) | 5 (4, 8) |
| Codeine | 6,778 | 3.3 (1.8) | 3 (2, 4) | 18.3 (6.2) | 20 (15, 20) | 83.3 (30.4) | 90 (68, 90) | 462 (6.8%) | 6.7 (4.1) | 6 (4, 8) |
| Hydrocodone (before rescheduling) | 74,987 | 3.5 (1.6) | 3 (2, 4) | 19.6 (5.8) | 20 (16, 20) | 121.1 (49.3) | 100 (90, 150) | 7,922 (10.6%) | 6.4 (3.3) | 6 (4, 8) |
| Other | 418 | 3.5 (1.8) | 3 (3, 4) | 19.0 (5.0) | 20 (16, 20) | 432.7 (117.6) | 460 (368, 460) | ***** | 6.6 (3.4) | 5 (4, 9) |

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Number of Patients | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|------------------------------------|--------------------|--------------|--------------|----------------------------|--------------|--------------------------------|----------------|-------------------------|------------|--------------|
| | | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) | Median (IQR) |
| Tooth extraction, continued | | | | | | | | | | |
| 41-64 | 44,372 | 3.4 (1.7) | 3 (2, 4) | 18.2 (6.8) | 20 (15, 20) | 116.7 (68.4) | 100 (75, 150) | 2,702 (6.1%) | 8.3 (4.4) | 7 (5, 11) |
| Schedule II | 10,119 | 3.5 (1.8) | 3 (2, 4) | 19.3 (7.4) | 20 (15, 20) | 141.5 (76.9) | 135 (90, 158) | 632 (6.2%) | 8.6 (4.4) | 8 (5, 11) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 3.5 (1.9) | 3 (2, 5) | 20.6 (9.8) | 20 (12, 25) | 197.0 (93.4) | 160 (144, 240) | ***** (14.8%) | 9.0 (4.5) | 8 (6, 13) |
| Hydrocodone (after rescheduling) | 4,523 | 3.4 (1.6) | 3 (2, 4) | 18.2 (6.4) | 18 (15, 20) | 109.9 (49.8) | 100 (75, 140) | 214 (4.7%) | 9.0 (4.3) | 8 (6, 12) |
| Oxycodone | 5,444 | 3.6 (2.0) | 3 (2, 4) | 20.1 (8.0) | 20 (15, 24) | 167.9 (84.0) | 150 (120, 225) | 402 (7.4%) | 8.4 (4.5) | 8 (5, 10) |
| Morphine | ***** | 5.0 (3.6) | 4 (3, 8) | 17.5 (5.0) | 20 (15, 20) | 237.5 (75.0) | 250 (175, 300) | ***** (50.0%) | 10.5 (3.5) | 11 (8, 13) |
| Other | ***** | 3.4 (2.2) | 3 (2, 4) | 19.7 (7.3) | 20 (16, 20) | 122.6 (114.7) | 100 (80, 125) | ***** (8.3%) | 8.3 (5.9) | 7 (4, 9) |
| Other Schedule | 34,253 | 3.3 (1.7) | 3 (2, 4) | 17.9 (6.6) | 18 (15, 20) | 109.4 (63.9) | 100 (75, 126) | 2,070 (6.0%) | 8.2 (4.4) | 7 (5, 11) |
| Tramadol | 681 | 4.0 (2.9) | 3 (3, 5) | 21.4 (11.1) | 20 (16, 24) | 100.5 (53.3) | 100 (75, 105) | 38 (5.6%) | 7.4 (4.5) | 7 (4, 10) |
| Codeine | 5,845 | 3.2 (1.8) | 3 (2, 4) | 17.4 (5.4) | 16 (12, 20) | 79.4 (27.3) | 72 (54, 90) | 282 (4.8%) | 8.6 (4.8) | 8 (5, 12) |
| Hydrocodone (before rescheduling) | 27,276 | 3.3 (1.6) | 3 (2, 4) | 17.9 (6.6) | 18 (15, 20) | 111.1 (53.0) | 100 (80, 150) | 1,726 (6.3%) | 8.1 (4.3) | 7 (5, 10) |
| Other | 451 | 3.3 (1.9) | 3 (2, 4) | 18.0 (7.0) | 18 (15, 20) | 407.8 (159.1) | 368 (345, 460) | 24 (5.3%) | 7.5 (4.5) | 7 (4, 10) |
| 65+ | 5,091 | 3.5 (2.0) | 3 (2, 4) | 18.3 (7.7) | 18 (12, 20) | 112.3 (67.8) | 100 (75, 135) | 251 (4.9%) | 8.7 (4.6) | 8 (5, 11) |
| Schedule II | 1,041 | 3.8 (2.2) | 3 (3, 5) | 20.1 (9.0) | 20 (15, 24) | 138.8 (75.0) | 120 (90, 150) | 41 (3.9%) | 9.1 (6.0) | 8 (5, 13) |
| Oxymorphone | 0 | - | - | - | - | - | - | - | - | - |
| Hydromorphone | ***** | 6.0 (2.6) | 5 (5, 7) | 28.0 (19.2) | 20 (20, 30) | 272.0 (192.7) | 160 (160, 480) | ***** (40.0%) | 14.0 (2.8) | 14 (12, 16) |
| Hydrocodone (after rescheduling) | 540 | 3.6 (2.2) | 3 (2, 4) | 18.6 (7.2) | 20 (15, 20) | 110.4 (48.5) | 100 (80, 135) | 22 (4.1%) | 9.5 (7.2) | 7 (5, 13) |
| Oxycodone | 489 | 3.9 (2.2) | 3 (3, 5) | 21.6 (10.4) | 20 (15, 25) | 169.4 (83.9) | 150 (120, 225) | ***** | 8.0 (4.0) | 8 (6, 9) |
| Morphine | 0 | - | - | - | - | - | - | - | - | - |
| Other | ***** | 4.0 (1.4) | 4 (3, 5) | 21.3 (7.7) | 24 (12, 28) | 106.4 (38.6) | 120 (60, 140) | 0 (0.0%) | - | - |
| Other Schedule | 4,050 | 3.4 (1.9) | 3 (2, 4) | 17.9 (7.2) | 16 (12, 20) | 105.5 (64.0) | 90 (68, 120) | 210 (5.2%) | 8.6 (4.3) | 8 (5, 11) |
| Tramadol | 142 | 4.7 (4.2) | 3 (3, 5) | 22.8 (15.3) | 20 (15, 25) | 109.3 (76.4) | 100 (60, 120) | ***** | 10.1 (8.4) | 10 (3, 12) |
| Codeine | 1,003 | 3.2 (1.6) | 3 (2, 4) | 17.2 (5.8) | 16 (12, 20) | 77.7 (28.7) | 72 (54, 90) | 37 (3.7%) | 7.5 (3.9) | 7 (5, 8) |
| Hydrocodone (before rescheduling) | 2,825 | 3.4 (1.8) | 3 (2, 4) | 17.9 (7.0) | 16 (12, 20) | 107.2 (50.0) | 100 (75, 128) | 157 (5.6%) | 8.9 (4.2) | 8 (6, 11) |
| Other | 80 | 3.6 (3.0) | 3 (2, 4) | 16.8 (4.4) | 16 (13, 20) | 383.5 (108.1) | 368 (299, 460) | ***** | 8.1 (3.1) | 7 (7, 9) |

*All surgeries population excluded patients with any prior surgery before index

Table 2. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Age Group (years) | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|---|--------------------|-----------|----------------------------|-----------|--------------------------------|-----------|-------------------------|----------------|-----------|
| | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) |
| *****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented. | | | | | | | | | |

Table 3. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year

| Surgery | Year | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | |
|------------------------------------|---------|--------------------|-----------|----------------------------|-------------|--------------------------------|----------------|-------------------------|------------|
| | | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) |
| All surgeries* | | | | | | | | | |
| Total | 935,443 | 5.3 (3.6) | 5 (3, 6) | 36.8 (21.5) | 30 (24, 40) | 264.2 (203.6) | 225 (150, 300) | 167,423 (17.9%) | 9.7 (5.3) |
| 2009 | 31,999 | 4.9 (3.1) | 4 (3, 5) | 33.3 (17.3) | 30 (20, 40) | 257.1 (201.3) | 225 (150, 300) | 5,506 (17.2%) | 8.6 (4.8) |
| 2010 | 134,072 | 4.8 (3.1) | 4 (3, 5) | 33.3 (17.7) | 30 (20, 40) | 253.4 (196.3) | 225 (150, 300) | 22,211 (16.6%) | 8.7 (4.9) |
| 2011 | 162,624 | 5.2 (3.4) | 5 (3, 6) | 35.9 (19.8) | 30 (24, 40) | 252.8 (184.6) | 225 (150, 300) | 30,388 (18.7%) | 9.5 (5.1) |
| 2012 | 156,469 | 5.3 (3.5) | 5 (3, 6) | 36.7 (20.9) | 30 (25, 40) | 259.5 (192.7) | 225 (150, 300) | 29,384 (18.8%) | 9.6 (5.2) |
| 2013 | 159,142 | 5.4 (3.6) | 5 (3, 6) | 36.9 (21.6) | 30 (24, 40) | 261.4 (197.0) | 225 (150, 300) | 29,587 (18.6%) | 9.8 (5.3) |
| 2014 | 162,790 | 5.6 (3.8) | 5 (3, 7) | 38.4 (23.1) | 30 (24, 45) | 273.9 (217.3) | 225 (150, 300) | 29,477 (18.1%) | 10.1 (5.4) |
| 2015 | 128,347 | 5.9 (4.0) | 5 (3, 7) | 40.3 (25.4) | 30 (25, 50) | 288.8 (232.8) | 225 (150, 338) | 20,870 (16.3%) | 10.8 (5.6) |
| Appendectomy (laparoscopic) | | | | | | | | | |
| Total | 53,428 | 4.5 (2.5) | 4 (3, 5) | 31.7 (10.7) | 30 (30, 40) | 208.6 (103.6) | 200 (150, 225) | 3,939 (7.4%) | 8.1 (4.9) |
| 2009 | 1,775 | 4.6 (2.7) | 4 (3, 5) | 31.8 (10.4) | 30 (30, 40) | 224.3 (135.8) | 200 (150, 250) | 165 (9.3%) | 7.8 (4.4) |
| 2010 | 7,992 | 4.4 (2.5) | 4 (3, 5) | 31.9 (10.3) | 30 (30, 40) | 222.9 (130.3) | 200 (150, 250) | 670 (8.4%) | 7.8 (4.6) |
| 2011 | 9,126 | 4.4 (2.5) | 4 (3, 5) | 31.5 (9.8) | 30 (30, 36) | 203.8 (91.2) | 200 (150, 225) | 747 (8.2%) | 8.1 (4.7) |
| 2012 | 8,920 | 4.4 (2.4) | 4 (3, 5) | 31.9 (11.1) | 30 (30, 40) | 206.4 (95.5) | 200 (150, 225) | 657 (7.4%) | 8.2 (5.0) |
| 2013 | 8,899 | 4.5 (2.7) | 4 (3, 5) | 31.6 (10.9) | 30 (30, 40) | 204.9 (100.8) | 200 (150, 225) | 680 (7.6%) | 8.2 (5.0) |
| 2014 | 9,191 | 4.6 (2.6) | 4 (3, 5) | 31.7 (11.1) | 30 (30, 40) | 204.6 (96.1) | 200 (150, 225) | 596 (6.5%) | 8.0 (4.9) |
| 2015 | 7,525 | 4.8 (2.5) | 4 (3, 5) | 32.0 (10.9) | 30 (30, 40) | 207.7 (96.1) | 200 (150, 225) | 424 (5.6%) | 8.8 (5.2) |
| Appendectomy (nonspecific) | | | | | | | | | |
| Total | 8,035 | 4.8 (2.8) | 4 (3, 5) | 32.2 (12.2) | 30 (25, 40) | 219.5 (124.9) | 200 (150, 250) | 1,186 (14.8%) | 8.4 (4.4) |
| 2009 | 403 | 4.4 (2.2) | 4 (3, 5) | 31.3 (9.7) | 30 (28, 35) | 229.8 (133.5) | 200 (150, 250) | 58 (14.4%) | 6.6 (2.9) |
| 2010 | 1,562 | 4.6 (2.7) | 4 (3, 5) | 32.0 (11.6) | 30 (25, 40) | 233.9 (148.0) | 200 (150, 300) | 243 (15.6%) | 8.0 (3.9) |
| 2011 | 1,784 | 4.8 (2.8) | 5 (3, 5) | 32.4 (12.3) | 30 (30, 40) | 215.4 (109.1) | 200 (150, 250) | 271 (15.2%) | 8.6 (4.9) |
| 2012 | 1,368 | 4.8 (2.7) | 4 (3, 5) | 31.8 (11.4) | 30 (25, 40) | 209.4 (134.5) | 188 (150, 225) | 205 (15.0%) | 8.4 (4.5) |
| 2013 | 1,128 | 4.9 (3.0) | 4 (3, 5) | 32.3 (12.8) | 30 (25, 40) | 215.1 (110.6) | 200 (150, 250) | 168 (14.9%) | 8.6 (4.8) |
| 2014 | 1,079 | 5.1 (3.1) | 5 (3, 6) | 32.3 (13.1) | 30 (25, 40) | 215.7 (109.6) | 200 (150, 250) | 154 (14.3%) | 8.5 (4.0) |
| 2015 | 711 | 5.2 (2.9) | 5 (3, 6) | 33.4 (13.5) | 30 (28, 40) | 224.8 (123.1) | 200 (150, 270) | 87 (12.2%) | 9.2 (4.7) |

Table 3. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year

| Surgery | Year | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | |
|------------------------------------|---------|--------------------|-----------|----------------------------|-------------|--------------------------------|----------------|-------------------------|------------|
| | | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) |
| Bunionectomy | | | | | | | | | |
| Total | 43,163 | 5.6 (3.1) | 5 (4, 7) | 37.8 (15.2) | 30 (30, 40) | 280.9 (174.2) | 225 (150, 338) | 9,554 (22.1%) | 8.1 (5.0) |
| 2009 | 1,661 | 5.3 (2.9) | 5 (4, 6) | 35.7 (13.7) | 30 (30, 40) | 289.0 (194.6) | 225 (150, 338) | 414 (24.9%) | 7.1 (4.8) |
| 2010 | 5,813 | 5.3 (2.8) | 5 (4, 6) | 36.2 (13.5) | 30 (30, 40) | 285.2 (187.9) | 225 (150, 320) | 1,433 (24.7%) | 7.7 (4.7) |
| 2011 | 7,661 | 5.4 (3.1) | 5 (4, 6) | 36.6 (14.7) | 30 (30, 40) | 264.7 (162.9) | 225 (150, 300) | 1,760 (23.0%) | 8.2 (5.1) |
| 2012 | 7,650 | 5.5 (3.2) | 5 (4, 7) | 37.6 (14.8) | 30 (30, 40) | 274.4 (167.8) | 225 (150, 300) | 1,676 (21.9%) | 7.9 (4.9) |
| 2013 | 7,650 | 5.7 (3.1) | 5 (4, 7) | 38.2 (15.4) | 30 (30, 45) | 281.8 (172.0) | 225 (150, 338) | 1,671 (21.8%) | 8.2 (5.1) |
| 2014 | 7,631 | 5.7 (3.1) | 5 (4, 7) | 38.9 (16.5) | 35 (30, 50) | 286.8 (175.7) | 225 (150, 375) | 1,638 (21.5%) | 8.4 (5.2) |
| 2015 | 5,097 | 5.9 (3.2) | 5 (4, 7) | 40.2 (16.1) | 40 (30, 50) | 297.7 (175.9) | 250 (180, 375) | 962 (18.9%) | 8.6 (5.0) |
| Coronary artery bypassgraft | | | | | | | | | |
| Total | 33,289 | 7.2 (4.4) | 6 (5, 8) | 46.3 (20.3) | 40 (30, 60) | 306.4 (191.8) | 250 (200, 375) | 7,101 (21.3%) | 11.7 (5.6) |
| 2009 | 832 | 6.8 (4.1) | 6 (5, 8) | 46.3 (17.5) | 40 (30, 50) | 401.0 (319.1) | 300 (225, 450) | 228 (27.4%) | 10.6 (5.1) |
| 2010 | 3,467 | 6.8 (4.6) | 6 (5, 8) | 46.8 (21.1) | 40 (30, 60) | 384.7 (294.4) | 300 (210, 450) | 951 (27.4%) | 11.3 (5.2) |
| 2011 | 6,477 | 6.8 (4.1) | 6 (5, 8) | 45.6 (18.7) | 40 (30, 50) | 288.6 (155.1) | 250 (200, 375) | 1,496 (23.1%) | 11.5 (5.8) |
| 2012 | 6,019 | 7.0 (4.3) | 6 (5, 8) | 45.6 (19.5) | 40 (30, 55) | 287.4 (162.1) | 250 (200, 375) | 1,270 (21.1%) | 11.7 (5.5) |
| 2013 | 5,903 | 7.2 (4.4) | 6 (5, 8) | 45.7 (20.0) | 40 (30, 50) | 291.8 (163.0) | 250 (200, 375) | 1,245 (21.1%) | 12.0 (5.9) |
| 2014 | 6,009 | 7.4 (4.4) | 6 (5, 10) | 46.3 (21.2) | 40 (30, 60) | 295.0 (174.6) | 250 (200, 375) | 1,145 (19.1%) | 11.9 (5.5) |
| 2015 | 4,582 | 7.9 (4.5) | 7 (5, 10) | 48.6 (22.1) | 45 (30, 60) | 314.0 (180.9) | 300 (200, 375) | 766 (16.7%) | 12.3 (5.8) |
| Cesarean section | | | | | | | | | |
| Total | 248,281 | 4.7 (2.6) | 5 (3, 5) | 32.5 (9.6) | 30 (30, 40) | 234.5 (103.4) | 225 (150, 300) | 29,512 (11.9%) | 8.0 (4.1) |
| 2009 | 10,925 | 4.7 (2.6) | 5 (3, 5) | 32.1 (9.1) | 30 (30, 40) | 245.4 (135.6) | 225 (150, 300) | 1,444 (13.2%) | 7.7 (4.0) |
| 2010 | 45,772 | 4.6 (2.5) | 4 (3, 5) | 32.2 (9.4) | 30 (30, 40) | 247.0 (132.9) | 225 (150, 300) | 5,980 (13.1%) | 7.8 (4.0) |
| 2011 | 43,123 | 4.6 (2.6) | 4 (3, 5) | 32.4 (9.4) | 30 (30, 40) | 230.9 (90.6) | 225 (150, 300) | 5,313 (12.3%) | 7.9 (4.1) |
| 2012 | 39,882 | 4.7 (2.7) | 4 (3, 5) | 32.5 (9.6) | 30 (30, 40) | 231.9 (93.5) | 225 (150, 300) | 4,927 (12.4%) | 8.0 (4.1) |
| 2013 | 38,781 | 4.8 (2.6) | 5 (3, 5) | 32.4 (9.7) | 30 (30, 40) | 229.1 (90.8) | 225 (150, 300) | 4,615 (11.9%) | 8.1 (4.2) |
| 2014 | 38,849 | 4.9 (2.6) | 5 (3, 5) | 32.7 (9.9) | 30 (30, 40) | 230.2 (93.0) | 225 (150, 300) | 4,311 (11.1%) | 8.4 (4.3) |
| 2015 | 30,949 | 5.0 (2.6) | 5 (3, 6) | 33.1 (9.9) | 30 (30, 40) | 233.2 (94.2) | 225 (150, 300) | 2,922 (9.4%) | 8.4 (4.2) |

Table 3. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year

| Surgery | Year | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Re-fills N (%) | Time to Re-fill in Days | |
|---------------------------------------|---------|--------------------|-----------|----------------------------|-------------|--------------------------------|----------------|----------------|-------------------------|--------------|
| | | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) |
| Cholecystectomy (laparoscopic) | | | | | | | | | | |
| Total | 149,026 | 4.7 (2.7) | 4 (3, 5) | 31.6 (10.8) | 30 (30, 40) | 210.3 (112.9) | 200 (150, 225) | 10,691 (7.2%) | 8.4 (5.0) | 7 (5, 11) |
| 2009 | 4,436 | 4.6 (2.4) | 4 (3, 5) | 31.6 (10.0) | 30 (26, 40) | 237.8 (151.1) | 200 (150, 296) | 386 (8.7%) | 7.9 (4.6) | 7 (4, 11) |
| 2010 | 18,530 | 4.6 (2.6) | 4 (3, 5) | 31.7 (10.0) | 30 (30, 40) | 233.4 (144.3) | 200 (150, 263) | 1,535 (8.3%) | 7.5 (4.6) | 6 (4, 10) |
| 2011 | 27,633 | 4.7 (2.8) | 4 (3, 5) | 31.3 (10.9) | 30 (25, 36) | 203.2 (121.0) | 188 (150, 225) | 2,185 (7.9%) | 8.4 (5.1) | 7 (5, 12) |
| 2012 | 26,809 | 4.7 (2.7) | 4 (3, 5) | 31.5 (10.8) | 30 (28, 40) | 204.9 (100.1) | 200 (150, 225) | 2,002 (7.5%) | 8.4 (4.9) | 7 (5, 11) |
| 2013 | 25,891 | 4.8 (2.7) | 4 (3, 5) | 31.4 (10.6) | 30 (28, 40) | 204.2 (98.6) | 188 (150, 225) | 1,856 (7.2%) | 8.5 (5.1) | 7 (5, 12) |
| 2014 | 25,659 | 4.8 (2.7) | 5 (3, 5) | 31.6 (11.0) | 30 (30, 40) | 207.1 (101.4) | 200 (150, 225) | 1,673 (6.5%) | 8.7 (5.3) | 7 (5, 12) |
| 2015 | 20,068 | 5.0 (2.7) | 5 (3, 5) | 32.3 (11.5) | 30 (30, 40) | 211.6 (101.7) | 200 (150, 233) | 1,054 (5.3%) | 8.8 (5.4) | 8 (5, 12) |
| Cholecystectomy (nonspecific) | | | | | | | | | | |
| Total | 4,873 | 5.4 (3.3) | 5 (3, 6) | 33.7 (15.4) | 30 (25, 40) | 232.3 (143.7) | 210 (150, 300) | 840 (17.2%) | 9.8 (5.0) | 9 (6, 13) |
| 2009 | 124 | 5.0 (2.6) | 5 (3, 6) | 31.3 (10.1) | 30 (25, 35) | 234.2 (136.9) | 225 (150, 281) | 16 (12.9%) | 8.9 (5.3) | 8 (5, 13) |
| 2010 | 471 | 5.0 (2.8) | 5 (3, 6) | 34.2 (12.2) | 30 (30, 40) | 259.6 (175.1) | 225 (150, 300) | 102 (21.7%) | 9.3 (4.4) | 9 (5, 13) |
| 2011 | 1,031 | 5.3 (3.1) | 5 (3, 6) | 33.9 (15.7) | 30 (25, 40) | 223.9 (128.5) | 200 (150, 300) | 189 (18.3%) | 9.4 (5.0) | 9 (6, 12) |
| 2012 | 918 | 5.6 (3.9) | 5 (3, 7) | 33.9 (18.5) | 30 (25, 40) | 228.4 (167.4) | 200 (150, 280) | 131 (14.3%) | 10.1 (5.4) | 10 (6, 13) |
| 2013 | 877 | 5.4 (3.1) | 5 (3, 6) | 32.9 (13.6) | 30 (25, 40) | 223.9 (124.3) | 224 (150, 300) | 174 (19.8%) | 10.1 (4.9) | 10 (6, 14) |
| 2014 | 858 | 5.6 (3.4) | 5 (3, 7) | 34.0 (16.1) | 30 (25, 40) | 236.3 (141.7) | 225 (150, 300) | 147 (17.1%) | 9.7 (5.4) | 9 (6, 12) |
| 2015 | 594 | 5.6 (3.2) | 5 (4, 7) | 33.7 (14.5) | 30 (28, 40) | 237.6 (129.2) | 225 (150, 300) | 81 (13.6%) | 10.2 (5.1) | 9 (7, 13) |
| Hip fracture treatment | | | | | | | | | | |
| Total | 11,939 | 7.8 (5.4) | 6 (5, 10) | 49.7 (28.4) | 40 (30, 60) | 355.3 (258.1) | 300 (175, 450) | 4,481 (37.5%) | 10.8 (6.0) | 10 (7, 14) |
| 2009 | 232 | 7.3 (4.6) | 6 (5, 8) | 49.0 (23.3) | 40 (30, 60) | 369.4 (231.2) | 300 (200, 450) | 103 (44.4%) | 9.6 (4.4) | 9 (6, 13) |
| 2010 | 966 | 7.7 (5.3) | 6 (5, 10) | 56.0 (27.1) | 50 (40, 60) | 440.0 (292.7) | 375 (250, 500) | 440 (45.5%) | 10.3 (5.6) | 9 (7, 13) |
| 2011 | 2,358 | 7.7 (5.4) | 6 (5, 10) | 48.3 (27.2) | 40 (30, 60) | 339.0 (240.1) | 300 (150, 450) | 875 (37.1%) | 10.8 (6.1) | 10 (7, 14) |
| 2012 | 2,174 | 7.7 (5.5) | 6 (5, 10) | 49.5 (29.3) | 40 (30, 60) | 352.1 (257.6) | 300 (160, 450) | 843 (38.8%) | 10.7 (6.0) | 10 (6, 14) |
| 2013 | 2,199 | 8.0 (5.4) | 7 (5, 10) | 49.1 (27.9) | 40 (30, 60) | 341.1 (238.1) | 300 (150, 450) | 802 (36.5%) | 10.7 (6.4) | 10 (6, 14) |
| 2014 | 2,298 | 7.8 (5.4) | 6 (5, 10) | 48.5 (29.8) | 40 (30, 60) | 348.8 (272.5) | 300 (150, 450) | 816 (35.5%) | 11.0 (6.0) | 10 (7, 15) |
| 2015 | 1,712 | 8.1 (5.5) | 7 (5, 10) | 50.3 (28.7) | 42 (30, 60) | 359.0 (261.0) | 300 (150, 450) | 602 (35.2%) | 11.0 (5.7) | 10 (7, 15) |

Table 3. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year

| Surgery | Year | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Time to Re-fill in Days | | |
|--|--------|--------------------|-----------|----------------------------|-------------|--------------------------------|----------------|-------------------------|----------------|------------|
| | | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Re-fills N (%) | Mean (SD) |
| Hip replacement | | | | | | | | | | |
| Total | 42,788 | 8.1 (4.8) | 7 (5, 10) | 64.0 (27.3) | 60 (40, 80) | 473.5 (265.8) | 450 (300, 600) | 13,142 (30.7%) | 11.2 (5.4) | 11 (7, 14) |
| 2009 | 910 | 7.7 (4.5) | 7 (5, 9) | 62.5 (24.5) | 60 (45, 80) | 495.5 (281.2) | 450 (300, 600) | 338 (37.1%) | 10.7 (5.4) | 10 (7, 14) |
| 2010 | 3,604 | 7.6 (4.2) | 7 (5, 9) | 62.5 (25.4) | 60 (40, 80) | 489.5 (288.6) | 450 (300, 600) | 1,270 (35.2%) | 10.6 (5.3) | 10 (7, 14) |
| 2011 | 6,990 | 7.7 (4.6) | 7 (5, 10) | 60.5 (25.8) | 60 (40, 80) | 443.1 (249.2) | 400 (300, 600) | 2,362 (33.8%) | 11.0 (5.2) | 10 (7, 14) |
| 2012 | 7,044 | 7.7 (4.4) | 7 (5, 10) | 62.0 (27.2) | 60 (40, 80) | 452.1 (262.0) | 400 (300, 600) | 2,299 (32.6%) | 10.9 (5.2) | 10 (7, 14) |
| 2013 | 7,855 | 8.0 (5.0) | 7 (5, 10) | 62.5 (26.7) | 60 (40, 80) | 459.8 (251.3) | 450 (300, 600) | 2,484 (31.6%) | 11.2 (5.3) | 11 (7, 14) |
| 2014 | 8,930 | 8.4 (4.8) | 7 (5, 10) | 65.2 (27.0) | 60 (50, 90) | 481.6 (259.7) | 450 (300, 600) | 2,545 (28.5%) | 11.3 (5.5) | 11 (7, 14) |
| 2015 | 7,455 | 9.1 (5.1) | 8 (5, 10) | 70.1 (29.7) | 60 (50, 90) | 516.2 (285.5) | 450 (300, 675) | 1,844 (24.7%) | 12.0 (5.7) | 12 (8, 15) |
| Hysterectomy (non-laparoscopic) | | | | | | | | | | |
| Total | 11,600 | 4.9 (2.7) | 5 (3, 5) | 32.1 (11.6) | 30 (30, 40) | 227.6 (130.2) | 225 (150, 263) | 1,488 (12.8%) | 8.7 (4.9) | 7 (5, 12) |
| 2009 | 531 | 4.8 (2.8) | 4 (3, 5) | 32.5 (10.4) | 30 (28, 40) | 263.0 (174.7) | 225 (150, 300) | 104 (19.6%) | 8.7 (5.0) | 7 (5, 12) |
| 2010 | 2,004 | 4.6 (2.3) | 4 (3, 5) | 32.1 (10.3) | 30 (30, 40) | 255.7 (161.1) | 225 (150, 300) | 323 (16.1%) | 8.7 (4.9) | 8 (5, 12) |
| 2011 | 2,326 | 4.7 (2.6) | 4 (3, 5) | 31.4 (11.0) | 30 (25, 35) | 217.0 (109.4) | 225 (150, 240) | 298 (12.8%) | 8.3 (4.7) | 7 (5, 12) |
| 2012 | 1,908 | 4.9 (2.9) | 5 (3, 5) | 32.3 (12.4) | 30 (30, 40) | 221.3 (146.8) | 225 (150, 250) | 229 (12.0%) | 8.4 (4.7) | 7 (5, 11) |
| 2013 | 1,891 | 5.0 (2.7) | 5 (3, 5) | 32.2 (11.6) | 30 (30, 40) | 218.9 (101.6) | 225 (150, 250) | 234 (12.4%) | 9.4 (5.0) | 8 (6, 13) |
| 2014 | 1,744 | 4.9 (2.7) | 5 (3, 5) | 32.0 (12.0) | 30 (30, 40) | 216.3 (109.2) | 200 (150, 225) | 194 (11.1%) | 8.8 (4.8) | 7 (5, 12) |
| 2015 | 1,196 | 5.2 (2.9) | 5 (3, 6) | 32.9 (13.2) | 30 (30, 40) | 225.6 (116.7) | 225 (150, 256) | 106 (8.9%) | 8.9 (5.1) | 8 (5, 12) |
| Hysterectomy (laparoscopic) | | | | | | | | | | |
| Total | 11,675 | 4.8 (2.6) | 4 (3, 5) | 32.0 (10.2) | 30 (30, 40) | 229.8 (114.1) | 225 (150, 263) | 1,397 (12.0%) | 8.8 (4.9) | 8 (5, 12) |
| 2009 | 386 | 4.8 (2.8) | 4 (3, 5) | 31.2 (8.0) | 30 (30, 30) | 251.8 (148.4) | 225 (150, 300) | 60 (15.5%) | 8.9 (4.5) | 8 (6, 12) |
| 2010 | 1,604 | 4.5 (2.3) | 4 (3, 5) | 31.7 (10.0) | 30 (30, 40) | 255.3 (156.2) | 225 (150, 300) | 221 (13.8%) | 7.8 (4.7) | 7 (4, 11) |
| 2011 | 1,971 | 4.6 (2.7) | 4 (3, 5) | 31.6 (9.9) | 30 (30, 36) | 222.1 (106.1) | 225 (150, 263) | 237 (12.0%) | 8.3 (4.7) | 7 (5, 11) |
| 2012 | 2,060 | 4.6 (2.4) | 4 (3, 5) | 31.9 (10.0) | 30 (30, 40) | 223.7 (96.9) | 225 (150, 263) | 258 (12.5%) | 9.5 (4.7) | 9 (6, 14) |
| 2013 | 2,162 | 4.9 (2.7) | 5 (3, 5) | 31.9 (10.4) | 30 (30, 36) | 221.3 (98.4) | 225 (150, 240) | 258 (11.9%) | 9.0 (5.1) | 8 (5, 13) |
| 2014 | 2,068 | 4.9 (2.5) | 5 (3, 5) | 32.2 (10.6) | 30 (30, 40) | 227.6 (104.0) | 225 (150, 270) | 223 (10.8%) | 8.9 (5.4) | 8 (5, 12) |
| 2015 | 1,424 | 5.0 (2.6) | 5 (3, 5) | 32.8 (10.3) | 30 (30, 40) | 230.9 (113.0) | 225 (150, 270) | 140 (9.8%) | 9.4 (4.9) | 8 (6, 13) |

Table 3. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year

| Surgery | Year | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Re-fills N (%) | Time to Re-fill in Days | |
|-----------------------------------|--------|--------------------|-----------|----------------------------|-------------|--------------------------------|----------------|----------------|-------------------------|--------------|
| | | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) |
| Knee arthroplasty | | | | | | | | | | |
| Total | 92,819 | 8.1 (4.7) | 7 (5, 10) | 63.6 (27.6) | 60 (40, 80) | 493.5 (281.0) | 450 (300, 600) | 56,986 (61.4%) | 10.9 (5.2) | 10 (7, 14) |
| 2009 | 1,732 | 7.5 (4.3) | 6 (5, 9) | 60.2 (25.6) | 60 (40, 75) | 491.3 (305.4) | 450 (300, 600) | 1,167 (67.4%) | 10.0 (5.1) | 9 (6, 13) |
| 2010 | 6,933 | 7.5 (4.2) | 7 (5, 9) | 61.8 (25.7) | 60 (40, 80) | 499.8 (283.8) | 450 (300, 600) | 4,728 (68.2%) | 10.3 (5.1) | 9 (7, 13) |
| 2011 | 15,774 | 7.5 (4.3) | 7 (5, 9) | 59.2 (25.2) | 60 (40, 75) | 449.3 (253.3) | 400 (300, 600) | 9,962 (63.2%) | 10.4 (4.9) | 10 (7, 13) |
| 2012 | 16,398 | 7.7 (4.4) | 7 (5, 10) | 61.1 (26.5) | 60 (40, 80) | 467.3 (265.5) | 450 (300, 600) | 10,309 (62.9%) | 10.7 (5.0) | 10 (7, 14) |
| 2013 | 17,082 | 7.9 (4.6) | 7 (5, 10) | 62.4 (27.2) | 60 (40, 80) | 481.6 (270.7) | 450 (300, 600) | 10,616 (62.1%) | 10.8 (5.2) | 10 (7, 14) |
| 2014 | 19,101 | 8.3 (4.8) | 7 (5, 10) | 65.1 (27.9) | 60 (45, 80) | 505.7 (283.9) | 450 (300, 600) | 11,460 (60.0%) | 11.2 (5.2) | 11 (7, 14) |
| 2015 | 15,799 | 9.1 (5.2) | 8 (5, 10) | 71.6 (30.3) | 60 (50, 90) | 560.6 (311.2) | 450 (338, 675) | 8,744 (55.3%) | 12.0 (5.5) | 12 (8, 15) |
| Laminectomy/discectomy | | | | | | | | | | |
| Total | 13,935 | 8.2 (4.7) | 7 (5, 10) | 60.2 (25.5) | 60 (40, 75) | 459.2 (264.2) | 450 (300, 600) | 2,396 (17.2%) | 10.9 (6.0) | 10 (6, 15) |
| 2009 | 398 | 7.8 (4.3) | 7 (5, 10) | 58.6 (23.5) | 60 (40, 70) | 496.7 (308.6) | 450 (300, 600) | 66 (16.6%) | 10.0 (5.1) | 9 (7, 14) |
| 2010 | 1,674 | 7.7 (4.7) | 6 (5, 10) | 57.8 (24.4) | 60 (40, 60) | 454.7 (283.4) | 400 (300, 600) | 296 (17.7%) | 10.7 (6.3) | 9 (6, 15) |
| 2011 | 2,309 | 7.9 (4.6) | 7 (5, 10) | 58.3 (24.2) | 60 (40, 65) | 440.8 (256.2) | 400 (270, 563) | 415 (18.0%) | 10.4 (5.8) | 9 (6, 14) |
| 2012 | 2,301 | 7.9 (4.4) | 7 (5, 10) | 59.0 (25.5) | 60 (40, 70) | 444.2 (251.1) | 400 (300, 600) | 404 (17.6%) | 11.4 (6.0) | 11 (7, 15) |
| 2013 | 2,465 | 8.1 (4.6) | 7 (5, 10) | 59.4 (25.2) | 60 (40, 70) | 448.2 (245.7) | 450 (300, 600) | 428 (17.4%) | 10.5 (5.8) | 9 (6, 15) |
| 2014 | 2,683 | 8.6 (5.0) | 7 (5, 10) | 62.5 (25.9) | 60 (40, 80) | 476.1 (265.7) | 450 (300, 600) | 467 (17.4%) | 11.3 (6.0) | 11 (6, 15) |
| 2015 | 2,105 | 8.9 (5.1) | 8 (5, 10) | 63.6 (27.0) | 60 (45, 80) | 483.4 (277.5) | 450 (300, 600) | 320 (15.2%) | 11.6 (6.2) | 11 (7, 15) |
| Spinal fusion (all levels) | | | | | | | | | | |
| Total | 29,292 | 9.1 (5.4) | 8 (5, 10) | 66.9 (29.7) | 60 (50, 90) | 539.0 (360.6) | 450 (300, 675) | 9,734 (33.2%) | 11.9 (6.1) | 11 (7, 15) |
| 2009 | 734 | 8.5 (5.0) | 7 (5, 10) | 62.1 (26.9) | 60 (40, 80) | 524.1 (365.3) | 450 (300, 675) | 265 (36.1%) | 11.0 (5.5) | 10 (7, 15) |
| 2010 | 2,939 | 8.5 (5.1) | 7 (5, 10) | 64.7 (28.8) | 60 (40, 80) | 539.7 (396.5) | 450 (300, 675) | 987 (33.6%) | 11.2 (6.0) | 10 (7, 15) |
| 2011 | 4,854 | 8.6 (5.1) | 7 (5, 10) | 64.1 (28.4) | 60 (40, 80) | 508.8 (337.8) | 450 (300, 615) | 1,632 (33.6%) | 11.6 (5.9) | 11 (7, 15) |
| 2012 | 4,962 | 8.9 (5.4) | 8 (5, 10) | 65.6 (28.4) | 60 (50, 84) | 521.8 (331.3) | 450 (300, 675) | 1,650 (33.3%) | 11.7 (6.0) | 11 (7, 15) |
| 2013 | 5,238 | 9.0 (5.5) | 8 (5, 10) | 66.2 (29.5) | 60 (50, 90) | 528.6 (335.2) | 450 (300, 675) | 1,771 (33.8%) | 11.9 (6.0) | 11 (7, 15) |
| 2014 | 5,884 | 9.4 (5.5) | 8 (5, 10) | 68.3 (30.7) | 60 (50, 90) | 554.6 (405.7) | 450 (300, 675) | 1,965 (33.4%) | 12.1 (6.4) | 11 (8, 15) |
| 2015 | 4,681 | 10.1 (5.8) | 9 (6, 13) | 72.2 (31.7) | 60 (50, 90) | 582.6 (351.1) | 480 (360, 675) | 1,464 (31.3%) | 12.8 (6.5) | 12 (8, 16) |

Table 3. Descriptive Statistics for the Initial Dispensing of an Opioid Analgesic within 7 Days of Surgery in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Year

| Surgery | Year | Days' Supply | | Tablets/Capsules Dispensed | | Morphine Milligram Equivalents | | Re-fills N (%) | Time to Re-fill in Days | |
|-----------------------------------|---------|--------------------|------------|----------------------------|-------------|--------------------------------|----------------|----------------|-------------------------|--------------|
| | | Number of Patients | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) | Mean (SD) | Median (IQR) |
| Spinal fusion (1-3 levels) | | | | | | | | | | |
| Total | 20,908 | 9.0 (5.3) | 8 (5, 10) | 66.2 (28.9) | 60 (46, 90) | 526.6 (349.3) | 450 (300, 675) | 6,349 (30.4%) | 11.9 (6.2) | 11 (7, 15) |
| 2009 | 508 | 8.5 (4.8) | 7 (5, 10) | 62.8 (26.6) | 60 (40, 80) | 534.2 (377.6) | 450 (300, 675) | 158 (31.1%) | 11.2 (5.9) | 11 (7, 15) |
| 2010 | 1,954 | 8.4 (4.9) | 7 (5, 10) | 64.6 (27.6) | 60 (40, 80) | 524.2 (330.9) | 450 (300, 675) | 568 (29.1%) | 11.4 (5.9) | 10 (7, 15) |
| 2011 | 3,450 | 8.5 (5.0) | 7 (5, 10) | 63.6 (27.9) | 60 (40, 80) | 496.6 (314.7) | 450 (300, 600) | 1,045 (30.3%) | 11.7 (6.1) | 11 (7, 15) |
| 2012 | 3,606 | 8.8 (5.3) | 8 (5, 10) | 64.5 (26.7) | 60 (45, 80) | 506.2 (321.7) | 450 (300, 600) | 1,111 (30.8%) | 11.7 (6.0) | 11 (7, 15) |
| 2013 | 3,803 | 8.8 (5.3) | 8 (5, 10) | 65.0 (27.9) | 60 (45, 84) | 513.3 (316.7) | 450 (300, 675) | 1,216 (32.0%) | 11.8 (5.9) | 11 (7, 15) |
| 2014 | 4,267 | 9.3 (5.6) | 8 (5, 10) | 67.9 (30.1) | 60 (50, 90) | 545.6 (418.6) | 450 (300, 675) | 1,312 (30.7%) | 12.1 (6.4) | 11 (7, 15) |
| 2015 | 3,320 | 10.0 (5.7) | 8 (6, 12) | 71.4 (31.7) | 60 (50, 90) | 571.1 (350.4) | 450 (350, 675) | 939 (28.3%) | 13.0 (6.8) | 12 (8, 16) |
| Spinal fusion (4+ levels) | | | | | | | | | | |
| Total | 7,193 | 9.5 (5.7) | 8 (5, 11) | 70.1 (32.1) | 60 (50, 90) | 583.0 (376.8) | 450 (300, 675) | 3,036 (42.2%) | 11.7 (6.1) | 11 (7, 15) |
| 2009 | 186 | 8.9 (5.5) | 7 (5, 10) | 62.9 (27.9) | 60 (40, 80) | 513.5 (337.4) | 450 (300, 600) | 100 (53.8%) | 10.5 (4.6) | 10 (7, 14) |
| 2010 | 837 | 9.0 (5.5) | 8 (5, 10) | 67.7 (31.1) | 60 (48, 90) | 588.4 (428.5) | 450 (300, 720) | 381 (45.5%) | 10.9 (6.1) | 10 (6, 14) |
| 2011 | 1,222 | 8.9 (5.4) | 8 (5, 10) | 67.2 (29.2) | 60 (50, 90) | 555.5 (392.6) | 450 (300, 675) | 527 (43.1%) | 11.3 (5.6) | 11 (7, 14) |
| 2012 | 1,178 | 9.2 (5.6) | 8 (5, 10) | 69.9 (33.1) | 60 (50, 90) | 577.4 (358.7) | 450 (315, 675) | 490 (41.6%) | 11.7 (6.1) | 11 (7, 15) |
| 2013 | 1,251 | 9.6 (6.0) | 8 (5, 11) | 70.3 (33.6) | 60 (50, 90) | 575.0 (373.4) | 450 (300, 675) | 496 (39.6%) | 12.0 (6.2) | 11 (7, 15) |
| 2014 | 1,369 | 9.6 (5.5) | 8 (5, 12) | 70.6 (32.4) | 60 (50, 90) | 592.1 (364.9) | 480 (300, 720) | 576 (42.1%) | 12.0 (6.5) | 11 (8, 15) |
| 2015 | 1,150 | 10.6 (6.1) | 10 (7, 14) | 75.5 (32.5) | 75 (60, 90) | 623.4 (357.3) | 600 (375, 800) | 466 (40.5%) | 12.3 (6.0) | 12 (8, 15) |
| Tooth extraction | | | | | | | | | | |
| Total | 181,300 | 3.5 (1.7) | 3 (2, 4) | 19.7 (6.5) | 20 (15, 20) | 129.1 (65.0) | 113 (90, 150) | 14,976 (8.3%) | 6.9 (3.7) | 6 (4, 8) |
| 2009 | 6,920 | 3.4 (1.6) | 3 (2, 4) | 19.4 (6.3) | 20 (15, 20) | 137.3 (85.2) | 120 (90, 150) | 692 (10.0%) | 7.0 (3.8) | 6 (4, 8) |
| 2010 | 30,741 | 3.4 (1.7) | 3 (2, 4) | 19.4 (6.1) | 20 (15, 20) | 135.3 (76.3) | 120 (90, 150) | 3,032 (9.9%) | 6.7 (3.6) | 6 (4, 8) |
| 2011 | 29,207 | 3.5 (1.7) | 3 (2, 4) | 19.6 (6.4) | 20 (15, 20) | 128.6 (62.1) | 113 (90, 150) | 2,646 (9.1%) | 6.9 (3.7) | 6 (4, 8) |
| 2012 | 28,056 | 3.5 (1.7) | 3 (2, 4) | 19.7 (6.6) | 20 (15, 20) | 128.2 (62.3) | 113 (90, 150) | 2,524 (9.0%) | 6.7 (3.6) | 6 (4, 8) |
| 2013 | 31,121 | 3.5 (1.6) | 3 (2, 4) | 19.6 (6.1) | 20 (15, 20) | 126.5 (58.5) | 113 (90, 150) | 2,585 (8.3%) | 6.8 (3.6) | 6 (4, 8) |
| 2014 | 30,806 | 3.5 (1.7) | 3 (2, 4) | 19.7 (6.9) | 20 (15, 20) | 126.5 (62.6) | 113 (90, 150) | 2,143 (7.0%) | 7.0 (3.7) | 6 (4, 8) |
| 2015 | 24,449 | 3.6 (1.7) | 3 (3, 4) | 20.1 (6.6) | 20 (16, 24) | 127.5 (59.4) | 113 (90, 150) | 1,354 (5.5%) | 7.4 (3.9) | 7 (5, 9) |

*All surgeries population excluded patients with any prior surgery before index

Table 4a. Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Days' Supply for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Main independent variable in model: days' supply | | | | | | | | | | | | | |
|--|-----------------------|-----------|--|-----------|-----------|----------------------|----------------------|--|--|----------------------|----------------------|-----------|--|
| Surgery | Observed ¹ | | Modeled ^{2,3} | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | Value with lowest probability of re-fill |
| | | | First value with probability of re-fill below: | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | | |
| | Age group (years) | Mean (SD) | Median (IQR) | 50% | 25% | 20% | 15% | 10% | 1 | 3 | 5 | 7 | 14 |
| All surgeries | | | | | | | | | | | | | |
| All ages | 5.3 (3.6) | 5 (3, 6) | 1 (20.7%) | 1 (20.7%) | 2 (19.7%) | 8 (15.0%) | 20.7% (19.9%, 21.6%) | 18.9% (18.8%, 19.1%) | 17.3% (17.2%, 17.5%) | 15.6% (15.5%, 15.8%) | - | - | 10 (14.4%) |
| 18-40 | 4.5 (2.5) | 4 (3, 5) | 1 (14.3%) | 1 (14.3%) | 1 (14.3%) | 1 (14.3%) | 6 (9.8%) | 14.3% (13.2%, 15.3%) | 12.4% (12.2%, 12.6%) | 10.6% (10.4%, 10.7%) | 9.2% (9.0%, 9.5%) | - | 9 (8.9%) |
| 41-64 | 5.5 (3.7) | 5 (3, 7) | 1 (21.0%) | 1 (21.0%) | 5 (19.6%) | - | 21.0% (19.4%, 22.7%) | 20.7% (20.3%, 21.0%) | 19.6% (19.4%, 19.9%) | 18.8% (18.4%, 19.1%) | - | - | 9 (16.5%) |
| 65+ | 6.9 (4.5) | 5 (4, 8) | 1 (36.2%) | 9 (24.3%) | - | - | 36.2% (33.7%, 38.6%) | 32.2% (31.6%, 32.7%) | 29.7% (29.4%, 30.0%) | 27.5% (27.1%, 28.0%) | - | - | 9 (24.3%) |
| Appendectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | 4.5 (2.5) | 4 (3, 5) | 1 (10.3%) | 1 (10.3%) | 1 (10.3%) | 1 (10.3%) | 2 (8.7%) | 10.3% (7.7%, 13.0%) | 7.9% (7.4%, 8.3%) | 6.8% (6.3%, 7.2%) | 6.5% (5.7%, 7.3%) | - | 7 (6.5%) |
| 18-40 | 4.5 (2.4) | 4 (3, 5) | 1 (11.2%) | 1 (11.2%) | 1 (11.2%) | 1 (11.2%) | 2 (9.6%) | 11.2% (7.6%, 14.7%) | 8.2% (7.6%, 8.8%) | 6.8% (6.2%, 7.3%) | 6.0% (4.9%, 7.1%) | - | 7 (6.0%) |
| 41-64 | 4.5 (2.6) | 4 (3, 5) | 1 (9.0%) | 1 (9.0%) | 1 (9.0%) | 1 (9.0%) | 1 (9.0%) | 9.0% (4.5%, 13.5%) | 8.1% (7.3%, 8.9%) | 7.3% (6.5%, 8.0%) | 7.6% (6.0%, 9.1%) | - | 5 (7.3%) |
| 65+ | 4.8 (2.9) | 4 (3, 5) | - | - | - | - | - | - | - | - | - | - | - |
| Appendectomy (nonspecific) | | | | | | | | | | | | | |
| All ages | 4.8 (2.8) | 4 (3, 5) | 1 (19.5%) | 1 (19.5%) | 1 (19.5%) | 5 (13.6%) | - | 19.5% (7.6%, 31.4%) | 15.6% (13.9%, 17.2%) | 13.6% (12.2%, 15.0%) | 13.4% (10.7%, 16.2%) | - | 7 (13.4%) |
| 18-40 | 4.7 (2.5) | 4 (3, 5) | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 4.8 (2.9) | 4 (3, 5) | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | 5.2 (3.3) | 5 (3, 6) | - | - | - | - | - | - | - | - | - | - | - |
| Bunionectomy | | | | | | | | | | | | | |
| All ages | 5.6 (3.1) | 5 (4, 7) | 1 (20.2%) | 1 (20.2%) | - | - | 20.2% (14.5%, 25.9%) | 23.7% (22.8%, 24.5%) | 21.8% (21.1%, 22.5%) | 21.5% (20.5%, 22.5%) | - | - | 1 (20.2%) |
| 18-40 | 5.5 (3.0) | 5 (4, 7) | 1 (40.1%) | 9 (22.4%) | - | - | 40.1% (23.6%, 56.6%) | 33.7% (31.4%, 36.0%) | 29.8% (27.9%, 31.6%) | 29.9% (27.1%, 32.7%) | - | - | 9 (22.4%) |
| 41-64 | 5.5 (2.9) | 5 (4, 6) | 1 (16.3%) | 1 (16.3%) | 1 (16.3%) | - | 16.3% (8.9%, 23.6%) | 23.3% (22.1%, 24.6%) | 22.2% (21.2%, 23.2%) | 22.1% (20.6%, 23.5%) | - | - | 1 (16.3%) |
| 65+ | 5.7 (3.4) | 5 (4, 7) | 1 (16.2%) | 1 (16.2%) | 1 (16.2%) | 8 (14.6%) | 16.2% (7.1%, 25.2%) | 18.7% (17.2%, 20.3%) | 16.8% (15.6%, 17.9%) | 15.8% (14.2%, 17.4%) | - | - | 8 (14.6%) |
| Cesarean section | | | | | | | | | | | | | |
| All ages | 4.7 (2.6) | 5 (3, 5) | 1 (14.2%) | 1 (14.2%) | 1 (14.2%) | 1 (14.2%) | 7 (9.3%) | 14.2% (12.4%, 16.0%) | 13.3% (13.1%, 13.6%) | 11.2% (10.9%, 11.4%) | 9.3% (8.9%, 9.7%) | - | 7 (9.3%) |
| 18-40 | 4.7 (2.6) | 5 (3, 5) | 1 (14.3%) | 1 (14.3%) | 1 (14.3%) | 1 (14.3%) | 7 (9.3%) | 14.3% (12.5%, 16.1%) | 13.3% (13.0%, 13.6%) | 11.2% (10.9%, 11.4%) | 9.3% (8.9%, 9.7%) | - | 7 (9.3%) |
| 41-64 | 4.8 (2.7) | 5 (3, 5) | 1 (13.0%) | 1 (13.0%) | 1 (13.0%) | 1 (13.0%) | 7 (8.5%) | 13.0% (3.7%, 22.4%) | 14.6% (13.0%, 16.1%) | 11.5% (10.3%, 12.6%) | 8.5% (6.4%, 10.7%) | - | 7 (8.5%) |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cholecystectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | 4.7 (2.7) | 4 (3, 5) | 1 (11.5%) | 1 (11.5%) | 1 (11.5%) | 1 (11.5%) | 2 (9.3%) | 11.5% (9.5%, 13.5%) | 7.7% (7.4%, 8.0%) | 6.7% (6.5%, 6.9%) | 6.2% (5.7%, 6.7%) | - | 7 (6.2%) |
| 18-40 | 4.6 (2.6) | 4 (3, 5) | 1 (14.6%) | 1 (14.6%) | 1 (14.6%) | 1 (14.6%) | 4 (9.5%) | 14.6% (9.8%, 19.4%) | 10.3% (9.7%, 10.8%) | 8.5% (8.0%, 9.1%) | 6.9% (5.9%, 7.9%) | - | 7 (6.9%) |
| 41-64 | 4.7 (2.6) | 4 (3, 5) | 1 (9.4%) | 1 (9.4%) | 1 (9.4%) | 1 (9.4%) | 1 (9.4%) | 9.4% (6.7%, 12.1%) | 7.5% (7.0%, 7.9%) | 6.9% (6.5%, 7.3%) | 6.7% (5.9%, 7.4%) | - | 7 (6.7%) |
| 65+ | 4.9 (2.9) | 5 (3, 5) | 1 (11.9%) | 1 (11.9%) | 1 (11.9%) | 1 (11.9%) | 2 (7.5%) | 11.9% (8.5%, 15.3%) | 5.9% (5.5%, 6.4%) | 5.0% (4.6%, 5.3%) | 4.9% (4.3%, 5.6%) | - | 4 (4.9%) |
| Cholecystectomy (nonspecific) | | | | | | | | | | | | | |
| All ages | 5.4 (3.3) | 5 (3, 6) | 1 (22.1%) | 1 (22.1%) | 2 (16.2%) | - | 22.1% (8.4%, 35.7%) | 19.7% (17.5%, 21.9%) | 16.1% (14.3%, 17.9%) | 17.2% (14.2%, 20.2%) | - | - | 6 (16.0%) |
| 18-40 | 5.3 (3.4) | 5 (3, 6) | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 5.3 (3.4) | 5 (3, 6) | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | 5.5 (3.3) | 5 (4, 7) | - | - | - | - | - | - | - | - | - | - | - |
| Coronary artery bypass graft | | | | | | | | | | | | | |
| All ages | 7.2 (4.4) | 6 (5, 8) | 1 (32.4%) | 3 (24.7%) | 7 (19.9%) | - | 32.4% (25.0%, 39.8%) | 24.7% (23.4%, 26.0%) | 23.0% (22.2%, 23.7%) | 19.9% (19.1%, 20.7%) | - | - | 9 (18.6%) |
| 18-40 | 7.1 (4.6) | 6 (5, 8) | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 7.0 (4.2) | 6 (5, 8) | 1 (37.8%) | - | - | 37.8% (24.0%, 51.7%) | 32.0% (29.6%, 34.3%) | 30.5% (29.0%, 32.0%) | 27.9% (26.2%, 29.5%) | - | - | 9 (26.2%) | - |
| 65+ | 7.2 (4.5) | 6 (5, 8) | 1 (28.4%) | 2 (23.4%) | 5 (19.1%) | 8 (14.9%) | 28.4% (19.7%, 37.2%) | 21.1% (19.6%, 22.7%) | 19.1% (18.2%, 19.9%) | 15.9% (15.0%, 16.8%) | - | - | 9 (14.9%) |
| Hip fracture treatment | | | | | | | | | | | | | |
| All ages | 7.8 (5.4) | 6 (5, 10) | 2 (47.1%) | - | - | - | 53.9% (46.5%, 61.3%) | 43.2% (40.7%, 45.6%) | 39.3% (37.7%, 40.8%) | 36.7% (34.8%, 38.6%) | 31.5% (28.3%, 34.7%) | - | 13 (31.0%) |
| 18-40 | 7.9 (4.9) | 7 (5, 10) | 1 (38.8%) | - | - | - | 38.8% (0.0%, 79.4%) | 61.6% (54.3%, 69.0%) | 54.1% (49.4%, 58.7%) | 49.4% (44.1%, 54.6%) | 44 | | |

Table 4a. Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Days' Supply for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Main independent variable in model: days' supply | | | | | | | | | | | | | | | |
|--|-----------------------|-----------|--|------------|-----------|------------|----------------------|--|--|----------------------|----------------------|---|----|--|--|
| Surgery | Observed ¹ | | Modeled ^{2,3} | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | | Value with lowest probability of re-fill | |
| | | | First value with probability of re-fill below: | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | | | | |
| | Age group (years) | Mean (SD) | Median (IQR) | 50% | 25% | 20% | 15% | 10% | 1 | 3 | 5 | 7 | 14 | | |
| Hysterectomy (laparoscopic) | | | | | | | | | | | | | | | |
| All ages | 4.8 (2.6) | 4 (3, 5) | 1 (10.3%) | 1 (10.3%) | 1 (10.3%) | 1 (10.3%) | 10.3% (3.3%, 17.2%) | 12.7% (11.5%, 13.9%) | 11.8% (10.8%, 12.9%) | 11.5% (9.3%, 13.7%) | - | - | - | 1 (10.3%) | |
| 18-40 | 4.7 (2.5) | 4 (3, 5) | 1 (18.1%) | 1 (18.1%) | 1 (18.1%) | - | 18.1% (2.8%, 33.4%) | 15.2% (13.0%, 17.4%) | 15.2% (13.2%, 17.2%) | 15.1% (11.0%, 19.2%) | - | - | - | 7 (15.1%) | |
| 41-64 | 4.7 (2.6) | 4 (3, 5) | - | - | - | - | - | - | - | - | - | - | - | - | |
| 65+ | 4.9 (2.6) | 5 (3, 5) | - | - | - | - | - | - | - | - | - | - | - | - | |
| Hysterectomy (non-laparoscopic) | | | | | | | | | | | | | | | |
| All ages | 4.9 (2.7) | 5 (3, 5) | 1 (22.4%) | 1 (22.4%) | 2 (11.7%) | 2 (11.7%) | 22.4% (14.1%, 30.6%) | 13.6% (12.3%, 14.9%) | 12.6% (11.5%, 13.7%) | 11.7% (9.6%, 13.7%) | - | - | - | 7 (11.7%) | |
| 18-40 | 4.7 (2.5) | 4 (3, 5) | - | - | - | - | - | - | - | - | - | - | - | - | |
| 41-64 | 4.8 (2.7) | 5 (3, 5) | 1 (22.5%) | 1 (22.5%) | 2 (12.6%) | 2 (12.6%) | 22.5% (8.9%, 36.2%) | 14.3% (12.3%, 16.4%) | 13.4% (11.6%, 15.2%) | 14.6% (11.1%, 18.1%) | - | - | - | 2 (12.6%) | |
| 65+ | 5.0 (2.8) | 5 (3, 5) | - | - | - | - | - | - | - | - | - | - | - | - | |
| Knee arthroplasty | | | | | | | | | | | | | | | |
| All ages | 8.1 (4.7) | 7 (5, 10) | - | - | - | - | 65.0% (58.9%, 71.2%) | 69.5% (68.3%, 70.6%) | 66.5% (65.9%, 67.0%) | 62.1% (61.4%, 62.8%) | 55.4% (52.3%, 58.5%) | - | - | 13 (55.4%) | |
| 18-40 | 7.8 (4.4) | 7 (5, 10) | - | - | - | - | - | - | - | - | - | - | - | - | |
| 41-64 | 7.9 (4.6) | 7 (5, 10) | - | - | - | - | 75.5% (64.8%, 86.2%) | 75.3% (73.4%, 77.2%) | 73.0% (71.9%, 74.0%) | 70.4% (69.2%, 71.6%) | 67.9% (62.1%, 73.7%) | - | - | 10 (64.3%) | |
| 65+ | 8.1 (4.7) | 7 (5, 10) | - | - | - | - | 61.1% (53.7%, 68.6%) | 67.7% (66.3%, 69.0%) | 64.0% (63.4%, 64.7%) | 59.2% (58.3%, 60.0%) | 51.3% (47.8%, 54.9%) | - | - | 13 (51.2%) | |
| Laminectomy/discectomy | | | | | | | | | | | | | | | |
| All ages | 8.2 (4.7) | 7 (5, 10) | 1 (42.5%) | 3 (22.1%) | 4 (19.3%) | - | 42.5% (28.3%, 56.7%) | 22.1% (19.6%, 24.5%) | 18.2% (17.1%, 19.4%) | 16.8% (15.4%, 18.1%) | 17.5% (14.6%, 20.4%) | - | - | 10 (15.3%) | |
| 18-40 | 8.1 (4.6) | 7 (5, 10) | - | - | - | - | - | - | - | - | - | - | - | - | |
| 41-64 | 8.1 (4.7) | 7 (5, 10) | 1 (43.5%) | 3 (21.3%) | 4 (18.9%) | 15 (13.7%) | 43.5% (18.8%, 68.1%) | 21.3% (17.7%, 24.9%) | 18.2% (16.4%, 20.0%) | 16.8% (14.8%, 18.9%) | 17.1% (12.8%, 21.5%) | - | - | 15 (13.7%) | |
| 65+ | 8.3 (4.8) | 7 (5, 10) | 1 (43.3%) | 3 (22.3%) | 5 (19.2%) | - | 43.3% (22.5%, 64.1%) | 22.3% (17.9%, 26.8%) | 19.2% (17.1%, 21.2%) | 17.1% (14.8%, 19.4%) | 16.6% (11.8%, 21.4%) | - | - | 12 (15.6%) | |
| Spinal fusion (all levels) | | | | | | | | | | | | | | | |
| All ages | 9.1 (5.4) | 8 (5, 10) | 1 (49.0%) | - | - | - | 49.0% (35.8%, 62.2%) | 38.9% (36.6%, 41.2%) | 35.7% (34.6%, 36.8%) | 34.2% (33.1%, 35.4%) | 29.0% (27.0%, 31.1%) | - | - | 15 (28.0%) | |
| 18-40 | 8.9 (5.3) | 8 (5, 10) | 1 (44.5%) | - | - | - | 44.5% (6.9%, 82.0%) | 49.6% (42.7%, 56.4%) | 40.3% (36.8%, 43.8%) | 40.0% (36.1%, 43.9%) | 34.4% (27.6%, 41.2%) | - | - | 15 (30.9%) | |
| 41-64 | 8.9 (5.3) | 8 (5, 10) | 1 (45.5%) | - | - | - | 45.5% (25.6%, 65.3%) | 35.7% (32.5%, 38.9%) | 35.0% (33.4%, 36.7%) | 34.3% (32.6%, 36.0%) | 30.4% (27.3%, 33.6%) | - | - | 15 (29.6%) | |
| 65+ | 9.3 (5.6) | 8 (5, 10) | 2 (44.9%) | - | - | - | 51.9% (32.0%, 71.8%) | 40.3% (36.6%, 44.0%) | 35.4% (33.8%, 37.1%) | 33.0% (31.4%, 34.5%) | 26.6% (23.6%, 29.5%) | - | - | 15 (25.9%) | |
| Spinal fusion (1-3 levels) | | | | | | | | | | | | | | | |
| All ages | 9.0 (5.3) | 8 (5, 10) | 2 (42.1%) | - | - | - | 56.2% (40.0%, 72.4%) | 35.5% (32.8%, 38.2%) | 32.9% (31.7%, 34.2%) | 31.3% (30.0%, 32.6%) | 26.9% (24.5%, 29.3%) | - | - | 15 (25.1%) | |
| 18-40 | 8.9 (5.2) | 8 (5, 10) | - | - | - | - | - | - | - | - | - | - | - | - | |
| 41-64 | 8.8 (5.2) | 8 (5, 10) | 2 (38.0%) | - | - | - | 50.5% (24.4%, 76.6%) | 32.8% (29.1%, 36.5%) | 31.8% (29.9%, 33.7%) | 30.6% (28.7%, 32.5%) | 28.2% (24.5%, 32.0%) | - | - | 15 (25.7%) | |
| 65+ | 9.2 (5.5) | 8 (5, 10) | 2 (42.5%) | 14 (24.6%) | - | - | 55.6% (33.4%, 77.7%) | 36.5% (32.4%, 40.7%) | 34.1% (32.2%, 35.9%) | 31.2% (29.4%, 32.9%) | 24.6% (21.3%, 28.0%) | - | - | 15 (24.2%) | |
| Spinal fusion (4+ levels) | | | | | | | | | | | | | | | |
| All ages | 9.5 (5.7) | 8 (5, 11) | 1 (38.0%) | - | - | - | 38.0% (13.7%, 62.4%) | 51.9% (47.1%, 56.8%) | 45.5% (43.2%, 47.8%) | 43.6% (41.4%, 45.8%) | 37.1% (32.7%, 41.5%) | - | - | 15 (37.0%) | |
| 18-40 | 9.0 (5.3) | 8 (5, 10) | - | - | - | - | - | - | - | - | - | - | - | - | |
| 41-64 | 9.4 (5.6) | 8 (5, 11) | 1 (40.4%) | - | - | - | 40.4% (8.1%, 72.7%) | 45.6% (38.5%, 52.7%) | 46.9% (43.5%, 50.3%) | 46.2% (42.9%, 49.4%) | 38.2% (31.5%, 44.9%) | - | - | 13 (37.3%) | |
| 65+ | 9.7 (5.9) | 8 (5, 12) | 1 (23.2%) | 1 (23.2%) | - | - | 23.2% (0.0%, 64.0%) | 55.6% (47.6%, 63.7%) | 40.8% (37.3%, 44.4%) | 38.1% (34.7%, 41.4%) | 35.9% (29.2%, 42.6%) | - | - | 1 (23.2%) | |
| Tooth extraction | | | | | | | | | | | | | | | |
| All ages | 3.5 (1.7) | 3 (2, 4) | 1 (9.6%) | 1 (9.6%) | 1 (9.6%) | 1 (9.6%) | 9.6% (8.8%, 10.5%) | 8.6% (8.3%, 8.8%) | 7.2% (6.9%, 7.5%) | - | - | - | - | 5 (7.2%) | |
| 18-40 | 3.5 (1.6) | 3 (3, 4) | 1 (11.5%) | 1 (11.5%) | 1 (11.5%) | 3 (9.4%) | 11.5% (10.3%, 12.7%) | 9.4% (9.2%, 9.7%) | 7.8% (7.4%, 8.2%) | - | - | - | - | 5 (7.8%) | |
| 41-64 | 3.4 (1.7) | 3 (2, 4) | 1 (5.5%) | 1 (5.5%) | 1 (5.5%) | 1 (5.5%) | 5.5% (4.5%, 6.6%) | 6.1% (5.7%, 6.5%) | 5.5% (5.0%, 6.1%) | - | - | - | - | 4 (5.3%) | |
| 65+ | 3.5 (2.0) | 3 (2, 4) | - | - | - | - | - | - | - | - | - | - | - | - | |

¹Observed days' supply was evaluated in the overall population of post-surgical opioid initiators. All model estimates were derived after restricting this population to those with a days' supply of no more than the 90th percentile for their given surgery and with 90 or fewer initial days' supply.

²Re-fill probabilities are blank when the probability associated with all days' supply was greater than the indicated threshold or the days' supply values of interest were above the 90th percentile for a given surgery.

³Dashes indicate that a model was not run due to lack of sufficient outcome events.

Table 4b. Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Number of Tablets/Capsules Dispensed of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Main independent variable in model: tablets/capsules dispensed | | | | | | | | | | | | | |
|--|-------------------|--|--------------|-----------|------------|------------|------------|-----------|--|----------------------|--------------------------|--|----------------------|
| Observed ¹ | | Modeled ^{2,3} | | | | | | | | | | Value with lowest probability of re-fill | |
| | | First value with probability of re-fill below: | | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | |
| Surgery | Age group (years) | Mean (SD) | Median (IQR) | 50% | 25% | 20% | 15% | 10% | 10 | 15 | 20 | 20 | 60 |
| All surgeries | | | | | | | | | | | | | |
| All ages | | 36.8 (21.5) | 30 (24, 40) | 1 (24.4%) | 1 (24.4%) | 6 (19.3%) | 59 (14.9%) | | 17.7% (17.3%, 18.1%) | 17.1% (16.9%, 17.4%) | 17.1% (16.9%, 17.3%) | 16.5% (16.3%, 16.6%) | 14.7% (14.5%, 14.9%) |
| 18-40 | | 29.6 (12.4) | 30 (20, 30) | 1 (11.4%) | 1 (11.4%) | 1 (11.4%) | 1 (11.4%) | | 12.4% (11.9%, 13.0%) | 12.3% (12.0%, 12.7%) | 12.0% (11.7%, 12.2%) | 11.1% (10.9%, 11.2%) | 10.1% (9.6%, 10.6%) |
| 41-64 | | 39.6 (24.4) | 30 (24, 50) | 1 (26.2%) | 2 (24.4%) | 6 (19.6%) | | | 17.5% (16.6%, 18.4%) | 17.0% (16.4%, 17.5%) | 17.4% (16.9%, 17.8%) | 18.0% (17.8%, 18.3%) | 17.0% (16.6%, 17.3%) |
| 65+ | | 48.5 (26.5) | 40 (30, 60) | 1 (40.7%) | 60 (24.8%) | | | | 32.2% (31.1%, 33.3%) | 29.9% (29.1%, 30.7%) | 28.8% (28.1%, 29.4%) | 28.3% (28.0%, 28.7%) | 24.8% (24.5%, 25.1%) |
| Appendectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | | 31.7 (10.7) | 30 (30, 40) | 1 (25.1%) | 2 (20.9%) | 3 (17.7%) | 5 (13.2%) | 8 (9.7%) | 8.5% (7.0%, 9.9%) | 7.5% (6.7%, 8.4%) | 8.0% (7.4%, 8.5%) | 7.4% (7.1%, 7.7%) | 35 (6.9%) |
| 18-40 | | 31.8 (10.6) | 30 (30, 40) | 1 (24.6%) | 1 (24.6%) | 3 (17.9%) | 5 (13.7%) | 9 (9.6%) | 9.1% (7.3%, 11.0%) | 8.2% (7.0%, 9.4%) | 8.6% (7.8%, 9.3%) | 7.6% (7.1%, 8.0%) | 37 (6.7%) |
| 41-64 | | 32.1 (10.7) | 30 (30, 40) | 1 (21.2%) | 1 (21.2%) | 2 (17.8%) | 4 (13.2%) | 7 (9.5%) | 7.9% (5.3%, 10.4%) | 7.3% (5.8%, 8.9%) | 8.0% (7.0%, 8.9%) | 7.7% (7.1%, 8.2%) | 14 (7.3%) |
| 65+ | | 30.6 (11.2) | 30 (25, 30) | | | | | | | | | | |
| Appendectomy (nonspecific) | | | | | | | | | | | | | |
| All ages | | 32.2 (12.2) | 30 (25, 40) | 3 (42.7%) | 6 (24.6%) | 8 (18.5%) | 11 (14.2%) | | 15.2% (10.5%, 19.9%) | 13.0% (10.3%, 15.7%) | 14.5% (12.8%, 16.3%) | 13.8% (12.7%, 14.9%) | 15 (13.0%) |
| 18-40 | | 32.2 (11.7) | 30 (28, 40) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 32.6 (12.2) | 30 (30, 40) | - | - | - | - | - | - | - | - | - | - |
| 65+ | | 31.6 (13.0) | 30 (25, 36) | - | - | - | - | - | - | - | - | - | - |
| Bunionectomy | | | | | | | | | | | | | |
| All ages | | 37.8 (15.2) | 30 (30, 40) | 1 (30.6%) | 6 (24.6%) | | | | 21.9% (18.9%, 25.0%) | 20.4% (19.0%, 21.7%) | 20.1% (19.0%, 21.1%) | 21.6% (21.0%, 22.2%) | 21.1% (19.9%, 22.3%) |
| 18-40 | | 38.0 (15.5) | 30 (30, 42) | 4 (47.5%) | | | | | 35.0% (27.1%, 42.9%) | 30.3% (26.5%, 34.2%) | 28.8% (26.0%, 31.7%) | 30.5% (28.8%, 32.2%) | 28.4% (25.1%, 31.7%) |
| 41-64 | | 38.2 (14.9) | 35 (30, 45) | 1 (23.2%) | 1 (23.2%) | 12 (20.0%) | | | 20.2% (16.8%, 23.7%) | 19.8% (18.0%, 21.6%) | 20.0% (18.6%, 21.4%) | 21.8% (20.9%, 22.7%) | 22.5% (20.7%, 24.2%) |
| 65+ | | 37.0 (15.4) | 30 (30, 40) | 1 (20.5%) | 1 (20.5%) | 2 (19.7%) | 60 (14.9%) | | 16.4% (12.4%, 20.4%) | 15.7% (13.7%, 17.8%) | 15.7% (14.2%, 17.3%) | 16.7% (15.6%, 17.7%) | 14.9% (13.0%, 16.8%) |
| Cesarean section | | | | | | | | | | | | | |
| All ages | | 32.5 (9.6) | 30 (30, 40) | 1 (23.6%) | 1 (23.6%) | 4 (18.7%) | 9 (14.4%) | | 13.9% (12.5%, 15.3%) | 12.5% (11.8%, 13.2%) | 12.2% (11.8%, 12.6%) | 12.0% (11.9%, 12.2%) | 40 (11.6%) |
| 18-40 | | 32.5 (9.6) | 30 (30, 40) | 1 (22.0%) | 1 (22.0%) | 3 (19.1%) | 8 (14.7%) | | 13.7% (12.4%, 15.1%) | 12.5% (11.8%, 13.3%) | 12.2% (11.9%, 12.6%) | 12.0% (11.8%, 12.2%) | 40 (11.7%) |
| 41-64 | | 32.8 (9.4) | 30 (30, 40) | 3 (44.9%) | 7 (23.8%) | 9 (18.4%) | 12 (14.1%) | 33 (9.6%) | 16.6% (9.7%, 23.6%) | 12.3% (8.8%, 15.7%) | 11.9% (10.1%, 13.8%) | 12.9% (11.9%, 13.9%) | 37 (6.5%) |
| 65+ | | - | - | - | - | - | - | - | - | - | - | - | - |
| Cholecystectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | | 31.6 (10.8) | 30 (30, 40) | 1 (26.4%) | 2 (22.9%) | 3 (20.0%) | 6 (14.2%) | 11 (9.9%) | 10.4% (9.4%, 11.4%) | 8.6% (8.1%, 9.2%) | 8.1% (7.8%, 8.4%) | 7.0% (6.8%, 7.2%) | 40 (6.5%) |
| 18-40 | | 32.2 (10.3) | 30 (30, 40) | 1 (14.5%) | 1 (14.5%) | 1 (14.5%) | 1 (14.5%) | 25 (9.9%) | 13.4% (10.7%, 16.0%) | 12.2% (10.7%, 13.7%) | 11.0% (10.2%, 11.7%) | 9.1% (8.7%, 9.5%) | 40 (8.2%) |
| 41-64 | | 32.1 (10.7) | 30 (30, 40) | 1 (21.3%) | 1 (21.3%) | 2 (18.7%) | 4 (14.9%) | 9 (9.9%) | 9.4% (7.9%, 11.0%) | 8.0% (7.1%, 8.9%) | 7.7% (7.2%, 8.2%) | 7.3% (7.0%, 7.6%) | 37 (6.5%) |
| 65+ | | 30.5 (11.2) | 30 (24, 30) | 1 (33.6%) | 3 (21.8%) | 4 (18.0%) | 6 (12.8%) | 8 (10.0%) | 8.4% (7.0%, 9.7%) | 6.9% (6.2%, 7.5%) | 6.4% (5.9%, 6.9%) | 5.0% (4.8%, 5.3%) | 40 (4.9%) |
| Cholecystectomy (nonspecific) | | | | | | | | | | | | | |
| All ages | | 33.7 (15.4) | 30 (25, 40) | 1 (36.3%) | 6 (23.3%) | 9 (19.1%) | 16 (14.8%) | | 18.1% (12.0%, 24.2%) | 15.1% (11.6%, 18.6%) | 14.5% (12.3%, 16.7%) | 17.4% (15.7%, 19.0%) | 19 (14.5%) |
| 18-40 | | 35.5 (21.4) | 30 (30, 40) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 35.0 (14.8) | 30 (30, 40) | - | - | - | - | - | - | - | - | - | - |
| 65+ | | 32.5 (14.5) | 30 (25, 40) | - | - | - | - | - | - | - | - | - | - |
| Coronary artery bypass graft | | | | | | | | | | | | | |
| All ages | | 46.3 (20.3) | 40 (30, 60) | 5 (46.3%) | 15 (24.8%) | 51 (19.8%) | | | 31.4% (26.9%, 35.9%) | 24.8% (22.0%, 27.5%) | 22.7% (20.8%, 24.6%) | 23.7% (22.8%, 24.5%) | 19.2% (18.1%, 20.2%) |
| 18-40 | | 48.4 (20.0) | 48 (30, 60) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 47.8 (20.2) | 45 (30, 60) | 7 (48.6%) | | | | | 38.3% (28.1%, 48.6%) | 29.9% (24.1%, 35.7%) | 28.1% (24.1%, 32.1%) | 31.4% (29.6%, 33.2%) | 27.2% (25.2%, 29.2%) |
| 65+ | | 45.5 (20.2) | 40 (30, 50) | 3 (46.8%) | 12 (24.7%) | 20 (19.8%) | 51 (14.9%) | | 27.5% (22.6%, 32.4%) | 21.9% (18.9%, 25.0%) | 19.8% (17.7%, 21.9%) | 19.8% (18.8%, 20.7%) | 15.0% (13.8%, 16.2%) |
| Hip fracture treatment | | | | | | | | | | | | | |
| All ages | | 49.7 (28.4) | 40 (30, 60) | 9 (49.2%) | | | | | 48.1% (44.1%, 52.0%) | 43.7% (40.3%, 47.1%) | 41.0% (38.6%, 43.5%)</td | | |

Table 4b. Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Number of Tablets/Capsules Dispensed of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Main independent variable in model: tablets/capsules dispensed | | | | | | | | | | | | | |
|--|-------------------|--|--------------|------------|------------|------------|------------|----------|--|----------------------|----------------------|--|----------------------|
| Observed ¹ | | Modeled ^{2,3} | | | | | | | | | | Value with lowest probability of re-fill | |
| | | First value with probability of re-fill below: | | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | |
| Surgery | Age group (years) | Mean (SD) | Median (IQR) | 50% | 25% | 20% | 15% | 10% | 10 | 15 | 20 | 20 | 60 |
| Hip replacement | | | | | | | | | | | | | |
| All ages | | 64.0 (27.3) | 60 (40, 80) | 1 (43.6%) | 85 (24.7%) | - | - | - | 36.5% (32.7%, 40.4%) | 35.3% (32.7%, 37.9%) | 35.4% (33.2%, 37.5%) | 37.1% (35.9%, 38.3%) | 31.3% (30.6%, 32.1%) |
| 18-40 | | 70.3 (30.3) | 60 (50, 90) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 68.7 (27.5) | 60 (50, 90) | 4 (49.5%) | 91 (24.5%) | - | - | - | 42.7% (34.2%, 51.2%) | 39.7% (34.3%, 45.1%) | 38.5% (34.5%, 42.5%) | 39.4% (36.8%, 42.0%) | 36.2% (34.7%, 37.6%) |
| 65+ | | 61.2 (26.7) | 60 (40, 80) | 1 (35.4%) | 76 (24.8%) | 93 (19.9%) | - | - | 32.9% (28.6%, 37.2%) | 32.9% (30.0%, 35.8%) | 33.5% (31.0%, 35.9%) | 35.0% (33.6%, 36.4%) | 28.5% (27.5%, 29.4%) |
| Hysterectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | | 32.0 (10.2) | 30 (30, 40) | 1 (35.5%) | 4 (23.7%) | 6 (18.9%) | 9 (14.6%) | - | 13.7% (8.4%, 19.0%) | 11.5% (8.8%, 14.3%) | 11.5% (10.1%, 12.9%) | 11.8% (11.0%, 12.6%) | 18 (11.3%) |
| 18-40 | | 32.0 (10.4) | 30 (30, 40) | 1 (30.8%) | 4 (23.0%) | 6 (19.7%) | 14 (14.9%) | - | 16.1% (7.8%, 24.5%) | 14.8% (10.1%, 19.4%) | 15.0% (12.5%, 17.5%) | 15.0% (13.4%, 16.6%) | 16 (14.7%) |
| 41-64 | | 32.2 (9.9) | 30 (30, 40) | - | - | - | - | - | - | - | - | - | - |
| 65+ | | 31.1 (10.3) | 30 (30, 30) | - | - | - | - | - | - | - | - | - | - |
| Hysterectomy (non-laparoscopic) | | | | | | | | | | | | | |
| All ages | | 32.1 (11.6) | 30 (30, 40) | 5 (41.3%) | 8 (20.3%) | 9 (16.8%) | 10 (14.3%) | - | 14.3% (9.9%, 18.8%) | 10.6% (8.3%, 12.9%) | 12.6% (11.2%, 14.0%) | 12.2% (11.4%, 13.0%) | 15 (10.6%) |
| 18-40 | | 32.8 (12.2) | 30 (30, 40) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 32.8 (11.2) | 30 (30, 40) | 2 (39.8%) | 5 (20.6%) | 6 (17.2%) | 7 (14.8%) | - | 11.1% (6.4%, 15.9%) | 11.0% (7.9%, 14.2%) | 14.3% (11.9%, 16.6%) | 12.8% (11.2%, 14.3%) | 34 (10.1%) |
| 65+ | | 30.7 (11.5) | 30 (24, 30) | - | - | - | - | - | - | - | - | - | - |
| Knee arthroplasty | | | | | | | | | | | | | |
| All ages | | 63.6 (27.6) | 60 (40, 80) | - | - | - | - | - | 65.1% (61.7%, 68.5%) | 66.1% (64.0%, 68.2%) | 67.1% (65.5%, 68.6%) | 68.4% (67.6%, 69.3%) | 61.6% (61.0%, 62.2%) |
| 18-40 | | 61.3 (29.7) | 60 (40, 80) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 66.8 (28.8) | 60 (50, 90) | - | - | - | - | - | 68.4% (61.8%, 75.1%) | 71.0% (66.8%, 75.1%) | 72.9% (69.9%, 75.9%) | 75.2% (73.5%, 76.8%) | 70.2% (69.2%, 71.3%) |
| 65+ | | 62.5 (27.1) | 60 (40, 80) | 91 (49.6%) | - | - | - | - | 64.1% (60.1%, 68.2%) | 64.6% (62.1%, 67.1%) | 65.2% (63.4%, 67.0%) | 66.1% (65.1%, 67.1%) | 58.6% (57.9%, 59.2%) |
| Laminectomy/discectomy | | | | | | | | | | | | | |
| All ages | | 60.2 (25.5) | 60 (40, 75) | 1 (41.0%) | 19 (24.6%) | 33 (19.9%) | 77 (15.0%) | - | 30.7% (23.4%, 38.0%) | 26.9% (22.4%, 31.4%) | 24.1% (20.8%, 27.4%) | 20.6% (19.0%, 22.2%) | 16.9% (15.8%, 17.9%) |
| 18-40 | | 61.3 (25.6) | 60 (40, 80) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 61.3 (25.6) | 60 (40, 80) | 1 (16.9%) | 1 (16.9%) | 1 (16.9%) | - | - | 21.4% (10.7%, 32.0%) | 22.6% (16.1%, 29.1%) | 23.0% (18.4%, 27.6%) | 21.8% (19.3%, 24.3%) | 15.7% (14.1%, 17.3%) |
| 65+ | | 58.0 (25.0) | 60 (40, 65) | 1 (49.3%) | 23 (24.3%) | 32 (19.8%) | 70 (14.9%) | - | 36.8% (27.2%, 46.3%) | 31.1% (24.3%, 37.9%) | 26.5% (21.3%, 31.8%) | 20.5% (18.1%, 23.0%) | 18.3% (16.4%, 20.2%) |
| Spinal fusion (all levels) | | | | | | | | | | | | | |
| All ages | | 66.9 (29.7) | 60 (50, 90) | 5 (49.0%) | - | - | - | - | 42.7% (35.4%, 50.1%) | 38.7% (34.6%, 42.9%) | 36.5% (33.7%, 39.2%) | 35.1% (33.5%, 36.7%) | 33.7% (32.7%, 34.6%) |
| 18-40 | | 67.8 (32.7) | 60 (45, 90) | 1 (16.6%) | 1 (16.6%) | 1 (16.6%) | - | - | 34.2% (20.3%, 48.0%) | 40.6% (31.3%, 49.8%) | 43.9% (36.7%, 51.1%) | 43.5% (39.2%, 47.8%) | 37.4% (34.1%, 40.7%) |
| 41-64 | | 67.4 (29.7) | 60 (50, 90) | 4 (49.8%) | - | - | - | - | 41.1% (30.2%, 52.0%) | 36.7% (30.5%, 42.9%) | 34.3% (30.3%, 38.3%) | 33.3% (31.0%, 35.6%) | 33.2% (31.7%, 34.6%) |
| 65+ | | 66.2 (29.1) | 60 (48, 90) | 8 (49.3%) | - | - | - | - | 46.1% (35.5%, 56.7%) | 40.3% (34.3%, 46.3%) | 37.0% (32.8%, 41.2%) | 35.1% (32.8%, 37.4%) | 33.5% (32.1%, 34.9%) |
| Spinal fusion (1-3 levels) | | | | | | | | | | | | | |
| All ages | | 66.2 (28.9) | 60 (46, 90) | 9 (49.4%) | - | - | - | - | 47.4% (38.1%, 56.8%) | 39.9% (34.8%, 45.1%) | 35.6% (32.2%, 38.9%) | 32.6% (30.8%, 34.4%) | 30.6% (29.5%, 31.7%) |
| 18-40 | | 68.0 (31.9) | 60 (45, 90) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 66.8 (28.9) | 60 (50, 90) | 8 (50.0%) | - | - | - | - | 46.2% (32.8%, 59.6%) | 39.1% (31.5%, 46.6%) | 34.7% (29.9%, 39.4%) | 31.2% (28.6%, 33.8%) | 29.3% (27.6%, 30.9%) |
| 65+ | | 65.3 (28.2) | 60 (45, 90) | 9 (48.2%) | 90 (24.7%) | - | - | - | 46.1% (34.0%, 58.2%) | 38.5% (31.6%, 45.3%) | 34.4% (29.7%, 39.1%) | 32.7% (30.2%, 35.3%) | 31.5% (29.9%, 33.1%) |
| Spinal fusion (4+ levels) | | | | | | | | | | | | | |
| All ages | | 70.1 (32.1) | 60 (50, 90) | 1 (28.0%) | - | - | - | - | 37.9% (25.1%, 50.6%) | 41.6% (33.7%, 49.5%) | 44.0% (38.7%, 49.4%) | 45.9% (42.6%, 49.3%) | 43.7% (41.7%, 45.8%) |
| 18-40 | | 70.3 (34.8) | 60 (50, 90) | - | - | - | - | - | - | - | - | - | - |
| 41-64 | | 70.4 (31.8) | 60 (50, 90) | 1 (32.1%) | - | - | - | - | 35.4% (17.5%, 53.3%) | 37.2% (25.8%, 48.6%) | 39.1% (31.0%, 47.3%) | 42.6% (37.5%, 47.6%) | 46.1% (42.9%, 49.2%) |
| 65+ | | 69.8 (31.6) | 60 (50, 90) | 14 (50.0%) | - | - | - | - | 51.9% (34.1%, 69.7%) | 49.5% (38.7%, 60.4%) | 47.4% (39.9%, 55.0%) | 44.1% (39.5%, 48.8%) | 39.8% (36.6%, 43.1%) |
| Tooth extraction | | | | | | | | | | | | | |
| All ages | | 19.7 (6.5) | 20 (15, 20) | 1 (24.8%) | 1 (24.8%) | 2 (17.4%) | 3 (12.9%) | 5 (8.5%) | 7.3% (6.9%, 7.7%) | 9.3% (9.0%, 9.6%) | 8.2% (8.0%, 8.4%) | 7.4% (7.0%, 7.8%) | 8 (7.0%) |
| 18-40 | | 20 | | | | | | | | | | | |

Table 4c. Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Morphine Milligram Equivalents of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Main independent variable in model: morphine milligram equivalents | | | | | | | | | | | | | |
|--|---------------|----------------|--|-------------|-------------|-------------|-------------|----------------------|----------------------|--|----------------------|----------------------|--|
| Observed ¹ | | | Modeled ^{2,3} | | | | | | | | | | |
| | | | First value with probability of re-fill below: | | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | |
| Surgery | | | | | | | | | | | | | |
| Age group (years) | Mean (SD) | Median (IQR) | 50% | 25% | 20% | 15% | 10% | 50 | 100 | 200 | 300 | 400 | Value with lowest probability of re-fill |
| All surgeries | | | | | | | | | | | | | |
| All ages | 264.2 (203.6) | 225 (150, 300) | 1 (20.3%) | 1 (20.3%) | 4 (20.0%) | | | 16.8% (16.4%, 17.3%) | 16.0% (15.8%, 16.2%) | 15.7% (15.5%, 15.8%) | 15.8% (15.6%, 15.9%) | 16.3% (16.0%, 16.6%) | 450 (15.2%) |
| 18-40 | 209.4 (122.6) | 200 (150, 225) | 1 (11.6%) | 1 (11.6%) | 1 (11.6%) | 1 (11.6%) | | 11.6% (11.0%, 12.1%) | 11.4% (11.1%, 11.6%) | 10.8% (10.5%, 11.0%) | 11.5% (11.3%, 11.8%) | 11.9% (11.5%, 12.4%) | 191 (10.7%) |
| 41-64 | 293.0 (245.0) | 225 (150, 375) | 1 (20.7%) | 1 (20.7%) | 6 (19.9%) | | | 16.0% (15.2%, 16.8%) | 15.8% (15.4%, 16.3%) | 17.1% (16.8%, 17.4%) | 17.2% (16.9%, 17.6%) | 18.0% (17.4%, 18.5%) | 76 (15.6%) |
| 65+ | 346.8 (249.6) | 300 (160, 450) | 1 (41.6%) | 427 (25.0%) | | | | 31.1% (29.9%, 32.3%) | 27.7% (27.0%, 28.5%) | 27.1% (26.8%, 27.5%) | 25.6% (25.2%, 26.0%) | 25.6% (25.1%, 26.2%) | 450 (23.9%) |
| Appendectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | 208.6 (103.6) | 200 (150, 225) | 1 (19.5%) | 1 (19.5%) | 1 (19.5%) | 15 (14.8%) | 43 (9.9%) | 9.3% (7.7%, 10.8%) | 7.4% (6.8%, 8.0%) | 7.1% (6.6%, 7.7%) | 7.8% (7.1%, 8.5%) | | 204 (7.1%) |
| 18-40 | 209.9 (103.5) | 200 (150, 225) | 1 (17.0%) | 1 (17.0%) | 1 (17.0%) | 10 (14.9%) | 48 (10.0%) | 9.8% (7.9%, 11.7%) | 8.0% (7.2%, 8.8%) | 7.3% (6.6%, 8.1%) | 7.9% (6.9%, 8.8%) | | 216 (7.3%) |
| 41-64 | 212.5 (106.2) | 200 (150, 225) | 1 (15.5%) | 1 (15.5%) | 1 (15.5%) | 4 (14.8%) | 32 (10.0%) | 8.5% (5.7%, 11.2%) | 7.2% (6.2%, 8.3%) | 7.8% (6.7%, 8.9%) | 8.2% (7.0%, 9.4%) | | 99 (7.2%) |
| 65+ | 191.3 (94.2) | 150 (150, 225) | | | | | | | | | | | |
| Appendectomy (nonspecific) | | | | | | | | | | | | | |
| All ages | 219.5 (124.9) | 200 (150, 250) | 1 (39.3%) | 30 (24.8%) | 47 (19.8%) | 77 (14.9%) | | 19.1% (13.5%, 24.8%) | 13.2% (11.2%, 15.1%) | 14.3% (12.3%, 16.3%) | 17.6% (15.2%, 19.9%) | | 130 (12.5%) |
| 18-40 | 221.1 (130.3) | 200 (150, 250) | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 227.0 (127.0) | 200 (150, 300) | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | 202.8 (107.6) | 175 (150, 225) | - | - | - | - | - | - | - | - | - | - | - |
| Bunionectomy | | | | | | | | | | | | | |
| All ages | 280.9 (174.2) | 225 (150, 338) | 1 (40.0%) | 35 (24.9%) | 65 (19.9%) | | | 21.8% (18.7%, 24.9%) | 18.8% (17.5%, 20.0%) | 21.2% (20.5%, 21.9%) | 23.6% (22.7%, 24.5%) | 26.7% (25.0%, 28.5%) | 96 (18.7%) |
| 18-40 | 289.8 (178.3) | 225 (150, 350) | 1 (50.0%) | | | | | 32.6% (23.9%, 41.4%) | 29.1% (25.6%, 32.7%) | 29.4% (27.4%, 31.4%) | 31.1% (28.6%, 33.5%) | 39.8% (35.3%, 44.3%) | 241 (28.8%) |
| 41-64 | 289.6 (180.3) | 225 (150, 338) | 1 (37.5%) | 29 (24.7%) | 52 (19.9%) | | | 20.2% (16.4%, 24.0%) | 17.8% (16.2%, 19.5%) | 21.6% (20.6%, 22.6%) | 24.4% (23.1%, 25.7%) | 25.9% (23.5%, 28.2%) | 90 (17.7%) |
| 65+ | 261.3 (159.3) | 225 (150, 300) | 1 (30.4%) | 14 (24.8%) | 31 (20.0%) | 80 (15.0%) | | 16.9% (12.9%, 20.9%) | 14.9% (13.1%, 16.6%) | 16.1% (15.0%, 17.3%) | 18.5% (16.9%, 20.1%) | 21.6% (18.4%, 24.8%) | 94 (14.8%) |
| Cesarean section | | | | | | | | | | | | | |
| All ages | 234.5 (103.4) | 225 (150, 300) | 1 (17.0%) | 1 (17.0%) | 1 (17.0%) | 32 (15.0%) | | 14.0% (12.4%, 15.6%) | 12.1% (11.6%, 12.7%) | 11.8% (11.5%, 12.1%) | 12.4% (12.1%, 12.8%) | | 153 (11.4%) |
| 18-40 | 234.5 (103.4) | 225 (150, 300) | 1 (16.4%) | 1 (16.4%) | 1 (16.4%) | 27 (15.0%) | | 13.9% (12.3%, 15.5%) | 12.1% (11.6%, 12.6%) | 11.7% (11.5%, 12.0%) | 12.5% (12.2%, 12.8%) | | 153 (11.4%) |
| 41-64 | 237.0 (103.4) | 225 (150, 300) | 1 (32.6%) | 21 (24.9%) | 40 (20.0%) | 74 (15.0%) | | 18.1% (10.2%, 26.1%) | 13.1% (10.4%, 15.7%) | 12.7% (11.1%, 14.3%) | 11.4% (9.8%, 13.0%) | | 300 (11.4%) |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cholecystectomy (laparoscopic) | | | | | | | | | | | | | |
| All ages | 210.3 (112.9) | 200 (150, 225) | 1 (21.6%) | 1 (21.6%) | 5 (19.9%) | 21 (15.0%) | 56 (9.9%) | 10.4% (9.4%, 11.5%) | 8.1% (7.7%, 8.5%) | 6.6% (6.3%, 6.9%) | 6.7% (6.3%, 7.1%) | | 279 (6.1%) |
| 18-40 | 218.2 (109.7) | 200 (150, 250) | 1 (16.3%) | 1 (16.3%) | 1 (16.3%) | 17 (14.9%) | 134 (10.0%) | 13.0% (10.1%, 16.0%) | 11.2% (10.2%, 12.1%) | 8.3% (7.6%, 9.1%) | 8.5% (7.7%, 9.3%) | | 278 (7.3%) |
| 41-64 | 218.2 (124.1) | 200 (150, 250) | 1 (19.4%) | 1 (19.4%) | 1 (19.4%) | 15 (14.9%) | 47 (9.9%) | 9.7% (8.1%, 11.3%) | 7.9% (7.3%, 8.5%) | 6.9% (6.4%, 7.4%) | 6.8% (6.2%, 7.4%) | | 280 (6.2%) |
| 65+ | 194.3 (98.5) | 150 (150, 225) | 1 (19.1%) | 1 (19.1%) | 1 (19.1%) | 14 (14.9%) | 40 (10.0%) | 8.8% (7.6%, 10.1%) | 6.1% (5.6%, 6.5%) | 5.0% (4.6%, 5.4%) | 5.3% (4.6%, 6.0%) | | 205 (5.0%) |
| Cholecystectomy (nonspecific) | | | | | | | | | | | | | |
| All ages | 232.3 (143.7) | 210 (150, 300) | 1 (41.6%) | 24 (24.9%) | 37 (19.7%) | 61 (14.9%) | | 16.6% (11.1%, 22.0%) | 13.7% (11.3%, 16.1%) | 18.9% (15.8%, 21.9%) | 18.5% (15.8%, 21.2%) | 19.8% (11.7%, 27.8%) | 89 (13.5%) |
| 18-40 | 255.3 (201.2) | 225 (150, 300) | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 250.4 (154.5) | 225 (150, 300) | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | 217.2 (121.5) | 200 (150, 250) | - | - | - | - | - | - | - | - | - | - | - |
| Coronary artery bypass graft | | | | | | | | | | | | | |
| All ages | 306.4 (191.8) | 250 (200, 375) | 17 (49.7%) | 74 (24.8%) | 381 (20.0%) | | | 30.9% (26.2%, 35.7%) | 22.4% (20.5%, 24.2%) | 23.8% (22.8%, 24.8%) | 21.0% (20.0%, 22.0%) | 19.4% (18.0%, 20.9%) | 441 (18.8%) |
| 18-40 | 346.6 (208.1) | 300 (225, 450) | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 335.1 (212.8) | 300 (200, 375) | 29 (49.7%) | | | | | 38.1% (27.1%, 49.2%) | 28.1% (24.1%, 32.1%) | 31.7% (29.6%, 33.8%) | 28.6% (26.9%, 30.4%) | 29.0% (26.0%, 32.0%) | 268 (27.8%) |
| 65+ | 292.3 (179.0) | 250 (200, 375) | 12 (49.9%) | 55 (24.9%) | 83 (20.0%) | 402 (15.0%) | | 26.5% (21.3%, 31.6%) | 19.1% (16.8%, 21.3%) | 19.5% (18.5%, 20.5%) | 17.0% (15.9%, 18.1%) | 15.0% (13.4%, 16.7%) | 480 (13.2%) |
| Hip fracture treatment | | | | | | | | | | | | | |
| All ages | 355.3 (258.1) | 300 (175, 450) | 39 (49.9%) | | | | | 47.4% (43.3%, 51.4%) | 40.6% (37.8%, 43.5%) | 38.0% (36.3%, 39.7%) | 37.1% (35.2%, 38.9%) | 35.1% (33.3%, 37.0%) | 675 (31.5%) |
| 18-40 | 520.0 (325.7) | 450 (300, 675) | 1 (32.6%) | | | | | 45.1% (25.5%, 64.8%) | 51.6% (41.6%, 61.7%) | 52.0% (46.1%, 57.9%) | 49.9% (44.2%, 55.6%) | 54.9% (48.1%, 61.6%) | 1 (32.6%) |
| 41-64 | 412.8 (265.3) | 375 (225, 500) | 58 (50.0%) | | | | | 51.9% (40.8%, 63.0%) | 44.2% (37.7%, 50.8%) | 46.6% (42.5%, 50.7%) | 43.8% (40.0%, 47.6%) | 39.1% (35.7%, 42.6%) | 416 (39.0%) |
| 65+ | 296.4 (214.1) | 225 (150, 375) | 21 (| | | | | | | | | | |

Table 4c. Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics by Morphine Milligram Equivalents of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Surgery and Age Group

| Main independent variable in model: morphine milligram equivalents | | | | | | | | | | | | | | | |
|--|-----------------------|----------------|--|-------------|-------------|-------------|-----------|-------------------|----------------------|--|----------------------|----------------------|----------------------|--|--|
| Surgery | Observed ¹ | | Modeled ^{2,3} | | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | Value with lowest probability of re-fill | |
| | | | First value with probability of re-fill below: | | | | | | | Estimated probability of re-fill (95% CI) at value of: | | | | | |
| | Age group (years) | Mean (SD) | Median (IQR) | 50% | 25% | 20% | 15% | 10% | 50 | 100 | 200 | 300 | 400 | | |
| Hysterectomy (laparoscopic) | | | | | | | | | | | | | | | |
| All ages | 229.8 (114.1) | 225 (150, 263) | 1 (34.0%) | 15 (24.8%) | 26 (19.9%) | 44 (14.9%) | | | 13.8% (7.9%, 19.8%) | 10.4% (8.5%, 12.3%) | 11.7% (10.7%, 12.6%) | 14.0% (12.2%, 15.7%) | | 106 (10.4%) | |
| 18-40 | 233.6 (118.2) | 225 (150, 270) | 9 (48.9%) | 34 (24.9%) | 44 (20.0%) | 63 (14.9%) | | | 17.9% (8.5%, 27.3%) | 12.9% (9.6%, 16.1%) | 14.4% (12.7%, 16.1%) | 19.5% (16.2%, 22.7%) | | 94 (12.8%) | |
| 41-64 | 232.1 (114.6) | 225 (150, 280) | - | - | - | - | | | - | - | - | - | | - | |
| 65+ | 211.5 (98.5) | 200 (150, 225) | - | - | - | - | | | - | - | - | - | | - | |
| Hysterectomy (non-laparoscopic) | | | | | | | | | | | | | | | |
| All ages | 227.6 (130.2) | 225 (150, 263) | 21 (49.2%) | 41 (24.5%) | 48 (19.8%) | 59 (14.9%) | | | 18.7% (13.7%, 23.6%) | 10.1% (8.5%, 11.7%) | 11.9% (10.2%, 13.7%) | 13.4% (11.7%, 15.0%) | | 99 (10.1%) | |
| 18-40 | 244.2 (155.2) | 225 (150, 300) | - | - | - | - | | | - | - | - | - | | - | |
| 41-64 | 238.6 (131.1) | 225 (150, 300) | 4 (48.9%) | 29 (24.7%) | 38 (19.9%) | 53 (15.0%) | | | 15.7% (9.4%, 22.1%) | 10.9% (8.5%, 13.3%) | 15.3% (13.5%, 17.2%) | 12.7% (10.4%, 15.1%) | | 97 (10.9%) | |
| 65+ | 203.6 (105.4) | 188 (150, 225) | - | - | - | - | | | - | - | - | - | | - | |
| Knee arthroplasty | | | | | | | | | | | | | | | |
| All ages | 493.5 (281.0) | 450 (300, 600) | | | | | | | 64.3% (60.2%, 68.4%) | 66.3% (64.6%, 68.1%) | 66.8% (66.0%, 67.6%) | 64.9% (64.2%, 65.5%) | 62.9% (62.3%, 63.4%) | 838 (54.2%) | |
| 18-40 | 508.0 (320.6) | 450 (300, 600) | - | - | - | - | | | - | - | - | - | - | - | |
| 41-64 | 546.0 (305.0) | 450 (320, 675) | | | | | | | 64.7% (55.8%, 73.6%) | 70.8% (66.9%, 74.7%) | 74.5% (72.8%, 76.1%) | 73.2% (71.9%, 74.5%) | 71.7% (70.7%, 72.8%) | 1 (54.0%) | |
| 65+ | 474.3 (269.0) | 450 (300, 600) | - | - | - | - | | | 64.0% (59.3%, 68.7%) | 64.8% (62.7%, 66.8%) | 64.1% (63.2%, 65.0%) | 62.0% (61.2%, 62.7%) | 59.8% (59.1%, 60.4%) | 837 (50.5%) | |
| Laminectomy/discectomy | | | | | | | | | | | | | | | |
| All ages | 459.2 (264.2) | 450 (300, 600) | 1 (36.8%) | 104 (25.0%) | 187 (20.0%) | 651 (15.0%) | | | 30.2% (22.0%, 38.5%) | 25.3% (21.8%, 28.8%) | 19.4% (17.9%, 20.9%) | 16.8% (15.6%, 18.1%) | 16.5% (14.9%, 18.1%) | 684 (14.8%) | |
| 18-40 | 477.2 (279.4) | 450 (300, 600) | - | - | - | - | | | - | - | - | - | - | - | |
| 41-64 | 476.9 (270.0) | 450 (300, 600) | 1 (27.5%) | 56 (25.0%) | 199 (20.0%) | 337 (15.0%) | | | 25.2% (15.8%, 34.6%) | 23.3% (18.9%, 27.7%) | 19.9% (17.6%, 22.2%) | 16.4% (14.4%, 18.3%) | 14.1% (11.7%, 16.4%) | 389 (14.0%) | |
| 65+ | 425.1 (242.5) | 375 (250, 525) | 1 (47.6%) | 120 (24.9%) | 192 (20.0%) | 604 (15.0%) | | | 35.2% (24.7%, 45.6%) | 27.1% (21.6%, 32.7%) | 19.6% (17.2%, 22.0%) | 17.2% (15.3%, 19.2%) | 17.7% (15.2%, 20.3%) | 714 (12.9%) | |
| Spinal fusion (all levels) | | | | | | | | | | | | | | | |
| All ages | 66.9 (29.7) | 60 (50, 90) | 1 (42.7%) | | | | | | 37.6% (30.0%, 45.2%) | 34.7% (31.6%, 37.9%) | 33.2% (31.8%, 34.7%) | 33.6% (32.3%, 34.8%) | 32.8% (31.8%, 33.8%) | 807 (30.0%) | |
| 18-40 | 67.8 (32.7) | 60 (45, 90) | 1 (29.9%) | | | | | | 34.6% (20.9%, 48.4%) | 37.7% (30.7%, 44.8%) | 39.5% (35.0%, 43.9%) | 37.9% (33.8%, 42.0%) | 36.3% (32.9%, 39.7%) | 1 (29.9%) | |
| 41-64 | 67.4 (29.7) | 60 (50, 90) | 1 (48.0%) | | | | | | 37.6% (26.2%, 48.9%) | 32.3% (27.8%, 36.9%) | 31.2% (29.1%, 33.4%) | 33.7% (31.8%, 35.6%) | 32.6% (31.2%, 34.1%) | 798 (30.2%) | |
| 65+ | 66.2 (29.1) | 60 (48, 90) | 1 (39.3%) | | | | | | 37.7% (27.4%, 48.1%) | 36.3% (31.9%, 40.7%) | 34.0% (31.9%, 36.1%) | 32.6% (30.8%, 34.3%) | 32.3% (30.9%, 33.8%) | 830 (27.9%) | |
| Spinal fusion (1-3 levels) | | | | | | | | | | | | | | | |
| All ages | 66.2 (28.9) | 60 (46, 90) | 1 (41.6%) | | | | | | 36.6% (27.6%, 45.7%) | 33.6% (29.8%, 37.3%) | 31.2% (29.5%, 32.9%) | 30.8% (29.4%, 32.2%) | 30.2% (29.0%, 31.3%) | 803 (27.4%) | |
| 18-40 | 68.0 (31.9) | 60 (45, 90) | - | - | - | - | | | - | - | - | - | - | - | |
| 41-64 | 66.8 (28.9) | 60 (50, 90) | 1 (43.9%) | | | | | | 36.0% (21.6%, 50.3%) | 31.5% (25.9%, 37.2%) | 29.3% (26.8%, 31.8%) | 30.2% (28.1%, 32.3%) | 29.8% (28.1%, 31.5%) | 786 (27.0%) | |
| 65+ | 65.3 (28.2) | 60 (45, 90) | 1 (36.2%) | | | | | | 35.1% (23.7%, 46.5%) | 34.1% (29.2%, 39.0%) | 32.4% (30.0%, 34.8%) | 31.1% (29.1%, 33.1%) | 30.4% (28.8%, 32.0%) | 827 (26.3%) | |
| Spinal fusion (4+ levels) | | | | | | | | | | | | | | | |
| All ages | 70.1 (32.1) | 60 (50, 90) | 1 (45.8%) | | | | | | 44.5% (31.2%, 57.7%) | 43.4% (37.4%, 49.3%) | 42.0% (38.8%, 45.2%) | 41.7% (39.1%, 44.4%) | 42.4% (40.3%, 44.4%) | 1000 (38.5%) | |
| 18-40 | 70.3 (34.8) | 60 (50, 90) | - | - | - | - | | | - | - | - | - | - | - | |
| 41-64 | 70.4 (31.8) | 60 (50, 90) | 23 (49.9%) | | | | | | 44.4% (24.6%, 64.2%) | 38.9% (29.9%, 48.0%) | 39.4% (34.6%, 44.3%) | 44.3% (40.2%, 48.3%) | 43.8% (40.7%, 46.9%) | 1000 (30.6%) | |
| 65+ | 69.8 (31.6) | 60 (50, 90) | 79 (49.9%) | | | | | | 53.6% (37.2%, 70.1%) | 47.5% (39.7%, 55.4%) | 39.7% (35.3%, 44.0%) | 37.3% (33.4%, 41.2%) | 39.1% (35.9%, 42.3%) | 852 (32.2%) | |
| Tooth extraction | | | | | | | | | | | | | | | |
| All ages | 129.1 (65.0) | 113 (90, 150) | 1 (10.5%) | 1 (10.5%) | 1 (10.5%) | 1 (10.5%) | 4 (9.9%) | 7.5% (7.1%, 8.0%) | 8.4% (8.2%, 8.6%) | 8.3% (7.8%, 8.9%) | | | 38 (7.4%) | | |
| 18-40 | 134.0 (63.0) | 120 (100, 150) | 1 (11.4%) | 1 (11.4%) | 1 (11.4%) | 1 (11.4%) | 11 (9.9%) | 8.8% (8.2%, 9.4%) | 9.3% (9.1%, 9.6%) | 9.1% (8.4%, 9.7%) | | | 38 (8.7%) | | |
| 41-64 | 116.7 (68.4) | 100 (75, 150) | 1 (14.2%) | 1 (14.2%) | 1 (14.2%) | 1 (14.2%) | 8 (9.9%) | 4.8% (4.3%, 5.4%) | 5.7% (5.3%, 6.0%) | 6.5% (5.4%, 7.6%) | | | 45 (4.8%) | | |
| 65+ | 112.3 (67.8) | 100 (75, 135) | - | - | - | - | - | - | - | - | - | - | - | | |

¹Observed morphine mill

Table 5. Model Diagnostics for the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery Age group (years) | Independent variable: days' supply ¹ | | | | | Independent variable: tablets/capsules dispensed | | | | | Independent variable: morphine milligram equivalents | | | | |
|---------------------------------------|---|-------------|----------------------|-----------------|---------|--|-------------|----------------------|----|---------|--|-------------|----------------------|----|---------|
| | Model discrimination | | Hosmer-Lemeshow test | | | Model discrimination | | Hosmer-Lemeshow test | | | Model discrimination | | Hosmer-Lemeshow test | | |
| | AIC ² | C-statistic | Chi-square | DF ³ | P-value | AIC | C-statistic | Chi-square | DF | P-value | AIC | C-statistic | Chi-square | DF | P-value |
| All surgeries | | | | | | | | | | | | | | | |
| All ages | 678,037.4 | 0.763 | 81.3 | 8 | <.0001 | 646,660.5 | 0.752 | 117.3 | 8 | <.0001 | 623,968.6 | 0.745 | 110.3 | 8 | <.0001 |
| 18-40 | 314,458.1 | 0.623 | 17.6 | 8 | 0.0244 | 315,629.6 | 0.615 | 26.2 | 8 | 0.001 | 309,403.4 | 0.612 | 36.8 | 8 | <.0001 |
| 41-64 | 174,491.8 | 0.8 | 32.7 | 8 | <.0001 | 160,072.3 | 0.792 | 15.5 | 8 | 0.0502 | 150,748.4 | 0.785 | 13 | 8 | 0.1123 |
| 65+ | 186,825.8 | 0.81 | 13.7 | 8 | 0.0893 | 168,727.2 | 0.814 | 7 | 8 | 0.5322 | 161,556.7 | 0.811 | 11.8 | 8 | 0.1581 |
| Appendectomy (laparoscopic) | | | | | | | | | | | | | | | |
| All ages | 25,784.5 | 0.599 | 10.8 | 8 | 0.2148 | 25,089.3 | 0.595 | 10.3 | 8 | 0.2467 | 25,428.1 | 0.596 | 8.6 | 8 | 0.3738 |
| 18-40 | 14,920.7 | 0.602 | 11.8 | 8 | 0.1617 | 14,417.5 | 0.597 | 12.3 | 8 | 0.137 | 14,602.6 | 0.597 | 9.5 | 8 | 0.3025 |
| 41-64 | 8,415.7 | 0.604 | 12.2 | 8 | 0.1428 | 8,235.3 | 0.602 | 10.2 | 8 | 0.2514 | 8,290.4 | 0.604 | 10.8 | 8 | 0.2119 |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Appendectomy (nonspecific) | | | | | | | | | | | | | | | |
| All ages | 5,825.2 | 0.62 | 6.6 | 8 | 0.5803 | 6,031.1 | 0.62 | 15.7 | 8 | 0.0467 | 5,687.7 | 0.62 | 12.8 | 8 | 0.1188 |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Bunionectomy | | | | | | | | | | | | | | | |
| All ages | 40,218.6 | 0.601 | 16.9 | 8 | 0.0311 | 42,812.7 | 0.603 | 5.3 | 8 | 0.7227 | 39,695.9 | 0.608 | 7.8 | 8 | 0.457 |
| 18-40 | 8,009.9 | 0.583 | 5.3 | 8 | 0.7251 | 8,504.5 | 0.58 | 8.7 | 8 | 0.3666 | 7,817.7 | 0.59 | 5 | 8 | 0.7542 |
| 41-64 | 21,441.9 | 0.575 | 8.8 | 8 | 0.3563 | 22,675.7 | 0.579 | 6.7 | 8 | 0.5645 | 20,826.1 | 0.584 | 4.7 | 8 | 0.7936 |
| 65+ | 10,538.5 | 0.564 | 8.3 | 8 | 0.4054 | 11,402.1 | 0.568 | 6.2 | 8 | 0.6208 | 10,819.3 | 0.573 | 4.7 | 8 | 0.7894 |
| Cesarean section | | | | | | | | | | | | | | | |
| All ages | 165,270.5 | 0.585 | 13.7 | 8 | 0.0888 | 164,801.6 | 0.578 | 15.9 | 8 | 0.0439 | 161,336.4 | 0.58 | 15.9 | 8 | 0.0436 |
| 18-40 | 159,027.4 | 0.586 | 11.9 | 8 | 0.1571 | 158,595.9 | 0.579 | 21.4 | 8 | 0.0062 | 155,226.4 | 0.581 | 15.4 | 8 | 0.0521 |
| 41-64 | 6,143.8 | 0.592 | 7.8 | 8 | 0.4568 | 6,107.8 | 0.582 | 7.3 | 8 | 0.5087 | 6,014.5 | 0.576 | 7.4 | 8 | 0.4906 |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cholecystectomy (laparoscopic) | | | | | | | | | | | | | | | |
| All ages | 69,418.9 | 0.613 | 7.6 | 8 | 0.4746 | 68,648.3 | 0.611 | 7.7 | 8 | 0.4668 | 68,609.8 | 0.611 | 9.8 | 8 | 0.2788 |
| 18-40 | 21,972.9 | 0.61 | 8.1 | 8 | 0.421 | 21,506.8 | 0.604 | 5.3 | 8 | 0.7243 | 21,362.4 | 0.604 | 10.2 | 8 | 0.2529 |
| 41-64 | 28,667.3 | 0.593 | 13.4 | 8 | 0.0991 | 27,914.8 | 0.593 | 10.5 | 8 | 0.2329 | 27,726.4 | 0.595 | 14.1 | 8 | 0.0797 |
| 65+ | 18,457.7 | 0.6 | 14.2 | 8 | 0.0769 | 18,930.6 | 0.596 | 19.8 | 8 | 0.0113 | 19,229.6 | 0.595 | 20.9 | 8 | 0.0075 |
| Cholecystectomy (nonspecific) | | | | | | | | | | | | | | | |
| All ages | 3,848.9 | 0.628 | 5.1 | 8 | 0.7486 | 3,878.8 | 0.629 | 3 | 8 | 0.9326 | 3,828.2 | 0.634 | 6.3 | 8 | 0.6096 |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |

Table 5. Model Diagnostics for the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Independent variable: days' supply ¹ | | | | | | Independent variable: tablets/capsules dispensed | | | | | | Independent variable: morphine milligram equivalents | | | | | |
|--|---|-------------|------------|----------------------|---------|-----------|--|------------|----|----------------------|-----------|-------------|--|----|---------|----------------------|-------------|------------|
| | Model discrimination | | | Hosmer-Lemeshow test | | | Model discrimination | | | Hosmer-Lemeshow test | | | Model discrimination | | | Hosmer-Lemeshow test | | |
| | AIC ² | C-statistic | Chi-square | DF ³ | P-value | AIC | C-statistic | Chi-square | DF | P-value | AIC | C-statistic | Chi-square | DF | P-value | AIC | C-statistic | Chi-square |
| Age group (years) | | | | | | | | | | | | | | | | | | |
| Coronary artery bypass graft | | | | | | | | | | | | | | | | | | |
| All ages | 30,827.3 | 0.623 | 12.2 | 8 | 0.1442 | 30,549.2 | 0.622 | 5.9 | 8 | 0.6618 | 30,245.8 | 0.62 | 2.9 | 8 | 0.9423 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 11,542.9 | 0.591 | 7.2 | 8 | 0.5102 | 11,253.8 | 0.587 | 7.2 | 8 | 0.5143 | 10,916.7 | 0.586 | 4.6 | 8 | 0.7988 | | | |
| 65+ | 18,813.6 | 0.584 | 8.3 | 8 | 0.4021 | 18,831.3 | 0.584 | 7.8 | 8 | 0.4534 | 18,886.1 | 0.583 | 9.1 | 8 | 0.3358 | | | |
| Hip fracture treatment | | | | | | | | | | | | | | | | | | |
| All ages | 14,384.1 | 0.615 | 3.4 | 8 | 0.9082 | 14,197.5 | 0.612 | 10.3 | 8 | 0.2431 | 13,995.3 | 0.605 | 3.7 | 8 | 0.8808 | | | |
| 18-40 | 2,003.0 | 0.621 | 13.6 | 8 | 0.094 | 1,813.8 | 0.623 | 8.3 | 8 | 0.4023 | 1,696.0 | 0.619 | 7 | 8 | 0.54 | | | |
| 41-64 | 3,756.2 | 0.596 | 9.3 | 8 | 0.3163 | 3,591.9 | 0.601 | 13.8 | 8 | 0.088 | 3,456.6 | 0.602 | 2.3 | 8 | 0.9692 | | | |
| 65+ | 8,463.1 | 0.577 | 5.9 | 8 | 0.6556 | 8,609.2 | 0.578 | 2.5 | 8 | 0.961 | 8,675.7 | 0.569 | 5.1 | 8 | 0.7486 | | | |
| Hip replacement | | | | | | | | | | | | | | | | | | |
| All ages | 47,027.7 | 0.6 | 5 | 8 | 0.7586 | 49,366.6 | 0.606 | 11.6 | 8 | 0.169 | 46,965.9 | 0.593 | 18.7 | 8 | 0.0164 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 17,153.3 | 0.599 | 6.8 | 8 | 0.5624 | 17,803.8 | 0.604 | 7.5 | 8 | 0.4818 | 16,456.1 | 0.591 | 15.3 | 8 | 0.0538 | | | |
| 65+ | 28,815.6 | 0.596 | 12 | 8 | 0.1522 | 30,461.9 | 0.602 | 5.5 | 8 | 0.7085 | 29,472.8 | 0.586 | 6.5 | 8 | 0.5886 | | | |
| Hysterectomy (laparoscopic) | | | | | | | | | | | | | | | | | | |
| All ages | 7,481.3 | 0.622 | 7.5 | 8 | 0.4816 | 7,430.2 | 0.625 | 3.6 | 8 | 0.8882 | 7,394.2 | 0.624 | 16.9 | 8 | 0.0316 | | | |
| 18-40 | 3,307.8 | 0.608 | 7.9 | 8 | 0.4431 | 3,278.7 | 0.611 | 4.1 | 8 | 0.8448 | 3,207.1 | 0.616 | 3 | 8 | 0.936 | | | |
| 41-64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Hysterectomy (non-laparoscopic) | | | | | | | | | | | | | | | | | | |
| All ages | 7,500.7 | 0.668 | 9.2 | 8 | 0.3243 | 7,403.0 | 0.67 | 7.3 | 8 | 0.5048 | 7,318.5 | 0.673 | 9.5 | 8 | 0.3025 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 3,326.5 | 0.635 | 8.5 | 8 | 0.3869 | 3,245.7 | 0.64 | 4.2 | 8 | 0.8402 | 3,196.3 | 0.648 | 7.8 | 8 | 0.4511 | | | |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Knee arthroplasty | | | | | | | | | | | | | | | | | | |
| All ages | 108,769.7 | 0.597 | 8.5 | 8 | 0.3883 | 114,057.6 | 0.599 | 9.2 | 8 | 0.3292 | 113,798.8 | 0.59 | 7.9 | 8 | 0.4403 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 26,836.0 | 0.583 | 9.5 | 8 | 0.3019 | 27,675.9 | 0.585 | 6.7 | 8 | 0.5742 | 27,249.3 | 0.576 | 13.9 | 8 | 0.0857 | | | |
| 65+ | 81,377.8 | 0.581 | 13.4 | 8 | 0.0998 | 85,811.5 | 0.581 | 8.4 | 8 | 0.3918 | 85,982.1 | 0.57 | 12.2 | 8 | 0.1432 | | | |
| Laminectomy/discectomy | | | | | | | | | | | | | | | | | | |
| All ages | 11,916.6 | 0.586 | 10.1 | 8 | 0.261 | 11,538.9 | 0.59 | 9.5 | 8 | 0.3033 | 11,339.2 | 0.584 | 3.2 | 8 | 0.9179 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 4,944.4 | 0.615 | 12.8 | 8 | 0.1175 | 4,783.1 | 0.617 | 10.6 | 8 | 0.2249 | 4,639.6 | 0.618 | 6.9 | 8 | 0.5471 | | | |
| 65+ | 4,123.9 | 0.588 | 9.5 | 8 | 0.3053 | 4,016.2 | 0.602 | 3.7 | 8 | 0.8812 | 4,028.2 | 0.594 | 8 | 8 | 0.4317 | | | |

Table 5. Model Diagnostics for the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Independent variable: days' supply ¹ | | | | | | Independent variable: tablets/capsules dispensed | | | | | | Independent variable: morphine milligram equivalents | | | | | |
|-----------------------------------|---|-------------|------------|----------------------|---------|----------|--|------------|----|----------------------|----------|-------------|--|----|---------|----------------------|-------------|------------|
| | Model discrimination | | | Hosmer-Lemeshow test | | | Model discrimination | | | Hosmer-Lemeshow test | | | Model discrimination | | | Hosmer-Lemeshow test | | |
| | AIC ² | C-statistic | Chi-square | DF ³ | P-value | AIC | C-statistic | Chi-square | DF | P-value | AIC | C-statistic | Chi-square | DF | P-value | AIC | C-statistic | Chi-square |
| Age group (years) | | | | | | | | | | | | | | | | | | |
| Spinal fusion (all levels) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| All ages | 33,703.7 | 0.595 | 9 | 8 | 0.3382 | 33,708.7 | 0.592 | 2.4 | 8 | 0.9678 | 33,387.0 | 0.586 | 6.8 | 8 | 0.5625 | | | |
| 18-40 | 3,267.8 | 0.637 | 3.9 | 8 | 0.869 | 3,216.1 | 0.63 | 7.1 | 8 | 0.5305 | 3,175.9 | 0.634 | 3.4 | 8 | 0.9042 | | | |
| 41-64 | 14,990.9 | 0.608 | 11 | 8 | 0.202 | 14,872.8 | 0.609 | 3.6 | 8 | 0.8927 | 14,607.0 | 0.605 | 4.1 | 8 | 0.8496 | | | |
| 65+ | 15,240.1 | 0.579 | 3.9 | 8 | 0.8644 | 15,400.0 | 0.577 | 8.2 | 8 | 0.4179 | 15,392.0 | 0.565 | 10.1 | 8 | 0.261 | | | |
| Spinal fusion (1-3 levels) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| All ages | 23,419.8 | 0.586 | 10.2 | 8 | 0.253 | 23,469.0 | 0.585 | 5.6 | 8 | 0.6867 | 23,300.3 | 0.577 | 9.9 | 8 | 0.2719 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 10,330.3 | 0.599 | 9.3 | 8 | 0.3148 | 10,240.2 | 0.603 | 5.8 | 8 | 0.6698 | 10,089.2 | 0.597 | 7.1 | 8 | 0.5261 | | | |
| 65+ | 10,947.4 | 0.579 | 2.3 | 8 | 0.9705 | 11,090.8 | 0.577 | 10.9 | 8 | 0.208 | 11,101.9 | 0.564 | 12.9 | 8 | 0.1136 | | | |
| Spinal fusion (4+ levels) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| All ages | 8,630.5 | 0.603 | 6.3 | 8 | 0.6123 | 8,562.7 | 0.6 | 3.2 | 8 | 0.9201 | 8,610.4 | 0.592 | 9.3 | 8 | 0.3187 | | | |
| 18-40 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 41-64 | 3,910.4 | 0.609 | 10.6 | 8 | 0.2226 | 3,867.9 | 0.611 | 9 | 8 | 0.3414 | 3,860.7 | 0.599 | 13.2 | 8 | 0.1061 | | | |
| 65+ | 3,576.7 | 0.596 | 9.1 | 8 | 0.332 | 3,586.7 | 0.592 | 4.2 | 8 | 0.8394 | 3,628.8 | 0.583 | 9.5 | 8 | 0.3051 | | | |
| Tooth extraction | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| All ages | 96,120.0 | 0.607 | 29.9 | 8 | 0.0002 | 99,505.2 | 0.604 | 29.5 | 8 | 0.0003 | 97,084.4 | 0.603 | 34.4 | 8 | <.0001 | | | |
| 18-40 | 75,387.2 | 0.595 | 5.2 | 8 | 0.7329 | 77,791.3 | 0.592 | 16.2 | 8 | 0.04 | 75,908.6 | 0.589 | 11.9 | 8 | 0.157 | | | |
| 41-64 | 18,724.7 | 0.58 | 508.6 | 8 | <.0001 | 19,566.1 | 0.577 | 477.4 | 8 | <.0001 | 19,094.2 | 0.581 | 444.1 | 8 | <.0001 | | | |
| 65+ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |

¹Dashes indicate that a model was not run due to lack of sufficient outcome events.

²AIC: Akaike information criterion

³DF: Degrees of freedom

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | |
|---------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value |
| All surgeries | All Age Groups | Sex | 1 | 47.65 | <.0001 | 1 | 37.85 | <.0001 |
| | | Age Group | 2 | 2,483.66 | <.0001 | 2 | 2,329.50 | <.0001 |
| | | Baseline Medications | 1 | 1,350.04 | <.0001 | 1 | 1,352.02 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 136.26 | <.0001 | 4 | 135.47 | <.0001 |
| | | Comorbidity Score | | | | | | |
| | | Data Partner | 16 | 957.45 | <.0001 | 16 | 816.02 | <.0001 |
| | | Independent Variable | 5 | 1,526.70 | <.0001 | 6 | 299.1 | <.0001 |
| | | Year | 6 | 474.03 | <.0001 | 6 | 592.4 | <.0001 |
| | | Schedule | 1 | 947.17 | <.0001 | 1 | 664.57 | <.0001 |
| | | Surgery | 16 | 65,282.81 | <.0001 | 16 | 53,371.28 | <.0001 |
| | | Length of Stay | 3 | 593.54 | <.0001 | 3 | 506.7 | <.0001 |
| 18-40 | 18-40 | Sex | 1 | 33.43 | <.0001 | 1 | 34.1 | <.0001 |
| | | Age Group | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 657.95 | <.0001 | 1 | 669.1 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 151.67 | <.0001 | 4 | 144.47 | <.0001 |
| | | Comorbidity Score | | | | | | |
| | | Data Partner | 16 | 754.48 | <.0001 | 16 | 790.29 | <.0001 |
| | | Independent Variable | 6 | 734.74 | <.0001 | 5 | 89.03 | <.0001 |
| | | Year | 6 | 301.22 | <.0001 | 6 | 361.21 | <.0001 |
| | | Schedule | 1 | 948.04 | <.0001 | 1 | 839.5 | <.0001 |
| | | Surgery | 16 | 7,676.05 | <.0001 | 16 | 5,977.05 | <.0001 |
| 41-64 | 41-64 | Length of Stay | 3 | 71.36 | <.0001 | 3 | 59.96 | <.0001 |
| | | Sex | 1 | 2.5 | 0.1136 | 1 | 1.83 | 0.1761 |
| | | Age Group | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 512.85 | <.0001 | 1 | 531.4 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 27.61 | <.0001 | 4 | 20.93 | 0.0003 |
| | | Comorbidity Score | | | | | | |
| | | Data Partner | 16 | 216.18 | <.0001 | 16 | 156.57 | <.0001 |
| | | Independent Variable | 6 | 230.52 | <.0001 | 6 | 65.44 | <.0001 |
| | | Year | 6 | 125.84 | <.0001 | 6 | 148.64 | <.0001 |
| | | Schedule | 1 | 99.27 | <.0001 | 1 | 63.55 | <.0001 |
| | | Surgery | 16 | 22,867.98 | <.0001 | 16 | 17,668.20 | <.0001 |
| | | Length of Stay | 3 | 224.28 | <.0001 | 3 | 192.53 | <.0001 |
| | | | | | | | | |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|-----------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Appendectomy (laparoscopic) | 65+ | Sex | 1 | 25.6 | <.0001 | 1 | 15.3 | <.0001 | 1 | 15.13 | 0.0001 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 281.64 | <.0001 | 1 | 257.87 | <.0001 | 1 | 235.69 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 58.81 | <.0001 | 4 | 61.81 | <.0001 | 4 | 56.16 | <.0001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 161.39 | <.0001 | 15 | 60.73 | <.0001 | 15 | 75.03 | <.0001 |
| | | Independent Variable | 6 | 761.4 | <.0001 | 6 | 317.62 | <.0001 | 6 | 201.52 | <.0001 |
| | | Year | 6 | 74.23 | <.0001 | 6 | 108.97 | <.0001 | 6 | 194.52 | <.0001 |
| | | Schedule | 1 | 127.64 | <.0001 | 1 | 30.36 | <.0001 | 1 | 0.26 | 0.6108 |
| | | Surgery | 15 | 22,184.67 | <.0001 | 15 | 19,577.24 | <.0001 | 15 | 18,580.31 | <.0001 |
| | All Age Groups | Length of Stay | 3 | 278.14 | <.0001 | 3 | 252.85 | <.0001 | 3 | 224.6 | <.0001 |
| | | Sex | 1 | 1.73 | 0.1878 | 1 | 3.43 | 0.0638 | 1 | 3.05 | 0.0808 |
| | | Age Group | 2 | 55.66 | <.0001 | 2 | 59.21 | <.0001 | 2 | 56.31 | <.0001 |
| | | Baseline Medications | 1 | 100.18 | <.0001 | 1 | 97.44 | <.0001 | 1 | 104.63 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 3.81 | 0.4325 | 4 | 3.52 | 0.4742 | 4 | 4.09 | 0.3945 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 56.88 | <.0001 | 16 | 42.91 | 0.0003 | 16 | 40.25 | 0.0007 |
| | | Independent Variable | 6 | 38.69 | <.0001 | 5 | 15.15 | 0.0098 | 6 | 9.99 | 0.125 |
| | 18-40 | Year | 6 | 25.26 | 0.0003 | 6 | 30.56 | <.0001 | 6 | 34.88 | <.0001 |
| | | Schedule | 1 | 76.44 | <.0001 | 1 | 61.88 | <.0001 | 1 | 51.2 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 78.78 | <.0001 | 3 | 67.47 | <.0001 | 3 | 71.39 | <.0001 |
| | | Sex | 1 | 1.62 | 0.2038 | 1 | 3.42 | 0.0644 | 1 | 3.28 | 0.0702 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 72.36 | <.0001 | 1 | 75.86 | <.0001 | 1 | 81.85 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 2.1 | 0.7176 | 4 | 2.53 | 0.639 | 4 | 1.51 | 0.8246 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 33.48 | 0.0064 | 16 | 23.72 | 0.0958 | 16 | 19.54 | 0.2415 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|----------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Surgery | 41-64 | Sex | 1 | 1.28 | 0.2582 | 1 | 1.95 | 0.1626 | 1 | 1.39 | 0.2385 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 41.99 | <.0001 | 1 | 35.77 | <.0001 | 1 | 40.17 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 2.35 | 0.6718 | 4 | 3.09 | 0.5434 | 4 | 2.74 | 0.6023 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 32.93 | 0.0076 | 16 | 29.22 | 0.0225 | 16 | 33.1 | 0.0072 |
| | | Independent Variable | 6 | 2.74 | 0.8402 | 5 | 2.25 | 0.814 | 6 | 4 | 0.677 |
| | | Year | 6 | 11.64 | 0.0705 | 6 | 10.73 | 0.0969 | 6 | 12.92 | 0.0444 |
| | | Schedule | 1 | 17.68 | <.0001 | 1 | 16.02 | <.0001 | 1 | 11.58 | 0.0007 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | 65+ | Length of Stay | 3 | 32.48 | <.0001 | 3 | 28.2 | <.0001 | 3 | 32.81 | <.0001 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| Appendectomy (nonspecific) | All Age Groups | Comorbidity Score | | | | | | | | | |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | 1 | 0.12 | 0.7308 | 1 | 0.04 | 0.8498 | 1 | 0.01 | 0.9202 |
| | | Age Group | 2 | 20.85 | <.0001 | 2 | 20.37 | <.0001 | 2 | 14.51 | 0.0007 |
| | | Baseline Medications | 1 | 17.87 | <.0001 | 1 | 12.09 | 0.0005 | 1 | 7.59 | 0.0059 |
| | | Charlson/Elixhauser Combined | 4 | 5.77 | 0.2168 | 4 | 6.51 | 0.1643 | 4 | 6.27 | 0.18 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 27.98 | 0.0318 | 16 | 32.56 | 0.0085 | 16 | 28.48 | 0.0277 |
| | | Independent Variable | 6 | 8.64 | 0.1946 | 6 | 11.91 | 0.0641 | 6 | 22.01 | 0.0012 |
| | | Year | 6 | 2.32 | 0.8878 | 6 | 5.43 | 0.4904 | 6 | 3.66 | 0.7222 |
| | | Schedule | 1 | 0.89 | 0.3457 | 1 | 1.55 | 0.2124 | 1 | 6.44 | 0.0112 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 73.63 | <.0001 | 3 | 68.95 | <.0001 | 3 | 56.11 | <.0001 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|--------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Bunionectomy | 18-40 | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | 41-64 | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | 65+ | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| Bunionectomy | All Age Groups | Sex | 1 | 21.24 | <.0001 | 1 | 22.87 | <.0001 | 1 | 22.21 | <.0001 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|---------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 18-40 | 18-40 | Age Group | 2 | 382.44 | <.0001 | 2 | 402.38 | <.0001 | 2 | 370.36 | <.0001 |
| | | Baseline Medications | 1 | 123.32 | <.0001 | 1 | 139.33 | <.0001 | 1 | 126.97 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 8.44 | 0.0767 | 4 | 12.98 | 0.0114 | 4 | 10.62 | 0.0312 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 117.22 | <.0001 | 16 | 135.79 | <.0001 | 16 | 148.99 | <.0001 |
| | | Independent Variable | 6 | 24.16 | 0.0005 | 5 | 45.18 | <.0001 | 6 | 84.99 | <.0001 |
| | | Year | 6 | 39.15 | <.0001 | 6 | 42.68 | <.0001 | 6 | 35.59 | <.0001 |
| | | Schedule | 1 | 27.87 | <.0001 | 1 | 20.2 | <.0001 | 1 | 2.75 | 0.0971 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | 41-64 | Length of Stay | 3 | 28.02 | <.0001 | 3 | 24.67 | <.0001 | 3 | 24.98 | <.0001 |
| | | Sex | 1 | 3.11 | 0.078 | 1 | 2.52 | 0.1125 | 1 | 4.38 | 0.0363 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 23.3 | <.0001 | 1 | 27.31 | <.0001 | 1 | 27.11 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 2.51 | 0.6423 | 4 | 3.92 | 0.417 | 4 | 4.19 | 0.3803 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 33.59 | 0.0062 | 16 | 31.07 | 0.0132 | 16 | 36.87 | 0.0022 |
| | | Independent Variable | 6 | 14.14 | 0.0281 | 5 | 9.22 | 0.1007 | 6 | 23.49 | 0.0006 |
| | | Year | 6 | 30.64 | <.0001 | 6 | 30.53 | <.0001 | 6 | 31.68 | <.0001 |
| | 65+ | Schedule | 1 | 16.13 | <.0001 | 1 | 12.24 | 0.0005 | 1 | 7.86 | 0.0051 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 8.99 | 0.0295 | 3 | 5.22 | 0.1565 | 3 | 3.68 | 0.2978 |
| | | Sex | 1 | 16.49 | <.0001 | 1 | 17.65 | <.0001 | 1 | 15.01 | 0.0001 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 90.22 | <.0001 | 1 | 99.06 | <.0001 | 1 | 90.64 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 4.84 | 0.3042 | 4 | 7.72 | 0.1024 | 4 | 7.34 | 0.1189 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 80.35 | <.0001 | 16 | 106.08 | <.0001 | 16 | 107.06 | <.0001 |
| | 65+ | Independent Variable | 6 | 14.39 | 0.0256 | 5 | 27.54 | <.0001 | 6 | 54.07 | <.0001 |
| | | Year | 6 | 17.85 | 0.0066 | 6 | 19.86 | 0.0029 | 6 | 15.38 | 0.0175 |
| | | Schedule | 1 | 11.85 | 0.0006 | 1 | 5.92 | 0.015 | 1 | 0.05 | 0.8159 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 5.26 | 0.1534 | 3 | 4.01 | 0.2605 | 3 | 4.69 | 0.1963 |
| 65+ | | Sex | 1 | 3.55 | 0.0595 | 1 | 4.52 | 0.0336 | 1 | 3.69 | 0.0548 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Cesarean section | All Age Groups | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 13.01 | 0.0003 | 1 | 15.92 | <.0001 | 1 | 14.63 | 0.0001 |
| | | Charlson/Elixhauser Combined | 4 | 4.17 | 0.3839 | 4 | 6.07 | 0.194 | 4 | 4.76 | 0.3133 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 51.15 | <.0001 | 15 | 56.58 | <.0001 | 15 | 52.75 | <.0001 |
| | | Independent Variable | 6 | 10.5 | 0.1051 | 5 | 16.47 | 0.0056 | 6 | 25.65 | 0.0003 |
| | | Year | 6 | 12.14 | 0.0589 | 6 | 15.63 | 0.0159 | 6 | 16.51 | 0.0113 |
| | | Schedule | 1 | 2.83 | 0.0925 | 1 | 4.27 | 0.0387 | 1 | 1.01 | 0.3158 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 20.87 | 0.0001 | 3 | 19.4 | 0.0002 | 3 | 20.81 | 0.0001 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | 1 | 1.49 | 0.2215 | 1 | 1.22 | 0.2693 | 1 | 1.25 | 0.2633 |
| | | Baseline Medications | 1 | 291 | <.0001 | 1 | 292.45 | <.0001 | 1 | 282.19 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 66.86 | <.0001 | 4 | 61.84 | <.0001 | 4 | 59.51 | <.0001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 605.74 | <.0001 | 16 | 617.9 | <.0001 | 16 | 618.7 | <.0001 |
| | | Independent Variable | 6 | 357.99 | <.0001 | 5 | 17.58 | 0.0035 | 5 | 30.83 | <.0001 |
| | | Year | 6 | 75.86 | <.0001 | 6 | 106.72 | <.0001 | 6 | 128.43 | <.0001 |
| | | Schedule | 1 | 838.05 | <.0001 | 1 | 787.8 | <.0001 | 1 | 617.22 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 29.8 | <.0001 | 3 | 21.91 | <.0001 | 3 | 21.75 | <.0001 |
| 18-40 | 18-40 | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 269.96 | <.0001 | 1 | 273.5 | <.0001 | 1 | 267.03 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 75.07 | <.0001 | 4 | 68.36 | <.0001 | 4 | 65.71 | <.0001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 590.15 | <.0001 | 16 | 601.56 | <.0001 | 16 | 604.72 | <.0001 |
| | | Independent Variable | 6 | 340.57 | <.0001 | 5 | 16.15 | 0.0064 | 5 | 31.55 | <.0001 |
| | | Year | 6 | 79.49 | <.0001 | 6 | 108.24 | <.0001 | 6 | 130.93 | <.0001 |
| | | Schedule | 1 | 815.18 | <.0001 | 1 | 772.12 | <.0001 | 1 | 606.2 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 29.02 | <.0001 | 3 | 20.99 | 0.0001 | 3 | 20.53 | 0.0001 |
| 41-64 | 41-64 | Sex | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|-----------------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 65+ | 65+ | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 21.27 | <.0001 | 1 | 18.87 | <.0001 | 1 | 14.47 | 0.0001 |
| | | Charlson/Elixhauser Combined | 4 | 4.41 | 0.3538 | 4 | 3.12 | 0.5382 | 4 | 2.61 | 0.6247 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 30.19 | 0.0171 | 16 | 37.22 | 0.0019 | 16 | 35.63 | 0.0033 |
| | | Independent Variable | 6 | 22.87 | 0.0008 | 5 | 9.8 | 0.0812 | 5 | 4.89 | 0.4292 |
| | | Year | 6 | 5.02 | 0.5411 | 6 | 6.45 | 0.3752 | 6 | 5.1 | 0.5314 |
| | | Schedule | 1 | 21.58 | <.0001 | 1 | 16.11 | <.0001 | 1 | 12.11 | 0.0005 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 1.26 | 0.7392 | 3 | 1.5 | 0.6816 | 3 | 1.48 | 0.6859 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| Cholecystectomy (laparoscopic) | All Age Groups | Sex | 1 | 1.02 | 0.3127 | 1 | 0.3 | 0.5858 | 1 | 0.23 | 0.6348 |
| | | Age Group | 2 | 452.64 | <.0001 | 2 | 463.23 | <.0001 | 2 | 455.94 | <.0001 |
| | | Baseline Medications | 1 | 230.93 | <.0001 | 1 | 217.56 | <.0001 | 1 | 216.7 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 39.7 | <.0001 | 4 | 36.74 | <.0001 | 4 | 37.4 | <.0001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 135.37 | <.0001 | 16 | 119.7 | <.0001 | 16 | 120.82 | <.0001 |
| | | Independent Variable | 6 | 144.21 | <.0001 | 5 | 122.76 | <.0001 | 6 | 91.89 | <.0001 |
| | | Year | 6 | 39.66 | <.0001 | 6 | 47.54 | <.0001 | 6 | 56.43 | <.0001 |
| | | Schedule | 1 | 236.82 | <.0001 | 1 | 200.43 | <.0001 | 1 | 139.92 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 102.02 | <.0001 | 3 | 77.63 | <.0001 | 3 | 82.31 | <.0001 |
| | 18-40 | Sex | 1 | 1.14 | 0.2866 | 1 | 1.08 | 0.2994 | 1 | 1.01 | 0.3154 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 41-64 | 41-64 | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 117.14 | <.0001 | 1 | 95.88 | <.0001 | 1 | 94.64 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 29.02 | <.0001 | 4 | 29.22 | <.0001 | 4 | 32.11 | <.0001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 81.58 | <.0001 | 16 | 73.06 | <.0001 | 16 | 73.17 | <.0001 |
| | | Independent Variable | 6 | 76.93 | <.0001 | 5 | 46.06 | <.0001 | 6 | 35.84 | <.0001 |
| | | Year | 6 | 23.11 | 0.0008 | 6 | 26.78 | 0.0002 | 6 | 32.15 | <.0001 |
| | | Schedule | 1 | 94.27 | <.0001 | 1 | 80.69 | <.0001 | 1 | 49.24 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 7.48 | 0.058 | 3 | 3.45 | 0.3268 | 3 | 4.16 | 0.2449 |
| | | Sex | 1 | 3.37 | 0.0665 | 1 | 2.04 | 0.1528 | 1 | 1.75 | 0.1858 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 68.98 | <.0001 | 1 | 69.67 | <.0001 | 1 | 72.07 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 13.82 | 0.0079 | 4 | 14.06 | 0.0071 | 4 | 10.61 | 0.0314 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 75.47 | <.0001 | 16 | 65.67 | <.0001 | 16 | 66.3 | <.0001 |
| | | Independent Variable | 6 | 34.59 | <.0001 | 5 | 18.27 | 0.0026 | 6 | 21.27 | 0.0016 |
| | | Year | 6 | 18.8 | 0.0045 | 6 | 28.41 | <.0001 | 6 | 30.71 | <.0001 |
| | | Schedule | 1 | 101.97 | <.0001 | 1 | 86.55 | <.0001 | 1 | 66.62 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| 65+ | 65+ | Length of Stay | 3 | 39.38 | <.0001 | 3 | 38.35 | <.0001 | 3 | 40.47 | <.0001 |
| | | Sex | 1 | 1.28 | 0.2585 | 1 | 2.21 | 0.1374 | 1 | 1.98 | 0.1589 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 58.06 | <.0001 | 1 | 58.83 | <.0001 | 1 | 57.38 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 9.5 | 0.0498 | 4 | 7.23 | 0.124 | 4 | 8.72 | 0.0684 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 13.23 | 0.5846 | 15 | 17.71 | 0.2782 | 15 | 16.66 | 0.3394 |
| | | Independent Variable | 6 | 71.42 | <.0001 | 5 | 79.47 | <.0001 | 5 | 47.22 | <.0001 |
| | | Year | 6 | 10.06 | 0.1221 | 6 | 6.97 | 0.3235 | 6 | 9.78 | 0.1342 |
| | | Schedule | 1 | 43.51 | <.0001 | 1 | 36.39 | <.0001 | 1 | 25.57 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 75.88 | <.0001 | 3 | 66.85 | <.0001 | 3 | 67.98 | <.0001 |
| Cholecystectomy | All Age Groups | Sex | 1 | 1.38 | 0.2403 | 1 | 0.81 | 0.3673 | 1 | 1.11 | 0.291 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|---------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| (nonspecific) | 18-40 | Age Group | 2 | 36.4 | <.0001 | 2 | 39 | <.0001 | 2 | 41.76 | <.0001 |
| | | Baseline Medications | 1 | 8.38 | 0.0038 | 1 | 9.71 | 0.0018 | 1 | 10.44 | 0.0012 |
| | | Charlson/Elixhauser Combined | 4 | 1.42 | 0.8409 | 4 | 2.51 | 0.6424 | 4 | 3.49 | 0.48 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 20.1 | 0.2158 | 16 | 16.28 | 0.4336 | 16 | 17.89 | 0.3304 |
| | | Independent Variable | 5 | 7.5 | 0.1862 | 6 | 9.53 | 0.146 | 6 | 13.7 | 0.0331 |
| | | Year | 6 | 15.12 | 0.0193 | 6 | 15.41 | 0.0173 | 6 | 15.91 | 0.0142 |
| | | Schedule | 1 | 5.38 | 0.0203 | 1 | 5.97 | 0.0145 | 1 | 7.55 | 0.006 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 2.14 | 0.5442 | 3 | 2.22 | 0.529 | 3 | 1.61 | 0.658 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| 41-64 | 41-64 | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| 65+ | 65+ | Sex | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|------------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| Coronary artery bypass graft | All Age Groups | Sex | 1 | 23.47 | <.0001 | 1 | 13.25 | 0.0003 | 1 | 17.32 | <.0001 |
| | | Age Group | 2 | 349.57 | <.0001 | 2 | 375.67 | <.0001 | 2 | 352.8 | <.0001 |
| | | Baseline Medications | 1 | 91.68 | <.0001 | 1 | 89.27 | <.0001 | 1 | 92.88 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 31.9 | <.0001 | 4 | 26.91 | <.0001 | 4 | 31.35 | <.0001 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 67.08 | <.0001 | 16 | 77.11 | <.0001 | 16 | 71.92 | <.0001 |
| | | Independent Variable | 5 | 91.43 | <.0001 | 6 | 81.93 | <.0001 | 6 | 58.09 | <.0001 |
| | | Year | 6 | 32.47 | <.0001 | 6 | 45.84 | <.0001 | 6 | 61.52 | <.0001 |
| | | Schedule | 1 | 71.66 | <.0001 | 1 | 46.44 | <.0001 | 1 | 17.1 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| 18-40 | | Length of Stay | 3 | 4.57 | 0.2063 | 3 | 3.6 | 0.3075 | 3 | 3.06 | 0.3824 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| 41-64 | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | | | | | | | | | | |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | | |
|------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|--------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value | |
| 65+ | 65+ | Age Group | - | - | - | - | - | - | - | - | - | |
| | | Baseline Medications | 1 | 47.85 | <.0001 | 1 | 51.88 | <.0001 | 1 | 49.31 | <.0001 | |
| | | Charlson/Elixhauser Combined | 4 | 14.7 | 0.0054 | 4 | 7.83 | 0.0981 | 4 | 10.93 | 0.0274 | |
| | | Comorbidity Score | | | | | | | | | | |
| | | Data Partner | 16 | 46.7 | <.0001 | 16 | 49.79 | <.0001 | 16 | 45.86 | 0.0001 | |
| | | Independent Variable | 5 | 20.44 | 0.001 | 6 | 17.18 | 0.0087 | 6 | 9.27 | 0.1591 | |
| | | Year | 6 | 33.23 | <.0001 | 6 | 31.7 | <.0001 | 6 | 38.04 | <.0001 | |
| | | Schedule | 1 | 21.01 | <.0001 | 1 | 16.2 | <.0001 | 1 | 9.87 | 0.0017 | |
| | | Surgery | - | - | - | - | - | - | - | - | - | |
| | | Length of Stay | 3 | 5.98 | 0.1124 | 3 | 4.26 | 0.2346 | 3 | 3.48 | 0.324 | |
| | | Sex | 1 | 30.6 | <.0001 | 1 | 20.16 | <.0001 | 1 | 21.85 | <.0001 | |
| | | Age Group | - | - | - | - | - | - | - | - | - | |
| | | Baseline Medications | 1 | 42.72 | <.0001 | 1 | 36.39 | <.0001 | 1 | 42.92 | <.0001 | |
| | | Charlson/Elixhauser Combined | 4 | 19.93 | 0.0005 | 4 | 21.62 | 0.0002 | 4 | 23.6 | <.0001 | |
| | | Comorbidity Score | | | | | | | | | | |
| | | Data Partner | 15 | 33.66 | 0.0038 | 15 | 37.77 | 0.001 | 15 | 35.5 | 0.0021 | |
| | | Independent Variable | 5 | 72.1 | <.0001 | 6 | 75.77 | <.0001 | 6 | 58.64 | <.0001 | |
| | | Year | 6 | 6.4 | 0.3803 | 6 | 18 | 0.0062 | 6 | 26.9 | 0.0002 | |
| | | Schedule | 1 | 53.11 | <.0001 | 1 | 30.89 | <.0001 | 1 | 6.85 | 0.0089 | |
| | | Surgery | - | - | - | - | - | - | - | - | - | |
| Hip fracture treatment | All Age Groups | Length of Stay | 3 | 8.3 | 0.0402 | 3 | 9.43 | 0.0241 | 3 | 7.32 | 0.0623 | |
| | | Sex | 1 | 5.97 | 0.0145 | 1 | 5.96 | 0.0147 | 1 | 5.09 | 0.0241 | |
| | | Age Group | 2 | 108.06 | <.0001 | 2 | 112.54 | <.0001 | 2 | 106.03 | <.0001 | |
| | | Baseline Medications | 1 | 15.26 | <.0001 | 1 | 16.4 | <.0001 | 1 | 15.12 | 0.0001 | |
| | | Charlson/Elixhauser Combined | 4 | 3.72 | 0.4455 | 4 | 5.58 | 0.2324 | 4 | 4.18 | 0.3822 | |
| | | Comorbidity Score | | | | | | | | | | |
| | | Data Partner | 16 | 30.14 | 0.0173 | 16 | 25.28 | 0.0651 | 16 | 26.67 | 0.0453 | |
| | | Independent Variable | 6 | 76.27 | <.0001 | 6 | 71.26 | <.0001 | 6 | 40.82 | <.0001 | |
| | | Year | 6 | 11.18 | 0.0829 | 6 | 13.32 | 0.0382 | 6 | 13.65 | 0.0339 | |
| | | Schedule | 1 | 2.39 | 0.1225 | 1 | 6.29 | 0.0121 | 1 | 8.95 | 0.0028 | |
| | | Surgery | - | - | - | - | - | - | - | - | - | |
| | | Length of Stay | 3 | 22.89 | <.0001 | 3 | 20.65 | 0.0001 | 3 | 16.85 | 0.0008 | |
| 18-40 | | | Sex | 1 | 0.06 | 0.8038 | 1 | 0 | 0.9544 | 1 | 0.04 | 0.8352 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|-----------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 41-64 | 41-64 | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 4.26 | 0.039 | 1 | 4.9 | 0.0269 | 1 | 3.91 | 0.048 |
| | | Charlson/Elixhauser Combined | 4 | 0.9 | 0.9243 | 4 | 1.66 | 0.7973 | 4 | 1.04 | 0.9033 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 20.21 | 0.2111 | 16 | 24.03 | 0.0889 | 16 | 20.62 | 0.1935 |
| | | Independent Variable | 6 | 14.27 | 0.0268 | 6 | 9.9 | 0.1289 | 6 | 5.19 | 0.5192 |
| | | Year | 6 | 9.44 | 0.1503 | 6 | 9.05 | 0.171 | 6 | 9.04 | 0.1715 |
| | | Schedule | 1 | 0.39 | 0.5314 | 1 | 0.26 | 0.6131 | 1 | 0.03 | 0.8575 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | 65+ | Length of Stay | 3 | 9.92 | 0.0193 | 3 | 10.77 | 0.013 | 3 | 6.77 | 0.0796 |
| | | Sex | 1 | 6.99 | 0.0082 | 1 | 7.3 | 0.0069 | 1 | 4.1 | 0.043 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 0.75 | 0.3856 | 1 | 0.79 | 0.3746 | 1 | 0.08 | 0.7797 |
| | | Charlson/Elixhauser Combined | 4 | 1.21 | 0.8768 | 4 | 1.22 | 0.8742 | 4 | 1.23 | 0.8735 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 22.16 | 0.1381 | 16 | 20.06 | 0.2173 | 16 | 20.81 | 0.1858 |
| | | Independent Variable | 6 | 10.28 | 0.1132 | 6 | 18.85 | 0.0044 | 6 | 12.18 | 0.058 |
| | | Year | 6 | 11.87 | 0.0648 | 6 | 12.2 | 0.0577 | 6 | 13.71 | 0.0331 |
| | 65+ | Schedule | 1 | 0.73 | 0.3931 | 1 | 1.77 | 0.1839 | 1 | 1.7 | 0.1921 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 26.43 | <.0001 | 3 | 24.76 | <.0001 | 3 | 21.75 | <.0001 |
| | | Sex | 1 | 0.47 | 0.4944 | 1 | 0.74 | 0.3907 | 1 | 0.92 | 0.3383 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 14.4 | 0.0001 | 1 | 15.84 | <.0001 | 1 | 17.33 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 4.95 | 0.2923 | 4 | 7.17 | 0.1271 | 4 | 5.86 | 0.2096 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 16.46 | 0.3521 | 15 | 16.25 | 0.3659 | 15 | 15.56 | 0.4116 |
| Hip replacement | All Age Groups | Independent Variable | 6 | 60.9 | <.0001 | 6 | 69.43 | <.0001 | 6 | 44.84 | <.0001 |
| | | Year | 6 | 9.63 | 0.141 | 6 | 10.12 | 0.1196 | 6 | 8.46 | 0.2064 |
| | | Schedule | 1 | 2.06 | 0.1512 | 1 | 3.32 | 0.0686 | 1 | 7.64 | 0.0057 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 2.4 | 0.4934 | 3 | 1.88 | 0.5966 | 3 | 1.64 | 0.6508 |
| | | Sex | 1 | 6.86 | 0.0088 | 1 | 3.32 | 0.0683 | 1 | 2.14 | 0.1431 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|---------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 18-40 | 18-40 | Age Group | 2 | 147.67 | <.0001 | 2 | 169.73 | <.0001 | 2 | 140.4 | <.0001 |
| | | Baseline Medications | 1 | 107.6 | <.0001 | 1 | 124.48 | <.0001 | 1 | 118.33 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 5.34 | 0.2542 | 4 | 11.62 | 0.0204 | 4 | 9.77 | 0.0444 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 152.74 | <.0001 | 16 | 87.52 | <.0001 | 16 | 95 | <.0001 |
| | | Independent Variable | 6 | 321.67 | <.0001 | 6 | 471.22 | <.0001 | 6 | 201.41 | <.0001 |
| | | Year | 6 | 63.74 | <.0001 | 6 | 83.94 | <.0001 | 6 | 136.54 | <.0001 |
| | | Schedule | 1 | 99.74 | <.0001 | 1 | 22.39 | <.0001 | 1 | 2.29 | 0.1302 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 3.19 | 0.3638 | 3 | 9.57 | 0.0226 | 3 | 9.21 | 0.0267 |
| | 41-64 | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| 65+ | 41-64 | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | 1 | 2.89 | 0.0892 | 1 | 4.26 | 0.039 | 1 | 4.07 | 0.0436 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 29.41 | <.0001 | 1 | 39.03 | <.0001 | 1 | 39.75 | <.0001 |
| | 65+ | Charlson/Elixhauser Combined | 4 | 2.47 | 0.6504 | 4 | 1.52 | 0.823 | 4 | 0.98 | 0.9126 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 62.71 | <.0001 | 16 | 40.9 | 0.0006 | 16 | 36.62 | 0.0024 |
| | | Independent Variable | 6 | 129.45 | <.0001 | 6 | 177.38 | <.0001 | 6 | 72.39 | <.0001 |
| | | Year | 6 | 38.06 | <.0001 | 6 | 45.85 | <.0001 | 6 | 68.37 | <.0001 |
| | | Schedule | 1 | 36.07 | <.0001 | 1 | 7.68 | 0.0056 | 1 | 1.48 | 0.224 |
| | 65+ | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 2.04 | 0.5643 | 3 | 2.46 | 0.4824 | 3 | 3.88 | 0.2746 |
| 65+ | | Sex | 1 | 21.16 | <.0001 | 1 | 16.14 | <.0001 | 1 | 12.01 | 0.0005 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|-----------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Hysterectomy (laparoscopic) | All Age Groups | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 78.05 | <.0001 | 1 | 84.63 | <.0001 | 1 | 76.48 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 6.53 | 0.1632 | 4 | 11.98 | 0.0175 | 4 | 10.75 | 0.0295 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 98.93 | <.0001 | 15 | 58.11 | <.0001 | 15 | 70.66 | <.0001 |
| | | Independent Variable | 6 | 188.58 | <.0001 | 6 | 298.59 | <.0001 | 6 | 142.93 | <.0001 |
| | | Year | 6 | 29.13 | <.0001 | 6 | 39.23 | <.0001 | 6 | 67.1 | <.0001 |
| | | Schedule | 1 | 62.24 | <.0001 | 1 | 14.35 | 0.0002 | 1 | 0.94 | 0.3324 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 5.92 | 0.1157 | 3 | 13.43 | 0.0038 | 3 | 11.76 | 0.0083 |
| | 18-40 | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | 2 | 89.53 | <.0001 | 2 | 86.21 | <.0001 | 2 | 84.75 | <.0001 |
| | | Baseline Medications | 1 | 40.77 | <.0001 | 1 | 36.5 | <.0001 | 1 | 33.07 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 10.14 | 0.0381 | 4 | 9.17 | 0.057 | 4 | 11.35 | 0.0229 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 14.68 | 0.5485 | 16 | 17.42 | 0.3589 | 16 | 13.08 | 0.6672 |
| | | Independent Variable | 6 | 1.93 | 0.9264 | 5 | 12.32 | 0.0307 | 5 | 10.95 | 0.0524 |
| | | Year | 6 | 7.23 | 0.3005 | 6 | 12.28 | 0.056 | 6 | 9.75 | 0.1355 |
| | | Schedule | 1 | 17.17 | <.0001 | 1 | 16.88 | <.0001 | 1 | 25.65 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 6.61 | 0.0854 | 3 | 9.85 | 0.0199 | 3 | 7.72 | 0.0521 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 19.38 | <.0001 | 1 | 19.43 | <.0001 | 1 | 17.28 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 6.2 | 0.1844 | 4 | 3.82 | 0.4303 | 4 | 4.76 | 0.3133 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 16.87 | 0.394 | 16 | 18.18 | 0.3134 | 16 | 19.61 | 0.2382 |
| | | Independent Variable | 6 | 3.95 | 0.6828 | 5 | 7.1 | 0.2131 | 5 | 13.06 | 0.0228 |
| | | Year | 6 | 5.17 | 0.5226 | 6 | 9.26 | 0.1595 | 6 | 8.04 | 0.2351 |
| | | Schedule | 1 | 5.62 | 0.0178 | 1 | 6.34 | 0.0118 | 1 | 7.52 | 0.0061 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 7.95 | 0.0472 | 3 | 4.15 | 0.246 | 3 | 6.08 | 0.108 |
| 41-64 | | Sex | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|------------------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 65+ | 65+ | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| Hysterectomy (non-laparoscopic) | All Age Groups | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | 2 | 143.35 | <.0001 | 2 | 145.31 | <.0001 | 2 | 132.53 | <.0001 |
| | | Baseline Medications | 1 | 73.42 | <.0001 | 1 | 76.83 | <.0001 | 1 | 76.85 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 7.46 | 0.1133 | 4 | 5.44 | 0.2447 | 4 | 7.46 | 0.1135 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 18.15 | 0.3151 | 16 | 21.41 | 0.1634 | 16 | 23.85 | 0.0929 |
| | | Independent Variable | 6 | 12.22 | 0.0572 | 5 | 38.61 | <.0001 | 6 | 44.61 | <.0001 |
| | | Year | 6 | 9.27 | 0.1588 | 6 | 9.67 | 0.1392 | 6 | 18.75 | 0.0046 |
| | | Schedule | 1 | 19.39 | <.0001 | 1 | 18.69 | <.0001 | 1 | 31.83 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 39.82 | <.0001 | 3 | 47.2 | <.0001 | 3 | 40.12 | <.0001 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | 18-40 | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|-------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Knee arthroplasty | All Age Groups | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 42.39 | <.0001 | 1 | 37.28 | <.0001 | 1 | 32.73 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 3.86 | 0.4256 | 4 | 5.79 | 0.2156 | 4 | 5 | 0.2877 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 18.79 | 0.2794 | 16 | 20.74 | 0.1887 | 16 | 20.33 | 0.2058 |
| | | Independent Variable | 6 | 3.77 | 0.7075 | 5 | 5.82 | 0.3241 | 5 | 18.17 | 0.0027 |
| | | Year | 6 | 4.33 | 0.6324 | 6 | 6.4 | 0.3803 | 6 | 13.59 | 0.0345 |
| | | Schedule | 1 | 9.84 | 0.0017 | 1 | 11.19 | 0.0008 | 1 | 19.1 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 26.09 | <.0001 | 3 | 33.4 | <.0001 | 3 | 27.33 | <.0001 |
| 65+ | 65+ | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|---------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 18-40 | 18-40 | Age Group | 2 | 355.68 | <.0001 | 2 | 404.38 | <.0001 | 2 | 415.33 | <.0001 |
| | | Baseline Medications | 1 | 109.58 | <.0001 | 1 | 109.26 | <.0001 | 1 | 111.73 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 71.38 | <.0001 | 4 | 87.5 | <.0001 | 4 | 86.36 | <.0001 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 133.76 | <.0001 | 16 | 123.41 | <.0001 | 16 | 110.78 | <.0001 |
| | | Independent Variable | 6 | 738.15 | <.0001 | 6 | 847.45 | <.0001 | 6 | 437.58 | <.0001 |
| | | Year | 6 | 69.48 | <.0001 | 6 | 98.27 | <.0001 | 6 | 161.03 | <.0001 |
| | | Schedule | 1 | 39.94 | <.0001 | 1 | 2.25 | 0.1333 | 1 | 13.66 | 0.0002 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 288.35 | <.0001 | 3 | 334.07 | <.0001 | 3 | 321.05 | <.0001 |
| | 41-64 | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| 65+ | 41-64 | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| | | Sex | 1 | 1.97 | 0.1604 | 1 | 1.38 | 0.2394 | 1 | 2.36 | 0.1242 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 32.32 | <.0001 | 1 | 43.46 | <.0001 | 1 | 35.21 | <.0001 |
| | 65+ | Charlson/Elixhauser Combined | 4 | 6.59 | 0.1595 | 4 | 4.34 | 0.362 | 4 | 3.97 | 0.4097 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 65.32 | <.0001 | 16 | 61.65 | <.0001 | 16 | 61.29 | <.0001 |
| | | Independent Variable | 6 | 140.07 | <.0001 | 6 | 167.21 | <.0001 | 6 | 101.31 | <.0001 |
| | | Year | 6 | 32.11 | <.0001 | 6 | 31.39 | <.0001 | 6 | 42 | <.0001 |
| | | Schedule | 1 | 14 | 0.0002 | 1 | 0.14 | 0.7116 | 1 | 0.07 | 0.795 |
| | 65+ | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 63.55 | <.0001 | 3 | 81.11 | <.0001 | 3 | 72.17 | <.0001 |
| 65+ | | Sex | 1 | 2.51 | 0.1128 | 1 | 0.32 | 0.5732 | 1 | 0.45 | 0.5026 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|----------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Laminectomy/ discectomy | All Age Groups | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 77.78 | <.0001 | 1 | 69.19 | <.0001 | 1 | 78.86 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 67.66 | <.0001 | 4 | 84.34 | <.0001 | 4 | 85.16 | <.0001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 80.63 | <.0001 | 15 | 88.36 | <.0001 | 15 | 75.05 | <.0001 |
| | | Independent Variable | 6 | 616.52 | <.0001 | 6 | 687.73 | <.0001 | 6 | 350.72 | <.0001 |
| | | Year | 6 | 43.02 | <.0001 | 6 | 72.22 | <.0001 | 6 | 124.88 | <.0001 |
| | | Schedule | 1 | 27.14 | <.0001 | 1 | 3.47 | 0.0625 | 1 | 16.55 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | 18-40 | Length of Stay | 3 | 200 | <.0001 | 3 | 223.5 | <.0001 | 3 | 223.08 | <.0001 |
| | | Sex | 1 | 4.07 | 0.0435 | 1 | 4.61 | 0.0317 | 1 | 5.27 | 0.0217 |
| | | Age Group | 2 | 9.98 | 0.0068 | 2 | 11.42 | 0.0033 | 2 | 8.89 | 0.0117 |
| | | Baseline Medications | 1 | 33.16 | <.0001 | 1 | 34.62 | <.0001 | 1 | 24.64 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 14.36 | 0.0062 | 4 | 16.41 | 0.0025 | 4 | 15.47 | 0.0038 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 32.26 | 0.0092 | 16 | 23.73 | 0.0956 | 16 | 30.38 | 0.0161 |
| | | Independent Variable | 6 | 51.28 | <.0001 | 5 | 47.36 | <.0001 | 6 | 34.24 | <.0001 |
| | | Year | 6 | 1.28 | 0.9729 | 6 | 1.97 | 0.9225 | 6 | 2.15 | 0.9055 |
| | 41-64 | Schedule | 1 | 8.22 | 0.0041 | 1 | 4.86 | 0.0275 | 1 | 2.75 | 0.0972 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 43.17 | <.0001 | 3 | 35.94 | <.0001 | 3 | 28.81 | <.0001 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|-------------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 65+ | 65+ | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 25.52 | <.0001 | 1 | 21.86 | <.0001 | 1 | 18.02 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 11.67 | 0.02 | 4 | 10.47 | 0.0332 | 4 | 10.41 | 0.034 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 54.73 | <.0001 | 16 | 47.83 | <.0001 | 16 | 51.44 | <.0001 |
| | | Independent Variable | 6 | 21.95 | 0.0012 | 5 | 20.32 | 0.0011 | 6 | 17.88 | 0.0065 |
| | | Year | 6 | 2.18 | 0.9025 | 6 | 3.78 | 0.7068 | 6 | 3.76 | 0.7095 |
| | | Schedule | 1 | 2.29 | 0.1302 | 1 | 1.03 | 0.3098 | 1 | 0.26 | 0.6087 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 6.73 | 0.0812 | 3 | 6.98 | 0.0724 | 3 | 6.75 | 0.0802 |
| | | Sex | 1 | 2.98 | 0.0842 | 1 | 1.27 | 0.2588 | 1 | 3.54 | 0.0599 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 5.12 | 0.0236 | 1 | 10.25 | 0.0014 | 1 | 5.38 | 0.0204 |
| | | Charlson/Elixhauser Combined | 4 | 4.26 | 0.3714 | 4 | 3.97 | 0.4104 | 4 | 5.82 | 0.2132 |
| | | Comorbidity Score | | | | | | | | | |
| Spinal fusion (all levels) | All Age Groups | Data Partner | 15 | 10.91 | 0.7586 | 15 | 8.74 | 0.8906 | 15 | 13.87 | 0.5354 |
| | | Independent Variable | 6 | 19.75 | 0.0031 | 5 | 38.34 | <.0001 | 6 | 26.51 | 0.0002 |
| | | Year | 6 | 3.6 | 0.7312 | 6 | 2.93 | 0.8178 | 6 | 3.3 | 0.771 |
| | | Schedule | 1 | 4.29 | 0.0384 | 1 | 4.12 | 0.0424 | 1 | 2.08 | 0.1491 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 26.41 | <.0001 | 3 | 21.56 | <.0001 | 3 | 14.32 | 0.0025 |
| | | Sex | 1 | 44.02 | <.0001 | 1 | 43.21 | <.0001 | 1 | 39.79 | <.0001 |
| | | Age Group | 2 | 37.85 | <.0001 | 2 | 32.05 | <.0001 | 2 | 31.13 | <.0001 |
| | | Baseline Medications | 1 | 35.79 | <.0001 | 1 | 42.06 | <.0001 | 1 | 36 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 15.8 | 0.0033 | 4 | 17.35 | 0.0017 | 4 | 18.5 | 0.001 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 46.87 | <.0001 | 16 | 39.51 | 0.0009 | 16 | 41.21 | 0.0005 |
| | | Independent Variable | 6 | 94.94 | <.0001 | 6 | 52.93 | <.0001 | 6 | 8.6 | 0.1977 |
| | | Year | 6 | 6.93 | 0.3278 | 6 | 8.15 | 0.2272 | 6 | 10.14 | 0.1188 |
| | | Schedule | 1 | 0.29 | 0.589 | 1 | 0.46 | 0.4984 | 1 | 0.1 | 0.7499 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 451.51 | <.0001 | 3 | 424.47 | <.0001 | 3 | 396.95 | <.0001 |
| 18-40 | Sex | | 1 | 2.63 | 0.1049 | 1 | 3.28 | 0.0701 | 1 | 3.52 | 0.0608 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|---------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 41-64 | 41-64 | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 5.9 | 0.0151 | 1 | 6.75 | 0.0094 | 1 | 8.22 | 0.0042 |
| | | Charlson/Elixhauser Combined | 4 | 17.69 | 0.0014 | 4 | 19.85 | 0.0005 | 4 | 17.04 | 0.0019 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 15.03 | 0.5226 | 16 | 15.81 | 0.4664 | 16 | 19.49 | 0.244 |
| | | Independent Variable | 6 | 18.76 | 0.0046 | 6 | 9.1 | 0.1681 | 6 | 4.14 | 0.6575 |
| | | Year | 6 | 4.63 | 0.5918 | 6 | 5.41 | 0.4928 | 6 | 6.93 | 0.3273 |
| | | Schedule | 1 | 2.21 | 0.1373 | 1 | 1.91 | 0.1667 | 1 | 1.04 | 0.3075 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 63.56 | <.0001 | 3 | 52.21 | <.0001 | 3 | 57.36 | <.0001 |
| | 65+ | Sex | 1 | 10.69 | 0.0011 | 1 | 12.54 | 0.0004 | 1 | 10.1 | 0.0015 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 30.08 | <.0001 | 1 | 42.15 | <.0001 | 1 | 34.2 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 3.25 | 0.5173 | 4 | 3.04 | 0.5512 | 4 | 3.86 | 0.4253 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 40.59 | 0.0006 | 16 | 38.64 | 0.0012 | 16 | 38.23 | 0.0014 |
| | | Independent Variable | 6 | 23.61 | 0.0006 | 6 | 9.64 | 0.1405 | 6 | 5.99 | 0.4241 |
| | | Year | 6 | 12.7 | 0.0481 | 6 | 10.4 | 0.1087 | 6 | 11.67 | 0.0698 |
| | 65+ | Schedule | 1 | 1.28 | 0.2575 | 1 | 0.5 | 0.4804 | 1 | 2.63 | 0.1051 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 283.51 | <.0001 | 3 | 276.86 | <.0001 | 3 | 248.21 | <.0001 |
| | | Sex | 1 | 33.69 | <.0001 | 1 | 29.01 | <.0001 | 1 | 27.34 | <.0001 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 5.96 | 0.0147 | 1 | 4.53 | 0.0332 | 1 | 4.06 | 0.0439 |
| | | Charlson/Elixhauser Combined | 4 | 7.67 | 0.1046 | 4 | 9.87 | 0.0427 | 4 | 9.94 | 0.0415 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| Spinal fusion | All Age Groups | Data Partner | 15 | 9.3 | 0.8611 | 15 | 9.09 | 0.873 | 15 | 5.8 | 0.9829 |
| | | Independent Variable | 6 | 66.17 | <.0001 | 6 | 51.31 | <.0001 | 6 | 12.38 | 0.0539 |
| | | Year | 6 | 3.87 | 0.6937 | 6 | 8.76 | 0.1876 | 6 | 8.84 | 0.1827 |
| | | Schedule | 1 | 0.19 | 0.6652 | 1 | 0.91 | 0.3392 | 1 | 0.33 | 0.564 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 91.96 | <.0001 | 3 | 86.74 | <.0001 | 3 | 81.52 | <.0001 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|--------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| (1-3 levels) | | Age Group | 2 | 32.83 | <.0001 | 2 | 29.08 | <.0001 | 2 | 25.33 | <.0001 |
| | | Baseline Medications | 1 | 25.28 | <.0001 | 1 | 28.48 | <.0001 | 1 | 25.22 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 10.23 | 0.0367 | 4 | 11.27 | 0.0237 | 4 | 10.75 | 0.0296 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 32.38 | 0.0089 | 16 | 32.71 | 0.0081 | 16 | 31.57 | 0.0114 |
| | | Independent Variable | 6 | 74.78 | <.0001 | 6 | 56.24 | <.0001 | 6 | 8.01 | 0.2373 |
| | | Year | 6 | 9.18 | 0.1637 | 6 | 10.49 | 0.1054 | 6 | 11.96 | 0.0629 |
| | | Schedule | 1 | 0.73 | 0.3926 | 1 | 0.04 | 0.8508 | 1 | 0.07 | 0.7931 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 170.27 | <.0001 | 3 | 166.53 | <.0001 | 3 | 152.05 | <.0001 |
| 18-40 | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |
| 41-64 | | Sex | 1 | 13.27 | 0.0003 | 1 | 13.45 | 0.0002 | 1 | 12.26 | 0.0005 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 24.25 | <.0001 | 1 | 32.75 | <.0001 | 1 | 27.6 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 2.39 | 0.6644 | 4 | 3.73 | 0.4435 | 4 | 2.48 | 0.6491 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 30.76 | 0.0145 | 16 | 34.5 | 0.0046 | 16 | 31.76 | 0.0107 |
| | | Independent Variable | 6 | 21.29 | 0.0016 | 6 | 14.08 | 0.0288 | 6 | 3.34 | 0.7654 |
| | | Year | 6 | 7.13 | 0.3086 | 6 | 6.31 | 0.3896 | 6 | 7.35 | 0.2895 |
| | | Schedule | 1 | 1.31 | 0.2516 | 1 | 0.29 | 0.593 | 1 | 0.81 | 0.369 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 105 | <.0001 | 3 | 104.69 | <.0001 | 3 | 95.15 | <.0001 |
| 65+ | | Sex | 1 | 29.83 | <.0001 | 1 | 25.54 | <.0001 | 1 | 24.91 | <.0001 |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|------------------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| Spinal fusion (4+ levels) | All Age Groups | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 2.18 | 0.1398 | 1 | 1.15 | 0.2834 | 1 | 1.07 | 0.3003 |
| | | Charlson/Elixhauser Combined | 4 | 7.99 | 0.0918 | 4 | 9.2 | 0.0564 | 4 | 9.08 | 0.059 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 15 | 6.63 | 0.9671 | 15 | 9 | 0.8773 | 15 | 6.78 | 0.9635 |
| | | Independent Variable | 6 | 49.06 | <.0001 | 6 | 43.85 | <.0001 | 6 | 8.16 | 0.2266 |
| | | Year | 6 | 7.32 | 0.2927 | 6 | 8.51 | 0.2032 | 6 | 9.2 | 0.1627 |
| | | Schedule | 1 | 0.32 | 0.5728 | 1 | 0.19 | 0.6626 | 1 | 0.11 | 0.742 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 47.69 | <.0001 | 3 | 47.62 | <.0001 | 3 | 44.12 | <.0001 |
| | 18-40 | Sex | 1 | 5.41 | 0.02 | 1 | 6.61 | 0.0101 | 1 | 4.79 | 0.0286 |
| | | Age Group | 2 | 12.17 | 0.0023 | 2 | 10.43 | 0.0054 | 2 | 13.16 | 0.0014 |
| | | Baseline Medications | 1 | 11.23 | 0.0008 | 1 | 14.52 | 0.0001 | 1 | 12.48 | 0.0004 |
| | | Charlson/Elixhauser Combined | 4 | 10.44 | 0.0336 | 4 | 11.12 | 0.0252 | 4 | 9.83 | 0.0434 |
| | | Comorbidity Score | | | | | | | | | |
| | | Data Partner | 16 | 35.22 | 0.0037 | 16 | 32.88 | 0.0077 | 16 | 30.19 | 0.017 |
| | | Independent Variable | 6 | 34.13 | <.0001 | 6 | 16.46 | 0.0115 | 6 | 2.75 | 0.8395 |
| | | Year | 6 | 9.55 | 0.1451 | 6 | 10.67 | 0.0991 | 6 | 10.81 | 0.0945 |
| | 41-64 | Schedule | 1 | 0.07 | 0.786 | 1 | 0.71 | 0.401 | 1 | 0.05 | 0.8222 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 71.55 | <.0001 | 3 | 66.16 | <.0001 | 3 | 63.49 | <.0001 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | | | | | | | | | |
| | 65+ | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | | |
|------------------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|--|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value | |
| 65+ | 65+ | Age Group | - | - | - | - | - | - | - | - | - | |
| | | Baseline Medications | 1 | 4.66 | 0.0309 | 1 | 7.78 | 0.0053 | 1 | 5.74 | 0.0166 | |
| | | Charlson/Elixhauser Combined | 4 | 2.54 | 0.6375 | 4 | 3.43 | 0.4891 | 4 | 2.28 | 0.6837 | |
| | | Comorbidity Score | | | | | | | | | | |
| | | Data Partner | 16 | 35.16 | 0.0038 | 16 | 29.35 | 0.0217 | 16 | 29.56 | 0.0204 | |
| | | Independent Variable | 6 | 10 | 0.1245 | 6 | 7.96 | 0.2407 | 6 | 6.59 | 0.3609 | |
| | | Year | 6 | 9.57 | 0.1438 | 6 | 10.19 | 0.1167 | 6 | 10.75 | 0.0963 | |
| | | Schedule | 1 | 0.15 | 0.6974 | 1 | 0.02 | 0.891 | 1 | 1.98 | 0.159 | |
| | | Surgery | - | - | - | - | - | - | - | - | - | |
| | | Length of Stay | 3 | 52.65 | <.0001 | 3 | 51.44 | <.0001 | 3 | 42.62 | <.0001 | |
| | | Sex | 1 | 3.68 | 0.055 | 1 | 3.74 | 0.0533 | 1 | 2.28 | 0.131 | |
| | | Age Group | - | - | - | - | - | - | - | - | - | |
| | | Baseline Medications | 1 | 5.88 | 0.0153 | 1 | 6.3 | 0.0121 | 1 | 6.71 | 0.0096 | |
| | | Charlson/Elixhauser Combined | 4 | 1.93 | 0.7493 | 4 | 4.67 | 0.3224 | 4 | 4.96 | 0.2913 | |
| Tooth extraction | All Age Groups | Comorbidity Score | | | | | | | | | | |
| | | Data Partner | 15 | 11.56 | 0.7118 | 15 | 14.47 | 0.4899 | 15 | 10.58 | 0.782 | |
| | | Independent Variable | 6 | 21.8 | 0.0013 | 6 | 14.58 | 0.0237 | 6 | 10.89 | 0.0917 | |
| | | Year | 6 | 9.27 | 0.159 | 6 | 9.04 | 0.1715 | 6 | 6.12 | 0.4096 | |
| | | Schedule | 1 | 0 | 0.9663 | 1 | 1.39 | 0.2392 | 1 | 1.06 | 0.3043 | |
| | | Surgery | - | - | - | - | - | - | - | - | - | |
| | | Length of Stay | 3 | 15.97 | 0.0011 | 3 | 15.33 | 0.0016 | 3 | 15.82 | 0.0012 | |
| | | Sex | 1 | 10.34 | 0.0013 | 1 | 13.14 | 0.0003 | 1 | 13.74 | 0.0002 | |
| | | Age Group | 2 | 524.1 | <.0001 | 2 | 489.08 | <.0001 | 2 | 449.8 | <.0001 | |
| | | Baseline Medications | 1 | 229.27 | <.0001 | 1 | 247.78 | <.0001 | 1 | 245.86 | <.0001 | |
| | | Charlson/Elixhauser Combined | 4 | 57.02 | <.0001 | 4 | 55.47 | <.0001 | 4 | 52.26 | <.0001 | |
| | | Comorbidity Score | | | | | | | | | | |
| | | Data Partner | 16 | 222.92 | <.0001 | 16 | 227.15 | <.0001 | 16 | 225.55 | <.0001 | |
| | | Independent Variable | 4 | 119.9 | <.0001 | 5 | 93.77 | <.0001 | 6 | 12.7 | 0.048 | |
| | | Year | 6 | 259.41 | <.0001 | 6 | 283.83 | <.0001 | 6 | 260.99 | <.0001 | |
| | | Schedule | 1 | 84.49 | <.0001 | 1 | 64.35 | <.0001 | 1 | 81.68 | <.0001 | |
| | | Surgery | - | - | - | - | - | - | - | - | - | |
| | | Length of Stay | 3 | 52.95 | <.0001 | 3 | 48.32 | <.0001 | 3 | 52.19 | <.0001 | |
| 18-40 | | | | | | | | | | | | |
| Sex | | | 1 | 21.28 | <.0001 | 1 | 26.7 | <.0001 | 1 | 26.79 | <.0001 | |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | |
|---------|-------------------|------------------------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value |
| 41-64 | 41-64 | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 131.07 | <.0001 | 1 | 150.35 | <.0001 | 1 | 146.52 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 47.28 | <.0001 | 4 | 48.7 | <.0001 | 4 | 45.26 | <.0001 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 16 | 188.06 | <.0001 | 16 | 193.97 | <.0001 | 16 | 190.54 | <.0001 |
| | | Independent Variable | 4 | 142.48 | <.0001 | 5 | 107.53 | <.0001 | 6 | 9.8 | 0.1334 |
| | | Year | 6 | 222.75 | <.0001 | 6 | 242.92 | <.0001 | 6 | 230.24 | <.0001 |
| | | Schedule | 1 | 113.93 | <.0001 | 1 | 91.39 | <.0001 | 1 | 96.99 | <.0001 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | 65+ | Length of Stay | 3 | 24.89 | <.0001 | 3 | 16.52 | 0.0009 | 3 | 14.42 | 0.0024 |
| | | Sex | 1 | 1.76 | 0.1852 | 1 | 1.99 | 0.1585 | 1 | 1.62 | 0.2034 |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | 1 | 103.2 | <.0001 | 1 | 102.81 | <.0001 | 1 | 103.57 | <.0001 |
| | | Charlson/Elixhauser Combined | 4 | 14.89 | 0.0049 | 4 | 12.76 | 0.0125 | 4 | 11.47 | 0.0217 |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | 15 | 2,908.35 | <.0001 | 15 | 3,304.96 | <.0001 | 15 | 2,955.59 | <.0001 |
| | | Independent Variable | 4 | 6.52 | 0.1634 | 6 | 9.5 | 0.1474 | 6 | 19.66 | 0.0032 |
| | | Year | 6 | 52.87 | <.0001 | 6 | 57.42 | <.0001 | 6 | 46.79 | <.0001 |
| | 65+ | Schedule | 1 | 5.39 | 0.0203 | 1 | 6.73 | 0.0095 | 1 | 0.8 | 0.3721 |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | 3 | 27.15 | <.0001 | 3 | 21.11 | <.0001 | 3 | 30.26 | <.0001 |
| | | Sex | - | - | - | - | - | - | - | - | - |
| | | Age Group | - | - | - | - | - | - | - | - | - |
| | | Baseline Medications | - | - | - | - | - | - | - | - | - |
| | | Charlson/Elixhauser Combined | - | - | - | - | - | - | - | - | - |
| | | Comorbidity Score | - | - | - | - | - | - | - | - | - |
| | | Data Partner | - | - | - | - | - | - | - | - | - |
| | | Independent Variable | - | - | - | - | - | - | - | - | - |
| | | Year | - | - | - | - | - | - | - | - | - |
| | | Schedule | - | - | - | - | - | - | - | - | - |
| | | Surgery | - | - | - | - | - | - | - | - | - |
| | | Length of Stay | - | - | - | - | - | - | - | - | - |

Table 6. Likelihood Ratio Test Results for Model Terms in the Estimation of Re-fill Rates Associated with Initial Prescription Amounts of Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery and Age Group

| Surgery | Age group (years) | Model term | Main Independent Variable of Interest ¹ | | | | | | | | | | |
|---|-------------------|------------|--|------------|---------|----------------------------|------------|---------|--------------------------------|------------|---------|--|--|
| | | | Days' supply | | | Tablets/Capsules dispensed | | | Morphine milligram equivalents | | | | |
| | | | DF ² | Chi-square | P-value | DF | Chi-square | P-value | DF | Chi-square | P-value | | |
| ¹ Dashes indicate that a model was not run due to lack of sufficient outcome events or a term was not included in the model. | | | | | | | | | | | | | |
| ² DF: Degrees of freedom | | | | | | | | | | | | | |

Table 7. Odds Ratios for Re-filling Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery, and Age Group

| Surgery Age group (years) | Main independent variable of interest | | | | | |
|---------------------------------------|---------------------------------------|--------------|----------------------------|--------------|--------------------------------|--------------|
| | Days' supply | | Tablets/Capsules dispensed | | Morphine milligram equivalents | |
| | Odds Ratio ¹ | 95% CI | Odds Ratio ¹ | 95% CI | Odds Ratio ¹ | 95% CI |
| Appendectomy (laparoscopic) | | | | | | |
| All ages | 0.86 | (0.83, 0.90) | 0.85 | (0.81, 0.89) | 0.83 | (0.80, 0.87) |
| 18-40 | 0.82 | (0.78, 0.87) | 0.83 | (0.79, 0.88) | 0.79 | (0.75, 0.84) |
| 41-64 | 1.16 | (1.08, 1.26) | 1.06 | (0.98, 1.16) | 1.05 | (0.96, 1.14) |
| 65+ | 0.95 | (0.80, 1.14) | 0.95 | (0.79, 1.14) | 0.96 | (0.80, 1.15) |
| Appendectomy (nonspecific) | | | | | | |
| All ages | 1.75 | (1.63, 1.88) | 1.7 | (1.59, 1.83) | 1.66 | (1.54, 1.78) |
| 18-40 | 1.55 | (1.39, 1.72) | 1.54 | (1.38, 1.72) | 1.45 | (1.30, 1.62) |
| 41-64 | 2.38 | (2.13, 2.67) | 2.14 | (1.90, 2.41) | 2.11 | (1.87, 2.37) |
| 65+ | 1.97 | (1.60, 2.43) | 1.97 | (1.60, 2.43) | 1.97 | (1.59, 2.43) |
| Bunionectomy | | | | | | |
| All ages | 4.3 | (4.16, 4.45) | 4.05 | (3.90, 4.20) | 3.81 | (3.67, 3.95) |
| 18-40 | 4.79 | (4.52, 5.07) | 4.56 | (4.29, 4.84) | 4.1 | (3.86, 4.36) |
| 41-64 | 4.68 | (4.41, 4.96) | 4.11 | (3.84, 4.39) | 3.95 | (3.70, 4.21) |
| 65+ | 4.38 | (3.80, 5.06) | 4.2 | (3.63, 4.87) | 4.14 | (3.57, 4.80) |
| Cesarean section | | | | | | |
| All ages | 1.13 | (1.09, 1.17) | 1.11 | (1.06, 1.15) | 1.08 | (1.04, 1.13) |
| 18-40 | 1.31 | (1.24, 1.39) | 1.32 | (1.25, 1.40) | 1.25 | (1.18, 1.32) |
| 41-64 | 1.83 | (1.67, 2.00) | 1.65 | (1.50, 1.82) | 1.61 | (1.46, 1.78) |
| 65+ | - | - | - | - | - | - |
| Cholecystectomy (laparoscopic) | | | | | | |
| All ages | 0.98 | (0.95, 1.01) | 0.96 | (0.92, 0.99) | 0.93 | (0.90, 0.96) |
| 18-40 | 0.94 | (0.90, 0.98) | 0.94 | (0.90, 0.99) | 0.89 | (0.85, 0.93) |
| 41-64 | 1.13 | (1.06, 1.20) | 1.03 | (0.96, 1.10) | 1.01 | (0.95, 1.08) |
| 65+ | 1.01 | (0.88, 1.17) | 1.00 | (0.87, 1.16) | 1.01 | (0.87, 1.17) |
| Cholecystectomy (nonspecific) | | | | | | |
| All ages | 2.55 | (2.34, 2.77) | 2.42 | (2.22, 2.63) | 2.34 | (2.14, 2.55) |
| 18-40 | 3.14 | (2.52, 3.90) | 3.02 | (2.43, 3.76) | 2.81 | (2.25, 3.50) |
| 41-64 | 3.14 | (2.75, 3.60) | 2.82 | (2.45, 3.24) | 2.75 | (2.39, 3.16) |
| 65+ | 2.17 | (1.81, 2.61) | 2.07 | (1.72, 2.50) | 2.08 | (1.72, 2.51) |

Table 7. Odds Ratios for Re-filling Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery, and Age Group

| Surgery Age group (years) | Main independent variable of interest | | | | | |
|--|---------------------------------------|----------------|----------------------------|----------------|--------------------------------|----------------|
| | Days' supply | | Tablets/Capsules dispensed | | Morphine milligram equivalents | |
| | Odds Ratio ¹ | 95% CI | Odds Ratio ¹ | 95% CI | Odds Ratio ¹ | 95% CI |
| Coronary artery bypass graft | | | | | | |
| All ages | 3.83 | (3.64, 4.02) | 3.65 | (3.46, 3.85) | 3.39 | (3.22, 3.57) |
| 18-40 | 6.87 | (5.31, 8.89) | 6.49 | (5.00, 8.41) | 5.57 | (4.27, 7.28) |
| 41-64 | 4.72 | (4.33, 5.14) | 4.14 | (3.77, 4.55) | 3.91 | (3.56, 4.30) |
| 65+ | 3.42 | (2.94, 3.99) | 3.35 | (2.86, 3.92) | 3.31 | (2.83, 3.88) |
| Hip fracture treatment | | | | | | |
| All ages | 8.69 | (8.23, 9.17) | 8.04 | (7.60, 8.51) | 7.32 | (6.91, 7.75) |
| 18-40 | 12.47 | (11.05, 14.09) | 11.92 | (10.41, 13.65) | 9.67 | (8.39, 11.15) |
| 41-64 | 10.31 | (9.32, 11.41) | 8.72 | (7.81, 9.74) | 7.83 | (7.00, 8.75) |
| 65+ | 7.68 | (6.59, 8.97) | 7.35 | (6.28, 8.60) | 7.24 | (6.18, 8.47) |
| Hip replacement | | | | | | |
| All ages | 7.52 | (7.20, 7.85) | 7.64 | (7.28, 8.01) | 6.71 | (6.39, 7.04) |
| 18-40 | 7.76 | (6.55, 9.19) | 7.48 | (6.10, 9.18) | 6.56 | (5.31, 8.10) |
| 41-64 | 7.94 | (7.36, 8.55) | 7.62 | (6.98, 8.31) | 6.82 | (6.25, 7.44) |
| 65+ | 7.17 | (6.18, 8.32) | 7.33 | (6.29, 8.54) | 6.96 | (5.97, 8.12) |
| Hysterectomy (laparoscopic) | | | | | | |
| All ages | 1.62 | (1.52, 1.72) | 1.57 | (1.48, 1.67) | 1.52 | (1.43, 1.62) |
| 18-40 | 1.76 | (1.61, 1.92) | 1.75 | (1.60, 1.91) | 1.63 | (1.49, 1.79) |
| 41-64 | 1.81 | (1.64, 2.00) | 1.65 | (1.49, 1.83) | 1.62 | (1.46, 1.79) |
| 65+ | 1.2 | (0.94, 1.53) | 1.16 | (0.91, 1.48) | 1.14 | (0.88, 1.46) |
| Hysterectomy (non-laparoscopic) | | | | | | |
| All ages | 1.76 | (1.65, 1.87) | 1.7 | (1.59, 1.81) | 1.64 | (1.54, 1.75) |
| 18-40 | 2.24 | (2.01, 2.49) | 2.23 | (2.00, 2.48) | 2.1 | (1.88, 2.34) |
| 41-64 | 2.13 | (1.93, 2.36) | 1.92 | (1.72, 2.13) | 1.87 | (1.68, 2.08) |
| 65+ | 1.25 | (1.04, 1.50) | 1.21 | (1.01, 1.46) | 1.2 | (1.00, 1.45) |
| Knee arthroplasty | | | | | | |
| All ages | 28.69 | (27.55, 29.88) | 27.94 | (26.70, 29.23) | 24.9 | (23.81, 26.05) |
| 18-40 | 16.07 | (12.56, 20.56) | 12.03 | (9.22, 15.69) | 9.15 | (6.89, 12.17) |
| 41-64 | 33.83 | (31.49, 36.35) | 31.08 | (28.60, 33.79) | 29.11 | (26.78, 31.63) |
| 65+ | 25.85 | (22.32, 29.94) | 25.63 | (22.03, 29.81) | 24.69 | (21.20, 28.74) |

Table 7. Odds Ratios for Re-filling Opioid Analgesics for Patients with an Initial Dispensing of 90 Days or Less, in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015, by Independent Variable of Interest, Surgery, and Age Group

| Surgery Age group (years) | Main independent variable of interest | | | | | |
|-----------------------------------|---------------------------------------|----------------|----------------------------|---------------|--------------------------------|---------------|
| | Days' supply | | Tablets/Capsules dispensed | | Morphine milligram equivalents | |
| | Odds Ratio ¹ | 95% CI | Odds Ratio ¹ | 95% CI | Odds Ratio ¹ | 95% CI |
| Laminectomy/discectomy | | | | | | |
| All ages | 3.15 | (2.98, 3.33) | 3.09 | (2.91, 3.28) | 2.73 | (2.57, 2.90) |
| 18-40 | 2.33 | (2.09, 2.59) | 2.29 | (2.04, 2.57) | 1.89 | (1.68, 2.13) |
| 41-64 | 3.23 | (2.95, 3.54) | 2.85 | (2.57, 3.15) | 2.53 | (2.28, 2.81) |
| 65+ | 4.48 | (3.81, 5.26) | 4.58 | (3.88, 5.40) | 4.39 | (3.72, 5.19) |
| Spinal fusion (all levels) | | | | | | |
| All ages | 6.32 | (5.47, 7.29) | 5.52 | (4.74, 6.43) | 4.95 | (4.21, 5.82) |
| 18-40 | 2.78 | (1.88, 4.10) | 2.5 | (1.65, 3.79) | 2.37 | (1.55, 3.62) |
| 41-64 | 5.75 | (4.59, 7.19) | 4.94 | (3.90, 6.24) | 4.47 | (3.46, 5.76) |
| 65+ | 10.34 | (8.04, 13.29) | 8.74 | (6.70, 11.42) | 8.27 | (6.27, 10.91) |
| Spinal fusion (1-3 levels) | | | | | | |
| All ages | 6.59 | (6.28, 6.91) | 6.04 | (5.72, 6.37) | 5.26 | (4.99, 5.56) |
| 18-40 | 5.79 | (5.12, 6.54) | 5.09 | (4.43, 5.85) | 3.92 | (3.39, 4.53) |
| 41-64 | 6.06 | (5.60, 6.56) | 5.06 | (4.62, 5.54) | 4.65 | (4.25, 5.09) |
| 65+ | 7.83 | (6.71, 9.13) | 7.41 | (6.32, 8.68) | 6.88 | (5.86, 8.08) |
| Spinal fusion (4+ levels) | | | | | | |
| All ages | 10.96 | (10.26, 11.70) | 9.88 | (9.18, 10.64) | 8.15 | (7.55, 8.80) |
| 18-40 | 12.44 | (10.56, 14.65) | 10.3 | (8.54, 12.41) | 8.15 | (6.66, 9.98) |
| 41-64 | 11.03 | (9.95, 12.23) | 9.14 | (8.12, 10.28) | 7.55 | (6.67, 8.54) |
| 65+ | 11.28 | (9.53, 13.35) | 10.78 | (9.03, 12.87) | 9.8 | (8.19, 11.73) |

¹Odds ratios compare a given surgery vs. tooth extraction and are adjusted for age, sex, comorbidity score, year of opioid initiation, Data Partner, history of comedication use, and independent variable of interest (days' supply, tablets/capsules dispensed, or MMEs in index dispensings).

Figure 1. Re-fill Probability of Initial Dispensings for Patients with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 2. Re-fill Probability of Initial Dispensings for Patients with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 3. Re-fill Probability of Initial Dispensings for Patients with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 4. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 5. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 6. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Bunionectomy with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 7. Estimated and Observed Re-fill Probabilities of Initial Dispensing for Patients with a Cesarean Section with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 8. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 9. Estimated and Observed Re-fill Probabilities of Initial Dispensing for Patients with a Cholecystectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 10. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Coronary Artery Bypass Graft with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 11. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Fracture Treatment with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 12. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Replacement with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 13. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 14. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (non-laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 15. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Knee Arthroplasty with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 16. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Laminectomy/Discectomy with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 17. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (1-3 levels) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 18. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (4+ levels) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 19. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (all levels) with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 20. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Tooth Extraction with an Initial Dispensing of 90 Days or Fewer by Days' Supply of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 21. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 22. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 23. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Bunionectomy with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 24. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cesarean Section with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 25. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 26. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 27. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Coronary Artery Bypass Graft with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 28. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Fracture Treatment with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 29. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Replacement with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 30. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 31. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (non-laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 32. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Knee Arthroplasty with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 33. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Laminectomy/Discectomy with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 34. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (1-3 levels) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 35. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (4+ levels) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 36. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (all levels) with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 37. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Tooth Extraction with an Initial Dispensing of 90 Days or Fewer by Tablets/Capsules Dispensed of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 38. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 39. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with an Appendectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 40. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Bunionectomy with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 41. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cesarean Section with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 42. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 43. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Cholecystectomy (nonspecific) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 44. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Coronary Artery Bypass Graft with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 45. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Fracture Treatment with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 46. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hip Replacement with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 47. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 48. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Hysterectomy (non-laparoscopic) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 49. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Knee Arthroplasty with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 50. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Laminectomy/Discectomy with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 51. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (1-3 levels) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 52. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (4+ levels) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015




Figure 53. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Spinal Fusion (all levels) with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015





Figure 54. Estimated and Observed Re-fill Probabilities of Initial Dispensings for Patients with a Tooth Extraction with an Initial Dispensing of 90 Days or Fewer by Morphine Milligram Equivalents (MME) of Initial Dispensing in the Sentinel Distributed Database (SDD) from October 1, 2009 to September 30, 2015



**Appendix A. Dates of Available Data for Each Data Partner (DP) in the Sentinel Distributed Database (SDD)
up to Request End Date (September 30, 2015)**

| Data Partner ID | Start Date | End Date |
|-----------------|------------|------------|
| DP01 | 1/1/2004 | 09/30/2015 |
| DP02 | 1/1/2000 | 09/30/2015 |
| DP03 | 1/1/2000 | 09/30/2015 |
| DP04 | 1/1/2008 | 09/30/2015 |
| DP05 | 1/1/2000 | 09/30/2015 |
| DP06 | 1/1/2000 | 09/30/2015 |
| DP07 | 1/1/2000 | 09/30/2015 |
| DP08 | 1/1/2008 | 09/30/2015 |
| DP09 | 1/1/2000 | 09/30/2015 |
| DP10 | 1/1/2000 | 09/30/2015 |
| DP11 | 6/1/2017 | 09/30/2015 |
| DP12 | 1/1/2010 | 09/30/2015 |
| DP13 | 1/1/2005 | 09/30/2015 |
| DP14 | 1/1/2016 | 09/30/2015 |
| DP15 | 1/1/2000 | 09/30/2015 |
| DP16 | 1/1/2000 | 05/31/2015 |
| DP17 | 1/1/2012 | 09/30/2015 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|------------------------------------|---|-----------|
| Appendectomy (nonspecific) | | |
| 47 | Operations on appendix | ICD-9-CM |
| 47.0 | Appendectomy | ICD-9-CM |
| 47.09 | Other appendectomy | ICD-9-CM |
| 47.1 | Incidental appendectomy | ICD-9-CM |
| 47.19 | Other incidental appendectomy | ICD-9-CM |
| 44900 | Incision and drainage of appendiceal abscess, open | CPT-4 |
| 44950 | Appendectomy; | CPT-4 |
| 44955 | Appendectomy; when done for indicated purpose at time of other major procedure (not as separate procedure) (List separately in addition to code for primary procedure) | CPT-4 |
| 44960 | Appendectomy; for ruptured appendix with abscess or generalized peritonitis | CPT-4 |
| Appendectomy (laparoscopic) | | |
| 47.01 | Laparoscopic appendectomy | ICD-9-CM |
| 47.11 | Laparoscopic incidental appendectomy | ICD-9-CM |
| 44970 | Laparoscopy, surgical, appendectomy | CPT-4 |
| 44979 | Unlisted laparoscopy procedure, appendix | CPT-4 |
| 49315 | LAPAROSCOPY SURGICAL APPENDECTOMY | CPT-4 |
| 56315 | LAP SURG; APPENDECTOMY | CPT-4 |
| Bunionectomy | | |
| 77.5 | Excision and repair of bunion and other toe deformities | ICD-9-CM |
| 77.51 | Bunionectomy with soft tissue correction and osteotomy of the first metatarsal | ICD-9-CM |
| 77.52 | Bunionectomy with soft tissue correction and arthrodesis | ICD-9-CM |
| 77.53 | Other bunionectomy with soft tissue correction | ICD-9-CM |
| 77.54 | Excision or correction of bunionette | ICD-9-CM |
| 77.56 | Repair of hammer toe | ICD-9-CM |
| 77.57 | Repair of claw toe | ICD-9-CM |
| 77.58 | Other excision, fusion, and repair of toes | ICD-9-CM |
| 77.59 | Other bunionectomy | ICD-9-CM |
| 28110 | Osteotomy, partial excision, fifth metatarsal head (bunionette) (separate procedure) | CPT-4 |
| 28289 | Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; without implant | CPT-4 |
| 28290 | Correction, hallux valgus (bunion), with or without sesamoideectomy; simple exostectomy (eg, Silver type procedure) | CPT-4 |
| 28291 | Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; with implant | CPT-4 |
| 28292 | Correction, hallux valgus (bunionectomy), with sesamoideectomy, when performed; with resection of proximal phalanx base, when performed, any method | CPT-4 |
| 28293 | Correction, hallux valgus (bunion), with or without sesamoideectomy; resection of joint with implant | CPT-4 |
| 28294 | Correction, hallux valgus (bunion), with or without sesamoideectomy; with tendon transplants (eg, Joplin type procedure) | CPT-4 |
| 28295 | Correction, hallux valgus (bunionectomy), with sesamoideectomy, when performed; with proximal metatarsal osteotomy, any method | CPT-4 |
| 28296 | Correction, hallux valgus (bunionectomy), with sesamoideectomy, when performed; with distal metatarsal osteotomy, any method | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|---------------------------------------|---|-----------|
| 28297 | Correction, hallux valgus (bunionectomy), with sesamoidection, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method | CPT-4 |
| 28298 | Correction, hallux valgus (bunionectomy), with sesamoidection, when performed; with proximal phalanx osteotomy, any method | CPT-4 |
| 28299 | Correction, hallux valgus (bunionectomy), with sesamoidection, when performed; with double osteotomy, any method | CPT-4 |
| Cesarean Section | | |
| 74.0 | Classical cesarean section | ICD-9-CM |
| 74 | Cesarean section and removal of fetus | ICD-9-CM |
| 74.1 | Low cervical cesarean section | ICD-9-CM |
| 74.2 | Extraperitoneal cesarean section | ICD-9-CM |
| 74.4 | Cesarean section of other specified type | ICD-9-CM |
| 74.9 | Cesarean section of unspecified type | ICD-9-CM |
| 74.99 | Other cesarean section of unspecified type | ICD-9-CM |
| 59500 | Cesarean Section, Low Cervical, Including In-hospital | CPT-4 |
| 59501 | Cesarean Section, Low Cervical, Including In-hospital | CPT-4 |
| 59510 | Routine obstetric care including antepartum care, cesarean delivery, and postpartum care | CPT-4 |
| 59514 | Cesarean delivery only; | CPT-4 |
| 59515 | Cesarean delivery only; including postpartum care | CPT-4 |
| 59521 | Cesarean Section, Classic, Including In-hospital | CPT-4 |
| 59540 | Cesarean Section, Extraperitoneal, Including In-hospital | CPT-4 |
| 59541 | Cesarean Section, Extraperitoneal, Including In-hospital | CPT-4 |
| 59560 | Cesarean Section With Hysterectomy, Subtotal, Including | CPT-4 |
| 59561 | Cesarean Section With Hysterectomy, Subtotal, Including | CPT-4 |
| 59580 | Cesarean Section With Hysterectomy, Total, Including | CPT-4 |
| 59581 | Cesarean Section With Hysterectomy, Total, Including | CPT-4 |
| 59618 | Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery | CPT-4 |
| 59620 | Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; | CPT-4 |
| 59622 | Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery; including postpartum care | CPT-4 |
| Cholecystectomy (laparoscopic) | | |
| 51.23 | Laparoscopic cholecystectomy | ICD-9-CM |
| 51.24 | Laparoscopic partial cholecystectomy | ICD-9-CM |
| 47562 | Laparoscopy, surgical; cholecystectomy | CPT-4 |
| 47563 | Laparoscopy, surgical; cholecystectomy with cholangiography | CPT-4 |
| 47564 | Laparoscopy, surgical; cholecystectomy with exploration of common duct | CPT-4 |
| 49310 | LAPAROSCOPY, SURG.;CHOLECYSTECTOMY | CPT-4 |
| 56340 | Laparoscopy, surgical; cholecystectomy (any method) | CPT-4 |
| 56341 | Laparoscopy, surgical; cholecystectomy with cholangiography | CPT-4 |
| 56342 | Laparoscopy, surgical; cholecystectomy with exploration of common duct | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|--------------------------------------|--|-----------|
| Cholecystectomy (nonspecific) | | |
| 51.2 | Cholecystectomy | ICD-9-CM |
| 51.21 | Other partial cholecystectomy | ICD-9-CM |
| 51.22 | Cholecystectomy | ICD-9-CM |
| 47600 | Cholecystectomy; | CPT-4 |
| 47605 | Cholecystectomy; with cholangiography | CPT-4 |
| 47610 | Cholecystectomy with exploration of common duct; | CPT-4 |
| 47612 | Cholecystectomy with exploration of common duct; with choledochoenterostomy | CPT-4 |
| 47620 | Cholecystectomy with exploration of common duct; with transduodenal sphincterotomy or sphincteroplasty, with or without cholangiography | CPT-4 |
| Coronary Artery Bypass Graft | | |
| 36.1 | Bypass anastomosis for heart revascularization | ICD-9-CM |
| 36.10 | Aortocoronary bypass for heart revascularization, not otherwise specified | ICD-9-CM |
| 36.11 | (Aorto)coronary bypass of one coronary artery | ICD-9-CM |
| 36.12 | (Aorto)coronary bypass of two coronary arteries | ICD-9-CM |
| 36.13 | (Aorto)coronary bypass of three coronary arteries | ICD-9-CM |
| 36.14 | (Aorto)coronary bypass of four or more coronary arteries | ICD-9-CM |
| 36.15 | Single internal mammary-coronary artery bypass | ICD-9-CM |
| 36.16 | Double internal mammary-coronary artery bypass | ICD-9-CM |
| 36.17 | Abdominal-coronary artery bypass | ICD-9-CM |
| 36.19 | Other bypass anastomosis for heart revascularization | ICD-9-CM |
| 33510 | Coronary artery bypass, vein only; single coronary venous graft | CPT-4 |
| 33511 | Coronary artery bypass, vein only; 2 coronary venous grafts | CPT-4 |
| 33512 | Coronary artery bypass, vein only; 3 coronary venous grafts | CPT-4 |
| 33513 | Coronary artery bypass, vein only; 4 coronary venous grafts | CPT-4 |
| 33514 | Coronary artery bypass, vein only; 5 coronary venous grafts | CPT-4 |
| 33516 | Coronary artery bypass, vein only; 6 or more coronary venous grafts | CPT-4 |
| 33517 | Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure) | CPT-4 |
| 33518 | Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure) | CPT-4 |
| 33519 | Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure) | CPT-4 |
| 33530 | Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation | CPT-4 |
| 33520 | Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft | CPT-4 |
| 33521 | Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure) | CPT-4 |
| 33522 | Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure) | CPT-4 |
| 33523 | Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure) | CPT-4 |
| 33525 | Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts | CPT-4 |
| 33528 | Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-------|---|-----------|
| 33533 | Coronary artery bypass, using arterial graft(s); single arterial graft | CPT-4 |
| 33534 | Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts | CPT-4 |
| 33535 | Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts | CPT-4 |
| 33536 | Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts | CPT-4 |
| 4110F | Internal mammary artery graft performed for primary, isolated coronary artery bypass graft procedure (CABG) | CPT-II |

Cholecystectomy (laparoscopic)

| | | |
|-------|--|----------|
| 47562 | Laparoscopy, surgical; cholecystectomy | CPT-4 |
| 47564 | Laparoscopy, surgical; cholecystectomy with exploration of common duct | CPT-4 |
| 47563 | Laparoscopy, surgical; cholecystectomy with cholangiography | CPT-4 |
| 51.23 | Laparoscopic cholecystectomy | ICD-9-CM |
| 51.24 | Laparoscopic partial cholecystectomy | ICD-9-CM |
| 49310 | LAPAROSCOPY, SURG.;CHOLECYSTECTOMY | CPT-4 |
| 56340 | Laparoscopy, surgical; cholecystectomy (any method) | CPT-4 |
| 56341 | Laparoscopy, surgical; cholecystectomy with cholangiography | CPT-4 |
| 56342 | Laparoscopy, surgical; cholecystectomy with exploration of common duct | CPT-4 |

Cholecystectomy (nonspecific)

| | | |
|-------|---|----------|
| 51.2 | Cholecystectomy | ICD-9-CM |
| 51.21 | Other partial cholecystectomy | ICD-9-CM |
| 51.22 | Cholecystectomy | ICD-9-CM |
| 47600 | Cholecystectomy; | CPT-4 |
| 47605 | Cholecystectomy; with cholangiography | CPT-4 |
| 47610 | Cholecystectomy with exploration of common duct; | CPT-4 |
| 47612 | Cholecystectomy with exploration of common duct; with choledochoenterostomy | CPT-4 |
| 47620 | Cholecystectomy with exploration of common duct; with transduodenal sphincterotomy or sphincteroplasty, with or without cholangiography | CPT-4 |

Hip Fracture Treatment

| | | |
|-------|--|----------|
| 78.55 | Internal fixation of femur without fracture reduction | ICD-9-CM |
| 79.05 | Closed reduction of fracture of femur without internal fixation | ICD-9-CM |
| 79.15 | Closed reduction of fracture of femur with internal fixation | ICD-9-CM |
| 79.25 | Open reduction of fracture of femur without internal fixation | ICD-9-CM |
| 79.35 | Open reduction of fracture of femur with internal fixation | ICD-9-CM |
| 79.45 | Closed reduction of separated epiphysis of femur | ICD-9-CM |
| 79.55 | Open reduction of separated epiphysis of femur | ICD-9-CM |
| 27220 | Closed treatment of acetabulum (hip socket) fracture(s); with manipulation, with or without skeletal traction | CPT-4 |
| 27222 | Closed treatment of acetabulum (hip socket) fracture(s); without manipulation | CPT-4 |
| 27226 | Open treatment of posterior or anterior acetabular wall fracture, with internal fixation | CPT-4 |
| 27227 | Open treatment of acetabular fracture(s) involving anterior or posterior (one) column, or a fracture running transversely across the acetabulum, with internal fixation | CPT-4 |
| 27228 | Open treatment of acetabular fracture(s) involving anterior and posterior (two) columns, includes T-fracture and both column fracture with complete articular detachment, or single column or transverse fracture with associated acetabular wall fracture, with internal fixation | CPT-4 |
| 27230 | Closed treatment of femoral fracture, proximal end, neck; without manipulation | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-------|---|-----------|
| 27232 | Closed treatment of femoral fracture, proximal end, neck; with manipulation, with or without skeletal traction | CPT-4 |
| 27235 | Percutaneous skeletal fixation of femoral fracture, proximal end, neck | CPT-4 |
| 27236 | Open treatment of femoral fracture, proximal end, neck, internal fixation or prosthetic replacement | CPT-4 |
| 27238 | Closed treatment of intertrochanteric, peritrochanteric, or subtrochanteric femoral fracture; without manipulation | CPT-4 |
| 27240 | Closed treatment of intertrochanteric, peritrochanteric, or subtrochanteric femoral fracture; with manipulation, with or without skin or skeletal traction | CPT-4 |
| 27244 | Treatment of intertrochanteric, peritrochanteric, or subtrochanteric femoral fracture; with plate/screw type implant, with or without cerclage | CPT-4 |
| 27245 | Treatment of intertrochanteric, peritrochanteric, or subtrochanteric femoral fracture; with intramedullary implant, with or without interlocking screws and/or cerclage | CPT-4 |
| 27246 | Closed treatment of greater trochanteric fracture, without manipulation | CPT-4 |
| 27248 | Open treatment of greater trochanteric fracture, includes internal fixation, when performed | CPT-4 |
| 27254 | Open treatment of hip dislocation, traumatic, with acetabular wall and femoral head fracture, with or without internal or external fixation | CPT-4 |
| 27267 | Closed treatment of femoral fracture, proximal end, head; without manipulation | CPT-4 |
| 27268 | Closed treatment of femoral fracture, proximal end, head; with manipulation | CPT-4 |
| 27269 | Open treatment of femoral fracture, proximal end, head, includes internal fixation, when performed | CPT-4 |

Hip Replacement

| | | |
|-------|---|----------|
| 00.74 | Hip bearing surface, metal-on-polyethylene | ICD-9-CM |
| 00.75 | Hip bearing surface, metal-on-metal | ICD-9-CM |
| 00.76 | Hip bearing surface, ceramic-on-ceramic | ICD-9-CM |
| 00.77 | Hip bearing surface, ceramic-on-polyethylene | ICD-9-CM |
| 00.85 | Resurfacing hip, total, acetabulum and femoral head | ICD-9-CM |
| 00.86 | Resurfacing hip, partial, femoral head | ICD-9-CM |
| 00.87 | Resurfacing hip, partial, acetabulum | ICD-9-CM |
| 81.51 | Total hip replacement | ICD-9-CM |
| 81.52 | Partial hip replacement | ICD-9-CM |
| 27125 | Hemiarthroplasty, hip, partial (eg, femoral stem prosthesis, bipolar arthroplasty) | CPT-4 |
| 27126 | Partial Hip Replacement (hemiarthroplasty); Cup | CPT-4 |
| 27127 | Partial Hip Replacement (hemiarthroplasty); Cup With Acetabuloplasty | CPT-4 |
| 27130 | Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft | CPT-4 |
| 27132 | Conversion of previous hip surgery to total hip arthroplasty, with or without autograft or allograft | CPT-4 |
| 27134 | Revision of total hip arthroplasty; both components, with or without autograft or allograft | CPT-4 |
| 27137 | Revision of total hip arthroplasty; acetabular component only, with or without autograft or allograft | CPT-4 |
| 27138 | Revision of total hip arthroplasty; femoral component only, with or without allograft | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|--|---|-----------|
| Hysterectomy (non-laparoscopic) | | |
| 68.3 | Subtotal abdominal hysterectomy | ICD-9-CM |
| 68.39 | Other and unspecified subtotal abdominal hysterectomy | ICD-9-CM |
| 68.4 | Total abdominal hysterectomy | ICD-9-CM |
| 68.49 | Other and unspecified total abdominal hysterectomy | ICD-9-CM |
| 68.5 | Vaginal hysterectomy | ICD-9-CM |
| 68.59 | Other and unspecified vaginal hysterectomy | ICD-9-CM |
| 68.6 | Radical abdominal hysterectomy | ICD-9-CM |
| 68.69 | Other and unspecified radical abdominal hysterectomy | ICD-9-CM |
| 68.7 | Radical vaginal hysterectomy | ICD-9-CM |
| 68.79 | Other and unspecified radical vaginal hysterectomy | ICD-9-CM |
| 68.9 | Other and unspecified hysterectomy | ICD-9-CM |
| 58150 | Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s); | CPT-4 |
| 58152 | Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or without removal of ovary(s); with colpo-urethrocystopexy (eg, Marshall-Marchetti-Krantz, Burch) | CPT-4 |
| 58180 | Supracervical abdominal hysterectomy (subtotal hysterectomy), with or without removal of tube(s), with or without removal of ovary(s) | CPT-4 |
| 58200 | Total abdominal hysterectomy, including partial vaginectomy, with para-aortic and pelvic lymph node sampling, with or without removal of tube(s), with or without removal of ovary(s) | CPT-4 |
| 58210 | Radical abdominal hysterectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling (biopsy), with or without removal of tube(s), with or without removal of ovary(s) | CPT-4 |
| 58260 | Vaginal hysterectomy, for uterus 250 g or less; | CPT-4 |
| 58262 | Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s) | CPT-4 |
| 58263 | Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s), with repair of enterocele | CPT-4 |
| 58267 | Vaginal hysterectomy, for uterus 250 g or less; with colpo-urethrocystopexy (Marshall-Marchetti-Krantz type, Pereyra type) with or without endoscopic control | CPT-4 |
| 58270 | Vaginal hysterectomy, for uterus 250 g or less; with repair of enterocele | CPT-4 |
| 58275 | Vaginal hysterectomy, with total or partial vaginectomy; | CPT-4 |
| 58280 | Vaginal hysterectomy, with total or partial vaginectomy; with repair of enterocele | CPT-4 |
| 58285 | Vaginal hysterectomy, radical (Schauta type operation) | CPT-4 |
| 58290 | Vaginal hysterectomy, for uterus greater than 250 g; | CPT-4 |
| 58291 | Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s) | CPT-4 |
| 58292 | Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s), with repair of enterocele | CPT-4 |
| 58293 | Vaginal hysterectomy, for uterus greater than 250 g; with colpo-urethrocystopexy (Marshall-Marchetti-Krantz type, Pereyra type) with or without endoscopic control | CPT-4 |
| 58294 | Vaginal hysterectomy, for uterus greater than 250 g; with repair of enterocele | CPT-4 |
| Hysterectomy (laparoscopic) | | |
| 68.31 | Laparoscopic supracervical hysterectomy [LSH] | ICD-9-CM |
| 68.41 | Laparoscopic total abdominal hysterectomy | ICD-9-CM |
| 68.51 | Laparoscopically assisted vaginal hysterectomy (LAVH) | ICD-9-CM |
| 68.61 | Laparoscopic radical abdominal hysterectomy | ICD-9-CM |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-------|--|-----------|
| 68.71 | Laparoscopic radical vaginal hysterectomy [LRVH] | ICD-9-CM |
| 58541 | Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less; | CPT-4 |
| 58542 | Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s) | CPT-4 |
| 58543 | Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; | CPT-4 |
| 58544 | Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s) | CPT-4 |
| 58545 | Laparoscopy, surgical, myomectomy, excision; 1 to 4 intramural myomas with total weight of 250 g or less and/or removal of surface myomas | CPT-4 |
| 58546 | Laparoscopy, surgical, myomectomy, excision; 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g | CPT-4 |
| 58548 | Laparoscopy, surgical, with radical hysterectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling (biopsy), with removal of tube(s) and ovary(s), if performed | CPT-4 |
| 58550 | Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less; | CPT-4 |
| 58552 | Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s) | CPT-4 |
| 58553 | Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; | CPT-4 |
| 58554 | Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s) | CPT-4 |
| 58570 | Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less; | CPT-4 |
| 58571 | Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s) | CPT-4 |
| 58572 | Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; | CPT-4 |
| 58573 | Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s) | CPT-4 |
| S2078 | Laparoscopic supracervical hysterectomy (subtotal hysterectomy), with or without removal of tube(s), with or without removal of ovary(s) | HCPCS |

Knee arthroplasty

| | | |
|-------|--|----------|
| 81.54 | Total knee replacement | ICD-9-CM |
| 27437 | Arthroplasty, patella; without prosthesis | CPT-4 |
| 27440 | Arthroplasty, knee, tibial plateau; | CPT-4 |
| 27441 | Arthroplasty, knee, tibial plateau; with debridement and partial synovectomy | CPT-4 |
| 27442 | Arthroplasty, femoral condyles or tibial plateau(s), knee; | CPT-4 |
| 27443 | Arthroplasty, femoral condyles or tibial plateau(s), knee; with debridement and partial synovectomy | CPT-4 |
| 27445 | Arthroplasty, knee, hinge prosthesis (eg, Walldius type) | CPT-4 |
| 27446 | Arthroplasty, knee, condyle and plateau; medial OR lateral compartment | CPT-4 |
| 27447 | Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing (total knee arthroplasty) | CPT-4 |
| 27438 | Arthroplasty, patella; with prosthesis | CPT-4 |
| 27486 | Revision of total knee arthroplasty, with or without allograft; 1 component | CPT-4 |
| 27487 | Revision of total knee arthroplasty; femoral and entire tibial component | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-------------------------------|--|-----------|
| Laminectomy/Discectomy | | |
| 80.5 | Excision, destruction and other repair of intervertebral disc | ICD-9-CM |
| 80.50 | Excision or destruction of intervertebral disc, unspecified | ICD-9-CM |
| 80.51 | Excision of intervertebral disc | ICD-9-CM |
| 63020 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, cervical | CPT-4 |
| 63030 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, lumbar | CPT-4 |
| 63035 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; each additional interspace, cervical or lumbar (List separately in addition to code for primary procedure) | CPT-4 |
| 63040 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; cervical | CPT-4 |
| 63041 | Laminotomy (hemilaminectomy), For Herniated | CPT-4 |
| 63042 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; lumbar | CPT-4 |
| 63043 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional cervical interspace (List separately in addition to code for primary procedure) | CPT-4 |
| 63044 | Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional lumbar interspace (List separately in addition to code for primary procedure) | CPT-4 |
| 63055 | Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; thoracic | CPT-4 |
| 63056 | Lumbar decompression, transpedicular or CV approach | CPT-4 |
| 63057 | Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; each additional segment, thoracic or lumbar (List separately in addition to code for primary procedure) | CPT-4 |
| 63060 | Hemilaminectomy (laminectomy) For Herniated Intervertebral | CPT-4 |
| 63064 | Costovertebral approach with decompression of spinal cord or nerve root(s) (eg, herniated intervertebral disc), thoracic; single segment | CPT-4 |
| 63066 | Costovertebral approach with decompression of spinal cord or nerve root(s) (eg, herniated intervertebral disc), thoracic; each additional segment (List separately in addition to code for primary procedure) | CPT-4 |
| 63075 | Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; cervical, single interspace | CPT-4 |
| 63076 | Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; cervical, each additional interspace (List separately in addition to code for primary procedure) | CPT-4 |
| 63077 | Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; thoracic, single interspace | CPT-4 |
| 63078 | Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophytectomy; thoracic, each additional interspace (List separately in addition to code for primary procedure) | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-----------------------------------|--|-----------|
| Spinal fusion (all levels) | | |
| 81.00 | Spinal fusion, not otherwise specified | ICD-9-CM |
| 81.0 | Spinal fusion | ICD-9-CM |
| 81.01 | Atlas-axis spinal fusion | ICD-9-CM |
| 81.02 | Other cervical fusion of the anterior column, anterior technique | ICD-9-CM |
| 81.03 | Other cervical fusion of the posterior column, posterior technique | ICD-9-CM |
| 81.04 | Dorsal and dorsolumbar fusion of the anterior column, anterior technique | ICD-9-CM |
| 81.05 | Dorsal and dorsolumbar fusion of the posterior column, posterior technique | ICD-9-CM |
| 81.06 | Lumbar and lumbosacral fusion of the anterior column, anterior technique | ICD-9-CM |
| 81.07 | Lumbar and lumbosacral fusion of the posterior column, posterior technique | ICD-9-CM |
| 81.08 | Lumbar and lumbosacral fusion of the anterior column, posterior technique | ICD-9-CM |
| 81.61 | 360 degree spinal fusion, single incision approach | ICD-9-CM |
| 84.51 | Insertion of interbody spinal fusion device | ICD-9-CM |
| 81.3 | Refusion of spine | ICD-9-CM |
| 81.30 | Refusion of spine, not otherwise specified | ICD-9-CM |
| 81.31 | Refusion of Atlas-axis spine | ICD-9-CM |
| 81.32 | Refusion of other cervical spine, anterior column, anterior technique | ICD-9-CM |
| 81.33 | Refusion of other cervical spine, posterior column, posterior technique | ICD-9-CM |
| 81.34 | Refusion of dorsal and dorsolumbar spine, anterior column, anterior technique | ICD-9-CM |
| 81.35 | Refusion of dorsal and dorsolumbar spine, posterior column, posterior technique | ICD-9-CM |
| 81.36 | Refusion of lumbar and lumbosacral spine, anterior column, anterior technique | ICD-9-CM |
| 81.37 | Refusion of lumbar and lumbosacral spine, posterior column, posterior technique | ICD-9-CM |
| 81.38 | Refusion of lumbar and lumbosacral spine, anterior column, posterior technique | ICD-9-CM |
| 81.39 | Refusion of spine, not elsewhere classified | ICD-9-CM |
| 22532 | Arthrodesis, lateral extracavitory technique, including minimal discectomy to prepare interspace (other than for decompression); thoracic | CPT-4 |
| 22533 | Arthrodesis, lateral extracavitory technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar | CPT-4 |
| 22534 | Arthrodesis, lateral extracavitory technique, including minimal discectomy to prepare interspace (other than for decompression); thoracic or lumbar, each additional vertebral segment (List separately in addition to code for primary procedure) | CPT-4 |
| 22548 | Arthrodesis, anterior transoral or extraoral technique, clivus-C1-C2 (atlas-axis), with or without excision of odontoid process | CPT-4 |
| 22551 | Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below C2 | CPT-4 |
| 22552 | Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below C2, each additional interspace (List separately in addition to code for separate procedure) | CPT-4 |
| 22554 | Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below C2 | CPT-4 |
| 22556 | Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); thoracic | CPT-4 |
| 22558 | Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-------|--|-----------|
| 22585 | Arthrodesis, anterior interbody technique, including minimal disectomy to prepare interspace (other than for decompression); each additional interspace (List separately in addition to code for primary procedure) | CPT-4 |
| 22586 | Arthrodesis, pre-sacral interbody technique, including disc space preparation, disectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace | CPT-4 |
| 22590 | Arthrodesis, posterior technique, craniocervical (occiput-C2) | CPT-4 |
| 22595 | Arthrodesis, posterior technique, atlas-axis (C1-C2) | CPT-4 |
| 22600 | Arthrodesis, posterior or posterolateral technique, single level; cervical below C2 segment | CPT-4 |
| 22610 | Arthrodesis, posterior or posterolateral technique, single level; thoracic (with lateral transverse technique, when performed) | CPT-4 |
| 22612 | Arthrodesis, posterior or posterolateral technique, single level; lumbar (with lateral transverse technique, when performed) | CPT-4 |
| 22614 | Arthrodesis, posterior or posterolateral technique, single level; each additional vertebral segment (List separately in addition to code for primary procedure) | CPT-4 |
| 22630 | Arthrodesis, posterior interbody technique, including laminectomy and/or disectomy to prepare interspace (other than for decompression), single interspace; lumbar | CPT-4 |
| 22632 | Arthrodesis, posterior interbody technique, including laminectomy and/or disectomy to prepare interspace (other than for decompression), single interspace; each additional interspace (List separately in addition to code for primary procedure) | CPT-4 |
| 22633 | Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or disectomy sufficient to prepare interspace (other than for decompression), single interspace and segment; lumbar | CPT-4 |
| 22634 | Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or disectomy sufficient to prepare interspace (other than for decompression), single interspace and segment; each additional interspace and segment (List separately in addition to code for primary procedure) | CPT-4 |
| 81.63 | Fusion or refusion of 4-8 vertebrae | ICD-9-CM |
| 81.64 | Fusion or refusion of 9 or more vertebrae | ICD-9-CM |
| 22843 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 7 to 12 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22844 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 13 or more vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22847 | Anterior instrumentation; 8 or more vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22842 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22846 | Anterior instrumentation; 4 to 7 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 81.62 | Fusion or refusion of 2-3 vertebrae | ICD-9-CM |
| 22840 | Posterior non-segmental instrumentation (eg, Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure) | CPT-4 |
| 22845 | Anterior instrumentation; 2 to 3 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |

Appendix B. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Surgeries in this Request

| Code | Description | Code Type |
|-----------------------------------|---|-----------|
| Spinal fusion (1-3 levels) | | |
| 81.62 | Fusion or refusion of 2-3 vertebrae | ICD-9-CM |
| 22840 | Posterior non-segmental instrumentation (eg, Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure) | CPT-4 |
| 22845 | Anterior instrumentation; 2 to 3 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| Spinal fusion (4+ levels) | | |
| 81.63 | Fusion or refusion of 4-8 vertebrae | ICD-9-CM |
| 81.64 | Fusion or refusion of 9 or more vertebrae | ICD-9-CM |
| 22843 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 7 to 12 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22844 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 13 or more vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22847 | Anterior instrumentation; 8 or more vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22842 | Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| 22846 | Anterior instrumentation; 4 to 7 vertebral segments (List separately in addition to code for primary procedure) | CPT-4 |
| Tooth Extraction | | |
| 23.0 | Forceps extraction of tooth | ICD-9-CM |
| 23.01 | Extraction of deciduous tooth | ICD-9-CM |
| 23.09 | Extraction of other tooth | ICD-9-CM |
| 23.1 | Surgical removal of tooth | ICD-9-CM |
| 23.11 | Removal of residual root | ICD-9-CM |
| 23.19 | Other surgical extraction of tooth | ICD-9-CM |
| D7140 | extraction, erupted tooth or exposed root (elevation and/or forceps removal) | HCPCS |
| D7210 | extraction, erupted tooth requiring removal of bone and/or sectioning of tooth, and including elevation of mucoperiosteal flap if indicated | HCPCS |
| D7220 | removal of impacted tooth - soft tissue | HCPCS |
| D7230 | removal of impacted tooth - partially bony | HCPCS |
| D7240 | removal of impacted tooth - completely bony | HCPCS |

Appendix C. List of Generic and Brand Names of Products Used to Define Opioid Analgesics in this Request

| Generic Name | Brand Name |
|---|-----------------------------|
| Hydromorphone | |
| HYDROMORPHONE HCL | hydromorphone |
| HYDROMORPHONE HCL | Dilauidid |
| HYDROMORPHONE HCL | Exalgo ER |
| Meperidine | |
| MEPERIDINE HCL | Demerol |
| MEPERIDINE HCL | meperidine |
| MEPERIDINE HCL/PROMETHAZINE HCL | Meprozine |
| MEPERIDINE HCL | Meperitab |
| MEPERIDINE HCL/PROMETHAZINE HCL | meperidine-promethazine |
| Morphine | |
| MORPHINE SULFATE | morphine |
| MORPHINE SULFATE | Avinza |
| MORPHINE SULFATE | Kadian |
| MORPHINE SULFATE | MS Contin |
| MORPHINE SULFATE | Oramorph SR |
| MORPHINE SULFATE/NALTREXONE HCL | Embeda |
| MORPHINE SULFATE | MorphaBond ER |
| MORPHINE SULFATE | Arymo ER |
| Oxycodone | |
| IBUPROFEN/OXYCODONE HCL | ibuprofen-oxycodone |
| IBUPROFEN/OXYCODONE HCL | Combunox |
| OXYCODONE HCL | oxycodone |
| OXYCODONE HCL | OxyContin |
| OXYCODONE HCL | Roxicodone |
| OXYCODONE HCL | OxyIR |
| OXYCODONE HCL | Oxecta |
| OXYCODONE HCL | Dazidox |
| OXYCODONE HCL | Oxaydo |
| OXYCODONE HCL/ACETAMINOPHEN | Tylox |
| OXYCODONE HCL/ACETAMINOPHEN | oxycodone-acetaminophen |
| OXYCODONE HCL/ACETAMINOPHEN | Roxicet |
| OXYCODONE HCL/ACETAMINOPHEN | Percocet |
| OXYCODONE HCL/ACETAMINOPHEN | Magnacet |
| OXYCODONE HCL/ACETAMINOPHEN | Endocet |
| OXYCODONE HCL/ACETAMINOPHEN | Xolox |
| OXYCODONE HCL/ACETAMINOPHEN | Xartemis XR |
| OXYCODONE HCL/ACETAMINOPHEN | Primlev |
| OXYCODONE HCL/ACETAMINOPHEN | Primalev |
| OXYCODONE HCL/ACETAMINOPHEN | ALCET |
| OXYCODONE HCL/ASPIRIN | oxycodone-aspirin |
| OXYCODONE HCL/ASPIRIN | Endodan |
| OXYCODONE HCL/ASPIRIN | Percodan |
| OXYCODONE HCL/OXYCODONE TEREPHTHALATE/ASPIRIN | oxycodone HCl-oxycodone-ASA |
| OXYCODONE MYRISTATE | Xtampza ER |

Appendix C. List of Generic and Brand Names of Products Used to Define Opioid Analgesics in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| Oxymorphone | |
| OXYMORPHONE HCL | oxymorphone |
| OXYMORPHONE HCL | Opana ER |
| OXYMORPHONE HCL | Opana |
| Levorphanol | |
| LEVORPHANOL TARTRATE | levorphanol tartrate |
| LEVORPHANOL TARTRATE | Levo-Dromoran |
| Tapentadol | |
| TAPENTADOL HCL | Nucynta |
| TAPENTADOL HCL | Nucynta ER |
| Codeine | |
| ACETAMINOPHEN WITH CODEINE PHOSPHATE | Tylenol-Codeine #3 |
| ACETAMINOPHEN WITH CODEINE PHOSPHATE | Tylenol-Codeine #4 |
| CODEINE SULFATE | codeine sulfate |
| ACETAMINOPHEN WITH CODEINE PHOSPHATE | acetaminophen-codeine |
| BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE | butalbital-acetaminop-caf-cod |
| BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE | Phrenilin w/Caffeine-Codeine |
| ASPIRIN/CODEINE PHOSPHATE | Aspirin-Codeine #3 |
| CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE | Fiorinal-Codeine #3 |
| BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE | Fioricet with Codeine |
| CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE | Butalbital Compound W/Codeine |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | Panlor DC |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | Panlor SS |
| BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE | butalbital-acetaminop-caf-cod |
| ASPIRIN/CODEINE PHOSPHATE | Aspirin-Codeine #4 |
| ASPIRIN/CAFFEINE/DIHYDROCODEINE BITARTRATE | Synalgos-DC |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | Trezip |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | acetaminophen-caff-dihydrocod |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | Zerlor |
| CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE | Butalbital Compound-Codeine |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | acetaminophen-caff-dihydrocod |
| ACETAMINOPHEN WITH CODEINE PHOSPHATE | Cocet Plus |
| ACETAMINOPHEN WITH CODEINE PHOSPHATE | Cocet |
| CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE | Ascomp with Codeine |
| BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE PHOSPHATE | Fioricet with Codeine |
| CODEINE PHOSPHATE/BUTALBITAL/ASPIRIN/CAFFEINE | codeine-butalbital-ASA-caff |
| ASPIRIN/CAFFEINE/DIHYDROCODEINE BITARTRATE | aspirin-caffeine-dihydrocodein |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | Trezip |
| ACETAMINOPHEN WITH CODEINE PHOSPHATE | Vopac |
| ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE BITARTRATE | acetaminophen-caff-dihydrocod |
| ASPIRIN/CODEINE PHOSPHATE | aspirin-codeine |
| Hydrocodone | |
| HYDROCODONE BITARTRATE | Zohydro ER |
| HYDROCODONE BITARTRATE | Hysingla ER |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Vicodin |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Vicodin ES |

Appendix C. List of Generic and Brand Names of Products Used to Define Opioid Analgesics in this Request

| Generic Name | Brand Name |
|---|------------------------------|
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Vicodin HP |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Co-Gesic |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | hydrocodone-acetaminophen |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lortab |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Hydrogesic |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Margesic-H |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lorcet Plus |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lorcet 10/650 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Dolorex Forte |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Xodol 10/300 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Xodol 5/300 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Xodol 7.5/300 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Norco |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Norco |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lortab |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lortab 5-325 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lortab 7.5-325 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lortab 10-325 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Polygesic |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lorcet (hydrocodone) |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lorcet Plus |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Lorcet HD |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Norco |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Maxidone |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Zydome |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Anexsia |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Stagesic |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN | Verdrocet |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11 | Theracodophen-325 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11 | Theracodophen-650 |
| HYDROCODONE BITARTRATE/ACETAMINOPHEN/DIETARY SUPPLEMENT #11 | Theracodophen-Low-90 |
| HYDROCODONE/IBUPROFEN | Vicoprofen |
| HYDROCODONE/IBUPROFEN | Repxain |
| HYDROCODONE/IBUPROFEN | Ibudone |
| HYDROCODONE/IBUPROFEN | Xylon 10 |
| HYDROCODONE/IBUPROFEN | hydrocodone-ibuprofen |
| Pentazocine | |
| PENTAZOCINE HCL/ACETAMINOPHEN | Talacen |
| PENTAZOCINE HCL/NALOXONE HCL | Talwin NX |
| PENTAZOCINE HCL/NALOXONE HCL | pentazocine-naloxone |
| PENTAZOCINE HCL/ACETAMINOPHEN | pentazocine-acetaminophen |
| Propoxyphene | |
| PROPOXYPHENE HCL/ACETAMINOPHEN | propoxyphene-acetaminophen |
| PROPOXYPHENE NAPSYLATE | Darvon-N |
| PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN | Darvocet-N 100 |
| PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN | propoxyphene N-acetaminophen |

Appendix C. List of Generic and Brand Names of Products Used to Define Opioid Analgesics in this Request

| Generic Name | Brand Name |
|---|------------------------|
| PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN | Balacet 325 |
| PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN | Darvocet A500 |
| PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN | Propoxacet-N 100 |
| PROPOXYPHENE NAPSYLATE/ACETAMINOPHEN | Darvocet-N 50 |
| Tramadol | |
| TRAMADOL HCL | Ultram |
| TRAMADOL HCL | Ultram ER |
| TRAMADOL HCL | tramadol |
| TRAMADOL HCL | Ryzolt |
| TRAMADOL HCL | tramadol |
| TRAMADOL HCL | ConZip |
| TRAMADOL HCL | Rybix ODT |
| TRAMADOL HCL/ACETAMINOPHEN | Ultracef |
| TRAMADOL HCL/ACETAMINOPHEN | tramadol-acetaminophen |
| TRAMADOL HCL/DIETARY SUPPLEMENT,MISC. CB.11 | Theratramadol-60 |
| TRAMADOL HCL/DIETARY SUPPLEMENT,MISC. CB.11 | Theratramadol-90 |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| | Cancer | |
| 140 | MALIGNANT NEOPLASM OF LIP | ICD-9-CM Diagnosis |
| 140.0 | MAL NEOPLSM UP LIP VERMILION BORDR | ICD-9-CM Diagnosis |
| 140.1 | MAL NEOPLSM LW LIP VERMILION BORDR | ICD-9-CM Diagnosis |
| 140.3 | MALIG NEOPLSM UPPER LIP INNR ASPECT | ICD-9-CM Diagnosis |
| 140.4 | MALIG NEOPLASM LOW LIP INNR ASPECT | ICD-9-CM Diagnosis |
| 140.5 | MAL NEO LIP INNR ASPECT UNS UP/LW | ICD-9-CM Diagnosis |
| 140.6 | MALIGNANT NEOPLASM COMMISSURE LIP | ICD-9-CM Diagnosis |
| 140.8 | MALIGNANT NEOPLASM OTHER SITES LIP | ICD-9-CM Diagnosis |
| 140.9 | MAL NEOPLSM LIP VERMIL UNS UP/LW | ICD-9-CM Diagnosis |
| 141 | MALIGNANT NEOPLASM OF TONGUE | ICD-9-CM Diagnosis |
| 141.0 | MALIGNANT NEOPLASM BASE TONGUE | ICD-9-CM Diagnosis |
| 141.1 | MALIG NEOPLASM DORS SURFACE TONGUE | ICD-9-CM Diagnosis |
| 141.2 | MALIG NEOPLSM TIP&LAT BORDER TONGUE | ICD-9-CM Diagnosis |
| 141.3 | MALIG NEOPLSM VENTRAL SURFCE TONGUE | ICD-9-CM Diagnosis |
| 141.4 | MAL NEOPLSM ANT 2/3 TONGUE PART UNS | ICD-9-CM Diagnosis |
| 141.5 | MALIG NEOPLASM JUNC ZONE TONGUE | ICD-9-CM Diagnosis |
| 141.6 | MALIGNANT NEOPLASM LINGUAL TONSIL | ICD-9-CM Diagnosis |
| 141.8 | MALIG NEOPLASM OTHER SITES TONGUE | ICD-9-CM Diagnosis |
| 141.9 | MALIG NEOPLASM TONGUE UNSPEC SITE | ICD-9-CM Diagnosis |
| 142 | MALIG NEOPLASM MAJOR SALIV GLANDS | ICD-9-CM Diagnosis |
| 142.0 | MALIGNANT NEOPLASM OF PAROTID GLAND | ICD-9-CM Diagnosis |
| 142.1 | MALIG NEOPLASM SUBMANDIBULAR GLAND | ICD-9-CM Diagnosis |
| 142.2 | MALIGNANT NEOPLASM SUBLINGUAL GLAND | ICD-9-CM Diagnosis |
| 142.8 | MALIG NEOPLASM OTH MAJ SALIV GLANDS | ICD-9-CM Diagnosis |
| 142.9 | MALIG NEOPLASM SALIV GLAND UNSPEC | ICD-9-CM Diagnosis |
| 143 | MALIGNANT NEOPLASM OF GUM | ICD-9-CM Diagnosis |
| 143.0 | MALIGNANT NEOPLASM OF UPPER GUM | ICD-9-CM Diagnosis |
| 143.1 | MALIGNANT NEOPLASM OF LOWER GUM | ICD-9-CM Diagnosis |
| 143.8 | MALIGNANT NEOPLASM OTHER SITES GUM | ICD-9-CM Diagnosis |
| 143.9 | MALIGNANT NEOPLASM GUM UNSPEC SITE | ICD-9-CM Diagnosis |
| 144 | MALIGNANT NEOPLASM FLOOR MOUTH | ICD-9-CM Diagnosis |
| 144.0 | MALIG NEOPLASM ANT PRTN FLOOR MOUTH | ICD-9-CM Diagnosis |
| 144.1 | MALIG NEOPLASM LAT PRTN FLR MOUTH | ICD-9-CM Diagnosis |
| 144.8 | MALIG NEOPLASM OTH SITES FLR MOUTH | ICD-9-CM Diagnosis |
| 144.9 | MALIG NEOPLSM FLR MOUTH PART UNSPEC | ICD-9-CM Diagnosis |
| 145 | MALIG NEOPLSM OTH&UNSPEC PART MOUTH | ICD-9-CM Diagnosis |
| 145.0 | MALIGNANT NEOPLASM OF CHEEK MUCOSA | ICD-9-CM Diagnosis |
| 145.1 | MALIGNANT NEOPLASM VESTIBULE MOUTH | ICD-9-CM Diagnosis |
| 145.2 | MALIGNANT NEOPLASM OF HARD PALATE | ICD-9-CM Diagnosis |
| 145.3 | MALIGNANT NEOPLASM OF SOFT PALATE | ICD-9-CM Diagnosis |
| 145.4 | MALIGNANT NEOPLASM OF UVULA | ICD-9-CM Diagnosis |
| 145.5 | MALIGNANT NEOPLASM PALATE UNSPEC | ICD-9-CM Diagnosis |
| 145.6 | MALIGNANT NEOPLASM RETROMOLAR AREA | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 145.8 | MALIG NEOPLASM OTH SPEC PARTS MOUTH | ICD-9-CM Diagnosis |
| 145.9 | MALIG NEOPLASM MOUTH UNSPEC SITE | ICD-9-CM Diagnosis |
| 146 | MALIGNANT NEOPLASM OF OROPHARYNX | ICD-9-CM Diagnosis |
| 146.0 | MALIGNANT NEOPLASM OF TONSIL | ICD-9-CM Diagnosis |
| 146.1 | MALIGNANT NEOPLASM TONSILLAR FOSSA | ICD-9-CM Diagnosis |
| 146.2 | MALIG NEOPLASM TONSILLAR PILLARS | ICD-9-CM Diagnosis |
| 146.3 | MALIGNANT NEOPLASM OF VALLECUA | ICD-9-CM Diagnosis |
| 146.4 | MALIG NEOPLSM ANT ASPECT EPIGLOTTIS | ICD-9-CM Diagnosis |
| 146.5 | MALIG NEOPLSM JUNC RGN OROPHARYNX | ICD-9-CM Diagnosis |
| 146.6 | MALIG NEOPLASM LAT WALL OROPHARYNX | ICD-9-CM Diagnosis |
| 146.7 | MALIG NEOPLASM POST WALL OROPHARYNX | ICD-9-CM Diagnosis |
| 146.8 | MAL NEO OTH SPEC SITE OROPHARYNX | ICD-9-CM Diagnosis |
| 146.9 | MALIG NEOPLSM OROPHARYNX UNS SITE | ICD-9-CM Diagnosis |
| 147 | MALIGNANT NEOPLASM OF NASOPHARYNX | ICD-9-CM Diagnosis |
| 147.0 | MALIG NEOPLASM SUP WALL NASOPHARYNX | ICD-9-CM Diagnosis |
| 147.1 | MALIG NEOPLSM POST WALL NASOPHARYNX | ICD-9-CM Diagnosis |
| 147.2 | MALIG NEOPLASM LAT WALL NASOPHARYNX | ICD-9-CM Diagnosis |
| 147.3 | MALIG NEOPLASM ANT WALL NASOPHARYNX | ICD-9-CM Diagnosis |
| 147.8 | MAL NEO OTH SPEC SITE NASOPHARYNX | ICD-9-CM Diagnosis |
| 147.9 | MALIG NEOPLSM NASOPHARYNX UNS SITE | ICD-9-CM Diagnosis |
| 148 | MALIGNANT NEOPLASM OF HYPOPHARYNX | ICD-9-CM Diagnosis |
| 148.0 | MAL NEO POSTCRICOID RGN HYPOPHARYNX | ICD-9-CM Diagnosis |
| 148.1 | MALIGNANT NEOPLASM PYRIFORM SINUS | ICD-9-CM Diagnosis |
| 148.2 | MALIG NEOPLSM ARYEPIGLOTTIC FOLD | ICD-9-CM Diagnosis |
| 148.3 | MAL NEO POST HYPOPHARYNGEAL WALL | ICD-9-CM Diagnosis |
| 148.8 | MAL NEO OTH SPEC SITE HYPOPHARYNX | ICD-9-CM Diagnosis |
| 148.9 | MALIG NEOPLSM HYPOPHARYNX UNS SITE | ICD-9-CM Diagnosis |
| 149 | OTH MALIG NEO LIP-MOUTH-PHARYNX | ICD-9-CM Diagnosis |
| 149.0 | MALIGNANT NEOPLASM PHARYNX UNSPEC | ICD-9-CM Diagnosis |
| 149.1 | MALIGNANT NEOPLASM WALDEYERS RING | ICD-9-CM Diagnosis |
| 149.8 | MAL NEO OTH SITE WITHIN LIP&ORL CAV | ICD-9-CM Diagnosis |
| 149.9 | MAL NEO ILL-DEFIND SITE LIP&ORL CAV | ICD-9-CM Diagnosis |
| 150 | MALIGNANT NEOPLASM OF ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.0 | MALIG NEOPLASM CERVICAL ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.1 | MALIG NEOPLASM THORACIC ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.2 | MALIG NEOPLASM ABDOMINAL ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.3 | MALIG NEOPLASM UPPER1/3ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.4 | MALIG NEOPLASM MIDDLE1/3ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.5 | MALIG NEOPLASM LOWER1/3ESOPHAGUS | ICD-9-CM Diagnosis |
| 150.8 | MALIG NEOPLASM OTH SPEC PART ESOPH | ICD-9-CM Diagnosis |
| 150.9 | MALIG NEOPLASM ESOPH UNSPEC SITE | ICD-9-CM Diagnosis |
| 151 | MALIGNANT NEOPLASM OF STOMACH | ICD-9-CM Diagnosis |
| 151.0 | MALIGNANT NEOPLASM OF CARDIA | ICD-9-CM Diagnosis |
| 151.1 | MALIGNANT NEOPLASM OF PYLORUS | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 151.2 | MALIGNANT NEOPLASM PYLORIC ANTRUM | ICD-9-CM Diagnosis |
| 151.3 | MALIGNANT NEOPLASM FUNDUS STOMACH | ICD-9-CM Diagnosis |
| 151.4 | MALIGNANT NEOPLASM BODY STOMACH | ICD-9-CM Diagnosis |
| 151.5 | MALIG NEOPLSM LESR CURV STOMACH UNS | ICD-9-CM Diagnosis |
| 151.6 | MALIG NEOPLSM GT CURV STOMACH UNS | ICD-9-CM Diagnosis |
| 151.8 | MALIG NEOPLSM OTH SPEC SITE STOMACH | ICD-9-CM Diagnosis |
| 151.9 | MALIG NEOPLASM STOMACH UNSPEC SITE | ICD-9-CM Diagnosis |
| 152 | MALIG NEOPLSM SM INTEST INCL DUODUM | ICD-9-CM Diagnosis |
| 152.0 | MALIGNANT NEOPLASM OF DUODENUM | ICD-9-CM Diagnosis |
| 152.1 | MALIGNANT NEOPLASM OF JEJUNUM | ICD-9-CM Diagnosis |
| 152.2 | MALIGNANT NEOPLASM OF ILEUM | ICD-9-CM Diagnosis |
| 152.3 | MALIG NEOPLASM MECKELS DIVERTICULUM | ICD-9-CM Diagnosis |
| 152.8 | MAL NEOPLSM OTH SPEC SITE SM INTEST | ICD-9-CM Diagnosis |
| 152.9 | MALIG NEOPLSM SM INTEST UNSPEC SITE | ICD-9-CM Diagnosis |
| 153 | MALIGNANT NEOPLASM OF COLON | ICD-9-CM Diagnosis |
| 153.0 | MALIGNANT NEOPLASM HEPATIC FLEXURE | ICD-9-CM Diagnosis |
| 153.1 | MALIGNANT NEOPLASM TRANSVERSE COLON | ICD-9-CM Diagnosis |
| 153.2 | MALIGNANT NEOPLASM DESCENDING COLON | ICD-9-CM Diagnosis |
| 153.3 | MALIGNANT NEOPLASM OF SIGMOID COLON | ICD-9-CM Diagnosis |
| 153.4 | MALIGNANT NEOPLASM OF CECUM | ICD-9-CM Diagnosis |
| 153.5 | MALIGNANT NEOPLASM OF APPENDIX | ICD-9-CM Diagnosis |
| 153.6 | MALIGNANT NEOPLASM ASCENDING COLON | ICD-9-CM Diagnosis |
| 153.7 | MALIGNANT NEOPLASM SPLENIC FLEXURE | ICD-9-CM Diagnosis |
| 153.8 | MAL NEOPLSM OTH SPEC SITE LG INTEST | ICD-9-CM Diagnosis |
| 153.9 | MALIG NEOPLASM COLON UNSPEC SITE | ICD-9-CM Diagnosis |
| 154 | MAL NEO RECT RECTOSIGMOID JUNC&ANUS | ICD-9-CM Diagnosis |
| 154.0 | MALIG NEOPLASM RECTOSIGMOID JUNC | ICD-9-CM Diagnosis |
| 154.1 | MALIGNANT NEOPLASM OF RECTUM | ICD-9-CM Diagnosis |
| 154.2 | MALIGNANT NEOPLASM OF ANAL CANAL | ICD-9-CM Diagnosis |
| 154.3 | MALIGNANT NEOPLASM ANUS UNSPEC SITE | ICD-9-CM Diagnosis |
| 154.8 | MAL NEO OTH SITE RECTM/SIG/ANUS | ICD-9-CM Diagnosis |
| 155 | MALIG NEOPLASM LIVER&INTRAHEP BDS | ICD-9-CM Diagnosis |
| 155.0 | MALIGNANT NEOPLASM OF LIVER PRIMARY | ICD-9-CM Diagnosis |
| 155.1 | MALIGNANT NEOPLASM INTRAHEPATIC BDS | ICD-9-CM Diagnosis |
| 155.2 | MAL NEOPLSM LIVR NOT SPEC PRIM/SEC | ICD-9-CM Diagnosis |
| 156 | MALIG NEOPLSM GALLBLADD&XTRAHEP BDS | ICD-9-CM Diagnosis |
| 156.0 | MALIGNANT NEOPLASM OF GALLBLADDER | ICD-9-CM Diagnosis |
| 156.1 | MALIGNANT NEOPLASM EXTRAHEPATIC BDS | ICD-9-CM Diagnosis |
| 156.2 | MALIGNANT NEOPLASM AMPULLA VATER | ICD-9-CM Diagnosis |
| 156.8 | MAL NEO OTH SITE GB&XTRAHEP BDS | ICD-9-CM Diagnosis |
| 156.9 | MAL NEO BILI TRACT PART UNS SITE | ICD-9-CM Diagnosis |
| 157 | MALIGNANT NEOPLASM OF PANCREAS | ICD-9-CM Diagnosis |
| 157.0 | MALIGNANT NEOPLASM HEAD PANCREAS | ICD-9-CM Diagnosis |
| 157.1 | MALIGNANT NEOPLASM BODY PANCREAS | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 157.2 | MALIGNANT NEOPLASM TAIL PANCREAS | ICD-9-CM Diagnosis |
| 157.3 | MALIGNANT NEOPLASM PANCREATIC DUCT | ICD-9-CM Diagnosis |
| 157.4 | MALIG NEOPLASM ISLETS LANGERHANS | ICD-9-CM Diagnosis |
| 157.8 | MALIG NEOPLASM OTH SPEC SITES PANC | ICD-9-CM Diagnosis |
| 157.9 | MALIG NEOPLASM PANCREAS PART UNSPEC | ICD-9-CM Diagnosis |
| 158 | MALIG NEOPLASM RETROPERITON&PERITON | ICD-9-CM Diagnosis |
| 158.0 | MALIGNANT NEOPLASM RETROPERITONEUM | ICD-9-CM Diagnosis |
| 158.8 | MALIG NEOPLASM SPEC PARTS PERITON | ICD-9-CM Diagnosis |
| 158.9 | MALIG NEOPLASM PERITONEUM UNSPEC | ICD-9-CM Diagnosis |
| 159 | MAL NEO DIGES ORGANS&PANCREAS OTH | ICD-9-CM Diagnosis |
| 159.0 | MALIG NEOPLSM INTST TRACT PART UNS | ICD-9-CM Diagnosis |
| 159.1 | MALIGNANT NEOPLASM OF SPLEEN NEC | ICD-9-CM Diagnosis |
| 159.8 | MAL NEO OTH DIGESTV SYS&INTRA-ABD | ICD-9-CM Diagnosis |
| 159.9 | MAL NEO ILL-DEFIND DIGESTV&PERITON | ICD-9-CM Diagnosis |
| 160 | MAL NEO NASL CAV/MID EAR&ACSS SINUS | ICD-9-CM Diagnosis |
| 160.0 | MALIGNANT NEOPLASM NASAL CAVITIES | ICD-9-CM Diagnosis |
| 160.1 | MALIG NEO AUD TUBE-MID EAR&MASTOID | ICD-9-CM Diagnosis |
| 160.2 | MALIGNANT NEOPLASM MAXILLARY SINUS | ICD-9-CM Diagnosis |
| 160.3 | MALIGNANT NEOPLASM ETHMOIDAL SINUS | ICD-9-CM Diagnosis |
| 160.4 | MALIGNANT NEOPLASM OF FRONTAL SINUS | ICD-9-CM Diagnosis |
| 160.5 | MALIGNANT NEOPLASM SPHENOIDAL SINUS | ICD-9-CM Diagnosis |
| 160.8 | MAL NEO OTH SITE NASL-MID EAR&SINUS | ICD-9-CM Diagnosis |
| 160.9 | MAL NEO NASL CAV MID EAR SINUS UNS | ICD-9-CM Diagnosis |
| 161 | MALIGNANT NEOPLASM OF LARYNX | ICD-9-CM Diagnosis |
| 161.0 | MALIGNANT NEOPLASM OF GLOTTIS | ICD-9-CM Diagnosis |
| 161.1 | MALIGNANT NEOPLASM OF SUPRAGLOTTIS | ICD-9-CM Diagnosis |
| 161.2 | MALIGNANT NEOPLASM OF SUBGLOTTIS | ICD-9-CM Diagnosis |
| 161.3 | MALIG NEOPLASM LARYNGEAL CARTILAGES | ICD-9-CM Diagnosis |
| 161.8 | MALIG NEOPLSM OTH SPEC SITES LARYNX | ICD-9-CM Diagnosis |
| 161.9 | MALIG NEOPLASM LARYNX UNSPEC SITE | ICD-9-CM Diagnosis |
| 162 | MALIG NEOPLASM TRACH BRONCHUS&LUNG | ICD-9-CM Diagnosis |
| 162.0 | MALIGNANT NEOPLASM OF TRACHEA | ICD-9-CM Diagnosis |
| 162.2 | MALIGNANT NEOPLASM OF MAIN BRONCHUS | ICD-9-CM Diagnosis |
| 162.3 | MALIG NEOPLSM UP LOBE BRONCHUS/LUNG | ICD-9-CM Diagnosis |
| 162.4 | MAL NEOPLSM MID LOBE BRONCHUS/LUNG | ICD-9-CM Diagnosis |
| 162.5 | MALIG NEOPLSM LW LOBE BRONCHUS/LUNG | ICD-9-CM Diagnosis |
| 162.8 | MAL NEOPLSM OTH PART BRONCHUS/LUNG | ICD-9-CM Diagnosis |
| 162.9 | MAL NEOPLSM BRONCHUS&LUNG UNS SITE | ICD-9-CM Diagnosis |
| 163 | MALIGNANT NEOPLASM OF PLEURA | ICD-9-CM Diagnosis |
| 163.0 | MALIGNANT NEOPLASM PARIETAL PLEURA | ICD-9-CM Diagnosis |
| 163.1 | MALIGNANT NEOPLASM VISCERAL PLEURA | ICD-9-CM Diagnosis |
| 163.8 | MALIG NEOPLASM OTH SPEC SITES PLEU | ICD-9-CM Diagnosis |
| 163.9 | MALIG NEOPLASM PLEURA UNSPEC SITE | ICD-9-CM Diagnosis |
| 164 | MALIG NEOPLASM THYMUS HEART&MEDIAST | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 164.0 | MALIGNANT NEOPLASM OF THYMUS | ICD-9-CM Diagnosis |
| 164.1 | MALIGNANT NEOPLASM OF HEART | ICD-9-CM Diagnosis |
| 164.2 | MALIG NEOPLASM ANTERIOR MEDIASTINUM | ICD-9-CM Diagnosis |
| 164.3 | MALIG NEOPLASM POSTERIOR MEDIAST | ICD-9-CM Diagnosis |
| 164.8 | MALIG NEOPLASM OTH PARTS MEDIAST | ICD-9-CM Diagnosis |
| 164.9 | MALIG NEOPLASM MEDIAST PART UNSPEC | ICD-9-CM Diagnosis |
| 165 | MAL NEO RESP&THOR ORGANS OTH | ICD-9-CM Diagnosis |
| 165.0 | MAL NEOPLSM UP RESP TRACT PART UNS | ICD-9-CM Diagnosis |
| 165.8 | MAL NEO OTH W/IN RESP/THORAX | ICD-9-CM Diagnosis |
| 165.9 | MALIG NEO ILL-DEF W/IN RESP SYS | ICD-9-CM Diagnosis |
| 170 | MALIG NEOPLASM BONE&ARTICLR CART | ICD-9-CM Diagnosis |
| 170.0 | MALIG NEOPLSM BNS SKULL&FCE NO MAND | ICD-9-CM Diagnosis |
| 170.1 | MALIGNANT NEOPLASM OF MANDIBLE | ICD-9-CM Diagnosis |
| 170.2 | MAL NEO VERT COLMN NOT SACRM&COCCYX | ICD-9-CM Diagnosis |
| 170.3 | MALIG NEOPLASM RIBS STERNUM&CLAV | ICD-9-CM Diagnosis |
| 170.4 | MALIG NEOPLSM SCAP&LNG BNS UP LIMB | ICD-9-CM Diagnosis |
| 170.5 | MALIG NEOPLASM SHORT BNS UPPER LIMB | ICD-9-CM Diagnosis |
| 170.6 | MAL NEOPLSM PELV BNS SACRUM&COCCYX | ICD-9-CM Diagnosis |
| 170.7 | MALIG NEOPLASM LONG BNS LOWER LIMB | ICD-9-CM Diagnosis |
| 170.8 | MALIG NEOPLASM SHORT BNS LOWER LIMB | ICD-9-CM Diagnosis |
| 170.9 | MAL NEO BN&ARTICLR CART SITE UNS | ICD-9-CM Diagnosis |
| 171 | MALIG NEOPLSM CNCTV&OTH SOFT TISSUE | ICD-9-CM Diagnosis |
| 171.0 | MAL NEO CNCTV&OTH SFT TISS HEAD&NCK | ICD-9-CM Diagnosis |
| 171.2 | MAL NEO SFT TISS UP LIMB W/SHLD | ICD-9-CM Diagnosis |
| 171.3 | MAL NEO OTH SFT TISS LW LIMB W/HIP | ICD-9-CM Diagnosis |
| 171.4 | MAL NEOPLSM CNCTV&OTH SFT TISS THOR | ICD-9-CM Diagnosis |
| 171.5 | MALIG NEOPLSM CNCTV&SFT TISS ABD | ICD-9-CM Diagnosis |
| 171.6 | MAL NEOPLSM CNCTV&OTH SFT TISS PELV | ICD-9-CM Diagnosis |
| 171.7 | MAL NEO CNCTV&OTH SFT TISS TRNK | ICD-9-CM Diagnosis |
| 171.8 | MAL NEO OTH SITE CNCTV&OTH SFT TISS | ICD-9-CM Diagnosis |
| 171.9 | MAL NEO CNCTV&OTH SFT TISS SITE UNS | ICD-9-CM Diagnosis |
| 172 | MALIGNANT MELANOMA OF SKIN | ICD-9-CM Diagnosis |
| 172.0 | MALIGNANT MELANOMA OF SKIN OF LIP | ICD-9-CM Diagnosis |
| 172.1 | MALIG MELANOMA SKN EYELD W/CANTHUS | ICD-9-CM Diagnosis |
| 172.2 | MAL MELNOMA EAR&XTRNL AUDITRY CANL | ICD-9-CM Diagnosis |
| 172.3 | MALIG MELANOMA SKN OTH&UNS PART FCE | ICD-9-CM Diagnosis |
| 172.4 | MALIGNANT MELANOMA SKIN SCALP&NECK | ICD-9-CM Diagnosis |
| 172.5 | MALIG MELANOMA SKIN TRNK NO SCROTUM | ICD-9-CM Diagnosis |
| 172.6 | MALIG MELANOMA SKN UP LIMB W/SHLD | ICD-9-CM Diagnosis |
| 172.7 | MALIG MELANOMA SKN LOW LIMB W/HIP | ICD-9-CM Diagnosis |
| 172.8 | MALIG MELANOMA OTH SPEC SITES SKIN | ICD-9-CM Diagnosis |
| 172.9 | MELANOMA OF SKIN, SITE UNSPECIFIED | ICD-9-CM Diagnosis |
| 173 | OTHER & UNS MALIGNANT NEOPLASM SKIN | ICD-9-CM Diagnosis |
| 173.0 | OTHER UNS MALIG NEOPLASM SKIN LIP | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 173.00 | UNS MALIGNANT NEOPLASM SKIN LIP | ICD-9-CM Diagnosis |
| 173.01 | BASAL CELL CARCINOMA OF SKIN OF LIP | ICD-9-CM Diagnosis |
| 173.02 | SQUAMOUS CELL CARCINOMA SKIN OF LIP | ICD-9-CM Diagnosis |
| 173.09 | OTHER SPEC MALIG NEOPLASM SKIN LIP | ICD-9-CM Diagnosis |
| 173.1 | OTH UNS MAL NEOPLSM EYELD W/CANTHUS | ICD-9-CM Diagnosis |
| 173.10 | UNS MALIG NEOPLSM EYELID W/CANTHUS | ICD-9-CM Diagnosis |
| 173.11 | BASAL CELL CA EYELID INCL CANTHUS | ICD-9-CM Diagnosis |
| 173.12 | SQAUM CELL CA EYELID INCL CANTHUS | ICD-9-CM Diagnosis |
| 173.19 | OTH SPEC MAL NEO EYELD W/CANTHUS | ICD-9-CM Diagnosis |
| 173.2 | OTH UNS MAL NEO EAR EXT AUD CANAL | ICD-9-CM Diagnosis |
| 173.20 | UNS MAL NEO SKN EAR EXT AUD CANAL | ICD-9-CM Diagnosis |
| 173.21 | BASAL CELL CA SKN EAR EXT AUD CANAL | ICD-9-CM Diagnosis |
| 173.22 | SQ CELL CA SKIN EAR EXT AUD CANAL | ICD-9-CM Diagnosis |
| 173.29 | OTH MAL NEO SKIN EAR EXT AUD CANAL | ICD-9-CM Diagnosis |
| 173.3 | OTH MAL NEO SKIN OTH&UNS PART FACE | ICD-9-CM Diagnosis |
| 173.30 | UNS MAL NEO SKIN OTH UNS PART FACE | ICD-9-CM Diagnosis |
| 173.31 | BASAL CELL CA SKN OTH UNS PART FACE | ICD-9-CM Diagnosis |
| 173.32 | SQ CELL CA SKIN OTH UNS PARTS FACE | ICD-9-CM Diagnosis |
| 173.39 | OTH MAL NEO SKIN OTH UNS PART FACE | ICD-9-CM Diagnosis |
| 173.4 | OTH MALIG NEOPLASM SCALP SKIN NECK | ICD-9-CM Diagnosis |
| 173.40 | UNS MALIG NEOPLASM SCALP SKIN NECK | ICD-9-CM Diagnosis |
| 173.41 | BASAL CELL CA SCALP SKIN NECK | ICD-9-CM Diagnosis |
| 173.42 | SQUAMOUS CELL CA SCALP SKIN NECK | ICD-9-CM Diagnosis |
| 173.49 | OTH SPEC MALIG NEO SCALP SKIN NECK | ICD-9-CM Diagnosis |
| 173.5 | OTH MAL NEO SKIN TRUNK NO SCROTUM | ICD-9-CM Diagnosis |
| 173.50 | UNS MAL NEO SKIN TRUNK NO SCROTUM | ICD-9-CM Diagnosis |
| 173.51 | BASAL CELL CA SKIN TRUNK NO SCROTUM | ICD-9-CM Diagnosis |
| 173.52 | SQ CELL CA SKIN TRUNK NO SCROTUM | ICD-9-CM Diagnosis |
| 173.59 | OTH MAL NEO SKIN TRUNK NO SCROTUM | ICD-9-CM Diagnosis |
| 173.6 | OTH MAL NEO SKIN UP LIMB W/SHOULDER | ICD-9-CM Diagnosis |
| 173.60 | UNS MAL NEO SKIN UP LIMB W/SHOULDER | ICD-9-CM Diagnosis |
| 173.61 | BASL CELL CA SKN UP LIMB INCL SHLDR | ICD-9-CM Diagnosis |
| 173.62 | SQ CELL CA SKIN UP LIMB INCL SHLDR | ICD-9-CM Diagnosis |
| 173.69 | OTH MAL NEO SKIN UP LIMB W/SHLOUDER | ICD-9-CM Diagnosis |
| 173.7 | OTH MALIG NEO SKIN LW LIMB W/HIP | ICD-9-CM Diagnosis |
| 173.70 | UNS MALIG NEO SKIN LW LIMB W/HIP | ICD-9-CM Diagnosis |
| 173.71 | BASAL CELL CA SKIN LW LIMB INCL HIP | ICD-9-CM Diagnosis |
| 173.72 | SQ CELL CA SKIN LOW LIMB INCL HIP | ICD-9-CM Diagnosis |
| 173.79 | OTH SPEC MAL NEO SKN LW LIMB W/HIP | ICD-9-CM Diagnosis |
| 173.8 | OTH MALIG NEO OTH SPEC SITE SKIN | ICD-9-CM Diagnosis |
| 173.80 | UNS MALIG NEO OTH SPEC SITE SKIN | ICD-9-CM Diagnosis |
| 173.81 | BASAL CELL CA OTH SPEC SITES SKIN | ICD-9-CM Diagnosis |
| 173.82 | SQ CELL CA OTH SPEC SITES SKIN | ICD-9-CM Diagnosis |
| 173.89 | OTH SPEC MAL NEO OTH SPEC SITE SKN | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 173.9 | OTH UNS MALIG NEOPLSM SKIN SITE UNS | ICD-9-CM Diagnosis |
| 173.90 | UNS MALIG NEOPLASM SKIN SITE UNS | ICD-9-CM Diagnosis |
| 173.91 | BASAL CELL CARCINOMA SKIN SITE UNS | ICD-9-CM Diagnosis |
| 173.92 | SQUAMOUS CELL CA SKIN SITE UNS | ICD-9-CM Diagnosis |
| 173.99 | OTH SPEC MALIG NEOPLSM SKN SITE UNS | ICD-9-CM Diagnosis |
| 174 | MALIGNANT NEOPLASM OF FEMALE BREAST | ICD-9-CM Diagnosis |
| 174.0 | MALIG NEOPLSM NIPPLE&AREOLA FE BRST | ICD-9-CM Diagnosis |
| 174.1 | MALIG NEOPLASM CNTRL PRTN FE BREAST | ICD-9-CM Diagnosis |
| 174.2 | MALIG NEOPLSM UP-INNR QUAD FE BRST | ICD-9-CM Diagnosis |
| 174.3 | MALIG NEOPLSM LOW-INNR QUAD FE BRST | ICD-9-CM Diagnosis |
| 174.4 | MALIG NEOPLSM UP-OUTER QUAD FE BRST | ICD-9-CM Diagnosis |
| 174.5 | MALIG NEOPLSM LW-OUTER QUAD FE BRST | ICD-9-CM Diagnosis |
| 174.6 | MALIG NEOPLASM AX TAIL FE BREAST | ICD-9-CM Diagnosis |
| 174.8 | MALIG NEOPLSM OTH SPEC SITE FE BRST | ICD-9-CM Diagnosis |
| 174.9 | MALIG NEOPLASM BREAST UNSPEC SITE | ICD-9-CM Diagnosis |
| 175 | MALIGNANT NEOPLASM OF MALE BREAST | ICD-9-CM Diagnosis |
| 175.0 | MAL NEOPLSM NIPPLE&AREOLA MALE BRST | ICD-9-CM Diagnosis |
| 175.9 | MAL NEOPLSM OTH&UNS SITE MALE BRST | ICD-9-CM Diagnosis |
| 176 | KAPOSIS SARCOMA | ICD-9-CM Diagnosis |
| 176.0 | KAPOSIS SARCOMA OF SKIN | ICD-9-CM Diagnosis |
| 176.1 | KAPOSIS SARCOMA OF SOFT TISSUE | ICD-9-CM Diagnosis |
| 176.2 | KAPOSIS SARCOMA OF PALATE | ICD-9-CM Diagnosis |
| 176.3 | KAPOSIS SARCOMA GI SITES | ICD-9-CM Diagnosis |
| 176.4 | KAPOSIS SARCOMA OF LUNG | ICD-9-CM Diagnosis |
| 176.5 | KAPOSIS SARCOMA OF LYMPH NODES | ICD-9-CM Diagnosis |
| 176.8 | KAPOSIS SARCOMA OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 176.9 | KAPOSIS SARCOMA OF UNSPECIFIED SITE | ICD-9-CM Diagnosis |
| 179 | MALIG NEOPLASM UTERUS PART UNSPEC | ICD-9-CM Diagnosis |
| 180 | MALIGNANT NEOPLASM OF CERVIX UTERI | ICD-9-CM Diagnosis |
| 180.0 | MALIGNANT NEOPLASM OF ENDOCERVIX | ICD-9-CM Diagnosis |
| 180.1 | MALIGNANT NEOPLASM OF EXOCERVIX | ICD-9-CM Diagnosis |
| 180.8 | MALIG NEOPLASM OTH SPEC SITES CERV | ICD-9-CM Diagnosis |
| 180.9 | MALIG NEOPLSM CERV UTERI UNS SITE | ICD-9-CM Diagnosis |
| 181 | MALIGNANT NEOPLASM OF PLACENTA | ICD-9-CM Diagnosis |
| 182 | MALIGNANT NEOPLASM BODY UTERUS | ICD-9-CM Diagnosis |
| 182.0 | MAL NEOPLSM CORPUS UTERI NO ISTMUS | ICD-9-CM Diagnosis |
| 182.1 | MALIGNANT NEOPLASM OF ISTMUS | ICD-9-CM Diagnosis |
| 182.8 | MAL NEOPLSM OTH SPEC SITE BDY UTRUS | ICD-9-CM Diagnosis |
| 183 | MALIG NEOPLSM OVRY&OTH UTERN ADNEXA | ICD-9-CM Diagnosis |
| 183.0 | MALIGNANT NEOPLASM OF OVARY | ICD-9-CM Diagnosis |
| 183.2 | MALIGNANT NEOPLASM FALLOPIAN TUBE | ICD-9-CM Diagnosis |
| 183.3 | MALIG NEOPLASM BROAD LIG UTERUS | ICD-9-CM Diagnosis |
| 183.4 | MALIG NEOPLASM PARAMETRIUM UTERUS | ICD-9-CM Diagnosis |
| 183.5 | MALIG NEOPLASM ROUND LIG UTERUS | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 183.8 | MAL NEO OTH SPEC SITE UTERN ADNEXA | ICD-9-CM Diagnosis |
| 183.9 | MALIG NEOPLSM UTERN ADNEXA UNS SITE | ICD-9-CM Diagnosis |
| 184 | MALIG NEOPLSM OTH&UNS FE GENIT ORGN | ICD-9-CM Diagnosis |
| 184.0 | MALIGNANT NEOPLASM OF VAGINA | ICD-9-CM Diagnosis |
| 184.1 | MALIGNANT NEOPLASM OF LABIA MAJORA | ICD-9-CM Diagnosis |
| 184.2 | MALIGNANT NEOPLASM OF LABIA MINORA | ICD-9-CM Diagnosis |
| 184.3 | MALIGNANT NEOPLASM OF CLITORIS | ICD-9-CM Diagnosis |
| 184.4 | MALIG NEOPLASM VULVA UNSPEC SITE | ICD-9-CM Diagnosis |
| 184.8 | MAL NEO OTH SPEC SITE FE GNT ORGN | ICD-9-CM Diagnosis |
| 184.9 | MALIG NEOPLSM FE GNT ORGN SITE UNS | ICD-9-CM Diagnosis |
| 185 | MALIGNANT NEOPLASM OF PROSTATE | ICD-9-CM Diagnosis |
| 186 | MALIGNANT NEOPLASM OF TESTIS | ICD-9-CM Diagnosis |
| 186.0 | MALIG NEOPLASM UNDESCENDED TESTIS | ICD-9-CM Diagnosis |
| 186.9 | MALIG NEOPLASM OTHER&UNSPEC TESTIS | ICD-9-CM Diagnosis |
| 187 | MAL NEOPLSM PENIS&OTH MALE GNT ORGN | ICD-9-CM Diagnosis |
| 187.1 | MALIGNANT NEOPLASM OF PREPUCE | ICD-9-CM Diagnosis |
| 187.2 | MALIGNANT NEOPLASM OF GLANS PENIS | ICD-9-CM Diagnosis |
| 187.3 | MALIGNANT NEOPLASM OF BODY OF PENIS | ICD-9-CM Diagnosis |
| 187.4 | MALIG NEOPLASM PENIS PART UNSPEC | ICD-9-CM Diagnosis |
| 187.5 | MALIGNANT NEOPLASM OF EPIDIDYMIS | ICD-9-CM Diagnosis |
| 187.6 | MALIGNANT NEOPLASM SPERMATIC CORD | ICD-9-CM Diagnosis |
| 187.7 | MALIGNANT NEOPLASM OF SCROTUM | ICD-9-CM Diagnosis |
| 187.8 | MAL NEO OTH SPEC SITE MALE GNT ORGN | ICD-9-CM Diagnosis |
| 187.9 | MAL NEOPLSM MALE GNT ORGN SITE UNS | ICD-9-CM Diagnosis |
| 188 | MALIGNANT NEOPLASM OF BLADDER | ICD-9-CM Diagnosis |
| 188.0 | MALIG NEOPLASM TRIGONE URIN BLADD | ICD-9-CM Diagnosis |
| 188.1 | MALIG NEOPLASM DOME URINARY BLADDER | ICD-9-CM Diagnosis |
| 188.2 | MALIG NEOPLASM LAT WALL URIN BLADD | ICD-9-CM Diagnosis |
| 188.3 | MALIG NEOPLASM ANT WALL URIN BLADD | ICD-9-CM Diagnosis |
| 188.4 | MALIG NEOPLASM POST WALL URIN BLADD | ICD-9-CM Diagnosis |
| 188.5 | MALIGNANT NEOPLASM OF BLADDER NECK | ICD-9-CM Diagnosis |
| 188.6 | MALIGNANT NEOPLASM URETERIC ORIFICE | ICD-9-CM Diagnosis |
| 188.7 | MALIGNANT NEOPLASM OF URACHUS | ICD-9-CM Diagnosis |
| 188.8 | MALIG NEOPLASM OTH SPEC SITES BLADD | ICD-9-CM Diagnosis |
| 188.9 | MALIG NEOPLASM BLADDER PART UNSPEC | ICD-9-CM Diagnosis |
| 189 | MAL NEO KIDNEY&OTH&UNS URIN ORGN | ICD-9-CM Diagnosis |
| 189.0 | MALIG NEOPLASM KIDNEY EXCEPT PELVIS | ICD-9-CM Diagnosis |
| 189.1 | MALIGNANT NEOPLASM OF RENAL PELVIS | ICD-9-CM Diagnosis |
| 189.2 | MALIGNANT NEOPLASM OF URETER | ICD-9-CM Diagnosis |
| 189.3 | MALIGNANT NEOPLASM OF URETHRA | ICD-9-CM Diagnosis |
| 189.4 | MALIG NEOPLASM PARAURETHRAL GLANDS | ICD-9-CM Diagnosis |
| 189.8 | MAL NEOPLSM OTH SPEC SITE URIN ORGN | ICD-9-CM Diagnosis |
| 189.9 | MALIG NEOPLSM URIN ORGN SITE UNSPEC | ICD-9-CM Diagnosis |
| 190 | MALIGNANT NEOPLASM OF EYE | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 190.0 | MALIGNANT NEO EYEBALL | ICD-9-CM Diagnosis |
| 190.1 | MALIGNANT NEOPLASM OF ORBIT | ICD-9-CM Diagnosis |
| 190.2 | MALIGNANT NEOPLASM LACRIMAL GLAND | ICD-9-CM Diagnosis |
| 190.3 | MALIGNANT NEOPLASM OF CONJUNCTIVA | ICD-9-CM Diagnosis |
| 190.4 | MALIGNANT NEOPLASM OF CORNEA | ICD-9-CM Diagnosis |
| 190.5 | MALIGNANT NEOPLASM OF RETINA | ICD-9-CM Diagnosis |
| 190.6 | MALIGNANT NEOPLASM OF CHOROID | ICD-9-CM Diagnosis |
| 190.7 | MALIGNANT NEOPLASM OF LACRIMAL DUCT | ICD-9-CM Diagnosis |
| 190.8 | MALIG NEOPLASM OTHER SPEC SITES EYE | ICD-9-CM Diagnosis |
| 190.9 | MALIGNANT NEOPLASM EYE PART UNSPEC | ICD-9-CM Diagnosis |
| 191 | MALIGNANT NEOPLASM OF BRAIN | ICD-9-CM Diagnosis |
| 191.0 | MAL NEOPLSM CEREBRUM NO LOBES&VENTS | ICD-9-CM Diagnosis |
| 191.1 | MALIG NEOPLASM FRONTAL LOBE BRAIN | ICD-9-CM Diagnosis |
| 191.2 | MALIG NEOPLASM TEMPORAL LOBE BRAIN | ICD-9-CM Diagnosis |
| 191.3 | MALIG NEOPLASM PARIETAL LOBE BRAIN | ICD-9-CM Diagnosis |
| 191.4 | MALIG NEOPLASM OCCIPITAL LOBE BRAIN | ICD-9-CM Diagnosis |
| 191.5 | MALIGNANT NEOPLASM VENTRICLES BRAIN | ICD-9-CM Diagnosis |
| 191.6 | MALIGNANT NEOPLASM CEREBELLUM NOS | ICD-9-CM Diagnosis |
| 191.7 | MALIGNANT NEOPLASM OF BRAIN STEM | ICD-9-CM Diagnosis |
| 191.8 | MALIG NEOPLASM OTHER PARTS BRAIN | ICD-9-CM Diagnosis |
| 191.9 | MALIG NEOPLASM BRAIN UNSPEC SITE | ICD-9-CM Diagnosis |
| 192 | MALIG NEOPLSM OTH&UNS PART NERV SYS | ICD-9-CM Diagnosis |
| 192.0 | MALIGNANT NEOPLASM CRANIAL NERVES | ICD-9-CM Diagnosis |
| 192.1 | MALIG NEOPLASM CEREBRAL MENINGES | ICD-9-CM Diagnosis |
| 192.2 | MALIGNANT NEOPLASM OF SPINAL CORD | ICD-9-CM Diagnosis |
| 192.3 | MALIGNANT NEOPLASM SPINAL MENINGES | ICD-9-CM Diagnosis |
| 192.8 | MAL NEOPLSM OTH SPEC SITE NERV SYS | ICD-9-CM Diagnosis |
| 192.9 | MALIG NEOPLSM NERV SYS PART UNSPEC | ICD-9-CM Diagnosis |
| 193 | MALIGNANT NEOPLASM OF THYROID GLAND | ICD-9-CM Diagnosis |
| 194 | MAL NEO OTH ENDOCRN GLND&REL STRCT | ICD-9-CM Diagnosis |
| 194.0 | MALIGNANT NEOPLASM OF ADRENAL GLAND | ICD-9-CM Diagnosis |
| 194.1 | MALIG NEOPLASM PARATHYROID GLAND | ICD-9-CM Diagnosis |
| 194.3 | MALIG NEOPLASM PITUITARY | ICD-9-CM Diagnosis |
| 194.4 | MALIGNANT NEOPLASM OF PINEAL GLAND | ICD-9-CM Diagnosis |
| 194.5 | MALIGNANT NEOPLASM OF CAROTID BODY | ICD-9-CM Diagnosis |
| 194.6 | MAL NEO AORTC BDY&OTH PARAGANGLIA | ICD-9-CM Diagnosis |
| 194.8 | MAL NEO OTH ENDOCRN GLND&REL STRCT | ICD-9-CM Diagnosis |
| 194.9 | MAL NEOPLSM ENDOCRN GLAND SITE UNS | ICD-9-CM Diagnosis |
| 195 | MALIG NEOPLASM OTH&ILL-DEFIND SITES | ICD-9-CM Diagnosis |
| 195.0 | MALIGNANT NEOPLASM HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 195.1 | MALIGNANT NEOPLASM OF THORAX | ICD-9-CM Diagnosis |
| 195.2 | MALIGNANT NEOPLASM OF ABDOMEN | ICD-9-CM Diagnosis |
| 195.3 | MALIGNANT NEOPLASM OF PELVIS | ICD-9-CM Diagnosis |
| 195.4 | MALIGNANT NEOPLASM OF UPPER LIMB | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 195.5 | MALIGNANT NEOPLASM OF LOWER LIMB | ICD-9-CM Diagnosis |
| 195.8 | MALIGNANT NEOPLASM OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 196 | SEC&UNSPEC MALIG NEOPLASM NODES | ICD-9-CM Diagnosis |
| 196.0 | SEC&UNS MAL NEO NODES HEAD FCE&NCK | ICD-9-CM Diagnosis |
| 196.1 | SEC&UNS MAL NEOPLSM INTRATHR NODES | ICD-9-CM Diagnosis |
| 196.2 | SEC&UNS MAL NEOPLSM INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 196.3 | SEC&UNS MAL NEO NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 196.5 | SEC&UNS MAL NEO NODES ING/LEG | ICD-9-CM Diagnosis |
| 196.6 | SEC&UNS MAL NEOPLSM INTRAPELV NODES | ICD-9-CM Diagnosis |
| 196.8 | SEC&UNS MALIG NEOPLSM NODES MX SITE | ICD-9-CM Diagnosis |
| 196.9 | SEC&UNS MAL NEOPLSM NODES SITE UNS | ICD-9-CM Diagnosis |
| 197 | SEC MALIG NEOPLASM RESP&DIGESTV SYS | ICD-9-CM Diagnosis |
| 197.0 | SEC MALIGNANT NEOPLASM OF LUNG | ICD-9-CM Diagnosis |
| 197.1 | SEC MALIGNANT NEOPLASM MEDIASTINUM | ICD-9-CM Diagnosis |
| 197.2 | SEC MALIGNANT NEOPLASM OF PLEURA | ICD-9-CM Diagnosis |
| 197.3 | SEC MALIG NEOPLASM OTH RESP ORGN | ICD-9-CM Diagnosis |
| 197.4 | SEC MALIG NEOPLSM SM INTST W/DUODUM | ICD-9-CM Diagnosis |
| 197.5 | SEC MALIG NEOPLASM LG INTEST&RECT | ICD-9-CM Diagnosis |
| 197.6 | SEC MAL NEO RETROPERITON&PERITON | ICD-9-CM Diagnosis |
| 197.7 | SEC MALIGNANT NEOPLASM OF LIVER | ICD-9-CM Diagnosis |
| 197.8 | SEC MAL NEO OTH DIGESTV ORGN&SPLEEN | ICD-9-CM Diagnosis |
| 198 | SEC MALIG NEOPLASM OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 198.0 | SEC MALIGNANT NEOPLASM OF KIDNEY | ICD-9-CM Diagnosis |
| 198.1 | SEC MALIG NEOPLASM OTH URINARY ORGN | ICD-9-CM Diagnosis |
| 198.2 | SEC MALIGNANT NEOPLASM OF SKIN | ICD-9-CM Diagnosis |
| 198.3 | SEC MALIG NEOPLSM BRAIN&SPINAL CORD | ICD-9-CM Diagnosis |
| 198.4 | SEC MALIG NEOPLSM OTH PART NERV SYS | ICD-9-CM Diagnosis |
| 198.5 | SEC MALIG NEOPLASM BONE&BONE MARROW | ICD-9-CM Diagnosis |
| 198.6 | SEC MALIGNANT NEOPLASM OF OVARY | ICD-9-CM Diagnosis |
| 198.7 | SEC MALIG NEOPLASM ADRENAL GLAND | ICD-9-CM Diagnosis |
| 198.8 | SEC MALIG NEOPLASM OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 198.81 | SEC MALIGNANT NEOPLASM OF BREAST | ICD-9-CM Diagnosis |
| 198.82 | SEC MALIG NEOPLASM GENITAL ORGANS | ICD-9-CM Diagnosis |
| 198.89 | SEC MALIG NEOPLASM OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 199 | MALIG NEOPLASM WITHOUT SPEC SITE | ICD-9-CM Diagnosis |
| 199.0 | DISSEMINATED MALIGNANT NEOPLASM | ICD-9-CM Diagnosis |
| 199.1 | OTHER MALIG NEOPLASM UNSPEC SITE | ICD-9-CM Diagnosis |
| 199.2 | MALIG NEOPLSM ASSOC TRANSPLNT ORGAN | ICD-9-CM Diagnosis |
| 200 | LYMPH&RETIC&OTH LYMPH MALIG TUMOR | ICD-9-CM Diagnosis |
| 200.0 | RETICULOSARCOMA | ICD-9-CM Diagnosis |
| 200.00 | RETICULOSRCOM XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 200.01 | RETICULOSRCOM NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 200.02 | RETICULOSARCOMA INTRATHORACIC NODES | ICD-9-CM Diagnosis |
| 200.03 | RETICULOSARCOMA INTRA-ABD NODES | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 200.04 | RETICULOSRCOM NODES AX&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.05 | RETICULOSRCOM NODES ING RGN&LW LIMB | ICD-9-CM Diagnosis |
| 200.06 | RETICULOSARCOMA INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 200.07 | RETICULOSARCOMA OF SPLEEN | ICD-9-CM Diagnosis |
| 200.08 | RETICULOSARCOMA NODES MX SITES | ICD-9-CM Diagnosis |
| 200.1 | LYMPHOSARCOMA | ICD-9-CM Diagnosis |
| 200.10 | LYMPHOSRCOM XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 200.11 | LYMPHOSARCOMA NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 200.12 | LYMPHOSARCOMA INTRATHORACIC NODES | ICD-9-CM Diagnosis |
| 200.13 | LYMPHOSARCOMA INTRA-ABD LYMPH NODES | ICD-9-CM Diagnosis |
| 200.14 | LYMPHOSRCOM NODES AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.15 | LYMPHOSRCOM NODES ING RGN&LOW LIMB | ICD-9-CM Diagnosis |
| 200.16 | LYMPHOSARCOMA INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 200.17 | LYMPHOSARCOMA OF SPLEEN | ICD-9-CM Diagnosis |
| 200.18 | LYMPHOSARCOMA NODES MULTIPLE SITES | ICD-9-CM Diagnosis |
| 200.2 | BURKITT'S TUMOR OR LYMPHOMA | ICD-9-CM Diagnosis |
| 200.20 | BURKITT'S TUMOR/LYMPHOMA UNS | ICD-9-CM Diagnosis |
| 200.21 | BRKITS TUMR/LYMPHOMA NODES HEAD&NCK | ICD-9-CM Diagnosis |
| 200.22 | BRKITS TUMR/LYMPHOMA INTRATHR NODES | ICD-9-CM Diagnosis |
| 200.23 | BURKITT'S TUMR/LYMPHMA ABD LYMPH | ICD-9-CM Diagnosis |
| 200.24 | BURKITT'S TUMOR AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.25 | BURKITT'S TUMR/LYMPHOMA ING/LW LIMB | ICD-9-CM Diagnosis |
| 200.26 | BURKITT'S TUMOR INTRAPELVIC | ICD-9-CM Diagnosis |
| 200.27 | BURKITT'S TUMOR OR LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |
| 200.28 | BRKITS TUMR/LYMPHOMA NODES MX SITE | ICD-9-CM Diagnosis |
| 200.3 | MARGINAL ZONE LYMPHOMA | ICD-9-CM Diagnosis |
| 200.30 | MZ LYMPHOMA UNS SITE EXTRANOD&ORGAN | ICD-9-CM Diagnosis |
| 200.31 | MZ LYMPHOMA NODES HEAD FACE & NECK | ICD-9-CM Diagnosis |
| 200.32 | MZ LYMPHOMA INTRATHORACIC NODES | ICD-9-CM Diagnosis |
| 200.33 | MZ LYMPHOMA INTRA-ABDOMINAL NODES | ICD-9-CM Diagnosis |
| 200.34 | MZ LYMPHOMA NODES AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.35 | MZ LYMPHOMA NODES ING REG&LOW LIMB | ICD-9-CM Diagnosis |
| 200.36 | MZ LYMPHOMA INTRAPELVIC LYMPH NODES | ICD-9-CM Diagnosis |
| 200.37 | MARGINAL ZONE LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |
| 200.38 | MZ LYMPHOMA LYMPH NODES MULTI SITES | ICD-9-CM Diagnosis |
| 200.4 | MANTLE CELL LYMPHOMA | ICD-9-CM Diagnosis |
| 200.40 | MCL UNS SITE EXTRANODAL&SOLID ORGAN | ICD-9-CM Diagnosis |
| 200.41 | MCL LYMPH NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 200.42 | MCL INTRATHORACIC LYMPH NODES | ICD-9-CM Diagnosis |
| 200.43 | MCL INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM Diagnosis |
| 200.44 | MCL LYMPH NODES AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.45 | MCL NODES ING REGION&LOWER LIMB | ICD-9-CM Diagnosis |
| 200.46 | MCL INTRAPELVIC LYMPH NODES | ICD-9-CM Diagnosis |
| 200.47 | MANTLE CELL LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 200.48 | MCL LYMPH NODES MULTIPLE SITES | ICD-9-CM Diagnosis |
| 200.5 | PRIMARY CNTRL NERV SYS LYMPHOMA | ICD-9-CM Diagnosis |
| 200.50 | PRIM CNS LYMPHOMA UNS EXTRANOD&ORGN | ICD-9-CM Diagnosis |
| 200.51 | PRIM CNS LYMPHOMA HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 200.52 | PRIM CNS LYMPHOMA INTRATHOR NODES | ICD-9-CM Diagnosis |
| 200.53 | PRIM CNS LYMPHOMA INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 200.54 | PRIM CNS LYMPHOMA AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.55 | PRIM CNS LYMPHOMA INGUINAL&LOW LIMB | ICD-9-CM Diagnosis |
| 200.56 | PRIM CNS LYMPHOMA INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 200.57 | PRIMARY CNS LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |
| 200.58 | PRIM CNS LYMPHOMA MULTIPLE SITES | ICD-9-CM Diagnosis |
| 200.6 | ANAPLASTIC LARGE CELL LYMPHOMA | ICD-9-CM Diagnosis |
| 200.60 | ALCL UNS SITE EXTRANODAL&SOLID ORG | ICD-9-CM Diagnosis |
| 200.61 | ALC LYMPHOMA NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 200.62 | ALC LYMPHOMA INTRATHORACIC NODES | ICD-9-CM Diagnosis |
| 200.63 | ALC LYMPHOMA INTRA-ABDOMINAL NODES | ICD-9-CM Diagnosis |
| 200.64 | ALC LYMPHOMA NODES AXILLA&UP LIMB | ICD-9-CM Diagnosis |
| 200.65 | ALC LYMPHOMA NODES ING&LOW LIMB | ICD-9-CM Diagnosis |
| 200.66 | ALC LYMPHOMA INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 200.67 | ANAPLASTIC LRG CELL LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |
| 200.68 | ALC LYMPHOMA NODES MULTIPLE SITES | ICD-9-CM Diagnosis |
| 200.7 | LARGE CELL LYMPHOMA | ICD-9-CM Diagnosis |
| 200.70 | LCL UNS SITE EXTRANODAL&SOLID ORGAN | ICD-9-CM Diagnosis |
| 200.71 | LCL LYMPH NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 200.72 | LCL INTRATHORACIC LYMPH NODES | ICD-9-CM Diagnosis |
| 200.73 | LCL INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM Diagnosis |
| 200.74 | LCL LYMPH NODES AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 200.75 | LCL LYMPH NODES INGUINAL&LOWER LIMB | ICD-9-CM Diagnosis |
| 200.76 | LCL INTRAPELVIC LYMPH NODES | ICD-9-CM Diagnosis |
| 200.77 | LARGE CELL LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |
| 200.78 | LARGE CELL LYMPHOMA NODES MX SITES | ICD-9-CM Diagnosis |
| 200.8 | VARIANTS LYMPHOSRCOM&RETICULOSRCOM | ICD-9-CM Diagnosis |
| 200.80 | VARIANTS XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 200.81 | OTH VARNTS LYMPHOSARCOMA NODES HEAD | ICD-9-CM Diagnosis |
| 200.82 | OTH VARNTS LYMPHOSARCOMA THORAX | ICD-9-CM Diagnosis |
| 200.83 | OTH VARNTS LYMPHOSARCOMA INTRA-ABD | ICD-9-CM Diagnosis |
| 200.84 | OTH VARNTS LYMPHOSARCOMA AX&UP LIMB | ICD-9-CM Diagnosis |
| 200.85 | OTH VARNT LYMPHOSRCM ING REG&LW LIM | ICD-9-CM Diagnosis |
| 200.86 | OTH VARNTS LYMPHOSARCOMA INTRAPELV | ICD-9-CM Diagnosis |
| 200.87 | OTH VARIANTS LYMPHOSARCOMA SPLEEN | ICD-9-CM Diagnosis |
| 200.88 | OTH VARIANT LYMPHOSRCM NODE MX SITE | ICD-9-CM Diagnosis |
| 201 | HODGKINS DISEASE | ICD-9-CM Diagnosis |
| 201.0 | HODGKINS PARAGRANULOMA | ICD-9-CM Diagnosis |
| 201.00 | HODGKINS PARAGRN EXTRND UNS SITE | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 201.01 | HODGKIN PARAGRNULOM NODES HEAD&NCK | ICD-9-CM Diagnosis |
| 201.02 | HODGKIN PARAGRNULOM INTRATHOR NODES | ICD-9-CM Diagnosis |
| 201.03 | HODGKIN PARAGRNULOM INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 201.04 | HODGKINS PARAGRAN AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 201.05 | HODGKINS PARAGRNULOM ING &LW LIMB | ICD-9-CM Diagnosis |
| 201.06 | HODGKIN PARAGRNULOM INTRAPELV NODES | ICD-9-CM Diagnosis |
| 201.07 | HODGKINS PARAGRANULOMA OF SPLEEN | ICD-9-CM Diagnosis |
| 201.08 | HODGKINS PARAGRNULOM NODES MX SITES | ICD-9-CM Diagnosis |
| 201.1 | HODGKINS GRANULOMA | ICD-9-CM Diagnosis |
| 201.10 | HODGK GRANUL-EXTRNOD UNS SITE | ICD-9-CM Diagnosis |
| 201.11 | HODGKIN GRANULOMA NODES HEAD&NCK | ICD-9-CM Diagnosis |
| 201.12 | HODGKINS GRANULOMA INTRATHOR NODES | ICD-9-CM Diagnosis |
| 201.13 | HODGKINS GRANULOMA INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 201.14 | HODGKINS GRANULOMA NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 201.15 | HODGKINS GRANULOMA ING&LOWR LIMB | ICD-9-CM Diagnosis |
| 201.16 | HODGKINS GRANULOMA INTRAPELV NODES | ICD-9-CM Diagnosis |
| 201.17 | HODGKINS GRANULOMA OF SPLEEN | ICD-9-CM Diagnosis |
| 201.18 | HODGKINS GRANULOMA NODES MX SITES | ICD-9-CM Diagnosis |
| 201.2 | HODGKINS SARCOMA | ICD-9-CM Diagnosis |
| 201.20 | HODGKIN SRCOM XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 201.21 | HODGKINS SRCOM NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 201.22 | HODGKINS SRCOM INTRATHORACIC NODES | ICD-9-CM Diagnosis |
| 201.23 | HODGKINS SARCOMA INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 201.24 | HODGKINS SRCOM NODES AX&UPPER LIMB | ICD-9-CM Diagnosis |
| 201.25 | HODGKIN SRCOM NODES ING RGN&LW LIMB | ICD-9-CM Diagnosis |
| 201.26 | HODGKINS SARCOMA INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 201.27 | HODGKINS SARCOMA OF SPLEEN | ICD-9-CM Diagnosis |
| 201.28 | HODGKINS SARCOMA NODES MX SITES | ICD-9-CM Diagnosis |
| 201.4 | HODGKIN LYMPHCYT-HISTCYT | ICD-9-CM Diagnosis |
| 201.40 | HODG LYMPHOCYT-HISTIO UNS EXTRNOD | ICD-9-CM Diagnosis |
| 201.41 | HODG LYMPH-HISTIO HEAD FACE & NECK | ICD-9-CM Diagnosis |
| 201.42 | HODG LYMPH-HISTIO THORAX | ICD-9-CM Diagnosis |
| 201.43 | HODG LYMPH-HISTIO ABDOM | ICD-9-CM Diagnosis |
| 201.44 | HODG LYMPH-HISTIO AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 201.45 | HODG LYMPHO-HISTIO ING REG&LWR LIMB | ICD-9-CM Diagnosis |
| 201.46 | HODG LYMPH-HISTIO INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 201.47 | HODGKIN LYMPHCYT-HISTCYT SPLEEN | ICD-9-CM Diagnosis |
| 201.48 | HODG LYMPHOCYT-HISTIOCYT MX SITE | ICD-9-CM Diagnosis |
| 201.5 | HODGKINS DISEASE NODULAR SCLEROSIS | ICD-9-CM Diagnosis |
| 201.50 | HODG NODUL SCLEROS UNS SITE EXTRND | ICD-9-CM Diagnosis |
| 201.51 | HODG NODUL SCLERO HEAD FACE & NECK | ICD-9-CM Diagnosis |
| 201.52 | HODG NODUL SCLERO THORAX | ICD-9-CM Diagnosis |
| 201.53 | HODG NODUL SCLERO ABDOM | ICD-9-CM Diagnosis |
| 201.54 | HODG NODUL SCLERO AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 201.55 | HODG NODULR SCLROS ING REG&LW LIMB | ICD-9-CM Diagnosis |
| 201.56 | HODG NODUL SCLERO INTRAPELVIC | ICD-9-CM Diagnosis |
| 201.57 | HODGKINS NODULAR SCLEROSIS SPLEEN | ICD-9-CM Diagnosis |
| 201.58 | HODGKIN NODULR SCLER NODES MX SITE | ICD-9-CM Diagnosis |
| 201.6 | HODGKINS DISEASE MIXED CELLULARITY | ICD-9-CM Diagnosis |
| 201.60 | HODG NODL MIXD CELLR UNS SITE XTRND | ICD-9-CM Diagnosis |
| 201.61 | HODG MIX CELLR W/NODES HEAD&NECK | ICD-9-CM Diagnosis |
| 201.62 | HODGKINS MIX CELLR INTRATHOR NODES | ICD-9-CM Diagnosis |
| 201.63 | HODGKINS MIX CELLR INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 201.64 | HODGKINS MIX CELLR NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 201.65 | HODG MIX CELLR NOD ING REG&LW LMB | ICD-9-CM Diagnosis |
| 201.66 | HODGKINS MIX CELLR INTRAPELV NODES | ICD-9-CM Diagnosis |
| 201.67 | HODGKINS MIXED CELLULARITY SPLEEN | ICD-9-CM Diagnosis |
| 201.68 | HODGKINS MIX CELLR NODES MX SITES | ICD-9-CM Diagnosis |
| 201.7 | HODGKINS LYMPHOCYTIC DEPLETION | ICD-9-CM Diagnosis |
| 201.70 | HODG LYMPHOCYT DEPLET EXTRANOD | ICD-9-CM Diagnosis |
| 201.71 | HODG LYMPH DEPLET HEAD FACE & NECK | ICD-9-CM Diagnosis |
| 201.72 | HODG LYMPH DEPLET THORAX | ICD-9-CM Diagnosis |
| 201.73 | HODG LYMPH DEPLET ABDOM | ICD-9-CM Diagnosis |
| 201.74 | HODG LYMPH DEPLET AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 201.75 | HODG LYMPHO DPLT NOD ING REG&LW LMB | ICD-9-CM Diagnosis |
| 201.76 | HODG LYMPH DEPLET INTRAPELVIC | ICD-9-CM Diagnosis |
| 201.77 | HODGKINS LYMPHOCYTIC DEPLET SPLEEN | ICD-9-CM Diagnosis |
| 201.78 | HODG LYMPHOCYTIC DEPLET NOD MX SITE | ICD-9-CM Diagnosis |
| 201.9 | HODGKINS DISEASE, UNSPECIFIED TYPE | ICD-9-CM Diagnosis |
| 201.90 | HODG UNS TYPE/SITE EXTRND&SLID ORGN | ICD-9-CM Diagnosis |
| 201.91 | HODGKIN UNS TYPE NODES HEAD FCE&NCK | ICD-9-CM Diagnosis |
| 201.92 | HODGKINS UNS TYPE INTRATHOR NODES | ICD-9-CM Diagnosis |
| 201.93 | HODGKINS UNS TYPE INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 201.94 | HODGKINS UNS TYPE NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 201.95 | HODG UNS TYPE NODE ING REG&LWR LIMB | ICD-9-CM Diagnosis |
| 201.96 | HODGKINS UNS TYPE INTRAPELV NODES | ICD-9-CM Diagnosis |
| 201.97 | HODGKINS UNSPECIFIED TYPE OF SPLEEN | ICD-9-CM Diagnosis |
| 201.98 | HODGKINS UNSPEC TYPE NODES MX SITES | ICD-9-CM Diagnosis |
| 202 | OTH MAL NEO LYMPHOID&HISTCYT TISS | ICD-9-CM Diagnosis |
| 202.0 | NODULAR LYMPHOMA | ICD-9-CM Diagnosis |
| 202.00 | NODULR LYMPHOMA XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 202.01 | NODULAR LYMPHOMA NODES HEAD FCE&NCK | ICD-9-CM Diagnosis |
| 202.02 | NODULAR LYMPHOMA INTRATHOR NODES | ICD-9-CM Diagnosis |
| 202.03 | NODULAR LYMPHOMA INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 202.04 | NODULR LYMPHOMA NODES AX&UPPER LIMB | ICD-9-CM Diagnosis |
| 202.05 | NODULAR LYMPHOMA INGUIN&LOWER LIMB | ICD-9-CM Diagnosis |
| 202.06 | NODULAR LYMPHOMA INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 202.07 | NODULAR LYMPHOMA OF SPLEEN | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 202.08 | NODULAR LYMPHOMA NODES MX SITES | ICD-9-CM Diagnosis |
| 202.1 | MYCOSIS FUNGOIDES | ICD-9-CM Diagnosis |
| 202.10 | MYCOF FUNGOIDES XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 202.11 | MYCOF FUNGOIDES NODES HEAD FCE&NCK | ICD-9-CM Diagnosis |
| 202.12 | MYCOSIS FUNGOIDES INTRATHOR NODES | ICD-9-CM Diagnosis |
| 202.13 | MYCOSIS FUNGOIDES INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 202.14 | MYCOSIS FUNGOIDES NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 202.15 | MYCOSIS FUNGOIDES ING REG&LWR LIMB | ICD-9-CM Diagnosis |
| 202.16 | MYCOSIS FUNGOIDES INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 202.17 | MYCOSIS FUNGOIDES OF SPLEEN | ICD-9-CM Diagnosis |
| 202.18 | MYCOSIS FUNGOIDES NODES MX SITES | ICD-9-CM Diagnosis |
| 202.2 | SEZARYS DISEASE | ICD-9-CM Diagnosis |
| 202.20 | SEZARYS DZ UNS SITE EXTRANOD | ICD-9-CM Diagnosis |
| 202.21 | SEZARYS DZ LYMPH NODES HEAD&NECK | ICD-9-CM Diagnosis |
| 202.22 | SEZARYS DZ INTRATHORACIC LYMPH NODE | ICD-9-CM Diagnosis |
| 202.23 | SEZARYS DZ INTRA-ABD LYMPH NODES | ICD-9-CM Diagnosis |
| 202.24 | SEZARYS DZ LYMPH NOD AXLLA&UPPR LMB | ICD-9-CM Diagnosis |
| 202.25 | SEZARY DZ LYMPH NOD ING REG&LWR LMB | ICD-9-CM Diagnosis |
| 202.26 | SEZARYS DZ INTRAPELVIC LYMPH NODES | ICD-9-CM Diagnosis |
| 202.27 | SEZARYS DZ OF SPLEEN | ICD-9-CM Diagnosis |
| 202.28 | SEZARYS DZ LYMPH NODES MULT SITES | ICD-9-CM Diagnosis |
| 202.3 | MALIGNANT HISTIOCYTOSIS | ICD-9-CM Diagnosis |
| 202.30 | MAL HISTIOCYTOF XTRANOD&SOLID ORGN | ICD-9-CM Diagnosis |
| 202.31 | MAL HISTIOCYTOF NODES HEAD FCE&NCK | ICD-9-CM Diagnosis |
| 202.32 | MALIG HISTIOCYTOSIS INTRATHOR NODES | ICD-9-CM Diagnosis |
| 202.33 | MALIG HISTIOCYTOSIS INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 202.34 | MALIG HISTIOCYTOF NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 202.35 | MAL HISTIO NODES ING REG&LWR LMB | ICD-9-CM Diagnosis |
| 202.36 | MALIG HISTIOCYTOSIS INTRAPELV NODES | ICD-9-CM Diagnosis |
| 202.37 | MALIGNANT HISTIOCYTOSIS OF SPLEEN | ICD-9-CM Diagnosis |
| 202.38 | MALIG HISTIOCYTOSIS NODES MX SITES | ICD-9-CM Diagnosis |
| 202.4 | LEUKEMIC RETICULOENDOTHELIOSIS | ICD-9-CM Diagnosis |
| 202.40 | LEUKEMIC RETICULOENDOTHLO UNS SITE | ICD-9-CM Diagnosis |
| 202.41 | LEUKMIC RETICULONDOOTHLOS HEAD&NCK | ICD-9-CM Diagnosis |
| 202.42 | LEUKMC RETCULONDOOTHLOS THORAX NODE | ICD-9-CM Diagnosis |
| 202.43 | LEUKMC RTCULONDOOTHLOS INTRA-ABD | ICD-9-CM Diagnosis |
| 202.44 | LEUKMIC RETCULONDOOTHLOS AX&UP LMB | ICD-9-CM Diagnosis |
| 202.45 | LEUKM RTCULONDOOTHLO ING REG&LW LMB | ICD-9-CM Diagnosis |
| 202.46 | LEUKEMIC RETCULONDOOTHLOS INTRAPLVC | ICD-9-CM Diagnosis |
| 202.47 | LEUKEMIC RETICULOENDOTHELIOS SPLEEN | ICD-9-CM Diagnosis |
| 202.48 | LEUKEMIC RETICULOENDOTHLO MX SITES | ICD-9-CM Diagnosis |
| 202.5 | LETTERER-SIWE DISEASE | ICD-9-CM Diagnosis |
| 202.50 | LETTERER-SIWE DZ UNS XTRANOD | ICD-9-CM Diagnosis |
| 202.51 | LETTERER-SIWE DZ NODES HEAD&NECK | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 202.52 | LETTERER-SIWE DZ INTRATHORACIC NODE | ICD-9-CM Diagnosis |
| 202.53 | LETTERER-SIWE DZ INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 202.54 | LETTERER-SIWE DZ NODE AXILLA&UP LMB | ICD-9-CM Diagnosis |
| 202.55 | LETTERER-SIWE DZ NOD ING REG&LW LMB | ICD-9-CM Diagnosis |
| 202.56 | LETTERER-SIWE DZ INTRAPELVIC NODES | ICD-9-CM Diagnosis |
| 202.57 | LETTERER-SIWE DISEASE OF SPLEEN | ICD-9-CM Diagnosis |
| 202.58 | LETTERER-SIWE DZ NODE MULT SITES | ICD-9-CM Diagnosis |
| 202.6 | MALIGNANT MAST CELL TUMORS | ICD-9-CM Diagnosis |
| 202.60 | MAL MAST CELL TUMR UNS SITE XTRANOD | ICD-9-CM Diagnosis |
| 202.61 | MAL MAST CELL TUMRS NODES HEAD&NCK | ICD-9-CM Diagnosis |
| 202.62 | MAL MAST CELL TUMRS INTRATHR NODES | ICD-9-CM Diagnosis |
| 202.63 | MAL MAST CELL TUMRS INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 202.64 | MAL MASTOCYTOSIS AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 202.65 | MALIG MAST CELL TUMR ING REG&LW LMB | ICD-9-CM Diagnosis |
| 202.66 | MAL MAST CELL TUMRS INTRAPELV NODES | ICD-9-CM Diagnosis |
| 202.67 | MALIGNANT MAST CELL TUMORS SPLEEN | ICD-9-CM Diagnosis |
| 202.68 | MALIG MAST CELL TUMRS NODES MX SITE | ICD-9-CM Diagnosis |
| 202.7 | PERIPHERAL T-CELL LYMPHOMA | ICD-9-CM Diagnosis |
| 202.70 | PTL UNS SITE EXTRANODAL&SOLID ORGAN | ICD-9-CM Diagnosis |
| 202.71 | PTL LYMPH NODES HEAD FACE&NECK | ICD-9-CM Diagnosis |
| 202.72 | PTL INTRATHORCIC LYMPH NODES | ICD-9-CM Diagnosis |
| 202.73 | PTL INTRA-ABDOMINAL LYMPH NODES | ICD-9-CM Diagnosis |
| 202.74 | PTL LYMPH NODES AXILLA&UPPER LIMB | ICD-9-CM Diagnosis |
| 202.75 | PTL LYMPH NODES INGUINAL&LOW LIMB | ICD-9-CM Diagnosis |
| 202.76 | PTL INTRAPELVIC LYMPH NODES | ICD-9-CM Diagnosis |
| 202.77 | PERIPHERAL T-CELL LYMPHOMA SPLEEN | ICD-9-CM Diagnosis |
| 202.78 | PTL LYMPH NODES MULTIPLE SITES | ICD-9-CM Diagnosis |
| 202.8 | OTHER MALIGNANT LYMPHOMAS | ICD-9-CM Diagnosis |
| 202.80 | OTH MAL LYMPHOMA UNS SITE-EXTRNOD | ICD-9-CM Diagnosis |
| 202.81 | OTH MAL LYMPHOMAS NODES HEAD&NCK | ICD-9-CM Diagnosis |
| 202.82 | OTH MALIG LYMPHOMAS INTRATHOR NODES | ICD-9-CM Diagnosis |
| 202.83 | OTH MALIG LYMPHOMAS INTRA-ABD NODES | ICD-9-CM Diagnosis |
| 202.84 | OTH MAL LYMPHOMAS NODES AX&UP LIMB | ICD-9-CM Diagnosis |
| 202.85 | OTH MAL LYMPHOMAS ING REG&LOWR LIMB | ICD-9-CM Diagnosis |
| 202.86 | OTH MALIG LYMPHOMAS INTRAPELV NODES | ICD-9-CM Diagnosis |
| 202.87 | OTHER MALIGNANT LYMPHOMAS OF SPLEEN | ICD-9-CM Diagnosis |
| 202.88 | OTH MALIG LYMPHOMAS NODES MX SITES | ICD-9-CM Diagnosis |
| 202.9 | UNS MAL NEO LYMPHOID&HISTCYT TISS | ICD-9-CM Diagnosis |
| 202.90 | OTH&UNS MAL LYMPHOD-HSTIO XTRND UNS | ICD-9-CM Diagnosis |
| 202.91 | OTH&UNS MAL LYMPHOD-HSTIO HEAD | ICD-9-CM Diagnosis |
| 202.92 | OTH & UNS MAL LYMPHOID THORAX | ICD-9-CM Diagnosis |
| 202.93 | OTH & UNS MAL LYMPHOID ABDOM | ICD-9-CM Diagnosis |
| 202.94 | OTH & UNS MAL LYMPHOID AXILLA | ICD-9-CM Diagnosis |
| 202.95 | OTH & UNS MAL LYMPHOID INGUIN | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 202.96 | OTH & UNS MAL LYMPHOID PELVIC | ICD-9-CM Diagnosis |
| 202.97 | OTH&UNS MAL NEO LYMPHOD&HISTO SPLEN | ICD-9-CM Diagnosis |
| 202.98 | OTH & UNS MAL LYMPHOID MULT SITES | ICD-9-CM Diagnosis |
| 203 | MX MYELOMA&IMMUNOPROLIFERAT NEOPLSM | ICD-9-CM Diagnosis |
| 203.0 | MULTIPLE MYELOMA | ICD-9-CM Diagnosis |
| 203.00 | MM W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 203.01 | MULTIPLE MYELOMA IN REMISSION | ICD-9-CM Diagnosis |
| 203.02 | MULTIPLE MYELOMA IN RELAPSE | ICD-9-CM Diagnosis |
| 203.1 | PLASMA CELL LEUKEMIA | ICD-9-CM Diagnosis |
| 203.10 | PCL W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 203.11 | PLASMA CELL LEUKEMIA IN REMISSION | ICD-9-CM Diagnosis |
| 203.12 | PLASMA CELL LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 203.8 | OTHER IMMUNOPROLIFERATIVE NEOPLASMS | ICD-9-CM Diagnosis |
| 203.80 | OTH IMMUNOPROLIF NEOPLASM W/O REM | ICD-9-CM Diagnosis |
| 203.81 | OTH IMMUNOPROLIF NEOPLSM REMISSION | ICD-9-CM Diagnosis |
| 203.82 | OTH IMMUNOPROLIF NEOPLSM IN RELAPSE | ICD-9-CM Diagnosis |
| 204 | LYMPHOID LEUKEMIA | ICD-9-CM Diagnosis |
| 204.0 | ACUTE LYMPHOID LEUKEMIA | ICD-9-CM Diagnosis |
| 204.00 | ALL W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 204.01 | ACUTE LYMPHOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 204.02 | ACUTE LYMPHOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 204.1 | CHRONIC LYMPHOID LEUKEMIA | ICD-9-CM Diagnosis |
| 204.10 | CLL W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 204.11 | CHRONIC LYMPHOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 204.12 | CHRON LYMPHOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 204.2 | SUBACUTE LYMPHOID LEUKEMIA | ICD-9-CM Diagnosis |
| 204.20 | SUBACUTE LL W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 204.21 | SUBACUT LYMPHOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 204.22 | SUBACUTE LYMPHOID LEUKEMIA RELAPSE | ICD-9-CM Diagnosis |
| 204.8 | OTHER LYMPHOID LEUKEMIA | ICD-9-CM Diagnosis |
| 204.80 | OTH LL W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 204.81 | OTHER LYMPHOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 204.82 | OTHER LYMPHOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 204.9 | UNSPECIFIED LYMPHOID LEUKEMIA | ICD-9-CM Diagnosis |
| 204.90 | UNS LL W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 204.91 | UNSPEC LYMPHOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 204.92 | UNS LYMPHOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 205 | MYELOID LEUKEMIA | ICD-9-CM Diagnosis |
| 205.0 | ACUTE MYELOID LEUKEMIA | ICD-9-CM Diagnosis |
| 205.00 | AML W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 205.01 | ACUTE MYELOID LEUKEMIA IN REMISSION | ICD-9-CM Diagnosis |
| 205.02 | ACUTE MYELOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 205.1 | CHRONIC MYELOID LEUKEMIA | ICD-9-CM Diagnosis |
| 205.10 | CML W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 205.11 | CHRONIC MYELOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 205.12 | CHRONIC MYELOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 205.2 | SUBACUTE MYELOID LEUKEMIA | ICD-9-CM Diagnosis |
| 205.20 | SUBACUTE ML W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 205.21 | SUBACUTE MYELOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 205.22 | SUBACUT MYELOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 205.3 | MYELOID SARCOMA | ICD-9-CM Diagnosis |
| 205.30 | MYELOID SARCOMA W/O ACHIEVED REM | ICD-9-CM Diagnosis |
| 205.31 | MYELOID SARCOMA IN REMISSION | ICD-9-CM Diagnosis |
| 205.32 | MYELOID SARCOMA IN RELAPSE | ICD-9-CM Diagnosis |
| 205.8 | OTHER MYELOID LEUKEMIA | ICD-9-CM Diagnosis |
| 205.80 | OTH ML W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 205.81 | OTHER MYELOID LEUKEMIA IN REMISSION | ICD-9-CM Diagnosis |
| 205.82 | OTHER MYELOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 205.9 | UNSPECIFIED MYELOID LEUKEMIA | ICD-9-CM Diagnosis |
| 205.90 | UNS ML W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 205.91 | UNSPEC MYELOID LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 205.92 | UNS MYELOID LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 206 | MONOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 206.0 | ACUTE MONOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 206.00 | AML W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 206.01 | ACUTE MONOCYTIC LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 206.02 | ACUTE MONOCYTIC LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 206.1 | CHRONIC MONOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 206.10 | CML W/O MENTION ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 206.11 | CHRON MONOCYTIC LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 206.12 | CHRON MONOCYTIC LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 206.2 | SUBACUTE MONOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 206.20 | SUBACUTE ML W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 206.21 | SUBACUT MONOCYTIC LEUKEM REMISSION | ICD-9-CM Diagnosis |
| 206.22 | SUBACUTE MONOCYTIC LEUKEMIA RELAPSE | ICD-9-CM Diagnosis |
| 206.8 | OTHER MONOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 206.80 | OTH ML W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 206.81 | OTHER MONOCYTIC LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 206.82 | OTHER MONOCYTIC LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 206.9 | UNSPECIFIED MONOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 206.90 | UNS ML W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 206.91 | UNSPEC MONOCYTIC LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 206.92 | UNS MONOCYTIC LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 207 | OTHER SPECIFIED LEUKEMIA | ICD-9-CM Diagnosis |
| 207.0 | ACUTE ERYTHREMIA&ERYTHROLEUKEMIA | ICD-9-CM Diagnosis |
| 207.00 | ACUTE ERYTHREMIA & EL W/O REMISSION | ICD-9-CM Diagnosis |
| 207.01 | AC ERYTHREMIA&ERYTHROLEUKEM REMISS | ICD-9-CM Diagnosis |
| 207.02 | ACUTE ERYTHREMIA AND EL IN RELAPSE | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|---|--------------------|
| 207.1 | CHRONIC ERYTHREMIA | ICD-9-CM Diagnosis |
| 207.10 | CHRONIC ERYTHREMIA W/O REMISSION | ICD-9-CM Diagnosis |
| 207.11 | CHRONIC ERYTHREMIA IN REMISSION | ICD-9-CM Diagnosis |
| 207.12 | CHRONIC ERYTHREMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 207.2 | MEGAKARYOCYTIC LEUKEMIA | ICD-9-CM Diagnosis |
| 207.20 | MEGAKARYOCTIC LEUKEMIA W/O REMISSION | ICD-9-CM Diagnosis |
| 207.21 | MEGAKARYOCYTIC LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 207.22 | MEGAKARYOCYTIC LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 207.8 | OTHER SPECIFIED LEUKEMIA | ICD-9-CM Diagnosis |
| 207.80 | OTH SPEC LEUKEMIA W/O REMISSION | ICD-9-CM Diagnosis |
| 207.81 | OTHER SPECIFIED LEUKEMIA REMISSION | ICD-9-CM Diagnosis |
| 207.82 | OTHER SPECIFIED LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 208 | LEUKEMIA OF UNSPECIFIED CELL TYPE | ICD-9-CM Diagnosis |
| 208.0 | ACUTE LEUKEMIA UNSPEC CELL TYPE | ICD-9-CM Diagnosis |
| 208.00 | ACUTE LEUKEMIA UNS CELL W/O REMISSION | ICD-9-CM Diagnosis |
| 208.01 | ACUTE LEUKEMIA UNS CELL TYPE REMISSION | ICD-9-CM Diagnosis |
| 208.02 | ACUTE LEUKEMIA UNS CELL IN RELAPSE | ICD-9-CM Diagnosis |
| 208.1 | CHRONIC LEUKEMIA UNSPEC CELL TYPE | ICD-9-CM Diagnosis |
| 208.10 | CHRONIC LEUKEMIA UNS CELL W/O REMISSION | ICD-9-CM Diagnosis |
| 208.11 | CHRONIC LEUKEMIA UNS CELL TYPE REMISSION | ICD-9-CM Diagnosis |
| 208.12 | CHRONIC LEUKEMIA UNS CELL IN RELAPSE | ICD-9-CM Diagnosis |
| 208.2 | SUBACUTE LEUKEMIA UNSPEC CELL TYPE | ICD-9-CM Diagnosis |
| 208.20 | SUBACUTE LEUKEMIA UNS CELL W/O REMISSION | ICD-9-CM Diagnosis |
| 208.21 | SUBACUTE LEUKEMIA UNS CELL TYPE REMISSION | ICD-9-CM Diagnosis |
| 208.22 | SUBACUTE LEUKEMIA UNS CELL RELAPSE | ICD-9-CM Diagnosis |
| 208.8 | OTHER LEUKEMIA UNSPEC CELL TYPE | ICD-9-CM Diagnosis |
| 208.80 | OTH LEUKEMIA UNS CELL W/O REMISSION | ICD-9-CM Diagnosis |
| 208.81 | OTH LEUKEMIA UNS CELL TYPE REMISSION | ICD-9-CM Diagnosis |
| 208.82 | OTH LEUKEMIA UNS CELL IN RELAPSE | ICD-9-CM Diagnosis |
| 208.9 | UNSPECIFIED LEUKEMIA | ICD-9-CM Diagnosis |
| 208.90 | UNS LEUKEMIA W/O ACHIEVED REMISSION | ICD-9-CM Diagnosis |
| 208.91 | UNSPECIFIED LEUKEMIA IN REMISSION | ICD-9-CM Diagnosis |
| 208.92 | UNSPECIFIED LEUKEMIA IN RELAPSE | ICD-9-CM Diagnosis |
| 209 | NEUROENDOCRINE TUMORS | ICD-9-CM Diagnosis |
| 209.0 | MALIG CARCINOID TUMORS SMALL INTEST | ICD-9-CM Diagnosis |
| 209.00 | MAL CARCINOID TUMOR SM INTEST UNS | ICD-9-CM Diagnosis |
| 209.01 | MALIGNANT CARCINOID TUMOR DUODENUM | ICD-9-CM Diagnosis |
| 209.02 | MALIGNANT CARCINOID TUMOR JEJUNUM | ICD-9-CM Diagnosis |
| 209.03 | MALIGNANT CARCINOID TUMOR THE ILEUM | ICD-9-CM Diagnosis |
| 209.1 | MAL CARCINOID APPX LG INTEST RECTUM | ICD-9-CM Diagnosis |
| 209.10 | MAL CARCINOID TUMOR LG INTEST UNS | ICD-9-CM Diagnosis |
| 209.11 | MALIGNANT CARCINOID TUMOR APPENDIX | ICD-9-CM Diagnosis |
| 209.12 | MALIGNANT CARCINOID TUMOR CECUM | ICD-9-CM Diagnosis |
| 209.13 | MAL CARCINOID TUMOR ASCENDING COLON | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 209.14 | MAL CARCINOID TUMOR TRANSVRS COLON | ICD-9-CM Diagnosis |
| 209.15 | MALIG CARCINOID TUMOR DESCEND COLON | ICD-9-CM Diagnosis |
| 209.16 | MALIG CARCINOID TUMOR SIGMOID COLON | ICD-9-CM Diagnosis |
| 209.17 | MALIGNANT CARCINOID TUMOR OF RECTUM | ICD-9-CM Diagnosis |
| 209.2 | MAL CARCINOID TUMORS OTH & UNS SITE | ICD-9-CM Diagnosis |
| 209.20 | MAL CARCINOID TUMOR UNKN PRIM SITE | ICD-9-CM Diagnosis |
| 209.21 | MAL CARCINOID TUMOR BRONCHUS & LUNG | ICD-9-CM Diagnosis |
| 209.22 | MALIGNANT CARCINOID TUMOR THYMUS | ICD-9-CM Diagnosis |
| 209.23 | MALIGNANT CARCINOID TUMOR STOMACH | ICD-9-CM Diagnosis |
| 209.24 | MALIGNANT CARCINOID TUMOR OF KIDNEY | ICD-9-CM Diagnosis |
| 209.25 | MALIG CARCINOID TUMOR FOREGUT NOS | ICD-9-CM Diagnosis |
| 209.26 | MALIG CARCINOID TUMOR MIDGUT NOS | ICD-9-CM Diagnosis |
| 209.27 | MALIG CARCINOID TUMOR HINDGUT NOS | ICD-9-CM Diagnosis |
| 209.29 | MALIG CARCINOID TUMOR OTHER SITES | ICD-9-CM Diagnosis |
| 209.3 | MALIG PD NEUROENDOCRINE TUMORS | ICD-9-CM Diagnosis |
| 209.30 | MALIG PD NEUROENDOCRINE CA ANY SITE | ICD-9-CM Diagnosis |
| 209.31 | MERKEL CELL CARCINOMA OF THE FACE | ICD-9-CM Diagnosis |
| 209.32 | MERKEL CELL CARCINOMA SCALP & NECK | ICD-9-CM Diagnosis |
| 209.33 | MERKEL CELL CARCINOMA OF UPPER LIMB | ICD-9-CM Diagnosis |
| 209.34 | MERKEL CELL CARCINOMA OF LOWER LIMB | ICD-9-CM Diagnosis |
| 209.35 | MERKEL CELL CARCINOMA OF THE TRUNK | ICD-9-CM Diagnosis |
| 209.36 | MERKEL CELL CARCINOMA OF OTH SITES | ICD-9-CM Diagnosis |
| 209.4 | BENIGN CARCINOID TUMRS SMALL INTEST | ICD-9-CM Diagnosis |
| 209.40 | BENIGN CARCINOID TUMR SM INTEST UNS | ICD-9-CM Diagnosis |
| 209.41 | BENIGN CARCINOID TUMOR OF DUODENUM | ICD-9-CM Diagnosis |
| 209.42 | BENIGN CARCINOID TUMOR OF JEJUNUM | ICD-9-CM Diagnosis |
| 209.43 | BENIGN CARCINOID TUMOR OF THE ILEUM | ICD-9-CM Diagnosis |
| 209.5 | BENIGN CARCINOID APP LG INTEST RECT | ICD-9-CM Diagnosis |
| 209.50 | BENIGN CARCINOID TUMR LG INTEST UNS | ICD-9-CM Diagnosis |
| 209.51 | BENIGN CARCINOID TUMOR OF APPENDIX | ICD-9-CM Diagnosis |
| 209.52 | BENIGN CARCINOID TUMOR OF THE CECUM | ICD-9-CM Diagnosis |
| 209.53 | BENIGN CARCINOID TUMOR ASCEND COLON | ICD-9-CM Diagnosis |
| 209.54 | BENIGN CARCINOID TUMOR TRANS COLON | ICD-9-CM Diagnosis |
| 209.55 | BENIGN CARCINOID TUMR DESCEND COLON | ICD-9-CM Diagnosis |
| 209.56 | BENIGN CARCINOID TUMR SIGMOID COLON | ICD-9-CM Diagnosis |
| 209.57 | BENIGN CARCINOID TUMOR OF RECTUM | ICD-9-CM Diagnosis |
| 209.6 | BENIGN CARCINOID TUMR OTH&UNS SITE | ICD-9-CM Diagnosis |
| 209.60 | BENIGN CARCINOID TUMR UNK PRIM SITE | ICD-9-CM Diagnosis |
| 209.61 | BENIGN CARCINOID TUMR BRONCHUS LUNG | ICD-9-CM Diagnosis |
| 209.62 | BENIGN CARCINOID TUMOR OF THYMUS | ICD-9-CM Diagnosis |
| 209.63 | BENIGN CARCINOID TUMOR OF STOMACH | ICD-9-CM Diagnosis |
| 209.64 | BENIGN CARCINOID TUMOR OF KIDNEY | ICD-9-CM Diagnosis |
| 209.65 | BENIGN CARCINOID TUMOR FOREGUT NOS | ICD-9-CM Diagnosis |
| 209.66 | BENIGN CARCINOID TUMOR MIDGUT NOS | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 209.67 | BENIGN CARCINOID TUMOR HINDGUT NOS | ICD-9-CM Diagnosis |
| 209.69 | BENIGN CARCINOID TUMOR OTHER SITES | ICD-9-CM Diagnosis |
| 209.7 | SECONDARY NEUROENDOCRINE TUMORS | ICD-9-CM Diagnosis |
| 209.70 | SEC NEUROENDOCR TUMOR UNSPEC SITE | ICD-9-CM Diagnosis |
| 209.71 | SEC NEUROENDOCR TUMR DISTANT NODES | ICD-9-CM Diagnosis |
| 209.72 | SECONDRY NEUROENDOCRINE TUMOR LIVER | ICD-9-CM Diagnosis |
| 209.73 | SECONDARY NEUROENDOCRINE TUMOR BONE | ICD-9-CM Diagnosis |
| 209.74 | SEC NEUROENDOCRINE TUMOR PERITONEUM | ICD-9-CM Diagnosis |
| 209.75 | SECONDARY MERKEL CELL CARCINOMA | ICD-9-CM Diagnosis |
| 209.79 | SEC NEUROENDOCRINE TUMOR OTH SITES | ICD-9-CM Diagnosis |
| 210 | BEN NEOPLASM LIP ORAL CAV&PHARYNX | ICD-9-CM Diagnosis |
| 210.0 | BENIGN NEOPLASM OF LIP | ICD-9-CM Diagnosis |
| 210.1 | BENIGN NEOPLASM OF TONGUE | ICD-9-CM Diagnosis |
| 210.2 | BEN NEOPLASM MAJOR SALIVARY GLANDS | ICD-9-CM Diagnosis |
| 210.3 | BENIGN NEOPLASM OF FLOOR OF MOUTH | ICD-9-CM Diagnosis |
| 210.4 | BEN NEOPLASM OTH&UNSPEC PARTS MOUTH | ICD-9-CM Diagnosis |
| 210.5 | BENIGN NEOPLASM OF TONSIL | ICD-9-CM Diagnosis |
| 210.6 | BEN NEOPLASM OTH PARTS OROPHARYNX | ICD-9-CM Diagnosis |
| 210.7 | BENIGN NEOPLASM OF NASOPHARYNX | ICD-9-CM Diagnosis |
| 210.8 | BENIGN NEOPLASM OF HYPOPHARYNX | ICD-9-CM Diagnosis |
| 210.9 | BENIGN NEOPLASM PHARYNX UNSPECIFIED | ICD-9-CM Diagnosis |
| 211 | BEN NEOPLSM OTH PART DIGESTV SYSTEM | ICD-9-CM Diagnosis |
| 211.0 | BENIGN NEOPLASM OF ESOPHAGUS | ICD-9-CM Diagnosis |
| 211.1 | BENIGN NEOPLASM OF STOMACH | ICD-9-CM Diagnosis |
| 211.2 | BEN NEOPLASM DUODENUM JEJUNUM&ILEUM | ICD-9-CM Diagnosis |
| 211.3 | BENIGN NEOPLASM OF COLON | ICD-9-CM Diagnosis |
| 211.4 | BENIGN NEOPLASM RECTUM&ANAL CANAL | ICD-9-CM Diagnosis |
| 211.5 | BEN NEOPLASM LIVER&BILIARY PASSAGES | ICD-9-CM Diagnosis |
| 211.6 | BEN NEO PANC NO ISLETS LANGERHANS | ICD-9-CM Diagnosis |
| 211.7 | BENIGN NEOPLASM ISLETS LANGERHANS | ICD-9-CM Diagnosis |
| 211.8 | BEN NEOPLASM RETROPERITON&PERITON | ICD-9-CM Diagnosis |
| 211.9 | BEN NEO OTH&UNS SITE DIGESTV SYS | ICD-9-CM Diagnosis |
| 212 | BEN NEOPLASM RESP&INTRATHOR ORGN | ICD-9-CM Diagnosis |
| 212.0 | BEN NEO NASAL CAV MID EAR & SINUS | ICD-9-CM Diagnosis |
| 212.1 | BENIGN NEOPLASM OF LARYNX | ICD-9-CM Diagnosis |
| 212.2 | BENIGN NEOPLASM OF TRACHEA | ICD-9-CM Diagnosis |
| 212.3 | BENIGN NEOPLASM OF BRONCHUS&LUNG | ICD-9-CM Diagnosis |
| 212.4 | BENIGN NEOPLASM OF PLEURA | ICD-9-CM Diagnosis |
| 212.5 | BENIGN NEOPLASM OF MEDIASTINUM | ICD-9-CM Diagnosis |
| 212.6 | BENIGN NEOPLASM OF THYMUS | ICD-9-CM Diagnosis |
| 212.7 | BENIGN NEOPLASM OF HEART | ICD-9-CM Diagnosis |
| 212.8 | BEN NEO OTH SITE RESP&INTRATHR ORGN | ICD-9-CM Diagnosis |
| 212.9 | BEN NEO RESP&INTRATHR ORGN SITE UNS | ICD-9-CM Diagnosis |
| 213 | BEN NEOPLASM BONE&ARTICLR CARTILAGE | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------------|--------------------|
| 213.0 | BENIGN NEOPLASM BONES SKULL&FACE | ICD-9-CM Diagnosis |
| 213.1 | BENIGN NEOPLASM OF LOWER JAW BONE | ICD-9-CM Diagnosis |
| 213.2 | BEN NEO VERT COLMN NOT SACRM&COCCYX | ICD-9-CM Diagnosis |
| 213.3 | BEN NEOPLASM RIBS STERNUM&CLAVICLE | ICD-9-CM Diagnosis |
| 213.4 | BEN NEOPLSM SCAP&LNG BNS UPPER LIMB | ICD-9-CM Diagnosis |
| 213.5 | BEN NEOPLASM SHORT BONES UPPER LIMB | ICD-9-CM Diagnosis |
| 213.6 | BEN NEOPLASM PELV BNS SACRUM&COCCYX | ICD-9-CM Diagnosis |
| 213.7 | BEN NEOPLASM LONG BONES LOWER LIMB | ICD-9-CM Diagnosis |
| 213.8 | BEN NEOPLASM SHORT BONES LOWER LIMB | ICD-9-CM Diagnosis |
| 213.9 | BEN NEO BN&ARTICLR CART SITE UNS | ICD-9-CM Diagnosis |
| 214 | LIPOMA | ICD-9-CM Diagnosis |
| 214.0 | LIPOMA SKIN&SUBCUT TISSUE FACE | ICD-9-CM Diagnosis |
| 214.1 | LIPOMA OTH SKIN&SUBCUTANEOUS TISSUE | ICD-9-CM Diagnosis |
| 214.2 | LIPOMA OF INTRATHORACIC ORGANS | ICD-9-CM Diagnosis |
| 214.3 | LIPOMA OF INTRA-ABDOMINAL ORGANS | ICD-9-CM Diagnosis |
| 214.4 | LIPOMA OF SPERMATIC CORD | ICD-9-CM Diagnosis |
| 214.8 | LIPOMA OF OTHER SPECIFIED SITES | ICD-9-CM Diagnosis |
| 214.9 | LIPOMA OF UNSPECIFIED SITE | ICD-9-CM Diagnosis |
| 215 | OTH BEN NEOPLSM CNCTV&OTH SFT TISS | ICD-9-CM Diagnosis |
| 215.0 | OTH BEN NEO CNCTV&OTH TISS HEAD&NCK | ICD-9-CM Diagnosis |
| 215.2 | OTH BEN NEO OTH SFT TIS ARM W/SHLDR | ICD-9-CM Diagnosis |
| 215.3 | OTH BEN NEO OTH SFT TISS LEG W/ HIP | ICD-9-CM Diagnosis |
| 215.4 | OTH BEN NEO CNCTV&OTH SFT TISS THOR | ICD-9-CM Diagnosis |
| 215.5 | OTH BEN NEOPLSM CNCTV&SFT TISS ABD | ICD-9-CM Diagnosis |
| 215.6 | OTH BEN NEO CNCTV&OTH SFT TISS PELV | ICD-9-CM Diagnosis |
| 215.7 | OTH BEN NEO CNCTV&OTH TISS TRNK UNS | ICD-9-CM Diagnosis |
| 215.8 | OTH BEN NEO CNCTV&OTH TISS OTH SITE | ICD-9-CM Diagnosis |
| 215.9 | OTH BEN NEO CNCTV&OTH SFT TISS | ICD-9-CM Diagnosis |
| 216 | BENIGN NEOPLASM OF SKIN | ICD-9-CM Diagnosis |
| 216.0 | BENIGN NEOPLASM OF SKIN OF LIP | ICD-9-CM Diagnosis |
| 216.1 | BEN NEOPLASM EYELID INCL CANTHUS | ICD-9-CM Diagnosis |
| 216.2 | BEN NEOPLASM EAR&EXT AUDITRY CANAL | ICD-9-CM Diagnosis |
| 216.3 | BEN NEOPLSM SKN OTH&UNSPEC PART FCE | ICD-9-CM Diagnosis |
| 216.4 | BENIGN NEOPLASM SCALP&SKIN NECK | ICD-9-CM Diagnosis |
| 216.5 | BEN NEOPLASM SKIN TRUNK NO SCROTUM | ICD-9-CM Diagnosis |
| 216.6 | BEN NEOPLSM SKN UP LIMB INCL SHLDR | ICD-9-CM Diagnosis |
| 216.7 | BEN NEOPLASM SKIN LOW LIMB INCL HIP | ICD-9-CM Diagnosis |
| 216.8 | BENIGN NEOPLASM OTH SPEC SITES SKIN | ICD-9-CM Diagnosis |
| 216.9 | BENIGN NEOPLASM SKIN SITE UNSPEC | ICD-9-CM Diagnosis |
| 217 | BENIGN NEOPLASM OF BREAST | ICD-9-CM Diagnosis |
| 218 | UTERINE LEIOMYOMA | ICD-9-CM Diagnosis |
| 218.0 | SUBMUCOUS LEIOMYOMA OF UTERUS | ICD-9-CM Diagnosis |
| 218.1 | INTRAMURAL LEIOMYOMA OF UTERUS | ICD-9-CM Diagnosis |
| 218.2 | SUBSEROUS LEIOMYOMA OF UTERUS | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 218.9 | LEIOMYOMA OF UTERUS, UNSPECIFIED | ICD-9-CM Diagnosis |
| 219 | OTHER BENIGN NEOPLASM OF UTERUS | ICD-9-CM Diagnosis |
| 219.0 | BENIGN NEOPLASM OF CERVIX UTERI | ICD-9-CM Diagnosis |
| 219.1 | BENIGN NEOPLASM OF CORPUS UTERI | ICD-9-CM Diagnosis |
| 219.8 | BEN NEOPLASM OTH SPEC PARTS UTERUS | ICD-9-CM Diagnosis |
| 219.9 | BENIGN NEOPLASM UTERUS PART UNSPEC | ICD-9-CM Diagnosis |
| 220 | BENIGN NEOPLASM OF OVARY | ICD-9-CM Diagnosis |
| 221 | BEN NEOPLASM OTH FE GENITAL ORGANS | ICD-9-CM Diagnosis |
| 221.0 | BEN NEOPLSM FALLOP TUBE&UTERINE LIG | ICD-9-CM Diagnosis |
| 221.1 | BENIGN NEOPLASM OF VAGINA | ICD-9-CM Diagnosis |
| 221.2 | BENIGN NEOPLASM OF VULVA | ICD-9-CM Diagnosis |
| 221.8 | BEN NEO OTH SPEC SITE FE GNT ORGN | ICD-9-CM Diagnosis |
| 221.9 | BEN NEOPLSM FE GENIT ORGN SITE UNS | ICD-9-CM Diagnosis |
| 222 | BENIGN NEOPLASM MALE GENITAL ORGANS | ICD-9-CM Diagnosis |
| 222.0 | BENIGN NEOPLASM OF TESTIS | ICD-9-CM Diagnosis |
| 222.1 | BENIGN NEOPLASM OF PENIS | ICD-9-CM Diagnosis |
| 222.2 | BENIGN NEOPLASM OF PROSTATE | ICD-9-CM Diagnosis |
| 222.3 | BENIGN NEOPLASM OF EPIDIDYMIS | ICD-9-CM Diagnosis |
| 222.4 | BENIGN NEOPLASM OF SCROTUM | ICD-9-CM Diagnosis |
| 222.8 | BEN NEO OTH SPEC SITE MALE GNT ORGN | ICD-9-CM Diagnosis |
| 222.9 | BEN NEOPLSM MALE GNT ORGN SITE UNS | ICD-9-CM Diagnosis |
| 223 | BEN NEOPLASM KIDNEY&OTH URIN ORGN | ICD-9-CM Diagnosis |
| 223.0 | BEN NEOPLASM KIDNEY EXCEPT PELVIS | ICD-9-CM Diagnosis |
| 223.1 | BENIGN NEOPLASM OF RENAL PELVIS | ICD-9-CM Diagnosis |
| 223.2 | BENIGN NEOPLASM OF URETER | ICD-9-CM Diagnosis |
| 223.3 | BENIGN NEOPLASM OF BLADDER | ICD-9-CM Diagnosis |
| 223.8 | BEN NEOPLSM OTH SPEC SITE URIN ORGN | ICD-9-CM Diagnosis |
| 223.81 | BENIGN NEOPLASM OF URETHRA | ICD-9-CM Diagnosis |
| 223.89 | BEN NEOPLSM OTH SPEC SITE URIN ORGN | ICD-9-CM Diagnosis |
| 223.9 | BEN NEOPLASM URIN ORGAN SITE UNSPEC | ICD-9-CM Diagnosis |
| 224 | BENIGN NEOPLASM OF EYE | ICD-9-CM Diagnosis |
| 224.0 | BENIGN NEOPLASM EYEBALL | ICD-9-CM Diagnosis |
| 224.1 | BENIGN NEOPLASM OF ORBIT | ICD-9-CM Diagnosis |
| 224.2 | BENIGN NEOPLASM OF LACRIMAL GLAND | ICD-9-CM Diagnosis |
| 224.3 | BENIGN NEOPLASM OF CONJUNCTIVA | ICD-9-CM Diagnosis |
| 224.4 | BENIGN NEOPLASM OF CORNEA | ICD-9-CM Diagnosis |
| 224.5 | BENIGN NEOPLASM OF RETINA | ICD-9-CM Diagnosis |
| 224.6 | BENIGN NEOPLASM OF CHOROID | ICD-9-CM Diagnosis |
| 224.7 | BENIGN NEOPLASM OF LACRIMAL DUCT | ICD-9-CM Diagnosis |
| 224.8 | BENIGN NEOPLASM OTH SPEC PARTS EYE | ICD-9-CM Diagnosis |
| 224.9 | BENIGN NEOPLASM EYE PART UNSPEC | ICD-9-CM Diagnosis |
| 225 | BEN NEOPLSM BRAIN&OTH PART NERV SYS | ICD-9-CM Diagnosis |
| 225.0 | BENIGN NEOPLASM OF BRAIN | ICD-9-CM Diagnosis |
| 225.1 | BENIGN NEOPLASM OF CRANIAL NERVES | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 225.2 | BENIGN NEOPLASM CEREBRAL MENINGES | ICD-9-CM Diagnosis |
| 225.3 | BENIGN NEOPLASM OF SPINAL CORD | ICD-9-CM Diagnosis |
| 225.4 | BENIGN NEOPLASM OF SPINAL MENINGES | ICD-9-CM Diagnosis |
| 225.8 | BEN NEOPLSM OTH SPEC SITE NERV SYS | ICD-9-CM Diagnosis |
| 225.9 | BEN NEOPLSM NERV SYSTEM PART UNSPEC | ICD-9-CM Diagnosis |
| 226 | BENIGN NEOPLASM OF THYROID GLANDS | ICD-9-CM Diagnosis |
| 227 | BEN NEO OTH ENDOCRN GLND&REL STRCT | ICD-9-CM Diagnosis |
| 227.0 | BENIGN NEOPLASM OF ADRENAL GLAND | ICD-9-CM Diagnosis |
| 227.1 | BENIGN NEOPLASM PARATHYROID GLAND | ICD-9-CM Diagnosis |
| 227.3 | BEN NEO PITUITRY&CRANIOPHRYNGL DUCT | ICD-9-CM Diagnosis |
| 227.4 | BENIGN NEOPLASM OF PINEAL GLAND | ICD-9-CM Diagnosis |
| 227.5 | BENIGN NEOPLASM OF CAROTID BODY | ICD-9-CM Diagnosis |
| 227.6 | BEN NEO AORTC BDY&OTH PARAGANGLIA | ICD-9-CM Diagnosis |
| 227.8 | BEN NEO OTH ENDOCRN GLND&REL STRCT | ICD-9-CM Diagnosis |
| 227.9 | BEN NEOPLSM ENDOCRN GLAND SITE UNS | ICD-9-CM Diagnosis |
| 228 | HEMANGIOMA&LYMPHANGIOMA ANY SITE | ICD-9-CM Diagnosis |
| 228.0 | HEMANGIOMA, ANY SITE | ICD-9-CM Diagnosis |
| 228.00 | HEMANGIOMA OF UNSPECIFIED SITE | ICD-9-CM Diagnosis |
| 228.01 | HEMANGIOMA SKIN&SUBCUTANEOUS TISSUE | ICD-9-CM Diagnosis |
| 228.02 | HEMANGIOMA INTRACRANIAL STRUCTURES | ICD-9-CM Diagnosis |
| 228.03 | HEMANGIOMA OF RETINA | ICD-9-CM Diagnosis |
| 228.04 | HEMANGIOMA INTRA-ABD STRUCTURES | ICD-9-CM Diagnosis |
| 228.09 | HEMANGIOMA OF OTHER SITES | ICD-9-CM Diagnosis |
| 228.1 | LYMPHANGIOMA, ANY SITE | ICD-9-CM Diagnosis |
| 229 | BENIGN NEOPLASM OTHER&UNSPEC SITES | ICD-9-CM Diagnosis |
| 229.0 | BENIGN NEOPLASM OF LYMPH NODES | ICD-9-CM Diagnosis |
| 229.8 | BENIGN NEOPLASM OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 229.9 | BENIGN NEOPLASM OF UNSPECIFIED SITE | ICD-9-CM Diagnosis |
| 230 | CARCINOMA SITU OF DIGESTIVE ORGANS | ICD-9-CM Diagnosis |
| 230.0 | CA SITU LIP ORAL CAVITY&PHARYNX | ICD-9-CM Diagnosis |
| 230.1 | CARCINOMA IN SITU OF ESOPHAGUS | ICD-9-CM Diagnosis |
| 230.2 | CARCINOMA IN SITU OF STOMACH | ICD-9-CM Diagnosis |
| 230.3 | CARCINOMA IN SITU OF COLON | ICD-9-CM Diagnosis |
| 230.4 | CARCINOMA IN SITU OF RECTUM | ICD-9-CM Diagnosis |
| 230.5 | CARCINOMA IN SITU OF ANAL CANAL | ICD-9-CM Diagnosis |
| 230.6 | CARCINOMA SITU OF ANUS UNSPECIFIED | ICD-9-CM Diagnosis |
| 230.7 | CA SITU OTH&UNSPEC PARTS INTESTINE | ICD-9-CM Diagnosis |
| 230.8 | CARCINOMA SITU LIVER&BILIARY SYSTEM | ICD-9-CM Diagnosis |
| 230.9 | CA SITU OTH&UNSPEC DIGESTIVE ORGANS | ICD-9-CM Diagnosis |
| 231 | CARCINOMA SITU RESPIRATORY SYSTEM | ICD-9-CM Diagnosis |
| 231.0 | CARCINOMA IN SITU OF LARYNX | ICD-9-CM Diagnosis |
| 231.1 | CARCINOMA IN SITU OF TRACHEA | ICD-9-CM Diagnosis |
| 231.2 | CARCINOMA IN SITU OF BRONCHUS&LUNG | ICD-9-CM Diagnosis |
| 231.8 | CA SITU OTH SPEC PARTS RESP SYSTEM | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 231.9 | CA SITU RESP SYSTEM PART UNSPEC | ICD-9-CM Diagnosis |
| 232 | CARCINOMA IN SITU OF SKIN | ICD-9-CM Diagnosis |
| 232.0 | CARCINOMA IN SITU OF SKIN OF LIP | ICD-9-CM Diagnosis |
| 232.1 | CA SITU EYELID INCLUDING CANTHUS | ICD-9-CM Diagnosis |
| 232.2 | CA SITU SKIN EAR&EXT AUDITRY CANAL | ICD-9-CM Diagnosis |
| 232.3 | CA SITU SKIN OTH&UNSPEC PARTS FACE | ICD-9-CM Diagnosis |
| 232.4 | CARCINOMA SITU SCALP&SKIN NECK | ICD-9-CM Diagnosis |
| 232.5 | CA SITU SKIN TRUNK EXCEPT SCROTUM | ICD-9-CM Diagnosis |
| 232.6 | CA SITU SKIN UPPER LIMB INCL SHLDR | ICD-9-CM Diagnosis |
| 232.7 | CA SITU SKIN LOWER LIMB INCL HIP | ICD-9-CM Diagnosis |
| 232.8 | CARCINOMA SITU OTH SPEC SITES SKIN | ICD-9-CM Diagnosis |
| 232.9 | CARCINOMA SITU SKIN SITE UNSPEC | ICD-9-CM Diagnosis |
| 233 | CA SITU BREAST&GENITOURINARY SYSTEM | ICD-9-CM Diagnosis |
| 233.0 | CARCINOMA IN SITU OF BREAST | ICD-9-CM Diagnosis |
| 233.1 | CARCINOMA IN SITU OF CERVIX UTERI | ICD-9-CM Diagnosis |
| 233.2 | CA SITU OTH&UNSPEC PARTS UTERUS | ICD-9-CM Diagnosis |
| 233.3 | CA SITU OTH&UNSPEC FE GENITAL ORGN | ICD-9-CM Diagnosis |
| 233.30 | CA IN SITU UNS FEMALE GENITAL ORGAN | ICD-9-CM Diagnosis |
| 233.31 | CARCINOMA IN SITU VAGINA | ICD-9-CM Diagnosis |
| 233.32 | CARCINOMA IN SITU VULVA | ICD-9-CM Diagnosis |
| 233.39 | CA IN SITU OTH FEMALE GENITAL ORGAN | ICD-9-CM Diagnosis |
| 233.4 | CARCINOMA IN SITU OF PROSTATE | ICD-9-CM Diagnosis |
| 233.5 | CARCINOMA IN SITU OF PENIS | ICD-9-CM Diagnosis |
| 233.6 | CA SITU OTH&UNSPEC MALE GENIT ORGN | ICD-9-CM Diagnosis |
| 233.7 | CARCINOMA IN SITU OF BLADDER | ICD-9-CM Diagnosis |
| 233.9 | CA SITU OTH&UNSPEC URINARY ORGANS | ICD-9-CM Diagnosis |
| 234 | CARCINOMA SITU OTHER&UNSPEC SITES | ICD-9-CM Diagnosis |
| 234.0 | CARCINOMA IN SITU OF EYE | ICD-9-CM Diagnosis |
| 234.8 | CARCINOMA SITU OTHER SPEC SITES | ICD-9-CM Diagnosis |
| 234.9 | CARCINOMA IN SITU, SITE UNSPECIFIED | ICD-9-CM Diagnosis |
| 235 | NEOPLSM UNCERT BHV DIGESTV&RESP SYS | ICD-9-CM Diagnosis |
| 235.0 | NEOPLSM UNCERT BHV MAJ SALIV GLND | ICD-9-CM Diagnosis |
| 235.1 | NEO UNCERT BHV LIP ORL CAV&PHARYNX | ICD-9-CM Diagnosis |
| 235.2 | NEO UNCERT BHV STOMACH INTEST&RECT | ICD-9-CM Diagnosis |
| 235.3 | NEO UNCERT BHV LIVER&BILI PASSAGES | ICD-9-CM Diagnosis |
| 235.4 | NEO UNCERT BHV RETROPERITON&PERITON | ICD-9-CM Diagnosis |
| 235.5 | NEO UNCERT BHV OTH&UNS DIGESTV ORGN | ICD-9-CM Diagnosis |
| 235.6 | NEOPLASM UNCERTAIN BEHAVIOR LARYNX | ICD-9-CM Diagnosis |
| 235.7 | NEO UNCERT BHV TRACH BRONCHUS&LUNG | ICD-9-CM Diagnosis |
| 235.8 | NEO UNCERT BHV PLEU THYMUS&MEDIAST | ICD-9-CM Diagnosis |
| 235.9 | NEO UNCERT BHV OTH&UNS RESP ORGN | ICD-9-CM Diagnosis |
| 236 | NEOPLASM UNCERTAIN BEHAVIOR GU ORGN | ICD-9-CM Diagnosis |
| 236.0 | NEOPLASM UNCERTAIN BEHAVIOR UTERUS | ICD-9-CM Diagnosis |
| 236.1 | NEOPLASM UNCERTAIN BHV PLACENTA | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|-------------------------------------|--------------------|
| 236.2 | NEOPLASM UNCERTAIN BEHAVIOR OVARY | ICD-9-CM Diagnosis |
| 236.3 | NEO UNCERT BHV OTH&UNS FE GNT ORGN | ICD-9-CM Diagnosis |
| 236.4 | NEOPLASM UNCERTAIN BEHAVIOR TESTIS | ICD-9-CM Diagnosis |
| 236.5 | NEOPLASM UNCERTAIN BEHAVIOR PROS | ICD-9-CM Diagnosis |
| 236.6 | NEO UNCERT BHV UNS MALE GNT ORGN | ICD-9-CM Diagnosis |
| 236.7 | NEOPLASM UNCERTAIN BEHAVIOR BLADDER | ICD-9-CM Diagnosis |
| 236.9 | NEO UNCERT BHV OTH&UNS URIN ORGN | ICD-9-CM Diagnosis |
| 236.90 | NEOPLSM UNCERT BHV URIN ORGN UNSPEC | ICD-9-CM Diagnosis |
| 236.91 | NEOPLSM UNCERTAIN BHV KIDNEY&URETER | ICD-9-CM Diagnosis |
| 236.99 | NEO UNCERT BHV OTH&UNS URIN ORGN | ICD-9-CM Diagnosis |
| 237 | NEO UNCERT BHV ENDOCRN GLND&NRV SYS | ICD-9-CM Diagnosis |
| 237.0 | NEO UNCERT BHV PITUITARY GLAND | ICD-9-CM Diagnosis |
| 237.1 | NEOPLASM UNCERTAIN BHV PINEAL GLAND | ICD-9-CM Diagnosis |
| 237.2 | NEOPLSM UNCERTAIN BHV ADRENAL GLAND | ICD-9-CM Diagnosis |
| 237.3 | NEOPLASM UNCERTAIN BHV PARAGANGLIA | ICD-9-CM Diagnosis |
| 237.4 | NEO UNCERT BHV OTH&UNS ENDOCRN GLND | ICD-9-CM Diagnosis |
| 237.5 | NEOPLSM UNCERTAIN BHV BRAIN&SP CORD | ICD-9-CM Diagnosis |
| 237.6 | NEOPLASM UNCERTAIN BHV MENINGES | ICD-9-CM Diagnosis |
| 237.7 | NEUROFIBROMATOSIS | ICD-9-CM Diagnosis |
| 237.70 | NEUROFIBROMATOSIS, UNSPECIFIED | ICD-9-CM Diagnosis |
| 237.71 | NEUROFIBROMATOSIS, TYPE 1 | ICD-9-CM Diagnosis |
| 237.72 | NEUROFIBROMATOSIS, TYPE 2 | ICD-9-CM Diagnosis |
| 237.73 | SCHWANNOMATOSIS | ICD-9-CM Diagnosis |
| 237.79 | OTHER NEUROFIBROMATOSIS | ICD-9-CM Diagnosis |
| 237.9 | NEO UNCERT BHV OTH&UNS PART NRV SYS | ICD-9-CM Diagnosis |
| 238 | NEO UNCERT BHV OTH&UNS SITE&TISS | ICD-9-CM Diagnosis |
| 238.0 | NEOPLSM UNCERT BHV BN&ARTICLR CART | ICD-9-CM Diagnosis |
| 238.1 | NEO UNCERT BHV CNCTV&OTH SFT TISS | ICD-9-CM Diagnosis |
| 238.2 | NEOPLASM UNCERTAIN BEHAVIOR SKIN | ICD-9-CM Diagnosis |
| 238.3 | NEOPLASM UNCERTAIN BEHAVIOR BREAST | ICD-9-CM Diagnosis |
| 238.4 | NEO UNCERT BHV POLYCYTHEMIA VERA | ICD-9-CM Diagnosis |
| 238.5 | NEO UNCERT BHV HISTCYT&MAST CELLS | ICD-9-CM Diagnosis |
| 238.6 | NEOPLASM UNCERTAIN BHV PLASMA CELLS | ICD-9-CM Diagnosis |
| 238.7 | NEO UNCERT BHV OTH LYMPH&HEMATOPOT | ICD-9-CM Diagnosis |
| 238.71 | ESSENTIAL THROMBOCYTHEMIA | ICD-9-CM Diagnosis |
| 238.72 | LW GRADE MYELODYSPLSTC SYNDROME LES | ICD-9-CM Diagnosis |
| 238.73 | HIGH GRADE MYELODYSPLSTC SYND LES | ICD-9-CM Diagnosis |
| 238.74 | MYELODYSPLASTIC SYNDROME W/5Q DEL | ICD-9-CM Diagnosis |
| 238.75 | MYELODYSPLASTIC SYNDROME UNSPEC | ICD-9-CM Diagnosis |
| 238.76 | MYELOFIBROSIS W/MYELOID METAPLASIA | ICD-9-CM Diagnosis |
| 238.77 | POST-TRANSPLANT LYMPHOPROLIF D/O | ICD-9-CM Diagnosis |
| 238.79 | OTH LYMPHATIC&HEMATOPOIETIC TISSUES | ICD-9-CM Diagnosis |
| 238.8 | NEOPLSM UNCERTAIN BHV OTH SPEC SITE | ICD-9-CM Diagnosis |
| 238.9 | NEOPLASM UNCERTAIN BHV SITE UNSPEC | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|--|--------------------|
| 239 | NEOPLASMS OF UNSPECIFIED NATURE | ICD-9-CM Diagnosis |
| 239.0 | NEOPLASM UNSPEC NATR DIGESTV SYSTEM | ICD-9-CM Diagnosis |
| 239.1 | NEOPLASM UNSPEC NATURE RESP SYSTEM | ICD-9-CM Diagnosis |
| 239.2 | NEOPLSM UNSPEC NATR BN SFT TISS&SKN | ICD-9-CM Diagnosis |
| 239.3 | NEOPLASM UNSPECIFIED NATURE BREAST | ICD-9-CM Diagnosis |
| 239.4 | NEOPLASM UNSPECIFIED NATURE BLADDER | ICD-9-CM Diagnosis |
| 239.5 | NEOPLASM UNSPEC NATURE OTH GU ORGN | ICD-9-CM Diagnosis |
| 239.6 | NEOPLASM UNSPECIFIED NATURE BRAIN | ICD-9-CM Diagnosis |
| 239.7 | NEO UNS NATUR ENDOCRNE&OTH NERV SYS | ICD-9-CM Diagnosis |
| 239.8 | NEOPLASM UNSPEC NATR OTH SPEC SITES | ICD-9-CM Diagnosis |
| 239.81 | NEOPLSMS UNS NATR RETINA & CHOROID | ICD-9-CM Diagnosis |
| 239.89 | NEOPLSM UNSPEC NATR OTH SPEC SITES | ICD-9-CM Diagnosis |
| 239.9 | NEOPLASM UNSPEC NATURE SITE UNSPEC | ICD-9-CM Diagnosis |
| V66.2 | Convalescence and palliative care following chemotherapy | ICD-9-CM Diagnosis |
| V67.2 | Follow Up Examination Following Chemotherapy | ICD-9-CM Diagnosis |
| V58.1 | Cancer chemotherapy treatment | ICD-9-CM Diagnosis |
| V58.0 | Radiation therapy | ICD-9-CM Diagnosis |
| V66.1 | Radiation therapy | ICD-9-CM Diagnosis |
| 77401 | Radiation therapy | CPT-4 |
| 77402 | Radiation therapy | CPT-4 |
| 77403 | Radiation therapy | CPT-4 |
| 77404 | Radiation therapy | CPT-4 |
| 77405 | Radiation therapy | CPT-4 |
| 77406 | Radiation therapy | CPT-4 |
| 77407 | Radiation therapy | CPT-4 |
| 77408 | Radiation therapy | CPT-4 |
| 77409 | Radiation therapy | CPT-4 |
| 77410 | Radiation therapy | CPT-4 |
| 77411 | Radiation therapy | CPT-4 |
| 77412 | Radiation therapy | CPT-4 |
| 77413 | Radiation therapy | CPT-4 |
| 77414 | Radiation therapy | CPT-4 |
| 77415 | Radiation therapy | CPT-4 |
| 77416 | Radiation therapy | CPT-4 |
| 77417 | Radiation therapy | CPT-4 |
| 77418 | Radiation therapy | CPT-4 |
| 77419 | Radiation therapy | CPT-4 |
| 77420 | Radiation therapy | CPT-4 |
| 77421 | Radiation therapy | CPT-4 |
| 77422 | Radiation therapy | CPT-4 |
| 77423 | Radiation therapy | CPT-4 |
| 77424 | Radiation therapy | CPT-4 |
| 77425 | Radiation therapy | CPT-4 |
| 77426 | Radiation therapy | CPT-4 |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------|-----------|
| 77427 | Radiation therapy | CPT-4 |
| 77428 | Radiation therapy | CPT-4 |
| 77429 | Radiation therapy | CPT-4 |
| 77430 | Radiation therapy | CPT-4 |
| 77431 | Radiation therapy | CPT-4 |
| 77432 | Radiation therapy | CPT-4 |
| 77433 | Radiation therapy | CPT-4 |
| 77434 | Radiation therapy | CPT-4 |
| 77435 | Radiation therapy | CPT-4 |
| 77436 | Radiation therapy | CPT-4 |
| 77437 | Radiation therapy | CPT-4 |
| 77438 | Radiation therapy | CPT-4 |
| 77439 | Radiation therapy | CPT-4 |
| 77440 | Radiation therapy | CPT-4 |
| 77441 | Radiation therapy | CPT-4 |
| 77442 | Radiation therapy | CPT-4 |
| 77443 | Radiation therapy | CPT-4 |
| 77444 | Radiation therapy | CPT-4 |
| 77445 | Radiation therapy | CPT-4 |
| 77446 | Radiation therapy | CPT-4 |
| 77447 | Radiation therapy | CPT-4 |
| 77448 | Radiation therapy | CPT-4 |
| 77449 | Radiation therapy | CPT-4 |
| 77450 | Radiation therapy | CPT-4 |
| 77451 | Radiation therapy | CPT-4 |
| 77452 | Radiation therapy | CPT-4 |
| 77453 | Radiation therapy | CPT-4 |
| 77454 | Radiation therapy | CPT-4 |
| 77455 | Radiation therapy | CPT-4 |
| 77456 | Radiation therapy | CPT-4 |
| 77457 | Radiation therapy | CPT-4 |
| 77458 | Radiation therapy | CPT-4 |
| 77459 | Radiation therapy | CPT-4 |
| 77460 | Radiation therapy | CPT-4 |
| 77461 | Radiation therapy | CPT-4 |
| 77462 | Radiation therapy | CPT-4 |
| 77463 | Radiation therapy | CPT-4 |
| 77464 | Radiation therapy | CPT-4 |
| 77465 | Radiation therapy | CPT-4 |
| 77466 | Radiation therapy | CPT-4 |
| 77467 | Radiation therapy | CPT-4 |
| 77468 | Radiation therapy | CPT-4 |
| 77469 | Radiation therapy | CPT-4 |
| 77470 | Radiation therapy | CPT-4 |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------|-----------|
| 77471 | Radiation therapy | CPT-4 |
| 77472 | Radiation therapy | CPT-4 |
| 77473 | Radiation therapy | CPT-4 |
| 77474 | Radiation therapy | CPT-4 |
| 77475 | Radiation therapy | CPT-4 |
| 77476 | Radiation therapy | CPT-4 |
| 77477 | Radiation therapy | CPT-4 |
| 77478 | Radiation therapy | CPT-4 |
| 77479 | Radiation therapy | CPT-4 |
| 77480 | Radiation therapy | CPT-4 |
| 77481 | Radiation therapy | CPT-4 |
| 77482 | Radiation therapy | CPT-4 |
| 77483 | Radiation therapy | CPT-4 |
| 77484 | Radiation therapy | CPT-4 |
| 77485 | Radiation therapy | CPT-4 |
| 77486 | Radiation therapy | CPT-4 |
| 77487 | Radiation therapy | CPT-4 |
| 77488 | Radiation therapy | CPT-4 |
| 77489 | Radiation therapy | CPT-4 |
| 77490 | Radiation therapy | CPT-4 |
| 77491 | Radiation therapy | CPT-4 |
| 77492 | Radiation therapy | CPT-4 |
| 77493 | Radiation therapy | CPT-4 |
| 77494 | Radiation therapy | CPT-4 |
| 77495 | Radiation therapy | CPT-4 |
| 77496 | Radiation therapy | CPT-4 |
| 77497 | Radiation therapy | CPT-4 |
| 77498 | Radiation therapy | CPT-4 |
| 77499 | Radiation therapy | CPT-4 |
| 77520 | Radiation therapy | CPT-4 |
| 77523 | Radiation therapy | CPT-4 |
| 77750 | Radiation therapy | CPT-4 |
| 77751 | Radiation therapy | CPT-4 |
| 77752 | Radiation therapy | CPT-4 |
| 77753 | Radiation therapy | CPT-4 |
| 77754 | Radiation therapy | CPT-4 |
| 77755 | Radiation therapy | CPT-4 |
| 77756 | Radiation therapy | CPT-4 |
| 77757 | Radiation therapy | CPT-4 |
| 77758 | Radiation therapy | CPT-4 |
| 77759 | Radiation therapy | CPT-4 |
| 77760 | Radiation therapy | CPT-4 |
| 77761 | Radiation therapy | CPT-4 |
| 77762 | Radiation therapy | CPT-4 |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| 77763 | Radiation therapy | CPT-4 |
| 77764 | Radiation therapy | CPT-4 |
| 77765 | Radiation therapy | CPT-4 |
| 77766 | Radiation therapy | CPT-4 |
| 77767 | Radiation therapy | CPT-4 |
| 77768 | Radiation therapy | CPT-4 |
| 77769 | Radiation therapy | CPT-4 |
| 77770 | Radiation therapy | CPT-4 |
| 77771 | Radiation therapy | CPT-4 |
| 77772 | Radiation therapy | CPT-4 |
| 77773 | Radiation therapy | CPT-4 |
| 77774 | Radiation therapy | CPT-4 |
| 77775 | Radiation therapy | CPT-4 |
| 77776 | Radiation therapy | CPT-4 |
| 77777 | Radiation therapy | CPT-4 |
| 77778 | Radiation therapy | CPT-4 |
| 77779 | Radiation therapy | CPT-4 |
| 77780 | Radiation therapy | CPT-4 |
| 77781 | Radiation therapy | CPT-4 |
| 77782 | Radiation therapy | CPT-4 |
| 77783 | Radiation therapy | CPT-4 |
| 77784 | Radiation therapy | CPT-4 |
| 77785 | Radiation therapy | CPT-4 |
| 77786 | Radiation therapy | CPT-4 |
| 77787 | Radiation therapy | CPT-4 |
| 77788 | Radiation therapy | CPT-4 |
| 77789 | Radiation therapy | CPT-4 |
| 77790 | Radiation therapy | CPT-4 |
| 77791 | Radiation therapy | CPT-4 |
| 77792 | Radiation therapy | CPT-4 |
| 77793 | Radiation therapy | CPT-4 |
| 77794 | Radiation therapy | CPT-4 |
| 77795 | Radiation therapy | CPT-4 |
| 77796 | Radiation therapy | CPT-4 |
| 77797 | Radiation therapy | CPT-4 |
| 77798 | Radiation therapy | CPT-4 |
| 77799 | Radiation therapy | CPT-4 |
| J9000 | Cancer chemotherapy treatment | HCPCS |
| J9001 | Cancer chemotherapy treatment | HCPCS |
| J9002 | Cancer chemotherapy treatment | HCPCS |
| J9003 | Cancer chemotherapy treatment | HCPCS |
| J9004 | Cancer chemotherapy treatment | HCPCS |
| J9005 | Cancer chemotherapy treatment | HCPCS |
| J9006 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9007 | Cancer chemotherapy treatment | HCPCS |
| J9008 | Cancer chemotherapy treatment | HCPCS |
| J9009 | Cancer chemotherapy treatment | HCPCS |
| J9010 | Cancer chemotherapy treatment | HCPCS |
| J9011 | Cancer chemotherapy treatment | HCPCS |
| J9012 | Cancer chemotherapy treatment | HCPCS |
| J9013 | Cancer chemotherapy treatment | HCPCS |
| J9014 | Cancer chemotherapy treatment | HCPCS |
| J9015 | Cancer chemotherapy treatment | HCPCS |
| J9016 | Cancer chemotherapy treatment | HCPCS |
| J9017 | Cancer chemotherapy treatment | HCPCS |
| J9018 | Cancer chemotherapy treatment | HCPCS |
| J9019 | Cancer chemotherapy treatment | HCPCS |
| J9020 | Cancer chemotherapy treatment | HCPCS |
| J9021 | Cancer chemotherapy treatment | HCPCS |
| J9022 | Cancer chemotherapy treatment | HCPCS |
| J9023 | Cancer chemotherapy treatment | HCPCS |
| J9024 | Cancer chemotherapy treatment | HCPCS |
| J9025 | Cancer chemotherapy treatment | HCPCS |
| J9026 | Cancer chemotherapy treatment | HCPCS |
| J9027 | Cancer chemotherapy treatment | HCPCS |
| J9028 | Cancer chemotherapy treatment | HCPCS |
| J9029 | Cancer chemotherapy treatment | HCPCS |
| J9030 | Cancer chemotherapy treatment | HCPCS |
| J9031 | Cancer chemotherapy treatment | HCPCS |
| J9032 | Cancer chemotherapy treatment | HCPCS |
| J9033 | Cancer chemotherapy treatment | HCPCS |
| J9034 | Cancer chemotherapy treatment | HCPCS |
| J9035 | Cancer chemotherapy treatment | HCPCS |
| J9036 | Cancer chemotherapy treatment | HCPCS |
| J9037 | Cancer chemotherapy treatment | HCPCS |
| J9038 | Cancer chemotherapy treatment | HCPCS |
| J9039 | Cancer chemotherapy treatment | HCPCS |
| J9040 | Cancer chemotherapy treatment | HCPCS |
| J9041 | Cancer chemotherapy treatment | HCPCS |
| J9042 | Cancer chemotherapy treatment | HCPCS |
| J9043 | Cancer chemotherapy treatment | HCPCS |
| J9044 | Cancer chemotherapy treatment | HCPCS |
| J9045 | Cancer chemotherapy treatment | HCPCS |
| J9046 | Cancer chemotherapy treatment | HCPCS |
| J9047 | Cancer chemotherapy treatment | HCPCS |
| J9048 | Cancer chemotherapy treatment | HCPCS |
| J9049 | Cancer chemotherapy treatment | HCPCS |
| J9050 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9051 | Cancer chemotherapy treatment | HCPCS |
| J9052 | Cancer chemotherapy treatment | HCPCS |
| J9053 | Cancer chemotherapy treatment | HCPCS |
| J9054 | Cancer chemotherapy treatment | HCPCS |
| J9055 | Cancer chemotherapy treatment | HCPCS |
| J9056 | Cancer chemotherapy treatment | HCPCS |
| J9057 | Cancer chemotherapy treatment | HCPCS |
| J9058 | Cancer chemotherapy treatment | HCPCS |
| J9059 | Cancer chemotherapy treatment | HCPCS |
| J9060 | Cancer chemotherapy treatment | HCPCS |
| J9061 | Cancer chemotherapy treatment | HCPCS |
| J9062 | Cancer chemotherapy treatment | HCPCS |
| J9063 | Cancer chemotherapy treatment | HCPCS |
| J9064 | Cancer chemotherapy treatment | HCPCS |
| J9065 | Cancer chemotherapy treatment | HCPCS |
| J9066 | Cancer chemotherapy treatment | HCPCS |
| J9067 | Cancer chemotherapy treatment | HCPCS |
| J9068 | Cancer chemotherapy treatment | HCPCS |
| J9069 | Cancer chemotherapy treatment | HCPCS |
| J9070 | Cancer chemotherapy treatment | HCPCS |
| J9071 | Cancer chemotherapy treatment | HCPCS |
| J9072 | Cancer chemotherapy treatment | HCPCS |
| J9073 | Cancer chemotherapy treatment | HCPCS |
| J9074 | Cancer chemotherapy treatment | HCPCS |
| J9075 | Cancer chemotherapy treatment | HCPCS |
| J9076 | Cancer chemotherapy treatment | HCPCS |
| J9077 | Cancer chemotherapy treatment | HCPCS |
| J9078 | Cancer chemotherapy treatment | HCPCS |
| J9079 | Cancer chemotherapy treatment | HCPCS |
| J9080 | Cancer chemotherapy treatment | HCPCS |
| J9081 | Cancer chemotherapy treatment | HCPCS |
| J9082 | Cancer chemotherapy treatment | HCPCS |
| J9083 | Cancer chemotherapy treatment | HCPCS |
| J9084 | Cancer chemotherapy treatment | HCPCS |
| J9085 | Cancer chemotherapy treatment | HCPCS |
| J9086 | Cancer chemotherapy treatment | HCPCS |
| J9087 | Cancer chemotherapy treatment | HCPCS |
| J9088 | Cancer chemotherapy treatment | HCPCS |
| J9089 | Cancer chemotherapy treatment | HCPCS |
| J9090 | Cancer chemotherapy treatment | HCPCS |
| J9091 | Cancer chemotherapy treatment | HCPCS |
| J9092 | Cancer chemotherapy treatment | HCPCS |
| J9093 | Cancer chemotherapy treatment | HCPCS |
| J9094 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9095 | Cancer chemotherapy treatment | HCPCS |
| J9096 | Cancer chemotherapy treatment | HCPCS |
| J9097 | Cancer chemotherapy treatment | HCPCS |
| J9098 | Cancer chemotherapy treatment | HCPCS |
| J9099 | Cancer chemotherapy treatment | HCPCS |
| J9100 | Cancer chemotherapy treatment | HCPCS |
| J9101 | Cancer chemotherapy treatment | HCPCS |
| J9102 | Cancer chemotherapy treatment | HCPCS |
| J9103 | Cancer chemotherapy treatment | HCPCS |
| J9104 | Cancer chemotherapy treatment | HCPCS |
| J9105 | Cancer chemotherapy treatment | HCPCS |
| J9106 | Cancer chemotherapy treatment | HCPCS |
| J9107 | Cancer chemotherapy treatment | HCPCS |
| J9108 | Cancer chemotherapy treatment | HCPCS |
| J9109 | Cancer chemotherapy treatment | HCPCS |
| J9110 | Cancer chemotherapy treatment | HCPCS |
| J9111 | Cancer chemotherapy treatment | HCPCS |
| J9112 | Cancer chemotherapy treatment | HCPCS |
| J9113 | Cancer chemotherapy treatment | HCPCS |
| J9114 | Cancer chemotherapy treatment | HCPCS |
| J9115 | Cancer chemotherapy treatment | HCPCS |
| J9116 | Cancer chemotherapy treatment | HCPCS |
| J9117 | Cancer chemotherapy treatment | HCPCS |
| J9118 | Cancer chemotherapy treatment | HCPCS |
| J9119 | Cancer chemotherapy treatment | HCPCS |
| J9120 | Cancer chemotherapy treatment | HCPCS |
| J9121 | Cancer chemotherapy treatment | HCPCS |
| J9122 | Cancer chemotherapy treatment | HCPCS |
| J9123 | Cancer chemotherapy treatment | HCPCS |
| J9124 | Cancer chemotherapy treatment | HCPCS |
| J9125 | Cancer chemotherapy treatment | HCPCS |
| J9126 | Cancer chemotherapy treatment | HCPCS |
| J9127 | Cancer chemotherapy treatment | HCPCS |
| J9128 | Cancer chemotherapy treatment | HCPCS |
| J9129 | Cancer chemotherapy treatment | HCPCS |
| J9130 | Cancer chemotherapy treatment | HCPCS |
| J9131 | Cancer chemotherapy treatment | HCPCS |
| J9132 | Cancer chemotherapy treatment | HCPCS |
| J9133 | Cancer chemotherapy treatment | HCPCS |
| J9134 | Cancer chemotherapy treatment | HCPCS |
| J9135 | Cancer chemotherapy treatment | HCPCS |
| J9136 | Cancer chemotherapy treatment | HCPCS |
| J9137 | Cancer chemotherapy treatment | HCPCS |
| J9138 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9139 | Cancer chemotherapy treatment | HCPCS |
| J9140 | Cancer chemotherapy treatment | HCPCS |
| J9141 | Cancer chemotherapy treatment | HCPCS |
| J9142 | Cancer chemotherapy treatment | HCPCS |
| J9143 | Cancer chemotherapy treatment | HCPCS |
| J9144 | Cancer chemotherapy treatment | HCPCS |
| J9145 | Cancer chemotherapy treatment | HCPCS |
| J9146 | Cancer chemotherapy treatment | HCPCS |
| J9147 | Cancer chemotherapy treatment | HCPCS |
| J9148 | Cancer chemotherapy treatment | HCPCS |
| J9149 | Cancer chemotherapy treatment | HCPCS |
| J9150 | Cancer chemotherapy treatment | HCPCS |
| J9151 | Cancer chemotherapy treatment | HCPCS |
| J9152 | Cancer chemotherapy treatment | HCPCS |
| J9153 | Cancer chemotherapy treatment | HCPCS |
| J9154 | Cancer chemotherapy treatment | HCPCS |
| J9155 | Cancer chemotherapy treatment | HCPCS |
| J9156 | Cancer chemotherapy treatment | HCPCS |
| J9157 | Cancer chemotherapy treatment | HCPCS |
| J9158 | Cancer chemotherapy treatment | HCPCS |
| J9159 | Cancer chemotherapy treatment | HCPCS |
| J9160 | Cancer chemotherapy treatment | HCPCS |
| J9161 | Cancer chemotherapy treatment | HCPCS |
| J9162 | Cancer chemotherapy treatment | HCPCS |
| J9163 | Cancer chemotherapy treatment | HCPCS |
| J9164 | Cancer chemotherapy treatment | HCPCS |
| J9165 | Cancer chemotherapy treatment | HCPCS |
| J9166 | Cancer chemotherapy treatment | HCPCS |
| J9167 | Cancer chemotherapy treatment | HCPCS |
| J9168 | Cancer chemotherapy treatment | HCPCS |
| J9169 | Cancer chemotherapy treatment | HCPCS |
| J9170 | Cancer chemotherapy treatment | HCPCS |
| J9171 | Cancer chemotherapy treatment | HCPCS |
| J9172 | Cancer chemotherapy treatment | HCPCS |
| J9173 | Cancer chemotherapy treatment | HCPCS |
| J9174 | Cancer chemotherapy treatment | HCPCS |
| J9175 | Cancer chemotherapy treatment | HCPCS |
| J9176 | Cancer chemotherapy treatment | HCPCS |
| J9177 | Cancer chemotherapy treatment | HCPCS |
| J9178 | Cancer chemotherapy treatment | HCPCS |
| J9179 | Cancer chemotherapy treatment | HCPCS |
| J9180 | Cancer chemotherapy treatment | HCPCS |
| J9181 | Cancer chemotherapy treatment | HCPCS |
| J9182 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9183 | Cancer chemotherapy treatment | HCPCS |
| J9184 | Cancer chemotherapy treatment | HCPCS |
| J9185 | Cancer chemotherapy treatment | HCPCS |
| J9186 | Cancer chemotherapy treatment | HCPCS |
| J9187 | Cancer chemotherapy treatment | HCPCS |
| J9188 | Cancer chemotherapy treatment | HCPCS |
| J9189 | Cancer chemotherapy treatment | HCPCS |
| J9190 | Cancer chemotherapy treatment | HCPCS |
| J9191 | Cancer chemotherapy treatment | HCPCS |
| J9192 | Cancer chemotherapy treatment | HCPCS |
| J9193 | Cancer chemotherapy treatment | HCPCS |
| J9194 | Cancer chemotherapy treatment | HCPCS |
| J9195 | Cancer chemotherapy treatment | HCPCS |
| J9196 | Cancer chemotherapy treatment | HCPCS |
| J9197 | Cancer chemotherapy treatment | HCPCS |
| J9198 | Cancer chemotherapy treatment | HCPCS |
| J9199 | Cancer chemotherapy treatment | HCPCS |
| J9200 | Cancer chemotherapy treatment | HCPCS |
| J9201 | Cancer chemotherapy treatment | HCPCS |
| J9202 | Cancer chemotherapy treatment | HCPCS |
| J9203 | Cancer chemotherapy treatment | HCPCS |
| J9204 | Cancer chemotherapy treatment | HCPCS |
| J9205 | Cancer chemotherapy treatment | HCPCS |
| J9206 | Cancer chemotherapy treatment | HCPCS |
| J9207 | Cancer chemotherapy treatment | HCPCS |
| J9208 | Cancer chemotherapy treatment | HCPCS |
| J9209 | Cancer chemotherapy treatment | HCPCS |
| J9210 | Cancer chemotherapy treatment | HCPCS |
| J9211 | Cancer chemotherapy treatment | HCPCS |
| J9212 | Cancer chemotherapy treatment | HCPCS |
| J9213 | Cancer chemotherapy treatment | HCPCS |
| J9214 | Cancer chemotherapy treatment | HCPCS |
| J9215 | Cancer chemotherapy treatment | HCPCS |
| J9216 | Cancer chemotherapy treatment | HCPCS |
| J9217 | Cancer chemotherapy treatment | HCPCS |
| J9218 | Cancer chemotherapy treatment | HCPCS |
| J9219 | Cancer chemotherapy treatment | HCPCS |
| J9220 | Cancer chemotherapy treatment | HCPCS |
| J9221 | Cancer chemotherapy treatment | HCPCS |
| J9222 | Cancer chemotherapy treatment | HCPCS |
| J9223 | Cancer chemotherapy treatment | HCPCS |
| J9224 | Cancer chemotherapy treatment | HCPCS |
| J9225 | Cancer chemotherapy treatment | HCPCS |
| J9226 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9227 | Cancer chemotherapy treatment | HCPCS |
| J9228 | Cancer chemotherapy treatment | HCPCS |
| J9229 | Cancer chemotherapy treatment | HCPCS |
| J9230 | Cancer chemotherapy treatment | HCPCS |
| J9231 | Cancer chemotherapy treatment | HCPCS |
| J9232 | Cancer chemotherapy treatment | HCPCS |
| J9233 | Cancer chemotherapy treatment | HCPCS |
| J9234 | Cancer chemotherapy treatment | HCPCS |
| J9235 | Cancer chemotherapy treatment | HCPCS |
| J9236 | Cancer chemotherapy treatment | HCPCS |
| J9237 | Cancer chemotherapy treatment | HCPCS |
| J9238 | Cancer chemotherapy treatment | HCPCS |
| J9239 | Cancer chemotherapy treatment | HCPCS |
| J9240 | Cancer chemotherapy treatment | HCPCS |
| J9241 | Cancer chemotherapy treatment | HCPCS |
| J9242 | Cancer chemotherapy treatment | HCPCS |
| J9243 | Cancer chemotherapy treatment | HCPCS |
| J9244 | Cancer chemotherapy treatment | HCPCS |
| J9245 | Cancer chemotherapy treatment | HCPCS |
| J9246 | Cancer chemotherapy treatment | HCPCS |
| J9247 | Cancer chemotherapy treatment | HCPCS |
| J9248 | Cancer chemotherapy treatment | HCPCS |
| J9249 | Cancer chemotherapy treatment | HCPCS |
| J9250 | Cancer chemotherapy treatment | HCPCS |
| J9251 | Cancer chemotherapy treatment | HCPCS |
| J9252 | Cancer chemotherapy treatment | HCPCS |
| J9253 | Cancer chemotherapy treatment | HCPCS |
| J9254 | Cancer chemotherapy treatment | HCPCS |
| J9255 | Cancer chemotherapy treatment | HCPCS |
| J9256 | Cancer chemotherapy treatment | HCPCS |
| J9257 | Cancer chemotherapy treatment | HCPCS |
| J9258 | Cancer chemotherapy treatment | HCPCS |
| J9259 | Cancer chemotherapy treatment | HCPCS |
| J9260 | Cancer chemotherapy treatment | HCPCS |
| J9261 | Cancer chemotherapy treatment | HCPCS |
| J9262 | Cancer chemotherapy treatment | HCPCS |
| J9263 | Cancer chemotherapy treatment | HCPCS |
| J9264 | Cancer chemotherapy treatment | HCPCS |
| J9265 | Cancer chemotherapy treatment | HCPCS |
| J9266 | Cancer chemotherapy treatment | HCPCS |
| J9267 | Cancer chemotherapy treatment | HCPCS |
| J9268 | Cancer chemotherapy treatment | HCPCS |
| J9269 | Cancer chemotherapy treatment | HCPCS |
| J9270 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9271 | Cancer chemotherapy treatment | HCPCS |
| J9272 | Cancer chemotherapy treatment | HCPCS |
| J9273 | Cancer chemotherapy treatment | HCPCS |
| J9274 | Cancer chemotherapy treatment | HCPCS |
| J9275 | Cancer chemotherapy treatment | HCPCS |
| J9276 | Cancer chemotherapy treatment | HCPCS |
| J9277 | Cancer chemotherapy treatment | HCPCS |
| J9278 | Cancer chemotherapy treatment | HCPCS |
| J9279 | Cancer chemotherapy treatment | HCPCS |
| J9280 | Cancer chemotherapy treatment | HCPCS |
| J9281 | Cancer chemotherapy treatment | HCPCS |
| J9282 | Cancer chemotherapy treatment | HCPCS |
| J9283 | Cancer chemotherapy treatment | HCPCS |
| J9284 | Cancer chemotherapy treatment | HCPCS |
| J9285 | Cancer chemotherapy treatment | HCPCS |
| J9286 | Cancer chemotherapy treatment | HCPCS |
| J9287 | Cancer chemotherapy treatment | HCPCS |
| J9288 | Cancer chemotherapy treatment | HCPCS |
| J9289 | Cancer chemotherapy treatment | HCPCS |
| J9290 | Cancer chemotherapy treatment | HCPCS |
| J9291 | Cancer chemotherapy treatment | HCPCS |
| J9292 | Cancer chemotherapy treatment | HCPCS |
| J9293 | Cancer chemotherapy treatment | HCPCS |
| J9294 | Cancer chemotherapy treatment | HCPCS |
| J9295 | Cancer chemotherapy treatment | HCPCS |
| J9296 | Cancer chemotherapy treatment | HCPCS |
| J9297 | Cancer chemotherapy treatment | HCPCS |
| J9298 | Cancer chemotherapy treatment | HCPCS |
| J9299 | Cancer chemotherapy treatment | HCPCS |
| J9300 | Cancer chemotherapy treatment | HCPCS |
| J9301 | Cancer chemotherapy treatment | HCPCS |
| J9302 | Cancer chemotherapy treatment | HCPCS |
| J9303 | Cancer chemotherapy treatment | HCPCS |
| J9304 | Cancer chemotherapy treatment | HCPCS |
| J9305 | Cancer chemotherapy treatment | HCPCS |
| J9306 | Cancer chemotherapy treatment | HCPCS |
| J9307 | Cancer chemotherapy treatment | HCPCS |
| J9308 | Cancer chemotherapy treatment | HCPCS |
| J9309 | Cancer chemotherapy treatment | HCPCS |
| J9310 | Cancer chemotherapy treatment | HCPCS |
| J9311 | Cancer chemotherapy treatment | HCPCS |
| J9312 | Cancer chemotherapy treatment | HCPCS |
| J9313 | Cancer chemotherapy treatment | HCPCS |
| J9314 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9315 | Cancer chemotherapy treatment | HCPCS |
| J9316 | Cancer chemotherapy treatment | HCPCS |
| J9317 | Cancer chemotherapy treatment | HCPCS |
| J9318 | Cancer chemotherapy treatment | HCPCS |
| J9319 | Cancer chemotherapy treatment | HCPCS |
| J9320 | Cancer chemotherapy treatment | HCPCS |
| J9321 | Cancer chemotherapy treatment | HCPCS |
| J9322 | Cancer chemotherapy treatment | HCPCS |
| J9323 | Cancer chemotherapy treatment | HCPCS |
| J9324 | Cancer chemotherapy treatment | HCPCS |
| J9325 | Cancer chemotherapy treatment | HCPCS |
| J9326 | Cancer chemotherapy treatment | HCPCS |
| J9327 | Cancer chemotherapy treatment | HCPCS |
| J9328 | Cancer chemotherapy treatment | HCPCS |
| J9329 | Cancer chemotherapy treatment | HCPCS |
| J9330 | Cancer chemotherapy treatment | HCPCS |
| J9331 | Cancer chemotherapy treatment | HCPCS |
| J9332 | Cancer chemotherapy treatment | HCPCS |
| J9333 | Cancer chemotherapy treatment | HCPCS |
| J9334 | Cancer chemotherapy treatment | HCPCS |
| J9335 | Cancer chemotherapy treatment | HCPCS |
| J9336 | Cancer chemotherapy treatment | HCPCS |
| J9337 | Cancer chemotherapy treatment | HCPCS |
| J9338 | Cancer chemotherapy treatment | HCPCS |
| J9339 | Cancer chemotherapy treatment | HCPCS |
| J9340 | Cancer chemotherapy treatment | HCPCS |
| J9341 | Cancer chemotherapy treatment | HCPCS |
| J9342 | Cancer chemotherapy treatment | HCPCS |
| J9343 | Cancer chemotherapy treatment | HCPCS |
| J9344 | Cancer chemotherapy treatment | HCPCS |
| J9345 | Cancer chemotherapy treatment | HCPCS |
| J9346 | Cancer chemotherapy treatment | HCPCS |
| J9347 | Cancer chemotherapy treatment | HCPCS |
| J9348 | Cancer chemotherapy treatment | HCPCS |
| J9349 | Cancer chemotherapy treatment | HCPCS |
| J9350 | Cancer chemotherapy treatment | HCPCS |
| J9351 | Cancer chemotherapy treatment | HCPCS |
| J9352 | Cancer chemotherapy treatment | HCPCS |
| J9353 | Cancer chemotherapy treatment | HCPCS |
| J9354 | Cancer chemotherapy treatment | HCPCS |
| J9355 | Cancer chemotherapy treatment | HCPCS |
| J9356 | Cancer chemotherapy treatment | HCPCS |
| J9357 | Cancer chemotherapy treatment | HCPCS |
| J9358 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9359 | Cancer chemotherapy treatment | HCPCS |
| J9360 | Cancer chemotherapy treatment | HCPCS |
| J9361 | Cancer chemotherapy treatment | HCPCS |
| J9362 | Cancer chemotherapy treatment | HCPCS |
| J9363 | Cancer chemotherapy treatment | HCPCS |
| J9364 | Cancer chemotherapy treatment | HCPCS |
| J9365 | Cancer chemotherapy treatment | HCPCS |
| J9366 | Cancer chemotherapy treatment | HCPCS |
| J9367 | Cancer chemotherapy treatment | HCPCS |
| J9368 | Cancer chemotherapy treatment | HCPCS |
| J9369 | Cancer chemotherapy treatment | HCPCS |
| J9370 | Cancer chemotherapy treatment | HCPCS |
| J9371 | Cancer chemotherapy treatment | HCPCS |
| J9372 | Cancer chemotherapy treatment | HCPCS |
| J9373 | Cancer chemotherapy treatment | HCPCS |
| J9374 | Cancer chemotherapy treatment | HCPCS |
| J9375 | Cancer chemotherapy treatment | HCPCS |
| J9376 | Cancer chemotherapy treatment | HCPCS |
| J9377 | Cancer chemotherapy treatment | HCPCS |
| J9378 | Cancer chemotherapy treatment | HCPCS |
| J9379 | Cancer chemotherapy treatment | HCPCS |
| J9380 | Cancer chemotherapy treatment | HCPCS |
| J9381 | Cancer chemotherapy treatment | HCPCS |
| J9382 | Cancer chemotherapy treatment | HCPCS |
| J9383 | Cancer chemotherapy treatment | HCPCS |
| J9384 | Cancer chemotherapy treatment | HCPCS |
| J9385 | Cancer chemotherapy treatment | HCPCS |
| J9386 | Cancer chemotherapy treatment | HCPCS |
| J9387 | Cancer chemotherapy treatment | HCPCS |
| J9388 | Cancer chemotherapy treatment | HCPCS |
| J9389 | Cancer chemotherapy treatment | HCPCS |
| J9390 | Cancer chemotherapy treatment | HCPCS |
| J9391 | Cancer chemotherapy treatment | HCPCS |
| J9392 | Cancer chemotherapy treatment | HCPCS |
| J9393 | Cancer chemotherapy treatment | HCPCS |
| J9394 | Cancer chemotherapy treatment | HCPCS |
| J9395 | Cancer chemotherapy treatment | HCPCS |
| J9396 | Cancer chemotherapy treatment | HCPCS |
| J9397 | Cancer chemotherapy treatment | HCPCS |
| J9398 | Cancer chemotherapy treatment | HCPCS |
| J9399 | Cancer chemotherapy treatment | HCPCS |
| J9400 | Cancer chemotherapy treatment | HCPCS |
| J9401 | Cancer chemotherapy treatment | HCPCS |
| J9402 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9403 | Cancer chemotherapy treatment | HCPCS |
| J9404 | Cancer chemotherapy treatment | HCPCS |
| J9405 | Cancer chemotherapy treatment | HCPCS |
| J9406 | Cancer chemotherapy treatment | HCPCS |
| J9407 | Cancer chemotherapy treatment | HCPCS |
| J9408 | Cancer chemotherapy treatment | HCPCS |
| J9409 | Cancer chemotherapy treatment | HCPCS |
| J9410 | Cancer chemotherapy treatment | HCPCS |
| J9411 | Cancer chemotherapy treatment | HCPCS |
| J9412 | Cancer chemotherapy treatment | HCPCS |
| J9413 | Cancer chemotherapy treatment | HCPCS |
| J9414 | Cancer chemotherapy treatment | HCPCS |
| J9415 | Cancer chemotherapy treatment | HCPCS |
| J9416 | Cancer chemotherapy treatment | HCPCS |
| J9417 | Cancer chemotherapy treatment | HCPCS |
| J9418 | Cancer chemotherapy treatment | HCPCS |
| J9419 | Cancer chemotherapy treatment | HCPCS |
| J9420 | Cancer chemotherapy treatment | HCPCS |
| J9421 | Cancer chemotherapy treatment | HCPCS |
| J9422 | Cancer chemotherapy treatment | HCPCS |
| J9423 | Cancer chemotherapy treatment | HCPCS |
| J9424 | Cancer chemotherapy treatment | HCPCS |
| J9425 | Cancer chemotherapy treatment | HCPCS |
| J9426 | Cancer chemotherapy treatment | HCPCS |
| J9427 | Cancer chemotherapy treatment | HCPCS |
| J9428 | Cancer chemotherapy treatment | HCPCS |
| J9429 | Cancer chemotherapy treatment | HCPCS |
| J9430 | Cancer chemotherapy treatment | HCPCS |
| J9431 | Cancer chemotherapy treatment | HCPCS |
| J9432 | Cancer chemotherapy treatment | HCPCS |
| J9433 | Cancer chemotherapy treatment | HCPCS |
| J9434 | Cancer chemotherapy treatment | HCPCS |
| J9435 | Cancer chemotherapy treatment | HCPCS |
| J9436 | Cancer chemotherapy treatment | HCPCS |
| J9437 | Cancer chemotherapy treatment | HCPCS |
| J9438 | Cancer chemotherapy treatment | HCPCS |
| J9439 | Cancer chemotherapy treatment | HCPCS |
| J9440 | Cancer chemotherapy treatment | HCPCS |
| J9441 | Cancer chemotherapy treatment | HCPCS |
| J9442 | Cancer chemotherapy treatment | HCPCS |
| J9443 | Cancer chemotherapy treatment | HCPCS |
| J9444 | Cancer chemotherapy treatment | HCPCS |
| J9445 | Cancer chemotherapy treatment | HCPCS |
| J9446 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9447 | Cancer chemotherapy treatment | HCPCS |
| J9448 | Cancer chemotherapy treatment | HCPCS |
| J9449 | Cancer chemotherapy treatment | HCPCS |
| J9450 | Cancer chemotherapy treatment | HCPCS |
| J9451 | Cancer chemotherapy treatment | HCPCS |
| J9452 | Cancer chemotherapy treatment | HCPCS |
| J9453 | Cancer chemotherapy treatment | HCPCS |
| J9454 | Cancer chemotherapy treatment | HCPCS |
| J9455 | Cancer chemotherapy treatment | HCPCS |
| J9456 | Cancer chemotherapy treatment | HCPCS |
| J9457 | Cancer chemotherapy treatment | HCPCS |
| J9458 | Cancer chemotherapy treatment | HCPCS |
| J9459 | Cancer chemotherapy treatment | HCPCS |
| J9460 | Cancer chemotherapy treatment | HCPCS |
| J9461 | Cancer chemotherapy treatment | HCPCS |
| J9462 | Cancer chemotherapy treatment | HCPCS |
| J9463 | Cancer chemotherapy treatment | HCPCS |
| J9464 | Cancer chemotherapy treatment | HCPCS |
| J9465 | Cancer chemotherapy treatment | HCPCS |
| J9466 | Cancer chemotherapy treatment | HCPCS |
| J9467 | Cancer chemotherapy treatment | HCPCS |
| J9468 | Cancer chemotherapy treatment | HCPCS |
| J9469 | Cancer chemotherapy treatment | HCPCS |
| J9470 | Cancer chemotherapy treatment | HCPCS |
| J9471 | Cancer chemotherapy treatment | HCPCS |
| J9472 | Cancer chemotherapy treatment | HCPCS |
| J9473 | Cancer chemotherapy treatment | HCPCS |
| J9474 | Cancer chemotherapy treatment | HCPCS |
| J9475 | Cancer chemotherapy treatment | HCPCS |
| J9476 | Cancer chemotherapy treatment | HCPCS |
| J9477 | Cancer chemotherapy treatment | HCPCS |
| J9478 | Cancer chemotherapy treatment | HCPCS |
| J9479 | Cancer chemotherapy treatment | HCPCS |
| J9480 | Cancer chemotherapy treatment | HCPCS |
| J9481 | Cancer chemotherapy treatment | HCPCS |
| J9482 | Cancer chemotherapy treatment | HCPCS |
| J9483 | Cancer chemotherapy treatment | HCPCS |
| J9484 | Cancer chemotherapy treatment | HCPCS |
| J9485 | Cancer chemotherapy treatment | HCPCS |
| J9486 | Cancer chemotherapy treatment | HCPCS |
| J9487 | Cancer chemotherapy treatment | HCPCS |
| J9488 | Cancer chemotherapy treatment | HCPCS |
| J9489 | Cancer chemotherapy treatment | HCPCS |
| J9490 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9491 | Cancer chemotherapy treatment | HCPCS |
| J9492 | Cancer chemotherapy treatment | HCPCS |
| J9493 | Cancer chemotherapy treatment | HCPCS |
| J9494 | Cancer chemotherapy treatment | HCPCS |
| J9495 | Cancer chemotherapy treatment | HCPCS |
| J9496 | Cancer chemotherapy treatment | HCPCS |
| J9497 | Cancer chemotherapy treatment | HCPCS |
| J9498 | Cancer chemotherapy treatment | HCPCS |
| J9499 | Cancer chemotherapy treatment | HCPCS |
| J9500 | Cancer chemotherapy treatment | HCPCS |
| J9501 | Cancer chemotherapy treatment | HCPCS |
| J9502 | Cancer chemotherapy treatment | HCPCS |
| J9503 | Cancer chemotherapy treatment | HCPCS |
| J9504 | Cancer chemotherapy treatment | HCPCS |
| J9505 | Cancer chemotherapy treatment | HCPCS |
| J9506 | Cancer chemotherapy treatment | HCPCS |
| J9507 | Cancer chemotherapy treatment | HCPCS |
| J9508 | Cancer chemotherapy treatment | HCPCS |
| J9509 | Cancer chemotherapy treatment | HCPCS |
| J9510 | Cancer chemotherapy treatment | HCPCS |
| J9511 | Cancer chemotherapy treatment | HCPCS |
| J9512 | Cancer chemotherapy treatment | HCPCS |
| J9513 | Cancer chemotherapy treatment | HCPCS |
| J9514 | Cancer chemotherapy treatment | HCPCS |
| J9515 | Cancer chemotherapy treatment | HCPCS |
| J9516 | Cancer chemotherapy treatment | HCPCS |
| J9517 | Cancer chemotherapy treatment | HCPCS |
| J9518 | Cancer chemotherapy treatment | HCPCS |
| J9519 | Cancer chemotherapy treatment | HCPCS |
| J9520 | Cancer chemotherapy treatment | HCPCS |
| J9521 | Cancer chemotherapy treatment | HCPCS |
| J9522 | Cancer chemotherapy treatment | HCPCS |
| J9523 | Cancer chemotherapy treatment | HCPCS |
| J9524 | Cancer chemotherapy treatment | HCPCS |
| J9525 | Cancer chemotherapy treatment | HCPCS |
| J9526 | Cancer chemotherapy treatment | HCPCS |
| J9527 | Cancer chemotherapy treatment | HCPCS |
| J9528 | Cancer chemotherapy treatment | HCPCS |
| J9529 | Cancer chemotherapy treatment | HCPCS |
| J9530 | Cancer chemotherapy treatment | HCPCS |
| J9531 | Cancer chemotherapy treatment | HCPCS |
| J9532 | Cancer chemotherapy treatment | HCPCS |
| J9533 | Cancer chemotherapy treatment | HCPCS |
| J9534 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9535 | Cancer chemotherapy treatment | HCPCS |
| J9536 | Cancer chemotherapy treatment | HCPCS |
| J9537 | Cancer chemotherapy treatment | HCPCS |
| J9538 | Cancer chemotherapy treatment | HCPCS |
| J9539 | Cancer chemotherapy treatment | HCPCS |
| J9540 | Cancer chemotherapy treatment | HCPCS |
| J9541 | Cancer chemotherapy treatment | HCPCS |
| J9542 | Cancer chemotherapy treatment | HCPCS |
| J9543 | Cancer chemotherapy treatment | HCPCS |
| J9544 | Cancer chemotherapy treatment | HCPCS |
| J9545 | Cancer chemotherapy treatment | HCPCS |
| J9546 | Cancer chemotherapy treatment | HCPCS |
| J9547 | Cancer chemotherapy treatment | HCPCS |
| J9548 | Cancer chemotherapy treatment | HCPCS |
| J9549 | Cancer chemotherapy treatment | HCPCS |
| J9550 | Cancer chemotherapy treatment | HCPCS |
| J9551 | Cancer chemotherapy treatment | HCPCS |
| J9552 | Cancer chemotherapy treatment | HCPCS |
| J9553 | Cancer chemotherapy treatment | HCPCS |
| J9554 | Cancer chemotherapy treatment | HCPCS |
| J9555 | Cancer chemotherapy treatment | HCPCS |
| J9556 | Cancer chemotherapy treatment | HCPCS |
| J9557 | Cancer chemotherapy treatment | HCPCS |
| J9558 | Cancer chemotherapy treatment | HCPCS |
| J9559 | Cancer chemotherapy treatment | HCPCS |
| J9560 | Cancer chemotherapy treatment | HCPCS |
| J9561 | Cancer chemotherapy treatment | HCPCS |
| J9562 | Cancer chemotherapy treatment | HCPCS |
| J9563 | Cancer chemotherapy treatment | HCPCS |
| J9564 | Cancer chemotherapy treatment | HCPCS |
| J9565 | Cancer chemotherapy treatment | HCPCS |
| J9566 | Cancer chemotherapy treatment | HCPCS |
| J9567 | Cancer chemotherapy treatment | HCPCS |
| J9568 | Cancer chemotherapy treatment | HCPCS |
| J9569 | Cancer chemotherapy treatment | HCPCS |
| J9570 | Cancer chemotherapy treatment | HCPCS |
| J9571 | Cancer chemotherapy treatment | HCPCS |
| J9572 | Cancer chemotherapy treatment | HCPCS |
| J9573 | Cancer chemotherapy treatment | HCPCS |
| J9574 | Cancer chemotherapy treatment | HCPCS |
| J9575 | Cancer chemotherapy treatment | HCPCS |
| J9576 | Cancer chemotherapy treatment | HCPCS |
| J9577 | Cancer chemotherapy treatment | HCPCS |
| J9578 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9579 | Cancer chemotherapy treatment | HCPCS |
| J9580 | Cancer chemotherapy treatment | HCPCS |
| J9581 | Cancer chemotherapy treatment | HCPCS |
| J9582 | Cancer chemotherapy treatment | HCPCS |
| J9583 | Cancer chemotherapy treatment | HCPCS |
| J9584 | Cancer chemotherapy treatment | HCPCS |
| J9585 | Cancer chemotherapy treatment | HCPCS |
| J9586 | Cancer chemotherapy treatment | HCPCS |
| J9587 | Cancer chemotherapy treatment | HCPCS |
| J9588 | Cancer chemotherapy treatment | HCPCS |
| J9589 | Cancer chemotherapy treatment | HCPCS |
| J9590 | Cancer chemotherapy treatment | HCPCS |
| J9591 | Cancer chemotherapy treatment | HCPCS |
| J9592 | Cancer chemotherapy treatment | HCPCS |
| J9593 | Cancer chemotherapy treatment | HCPCS |
| J9594 | Cancer chemotherapy treatment | HCPCS |
| J9595 | Cancer chemotherapy treatment | HCPCS |
| J9596 | Cancer chemotherapy treatment | HCPCS |
| J9597 | Cancer chemotherapy treatment | HCPCS |
| J9598 | Cancer chemotherapy treatment | HCPCS |
| J9599 | Cancer chemotherapy treatment | HCPCS |
| J9600 | Cancer chemotherapy treatment | HCPCS |
| J9601 | Cancer chemotherapy treatment | HCPCS |
| J9602 | Cancer chemotherapy treatment | HCPCS |
| J9603 | Cancer chemotherapy treatment | HCPCS |
| J9604 | Cancer chemotherapy treatment | HCPCS |
| J9605 | Cancer chemotherapy treatment | HCPCS |
| J9606 | Cancer chemotherapy treatment | HCPCS |
| J9607 | Cancer chemotherapy treatment | HCPCS |
| J9608 | Cancer chemotherapy treatment | HCPCS |
| J9609 | Cancer chemotherapy treatment | HCPCS |
| J9610 | Cancer chemotherapy treatment | HCPCS |
| J9611 | Cancer chemotherapy treatment | HCPCS |
| J9612 | Cancer chemotherapy treatment | HCPCS |
| J9613 | Cancer chemotherapy treatment | HCPCS |
| J9614 | Cancer chemotherapy treatment | HCPCS |
| J9615 | Cancer chemotherapy treatment | HCPCS |
| J9616 | Cancer chemotherapy treatment | HCPCS |
| J9617 | Cancer chemotherapy treatment | HCPCS |
| J9618 | Cancer chemotherapy treatment | HCPCS |
| J9619 | Cancer chemotherapy treatment | HCPCS |
| J9620 | Cancer chemotherapy treatment | HCPCS |
| J9621 | Cancer chemotherapy treatment | HCPCS |
| J9622 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9623 | Cancer chemotherapy treatment | HCPCS |
| J9624 | Cancer chemotherapy treatment | HCPCS |
| J9625 | Cancer chemotherapy treatment | HCPCS |
| J9626 | Cancer chemotherapy treatment | HCPCS |
| J9627 | Cancer chemotherapy treatment | HCPCS |
| J9628 | Cancer chemotherapy treatment | HCPCS |
| J9629 | Cancer chemotherapy treatment | HCPCS |
| J9630 | Cancer chemotherapy treatment | HCPCS |
| J9631 | Cancer chemotherapy treatment | HCPCS |
| J9632 | Cancer chemotherapy treatment | HCPCS |
| J9633 | Cancer chemotherapy treatment | HCPCS |
| J9634 | Cancer chemotherapy treatment | HCPCS |
| J9635 | Cancer chemotherapy treatment | HCPCS |
| J9636 | Cancer chemotherapy treatment | HCPCS |
| J9637 | Cancer chemotherapy treatment | HCPCS |
| J9638 | Cancer chemotherapy treatment | HCPCS |
| J9639 | Cancer chemotherapy treatment | HCPCS |
| J9640 | Cancer chemotherapy treatment | HCPCS |
| J9641 | Cancer chemotherapy treatment | HCPCS |
| J9642 | Cancer chemotherapy treatment | HCPCS |
| J9643 | Cancer chemotherapy treatment | HCPCS |
| J9644 | Cancer chemotherapy treatment | HCPCS |
| J9645 | Cancer chemotherapy treatment | HCPCS |
| J9646 | Cancer chemotherapy treatment | HCPCS |
| J9647 | Cancer chemotherapy treatment | HCPCS |
| J9648 | Cancer chemotherapy treatment | HCPCS |
| J9649 | Cancer chemotherapy treatment | HCPCS |
| J9650 | Cancer chemotherapy treatment | HCPCS |
| J9651 | Cancer chemotherapy treatment | HCPCS |
| J9652 | Cancer chemotherapy treatment | HCPCS |
| J9653 | Cancer chemotherapy treatment | HCPCS |
| J9654 | Cancer chemotherapy treatment | HCPCS |
| J9655 | Cancer chemotherapy treatment | HCPCS |
| J9656 | Cancer chemotherapy treatment | HCPCS |
| J9657 | Cancer chemotherapy treatment | HCPCS |
| J9658 | Cancer chemotherapy treatment | HCPCS |
| J9659 | Cancer chemotherapy treatment | HCPCS |
| J9660 | Cancer chemotherapy treatment | HCPCS |
| J9661 | Cancer chemotherapy treatment | HCPCS |
| J9662 | Cancer chemotherapy treatment | HCPCS |
| J9663 | Cancer chemotherapy treatment | HCPCS |
| J9664 | Cancer chemotherapy treatment | HCPCS |
| J9665 | Cancer chemotherapy treatment | HCPCS |
| J9666 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9667 | Cancer chemotherapy treatment | HCPCS |
| J9668 | Cancer chemotherapy treatment | HCPCS |
| J9669 | Cancer chemotherapy treatment | HCPCS |
| J9670 | Cancer chemotherapy treatment | HCPCS |
| J9671 | Cancer chemotherapy treatment | HCPCS |
| J9672 | Cancer chemotherapy treatment | HCPCS |
| J9673 | Cancer chemotherapy treatment | HCPCS |
| J9674 | Cancer chemotherapy treatment | HCPCS |
| J9675 | Cancer chemotherapy treatment | HCPCS |
| J9676 | Cancer chemotherapy treatment | HCPCS |
| J9677 | Cancer chemotherapy treatment | HCPCS |
| J9678 | Cancer chemotherapy treatment | HCPCS |
| J9679 | Cancer chemotherapy treatment | HCPCS |
| J9680 | Cancer chemotherapy treatment | HCPCS |
| J9681 | Cancer chemotherapy treatment | HCPCS |
| J9682 | Cancer chemotherapy treatment | HCPCS |
| J9683 | Cancer chemotherapy treatment | HCPCS |
| J9684 | Cancer chemotherapy treatment | HCPCS |
| J9685 | Cancer chemotherapy treatment | HCPCS |
| J9686 | Cancer chemotherapy treatment | HCPCS |
| J9687 | Cancer chemotherapy treatment | HCPCS |
| J9688 | Cancer chemotherapy treatment | HCPCS |
| J9689 | Cancer chemotherapy treatment | HCPCS |
| J9690 | Cancer chemotherapy treatment | HCPCS |
| J9691 | Cancer chemotherapy treatment | HCPCS |
| J9692 | Cancer chemotherapy treatment | HCPCS |
| J9693 | Cancer chemotherapy treatment | HCPCS |
| J9694 | Cancer chemotherapy treatment | HCPCS |
| J9695 | Cancer chemotherapy treatment | HCPCS |
| J9696 | Cancer chemotherapy treatment | HCPCS |
| J9697 | Cancer chemotherapy treatment | HCPCS |
| J9698 | Cancer chemotherapy treatment | HCPCS |
| J9699 | Cancer chemotherapy treatment | HCPCS |
| J9700 | Cancer chemotherapy treatment | HCPCS |
| J9701 | Cancer chemotherapy treatment | HCPCS |
| J9702 | Cancer chemotherapy treatment | HCPCS |
| J9703 | Cancer chemotherapy treatment | HCPCS |
| J9704 | Cancer chemotherapy treatment | HCPCS |
| J9705 | Cancer chemotherapy treatment | HCPCS |
| J9706 | Cancer chemotherapy treatment | HCPCS |
| J9707 | Cancer chemotherapy treatment | HCPCS |
| J9708 | Cancer chemotherapy treatment | HCPCS |
| J9709 | Cancer chemotherapy treatment | HCPCS |
| J9710 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9711 | Cancer chemotherapy treatment | HCPCS |
| J9712 | Cancer chemotherapy treatment | HCPCS |
| J9713 | Cancer chemotherapy treatment | HCPCS |
| J9714 | Cancer chemotherapy treatment | HCPCS |
| J9715 | Cancer chemotherapy treatment | HCPCS |
| J9716 | Cancer chemotherapy treatment | HCPCS |
| J9717 | Cancer chemotherapy treatment | HCPCS |
| J9718 | Cancer chemotherapy treatment | HCPCS |
| J9719 | Cancer chemotherapy treatment | HCPCS |
| J9720 | Cancer chemotherapy treatment | HCPCS |
| J9721 | Cancer chemotherapy treatment | HCPCS |
| J9722 | Cancer chemotherapy treatment | HCPCS |
| J9723 | Cancer chemotherapy treatment | HCPCS |
| J9724 | Cancer chemotherapy treatment | HCPCS |
| J9725 | Cancer chemotherapy treatment | HCPCS |
| J9726 | Cancer chemotherapy treatment | HCPCS |
| J9727 | Cancer chemotherapy treatment | HCPCS |
| J9728 | Cancer chemotherapy treatment | HCPCS |
| J9729 | Cancer chemotherapy treatment | HCPCS |
| J9730 | Cancer chemotherapy treatment | HCPCS |
| J9731 | Cancer chemotherapy treatment | HCPCS |
| J9732 | Cancer chemotherapy treatment | HCPCS |
| J9733 | Cancer chemotherapy treatment | HCPCS |
| J9734 | Cancer chemotherapy treatment | HCPCS |
| J9735 | Cancer chemotherapy treatment | HCPCS |
| J9736 | Cancer chemotherapy treatment | HCPCS |
| J9737 | Cancer chemotherapy treatment | HCPCS |
| J9738 | Cancer chemotherapy treatment | HCPCS |
| J9739 | Cancer chemotherapy treatment | HCPCS |
| J9740 | Cancer chemotherapy treatment | HCPCS |
| J9741 | Cancer chemotherapy treatment | HCPCS |
| J9742 | Cancer chemotherapy treatment | HCPCS |
| J9743 | Cancer chemotherapy treatment | HCPCS |
| J9744 | Cancer chemotherapy treatment | HCPCS |
| J9745 | Cancer chemotherapy treatment | HCPCS |
| J9746 | Cancer chemotherapy treatment | HCPCS |
| J9747 | Cancer chemotherapy treatment | HCPCS |
| J9748 | Cancer chemotherapy treatment | HCPCS |
| J9749 | Cancer chemotherapy treatment | HCPCS |
| J9750 | Cancer chemotherapy treatment | HCPCS |
| J9751 | Cancer chemotherapy treatment | HCPCS |
| J9752 | Cancer chemotherapy treatment | HCPCS |
| J9753 | Cancer chemotherapy treatment | HCPCS |
| J9754 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9755 | Cancer chemotherapy treatment | HCPCS |
| J9756 | Cancer chemotherapy treatment | HCPCS |
| J9757 | Cancer chemotherapy treatment | HCPCS |
| J9758 | Cancer chemotherapy treatment | HCPCS |
| J9759 | Cancer chemotherapy treatment | HCPCS |
| J9760 | Cancer chemotherapy treatment | HCPCS |
| J9761 | Cancer chemotherapy treatment | HCPCS |
| J9762 | Cancer chemotherapy treatment | HCPCS |
| J9763 | Cancer chemotherapy treatment | HCPCS |
| J9764 | Cancer chemotherapy treatment | HCPCS |
| J9765 | Cancer chemotherapy treatment | HCPCS |
| J9766 | Cancer chemotherapy treatment | HCPCS |
| J9767 | Cancer chemotherapy treatment | HCPCS |
| J9768 | Cancer chemotherapy treatment | HCPCS |
| J9769 | Cancer chemotherapy treatment | HCPCS |
| J9770 | Cancer chemotherapy treatment | HCPCS |
| J9771 | Cancer chemotherapy treatment | HCPCS |
| J9772 | Cancer chemotherapy treatment | HCPCS |
| J9773 | Cancer chemotherapy treatment | HCPCS |
| J9774 | Cancer chemotherapy treatment | HCPCS |
| J9775 | Cancer chemotherapy treatment | HCPCS |
| J9776 | Cancer chemotherapy treatment | HCPCS |
| J9777 | Cancer chemotherapy treatment | HCPCS |
| J9778 | Cancer chemotherapy treatment | HCPCS |
| J9779 | Cancer chemotherapy treatment | HCPCS |
| J9780 | Cancer chemotherapy treatment | HCPCS |
| J9781 | Cancer chemotherapy treatment | HCPCS |
| J9782 | Cancer chemotherapy treatment | HCPCS |
| J9783 | Cancer chemotherapy treatment | HCPCS |
| J9784 | Cancer chemotherapy treatment | HCPCS |
| J9785 | Cancer chemotherapy treatment | HCPCS |
| J9786 | Cancer chemotherapy treatment | HCPCS |
| J9787 | Cancer chemotherapy treatment | HCPCS |
| J9788 | Cancer chemotherapy treatment | HCPCS |
| J9789 | Cancer chemotherapy treatment | HCPCS |
| J9790 | Cancer chemotherapy treatment | HCPCS |
| J9791 | Cancer chemotherapy treatment | HCPCS |
| J9792 | Cancer chemotherapy treatment | HCPCS |
| J9793 | Cancer chemotherapy treatment | HCPCS |
| J9794 | Cancer chemotherapy treatment | HCPCS |
| J9795 | Cancer chemotherapy treatment | HCPCS |
| J9796 | Cancer chemotherapy treatment | HCPCS |
| J9797 | Cancer chemotherapy treatment | HCPCS |
| J9798 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9799 | Cancer chemotherapy treatment | HCPCS |
| J9800 | Cancer chemotherapy treatment | HCPCS |
| J9801 | Cancer chemotherapy treatment | HCPCS |
| J9802 | Cancer chemotherapy treatment | HCPCS |
| J9803 | Cancer chemotherapy treatment | HCPCS |
| J9804 | Cancer chemotherapy treatment | HCPCS |
| J9805 | Cancer chemotherapy treatment | HCPCS |
| J9806 | Cancer chemotherapy treatment | HCPCS |
| J9807 | Cancer chemotherapy treatment | HCPCS |
| J9808 | Cancer chemotherapy treatment | HCPCS |
| J9809 | Cancer chemotherapy treatment | HCPCS |
| J9810 | Cancer chemotherapy treatment | HCPCS |
| J9811 | Cancer chemotherapy treatment | HCPCS |
| J9812 | Cancer chemotherapy treatment | HCPCS |
| J9813 | Cancer chemotherapy treatment | HCPCS |
| J9814 | Cancer chemotherapy treatment | HCPCS |
| J9815 | Cancer chemotherapy treatment | HCPCS |
| J9816 | Cancer chemotherapy treatment | HCPCS |
| J9817 | Cancer chemotherapy treatment | HCPCS |
| J9818 | Cancer chemotherapy treatment | HCPCS |
| J9819 | Cancer chemotherapy treatment | HCPCS |
| J9820 | Cancer chemotherapy treatment | HCPCS |
| J9821 | Cancer chemotherapy treatment | HCPCS |
| J9822 | Cancer chemotherapy treatment | HCPCS |
| J9823 | Cancer chemotherapy treatment | HCPCS |
| J9824 | Cancer chemotherapy treatment | HCPCS |
| J9825 | Cancer chemotherapy treatment | HCPCS |
| J9826 | Cancer chemotherapy treatment | HCPCS |
| J9827 | Cancer chemotherapy treatment | HCPCS |
| J9828 | Cancer chemotherapy treatment | HCPCS |
| J9829 | Cancer chemotherapy treatment | HCPCS |
| J9830 | Cancer chemotherapy treatment | HCPCS |
| J9831 | Cancer chemotherapy treatment | HCPCS |
| J9832 | Cancer chemotherapy treatment | HCPCS |
| J9833 | Cancer chemotherapy treatment | HCPCS |
| J9834 | Cancer chemotherapy treatment | HCPCS |
| J9835 | Cancer chemotherapy treatment | HCPCS |
| J9836 | Cancer chemotherapy treatment | HCPCS |
| J9837 | Cancer chemotherapy treatment | HCPCS |
| J9838 | Cancer chemotherapy treatment | HCPCS |
| J9839 | Cancer chemotherapy treatment | HCPCS |
| J9840 | Cancer chemotherapy treatment | HCPCS |
| J9841 | Cancer chemotherapy treatment | HCPCS |
| J9842 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9843 | Cancer chemotherapy treatment | HCPCS |
| J9844 | Cancer chemotherapy treatment | HCPCS |
| J9845 | Cancer chemotherapy treatment | HCPCS |
| J9846 | Cancer chemotherapy treatment | HCPCS |
| J9847 | Cancer chemotherapy treatment | HCPCS |
| J9848 | Cancer chemotherapy treatment | HCPCS |
| J9849 | Cancer chemotherapy treatment | HCPCS |
| J9850 | Cancer chemotherapy treatment | HCPCS |
| J9851 | Cancer chemotherapy treatment | HCPCS |
| J9852 | Cancer chemotherapy treatment | HCPCS |
| J9853 | Cancer chemotherapy treatment | HCPCS |
| J9854 | Cancer chemotherapy treatment | HCPCS |
| J9855 | Cancer chemotherapy treatment | HCPCS |
| J9856 | Cancer chemotherapy treatment | HCPCS |
| J9857 | Cancer chemotherapy treatment | HCPCS |
| J9858 | Cancer chemotherapy treatment | HCPCS |
| J9859 | Cancer chemotherapy treatment | HCPCS |
| J9860 | Cancer chemotherapy treatment | HCPCS |
| J9861 | Cancer chemotherapy treatment | HCPCS |
| J9862 | Cancer chemotherapy treatment | HCPCS |
| J9863 | Cancer chemotherapy treatment | HCPCS |
| J9864 | Cancer chemotherapy treatment | HCPCS |
| J9865 | Cancer chemotherapy treatment | HCPCS |
| J9866 | Cancer chemotherapy treatment | HCPCS |
| J9867 | Cancer chemotherapy treatment | HCPCS |
| J9868 | Cancer chemotherapy treatment | HCPCS |
| J9869 | Cancer chemotherapy treatment | HCPCS |
| J9870 | Cancer chemotherapy treatment | HCPCS |
| J9871 | Cancer chemotherapy treatment | HCPCS |
| J9872 | Cancer chemotherapy treatment | HCPCS |
| J9873 | Cancer chemotherapy treatment | HCPCS |
| J9874 | Cancer chemotherapy treatment | HCPCS |
| J9875 | Cancer chemotherapy treatment | HCPCS |
| J9876 | Cancer chemotherapy treatment | HCPCS |
| J9877 | Cancer chemotherapy treatment | HCPCS |
| J9878 | Cancer chemotherapy treatment | HCPCS |
| J9879 | Cancer chemotherapy treatment | HCPCS |
| J9880 | Cancer chemotherapy treatment | HCPCS |
| J9881 | Cancer chemotherapy treatment | HCPCS |
| J9882 | Cancer chemotherapy treatment | HCPCS |
| J9883 | Cancer chemotherapy treatment | HCPCS |
| J9884 | Cancer chemotherapy treatment | HCPCS |
| J9885 | Cancer chemotherapy treatment | HCPCS |
| J9886 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9887 | Cancer chemotherapy treatment | HCPCS |
| J9888 | Cancer chemotherapy treatment | HCPCS |
| J9889 | Cancer chemotherapy treatment | HCPCS |
| J9890 | Cancer chemotherapy treatment | HCPCS |
| J9891 | Cancer chemotherapy treatment | HCPCS |
| J9892 | Cancer chemotherapy treatment | HCPCS |
| J9893 | Cancer chemotherapy treatment | HCPCS |
| J9894 | Cancer chemotherapy treatment | HCPCS |
| J9895 | Cancer chemotherapy treatment | HCPCS |
| J9896 | Cancer chemotherapy treatment | HCPCS |
| J9897 | Cancer chemotherapy treatment | HCPCS |
| J9898 | Cancer chemotherapy treatment | HCPCS |
| J9899 | Cancer chemotherapy treatment | HCPCS |
| J9900 | Cancer chemotherapy treatment | HCPCS |
| J9901 | Cancer chemotherapy treatment | HCPCS |
| J9902 | Cancer chemotherapy treatment | HCPCS |
| J9903 | Cancer chemotherapy treatment | HCPCS |
| J9904 | Cancer chemotherapy treatment | HCPCS |
| J9905 | Cancer chemotherapy treatment | HCPCS |
| J9906 | Cancer chemotherapy treatment | HCPCS |
| J9907 | Cancer chemotherapy treatment | HCPCS |
| J9908 | Cancer chemotherapy treatment | HCPCS |
| J9909 | Cancer chemotherapy treatment | HCPCS |
| J9910 | Cancer chemotherapy treatment | HCPCS |
| J9911 | Cancer chemotherapy treatment | HCPCS |
| J9912 | Cancer chemotherapy treatment | HCPCS |
| J9913 | Cancer chemotherapy treatment | HCPCS |
| J9914 | Cancer chemotherapy treatment | HCPCS |
| J9915 | Cancer chemotherapy treatment | HCPCS |
| J9916 | Cancer chemotherapy treatment | HCPCS |
| J9917 | Cancer chemotherapy treatment | HCPCS |
| J9918 | Cancer chemotherapy treatment | HCPCS |
| J9919 | Cancer chemotherapy treatment | HCPCS |
| J9920 | Cancer chemotherapy treatment | HCPCS |
| J9921 | Cancer chemotherapy treatment | HCPCS |
| J9922 | Cancer chemotherapy treatment | HCPCS |
| J9923 | Cancer chemotherapy treatment | HCPCS |
| J9924 | Cancer chemotherapy treatment | HCPCS |
| J9925 | Cancer chemotherapy treatment | HCPCS |
| J9926 | Cancer chemotherapy treatment | HCPCS |
| J9927 | Cancer chemotherapy treatment | HCPCS |
| J9928 | Cancer chemotherapy treatment | HCPCS |
| J9929 | Cancer chemotherapy treatment | HCPCS |
| J9930 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|-------|-------------------------------|-----------|
| J9931 | Cancer chemotherapy treatment | HCPCS |
| J9932 | Cancer chemotherapy treatment | HCPCS |
| J9933 | Cancer chemotherapy treatment | HCPCS |
| J9934 | Cancer chemotherapy treatment | HCPCS |
| J9935 | Cancer chemotherapy treatment | HCPCS |
| J9936 | Cancer chemotherapy treatment | HCPCS |
| J9937 | Cancer chemotherapy treatment | HCPCS |
| J9938 | Cancer chemotherapy treatment | HCPCS |
| J9939 | Cancer chemotherapy treatment | HCPCS |
| J9940 | Cancer chemotherapy treatment | HCPCS |
| J9941 | Cancer chemotherapy treatment | HCPCS |
| J9942 | Cancer chemotherapy treatment | HCPCS |
| J9943 | Cancer chemotherapy treatment | HCPCS |
| J9944 | Cancer chemotherapy treatment | HCPCS |
| J9945 | Cancer chemotherapy treatment | HCPCS |
| J9946 | Cancer chemotherapy treatment | HCPCS |
| J9947 | Cancer chemotherapy treatment | HCPCS |
| J9948 | Cancer chemotherapy treatment | HCPCS |
| J9949 | Cancer chemotherapy treatment | HCPCS |
| J9950 | Cancer chemotherapy treatment | HCPCS |
| J9951 | Cancer chemotherapy treatment | HCPCS |
| J9952 | Cancer chemotherapy treatment | HCPCS |
| J9953 | Cancer chemotherapy treatment | HCPCS |
| J9954 | Cancer chemotherapy treatment | HCPCS |
| J9955 | Cancer chemotherapy treatment | HCPCS |
| J9956 | Cancer chemotherapy treatment | HCPCS |
| J9957 | Cancer chemotherapy treatment | HCPCS |
| J9958 | Cancer chemotherapy treatment | HCPCS |
| J9959 | Cancer chemotherapy treatment | HCPCS |
| J9960 | Cancer chemotherapy treatment | HCPCS |
| J9961 | Cancer chemotherapy treatment | HCPCS |
| J9962 | Cancer chemotherapy treatment | HCPCS |
| J9963 | Cancer chemotherapy treatment | HCPCS |
| J9964 | Cancer chemotherapy treatment | HCPCS |
| J9965 | Cancer chemotherapy treatment | HCPCS |
| J9966 | Cancer chemotherapy treatment | HCPCS |
| J9967 | Cancer chemotherapy treatment | HCPCS |
| J9968 | Cancer chemotherapy treatment | HCPCS |
| J9969 | Cancer chemotherapy treatment | HCPCS |
| J9970 | Cancer chemotherapy treatment | HCPCS |
| J9971 | Cancer chemotherapy treatment | HCPCS |
| J9972 | Cancer chemotherapy treatment | HCPCS |
| J9973 | Cancer chemotherapy treatment | HCPCS |
| J9974 | Cancer chemotherapy treatment | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------------------------------|--|--------------------|
| J9975 | Cancer chemotherapy treatment | HCPCS |
| J9976 | Cancer chemotherapy treatment | HCPCS |
| J9977 | Cancer chemotherapy treatment | HCPCS |
| J9978 | Cancer chemotherapy treatment | HCPCS |
| J9979 | Cancer chemotherapy treatment | HCPCS |
| J9980 | Cancer chemotherapy treatment | HCPCS |
| J9981 | Cancer chemotherapy treatment | HCPCS |
| J9982 | Cancer chemotherapy treatment | HCPCS |
| J9983 | Cancer chemotherapy treatment | HCPCS |
| J9984 | Cancer chemotherapy treatment | HCPCS |
| J9985 | Cancer chemotherapy treatment | HCPCS |
| J9986 | Cancer chemotherapy treatment | HCPCS |
| J9987 | Cancer chemotherapy treatment | HCPCS |
| J9988 | Cancer chemotherapy treatment | HCPCS |
| J9989 | Cancer chemotherapy treatment | HCPCS |
| J9990 | Cancer chemotherapy treatment | HCPCS |
| J9991 | Cancer chemotherapy treatment | HCPCS |
| J9992 | Cancer chemotherapy treatment | HCPCS |
| J9993 | Cancer chemotherapy treatment | HCPCS |
| J9994 | Cancer chemotherapy treatment | HCPCS |
| J9995 | Cancer chemotherapy treatment | HCPCS |
| J9996 | Cancer chemotherapy treatment | HCPCS |
| J9997 | Cancer chemotherapy treatment | HCPCS |
| J9998 | Cancer chemotherapy treatment | HCPCS |
| J9999 | Cancer chemotherapy treatment | HCPCS |
| G0256 | Radiation therapy | HCPCS |
| G0261 | Radiation therapy | HCPCS |
| 99.25 | Cancer chemotherapy treatment | ICD-9-CM Procedure |
| 92.21 | Radiation therapy | ICD-9-CM Procedure |
| 92.22 | Radiation therapy | ICD-9-CM Procedure |
| 92.23 | Radiation therapy | ICD-9-CM Procedure |
| 92.24 | Radiation therapy | ICD-9-CM Procedure |
| 92.25 | Radiation therapy | ICD-9-CM Procedure |
| 92.26 | Radiation therapy | ICD-9-CM Procedure |
| 92.27 | Radiation therapy | ICD-9-CM Procedure |
| 92.28 | Radiation therapy | ICD-9-CM Procedure |
| 92.29 | Radiation therapy | ICD-9-CM Procedure |
| Substance abuse history | | |
| 571.1 | Acute alcoholic hepatitis | ICD-9-CM Diagnosis |
| 303.0 | Acute alcoholic intoxication | ICD-9-CM Diagnosis |
| 303.01 | Acute alcoholic intoxication, continuous | ICD-9-CM Diagnosis |
| 303.02 | Acute alcoholic intoxication, episodic | ICD-9-CM Diagnosis |
| 303.03 | Acute alcoholic intoxication, in remission | ICD-9-CM Diagnosis |
| 303.00 | Acute alcoholic intoxication, unspecified | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|---|--------------------|
| 291 | Alcohol-induced mental disorders | ICD-9-CM Diagnosis |
| 291.1 | Alcohol-induced persisting amnestic disorder | ICD-9-CM Diagnosis |
| 291.2 | Alcohol-induced persisting dementia | ICD-9-CM Diagnosis |
| 291.5 | Alcohol-induced psychotic disorder with delusions | ICD-9-CM Diagnosis |
| 291.3 | Alcohol-induced psychotic disorder with hallucinations | ICD-9-CM Diagnosis |
| 303 | Alcohol dependence syndrome | ICD-9-CM Diagnosis |
| 291.82 | Alcohol induced sleep disorders | ICD-9-CM Diagnosis |
| 291.81 | Alcohol withdrawal | ICD-9-CM Diagnosis |
| 291.0 | Alcohol withdrawal delirium | ICD-9-CM Diagnosis |
| 571.2 | Alcoholic cirrhosis of liver | ICD-9-CM Diagnosis |
| 571.0 | Alcoholic fatty liver | ICD-9-CM Diagnosis |
| 304.4 | Amphetamine and other psychostimulant dependence | ICD-9-CM Diagnosis |
| 304.41 | Amphetamine and other psychostimulant dependence, continuous | ICD-9-CM Diagnosis |
| 304.42 | Amphetamine and other psychostimulant dependence, episodic | ICD-9-CM Diagnosis |
| 304.43 | Amphetamine and other psychostimulant dependence, in remission | ICD-9-CM Diagnosis |
| 304.40 | Amphetamine and other psychostimulant dependence, unspecified | ICD-9-CM Diagnosis |
| 304.3 | Cannabis dependence | ICD-9-CM Diagnosis |
| 304.31 | Cannabis dependence, continuous | ICD-9-CM Diagnosis |
| 304.32 | Cannabis dependence, episodic | ICD-9-CM Diagnosis |
| 304.33 | Cannabis dependence, in remission | ICD-9-CM Diagnosis |
| 304.30 | Cannabis dependence, unspecified | ICD-9-CM Diagnosis |
| 304.2 | Cocaine dependence | ICD-9-CM Diagnosis |
| 304.21 | Cocaine dependence, continuous | ICD-9-CM Diagnosis |
| 304.22 | Cocaine dependence, episodic | ICD-9-CM Diagnosis |
| 304.23 | Cocaine dependence, in remission | ICD-9-CM Diagnosis |
| 304.20 | Cocaine dependence, unspecified | ICD-9-CM Diagnosis |
| 304.8 | Combinations of drug dependence excluding opioid type drug | ICD-9-CM Diagnosis |
| 304.81 | Combinations of drug dependence excluding opioid type drug, continuous | ICD-9-CM Diagnosis |
| 304.82 | Combinations of drug dependence excluding opioid type drug, episodic | ICD-9-CM Diagnosis |
| 304.83 | Combinations of drug dependence excluding opioid type drug, in remission | ICD-9-CM Diagnosis |
| 304.80 | Combinations of drug dependence excluding opioid type drug, unspecified | ICD-9-CM Diagnosis |
| 304.7 | Combinations of opioid type drug with any other drug dependence | ICD-9-CM Diagnosis |
| 304.71 | Combinations of opioid type drug with any other drug dependence, continuous | ICD-9-CM Diagnosis |
| 304.72 | Combinations of opioid type drug with any other drug dependence, episodic | ICD-9-CM Diagnosis |
| 304.73 | Combinations of opioid type drug with any other drug dependence, in remission | ICD-9-CM Diagnosis |
| 304.70 | Combinations of opioid type drug with any other drug dependence, unspecified | ICD-9-CM Diagnosis |
| 292.81 | Drug-induced delirium | ICD-9-CM Diagnosis |
| 292 | Drug-induced mental disorders | ICD-9-CM Diagnosis |
| 292.84 | Drug-induced mood disorder | ICD-9-CM Diagnosis |
| 292.83 | Drug-induced persisting amnestic disorder | ICD-9-CM Diagnosis |
| 292.82 | Drug-induced persisting dementia | ICD-9-CM Diagnosis |
| 292.1 | Drug-induced psychotic disorder | ICD-9-CM Diagnosis |
| 292.11 | Drug-induced psychotic disorder with delusions | ICD-9-CM Diagnosis |
| 292.12 | Drug-induced psychotic disorder with hallucinations | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|--|--------------------|
| 304 | Drug dependence | ICD-9-CM Diagnosis |
| 292.85 | Drug induced sleep disorders | ICD-9-CM Diagnosis |
| 292.0 | Drug withdrawal | ICD-9-CM Diagnosis |
| 304.5 | Hallucinogen dependence | ICD-9-CM Diagnosis |
| 304.51 | Hallucinogen dependence, continuous | ICD-9-CM Diagnosis |
| 304.52 | Hallucinogen dependence, episodic | ICD-9-CM Diagnosis |
| 304.53 | Hallucinogen dependence, in remission | ICD-9-CM Diagnosis |
| 304.50 | Hallucinogen dependence, unspecified | ICD-9-CM Diagnosis |
| 291.4 | Idiosyncratic alcohol intoxication | ICD-9-CM Diagnosis |
| 648.3 | Maternal drug dependence complicating pregnancy, childbirth, or the puerperium | ICD-9-CM Diagnosis |
| 305 | Nondependent abuse of drugs | ICD-9-CM Diagnosis |
| 305.0 | Nondependent alcohol abuse | ICD-9-CM Diagnosis |
| 305.01 | Nondependent alcohol abuse, continuous | ICD-9-CM Diagnosis |
| 305.02 | Nondependent alcohol abuse, episodic | ICD-9-CM Diagnosis |
| 305.03 | Nondependent alcohol abuse, in remission | ICD-9-CM Diagnosis |
| 305.00 | Nondependent alcohol abuse, unspecified | ICD-9-CM Diagnosis |
| 305.7 | Nondependent amphetamine or related acting sympathomimetic abuse | ICD-9-CM Diagnosis |
| 305.71 | Nondependent amphetamine or related acting sympathomimetic abuse, continuous | ICD-9-CM Diagnosis |
| 305.72 | Nondependent amphetamine or related acting sympathomimetic abuse, episodic | ICD-9-CM Diagnosis |
| 305.73 | Nondependent amphetamine or related acting sympathomimetic abuse, in remission | ICD-9-CM Diagnosis |
| 305.70 | Nondependent amphetamine or related acting sympathomimetic abuse, unspecified | ICD-9-CM Diagnosis |
| 305.8 | Nondependent antidepressant type abuse | ICD-9-CM Diagnosis |
| 305.81 | Nondependent antidepressant type abuse, continuous | ICD-9-CM Diagnosis |
| 305.82 | Nondependent antidepressant type abuse, episodic | ICD-9-CM Diagnosis |
| 305.83 | Nondependent antidepressant type abuse, in remission | ICD-9-CM Diagnosis |
| 305.80 | Nondependent antidepressant type abuse, unspecified | ICD-9-CM Diagnosis |
| 305.2 | Nondependent cannabis abuse | ICD-9-CM Diagnosis |
| 305.21 | Nondependent cannabis abuse, continuous | ICD-9-CM Diagnosis |
| 305.22 | Nondependent cannabis abuse, episodic | ICD-9-CM Diagnosis |
| 305.23 | Nondependent cannabis abuse, in remission | ICD-9-CM Diagnosis |
| 305.20 | Nondependent cannabis abuse, unspecified | ICD-9-CM Diagnosis |
| 305.6 | Nondependent cocaine abuse | ICD-9-CM Diagnosis |
| 305.61 | Nondependent cocaine abuse, continuous | ICD-9-CM Diagnosis |
| 305.62 | Nondependent cocaine abuse, episodic | ICD-9-CM Diagnosis |
| 305.63 | Nondependent cocaine abuse, in remission | ICD-9-CM Diagnosis |
| 305.60 | Nondependent cocaine abuse, unspecified | ICD-9-CM Diagnosis |
| 305.3 | Nondependent hallucinogen abuse | ICD-9-CM Diagnosis |
| 305.31 | Nondependent hallucinogen abuse, continuous | ICD-9-CM Diagnosis |
| 305.32 | Nondependent hallucinogen abuse, episodic | ICD-9-CM Diagnosis |
| 305.33 | Nondependent hallucinogen abuse, in remission | ICD-9-CM Diagnosis |
| 305.30 | Nondependent hallucinogen abuse, unspecified | ICD-9-CM Diagnosis |
| 305.5 | Nondependent opioid abuse | ICD-9-CM Diagnosis |
| 305.51 | Nondependent opioid abuse, continuous | ICD-9-CM Diagnosis |
| 305.52 | Nondependent opioid abuse, episodic | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|--|--------------------|
| 305.53 | Nondependent opioid abuse, in remission | ICD-9-CM Diagnosis |
| 305.50 | Nondependent opioid abuse, unspecified | ICD-9-CM Diagnosis |
| 305.41 | Nondependent sedative hypnotic or anxiolytic abuse, continuous | ICD-9-CM Diagnosis |
| 305.4 | Nondependent sedative, hypnotic or anxiolytic abuse | ICD-9-CM Diagnosis |
| 305.42 | Nondependent sedative, hypnotic or anxiolytic abuse, episodic | ICD-9-CM Diagnosis |
| 305.43 | Nondependent sedative, hypnotic or anxiolytic abuse, in remission | ICD-9-CM Diagnosis |
| 305.40 | Nondependent sedative, hypnotic or anxiolytic abuse, unspecified | ICD-9-CM Diagnosis |
| 304.0 | Opioid type dependence | ICD-9-CM Diagnosis |
| 304.01 | Opioid type dependence, continuous | ICD-9-CM Diagnosis |
| 304.02 | Opioid type dependence, episodic | ICD-9-CM Diagnosis |
| 304.03 | Opioid type dependence, in remission | ICD-9-CM Diagnosis |
| 304.00 | Opioid type dependence, unspecified | ICD-9-CM Diagnosis |
| 303.9 | Other and unspecified alcohol dependence | ICD-9-CM Diagnosis |
| 303.91 | Other and unspecified alcohol dependence, continuous | ICD-9-CM Diagnosis |
| 303.92 | Other and unspecified alcohol dependence, episodic | ICD-9-CM Diagnosis |
| 303.93 | Other and unspecified alcohol dependence, in remission | ICD-9-CM Diagnosis |
| 303.90 | Other and unspecified alcohol dependence, unspecified | ICD-9-CM Diagnosis |
| 291.8 | Other specified alcohol-induced mental disorders | ICD-9-CM Diagnosis |
| 291.89 | Other specified alcohol-induced mental disorders | ICD-9-CM Diagnosis |
| 292.89 | Other specified drug-induced mental disorder | ICD-9-CM Diagnosis |
| 292.8 | Other specified drug-induced mental disorders | ICD-9-CM Diagnosis |
| 304.6 | Other specified drug dependence | ICD-9-CM Diagnosis |
| 304.61 | Other specified drug dependence, continuous | ICD-9-CM Diagnosis |
| 304.62 | Other specified drug dependence, episodic | ICD-9-CM Diagnosis |
| 304.63 | Other specified drug dependence, in remission | ICD-9-CM Diagnosis |
| 304.60 | Other specified drug dependence, unspecified | ICD-9-CM Diagnosis |
| 305.9 | Other, mixed, or unspecified nondependent drug abuse | ICD-9-CM Diagnosis |
| 305.91 | Other, mixed, or unspecified nondependent drug abuse, continuous | ICD-9-CM Diagnosis |
| 305.92 | Other, mixed, or unspecified nondependent drug abuse, episodic | ICD-9-CM Diagnosis |
| 305.93 | Other, mixed, or unspecified nondependent drug abuse, in remission | ICD-9-CM Diagnosis |
| 305.90 | Other, mixed, or unspecified nondependent drug abuse, unspecified | ICD-9-CM Diagnosis |
| 292.2 | Pathological drug intoxication | ICD-9-CM Diagnosis |
| 304.1 | Sedative, hypnotic or anxiolytic dependence | ICD-9-CM Diagnosis |
| 304.11 | Sedative, hypnotic or anxiolytic dependence, continuous | ICD-9-CM Diagnosis |
| 304.12 | Sedative, hypnotic or anxiolytic dependence, episodic | ICD-9-CM Diagnosis |
| 304.13 | Sedative, hypnotic or anxiolytic dependence, in remission | ICD-9-CM Diagnosis |
| 304.10 | Sedative, hypnotic or anxiolytic dependence, unspecified | ICD-9-CM Diagnosis |
| 291.9 | Unspecified alcohol-induced mental disorders | ICD-9-CM Diagnosis |
| 571.3 | Unspecified alcoholic liver damage | ICD-9-CM Diagnosis |
| 292.9 | Unspecified drug-induced mental disorder | ICD-9-CM Diagnosis |
| 304.9 | Unspecified drug dependence | ICD-9-CM Diagnosis |
| 304.91 | Unspecified drug dependence, continuous | ICD-9-CM Diagnosis |
| 304.92 | Unspecified drug dependence, episodic | ICD-9-CM Diagnosis |
| 304.93 | Unspecified drug dependence, in remission | ICD-9-CM Diagnosis |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|---|--------------------|
| 304.90 | Unspecified drug dependence, unspecified | ICD-9-CM Diagnosis |
| 94.62 | Alcohol detoxification | ICD-9-CM Procedure |
| 94.61 | Alcohol rehabilitation | ICD-9-CM Procedure |
| 94.63 | Alcohol rehabilitation and detoxification | ICD-9-CM Procedure |
| 94.6 | Alcohol and drug rehabilitation and detoxification | ICD-9-CM Procedure |
| 94.46 | Alcoholism counseling | ICD-9-CM Procedure |
| 94.69 | Combined alcohol and drug rehabilitation and detoxification | ICD-9-CM Procedure |
| 94.68 | Combined alcohol and drug detoxification | ICD-9-CM Procedure |
| 94.67 | Combined alcohol and drug rehabilitation | ICD-9-CM Procedure |
| 94.53 | Referral for alcoholism rehabilitation | ICD-9-CM Procedure |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | HCPCS |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | HCPCS |
| H0011 | Alcohol and/or drug services; acute detoxification (residential addiction program inpatient) | HCPCS |
| H0013 | Alcohol and/or drug services; acute detoxification (residential addiction program outpatient) | HCPCS |
| H0010 | Alcohol and/or drug services; subacute detoxification (residential addiction program inpatient) | HCPCS |
| H0012 | Alcohol and/or drug services; subacute detoxification (residential addiction program outpatient) | HCPCS |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | HCPCS |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | HCPCS |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | HCPCS |
| H0008 | Alcohol and/or drug services; subacute detoxification (hospital inpatient) | HCPCS |
| H2036 | Alcohol and/or other drug treatment program, per diem | HCPCS |
| H2035 | Alcohol and/or other drug treatment program, per hour | HCPCS |
| T1006 | Alcohol and/or substance abuse services, family/couple counseling | HCPCS |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | HCPCS |
| T1012 | Alcohol and/or substance abuse services, skills development | HCPCS |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | HCPCS |
| T1008 | Day treatment for individual alcohol and/or substance abuse services | HCPCS |
| T1010 | Meals for individuals receiving alcohol and/or substance abuse services (when meals not included in the program) | HCPCS |
| 4320F | Patient counseled regarding psychosocial and pharmacologic treatment options for alcohol dependence (SUD) | CPT-II |
| 1034F | Current tobacco smoker (CAD, CAP, COPD, PV) (DM) | CPT-II |
| 1035F | Current smokeless tobacco user (eg, chew, snuff) (PV) | |
| 305.1 | Tobacco use disorder | CPT-II |
| 4000F | Tobacco use cessation intervention, counseling (COPD, CAP, CAD, Asthma)(DM)(PV) | ICD-9-CM Diagnosis |
| 4001F | Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM)(PV) | CPT-II |
| 4004F | Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD) | CPT-II |
| 649.0 | Tobacco use disorder complicating pregnancy, childbirth, or the puerperium | CPT-II |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|--|--------------------|
| 649.03 | Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, antepartum condition or complication | ICD-9-CM Diagnosis |
| 649.02 | Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with mention of postpartum complication | ICD-9-CM Diagnosis |
| 649.01 | Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, delivered, with or without mention of antepartum condition | ICD-9-CM Diagnosis |
| 649.04 | Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication | ICD-9-CM Diagnosis |
| 649.00 | Tobacco use disorder complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care or not applicable | ICD-9-CM Diagnosis |
| 83887 | Nicotine | CPT-4 |
| 989.84 | Toxic effect of tobacco | ICD-9-CM Diagnosis |
| 99406 | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | CPT-4 |
| 99407 | Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes | CPT-4 |
| C9801 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | HCPCS |
| C9802 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes | HCPCS |
| G0375 | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes | HCPCS |
| G0376 | Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes | HCPCS |
| G0436 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | HCPCS |
| G0437 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes | HCPCS |
| G8093 | Newly diagnosed chronic obstructive pulmonary disease (copd) patient documented to have received smoking cessation intervention, within 3 months of diagnosis | HCPCS |
| G8094 | Newly diagnosed chronic obstructive pulmonary disease (copd) patient not documented to have received smoking cessation intervention, within 3 months of diagnosis | HCPCS |
| G8402 | Tobacco (smoke) use cessation intervention, counseling | HCPCS |
| G8403 | Tobacco (smoke) use cessation intervention not counseled | HCPCS |
| G8453 | Tobacco use cessation intervention, counseling | HCPCS |
| G8454 | Tobacco use cessation intervention not counseled, reason not specified | HCPCS |
| G8455 | Current tobacco smoker | HCPCS |
| G8456 | Current smokeless tobacco user | HCPCS |
| G8688 | Currently a smokeless tobacco user (eg, chew, snuff) and no exposure to secondhand smoke | HCPCS |
| G9016 | Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only] | HCPCS |
| S4990 | Nicotine patches, legend | HCPCS |
| S4991 | Nicotine patches, non-legend | HCPCS |
| S4995 | Smoking cessation gum | HCPCS |
| S9075 | Smoking cessation treatment | HCPCS |
| S9453 | Smoking cessation classes, non-physician provider, per session | HCPCS |

Appendix D. List of International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Category II (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) Diagnosis and Procedure Codes Used to Define Exclusion Criteria in this Request

| Code | Description | Code Type |
|--------|--|--------------------|
| V15.82 | Personal history of tobacco use | ICD-9-CM Diagnosis |
| J0571 | Buprenorphine, oral, 1 mg | HCPCS |
| J0570 | Buprenorphine implant, 74.2 mg | HCPCS |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | HCPCS |
| J0592 | Injection, buprenorphine HCl, 0.1 mg | HCPCS |
| J1230 | Injection, methadone HCl, up to 10 mg | HCPCS |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | HCPCS |
| J2212 | Injection, methylnaltrexone, 0.1 mg | HCPCS |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | HCPCS |
| J2315 | Injection, naltrexone, depot form, 1 mg | HCPCS |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | HCPCS |
| S0109 | Methadone, oral, 5 mg | HCPCS |

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exclusion Criteria in this Request

| Generic Name | Brand Name |
|--|---|
| | Substance abuse history or fentanyl use |
| BUPRENORPHINE | buprenorphine |
| BUPRENORPHINE | Butrans |
| BUPRENORPHINE HCL | Belbuca |
| BUPRENORPHINE HCL | Buprenex |
| BUPRENORPHINE HCL | buprenorphine HCl |
| BUPRENORPHINE HCL | buprenorphine HCl (bulk) |
| BUPRENORPHINE HCL | Probuphine |
| BUPRENORPHINE HCL | Subutex |
| BUPRENORPHINE HCL/NALOXONE HCL | Bunavail |
| BUPRENORPHINE HCL/NALOXONE HCL | buprenorphine-naloxone |
| BUPRENORPHINE HCL/NALOXONE HCL | Suboxone |
| BUPRENORPHINE HCL/NALOXONE HCL | Zubsolv |
| FENTANYL | Duragesic |
| FENTANYL | fentanyl |
| FENTANYL | fentanyl (bulk) |
| FENTANYL | Subsys |
| FENTANYL CITRATE | Abstral |
| FENTANYL CITRATE | Actiq |
| FENTANYL CITRATE | fentanyl citrate |
| FENTANYL CITRATE | fentanyl citrate (bulk) |
| FENTANYL CITRATE | Fentora |
| FENTANYL CITRATE | Lazanda |
| FENTANYL CITRATE | Onsolis |
| FENTANYL CITRATE IN 0.9 % SODIUM CHLORIDE/PF | fentanyl citrate-0.9%NaCl (PF) |
| FENTANYL CITRATE IN DEXTROSE 5% IN WATER/PF | fentanyl citrate in D5W (PF) |
| FENTANYL CITRATE/BUPIVACAINE HCL IN 0.9 % SODIUM CHLORIDE/PF | fentanyl (PF)-bupivacaine-NaCl |
| FENTANYL CITRATE/DROPERIDOL | fentanyl-droperidol |
| FENTANYL CITRATE/PF | fentanyl citrate (PF) |
| FENTANYL CITRATE/PF | Sublimaze (PF) |
| FENTANYL CITRATE/ROPIVACAINE HCL/SODIUM CHLORIDE 0.9%/PF | fentanyl-ropivacaine-NaCl (PF) |
| FENTANYL HCL | Ionsys |
| METHADONE HCL | Diskets |
| METHADONE HCL | Dolophine |
| METHADONE HCL | methadone |
| METHADONE HCL | methadone (bulk) |
| METHADONE HCL | Methadone Intensol |
| METHADONE HCL | Methadose |
| METHADONE HYDROCHLORIDE IN 0.9 % SODIUM CHLORIDE | methadone in 0.9 % sod. chlor |
| METHYLNALTREXONE BROMIDE | Relistor |
| MORPHINE SULFATE/NALTREXONE HCL | Embeda |
| NALTREXONE | naltrexone (bulk) |
| NALTREXONE HCL | naltrexone |
| NALTREXONE HCL | naltrexone HCl (bulk) |
| NALTREXONE HCL | Revia |
| NALTREXONE HYDROCHLORIDE DIHYDRATE | naltrexone HCl dihydrate(bulk) |
| NALTREXONE MICROSPHERES | Vivitrol |
| cder_ahr_wp012 | |

Appendix F. List of Morphine Milligram Equivalent (MME) Conversion Factors

| Ingredient | Conversion Factor |
|----------------|-------------------|
| Codeine | 0.15 |
| Dihydrocodeine | 0.25 |
| Hydrocodone | 1 |
| Hydromorphone | 4 |
| Levorphanol | 11 |
| Meperidine | 0.1 |
| Morphine | 1 |
| Oxycodone | 1.5 |
| Oxymorphone | 3 |
| Pentazocine | 0.37 |
| Propoxyphene | 0.23 |
| Tapentadol | 0.4 |
| Tramadol | 0.1 |

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|--|--------------------------------|
| Benzodiazepines | |
| ALPRAZOLAM | Xanax |
| ALPRAZOLAM | Xanax XR |
| ALPRAZOLAM | Alprazolam Intensol |
| ALPRAZOLAM | Niravam |
| ALPRAZOLAM | alprazolam |
| ALPRAZOLAM | alprazolam (bulk) |
| ALPRAZOLAM/DIETARY SUPPLEMENT,MISC COMBO NO.17 | Gabazolamine |
| AMITRIPTYLINE HCL/CHLORDIAZEPOXIDE | Limbitrol |
| AMITRIPTYLINE HCL/CHLORDIAZEPOXIDE | Limbitrol DS |
| AMITRIPTYLINE HCL/CHLORDIAZEPOXIDE | amitriptyline-chlordiazepoxide |
| CHLORDIAZEPOXIDE HCL | Librium |
| CHLORDIAZEPOXIDE HCL | chlordiazepoxide HCl |
| CHLORDIAZEPOXIDE/CLIDINIUM BROMIDE | Librax (with clidinium) |
| CHLORDIAZEPOXIDE/CLIDINIUM BROMIDE | chlordiazepoxide-clidinium |
| CLOBAZAM | Onfi |
| CLONAZEPAM | Klonopin |
| CLONAZEPAM | clonazepam |
| CLONAZEPAM | clonazepam (bulk) |
| CLORAZEPATE DIPOTASSIUM | clorazepate dipotassium |
| CLORAZEPATE DIPOTASSIUM | Tranxene T-Tab |
| CLORAZEPATE DIPOTASSIUM | Tranxene-SD |
| DIAZEPAM | Diazepam Intensol |
| DIAZEPAM | diazepam |
| DIAZEPAM | Valium |
| DIAZEPAM | diazepam (bulk) |
| DIAZEPAM | Diastat AcuDial |
| DIAZEPAM | Diastat |
| ESTAZOLAM | estazolam |
| ESTAZOLAM | Prosom |
| FLURAZEPAM HCL | flurazepam |
| FLURAZEPAM HCL | Dalmane |
| LORAZEPAM | Lorazepam Intensol |
| LORAZEPAM | lorazepam |
| LORAZEPAM | Ativan |
| LORAZEPAM | lorazepam (bulk) |
| LORAZEPAM IN 0.9 % SODIUM CHLORIDE | lorazepam in 0.9% sod chloride |
| LORAZEPAM IN 5 % DEXTROSE AND WATER | lorazepam in dextrose 5 % |
| MIDAZOLAM | midazolam (bulk) |
| MIDAZOLAM HCL | midazolam |
| MIDAZOLAM HCL IN 0.9 % SODIUM CHLORIDE | midazolam in 0.9 % sod chlorid |
| MIDAZOLAM HCL IN 0.9 % SODIUM CHLORIDE/PF | midazolam (PF) in 0.9 % NaCl |
| MIDAZOLAM HCL IN 5 % DEXTROSE AND WATER/PF | midazolam in dextrose 5 % (PF) |
| MIDAZOLAM HCL IN DEXTROSE 5% IN WATER | midazolam in dextrose 5 % |

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|---|--------------------------------|
| MIDAZOLAM HCL/PF | midazolam (PF) |
| OXAZEPAM | oxazepam |
| QUAZEPAM | quazepam |
| QUAZEPAM | Doral |
| TEMAZEPAM | temazepam |
| TEMAZEPAM | Restoril |
| TEMAZEPAM/DIETARY SUPPLEMENT NO.8 | Strazepam |
| TRIAZOLAM | Halcion |
| TRIAZOLAM | triazolam |
| Gabapentinoids | |
| GABAPENTIN | Fanatrex |
| GABAPENTIN | gabapentin |
| GABAPENTIN | Gralise |
| GABAPENTIN | Gralise 30-Day Starter Pack |
| GABAPENTIN | Neurontin |
| GABAPENTIN ENACARBIL | Horizant |
| GABAPENTIN/DIETARY SUPPLEMENT, MISC COMBO NO.11 | Therapentin-60 |
| GABAPENTIN/DIETARY SUPPLEMENT, MISC COMBO NO.11 | Therapentin-90 |
| PREGABALIN | Lyrica |
| Sedative hypnotics | |
| AMOBARBITAL SODIUM | Amytal |
| BUTABARBITAL SODIUM | Butisol |
| CHLORAL HYDRATE | chloral hydrate |
| CHLORAL HYDRATE | chloral hydrate (bulk) |
| CHLORAL HYDRATE | Somnote |
| DICHLORALPHENAZONE | dichloralphenazone (bulk) |
| DOXEPIN HCL | Silenor |
| ESZOPICLONE | eszopiclone |
| ESZOPICLONE | Lunesta |
| MELATONIN | melatonin (bulk) |
| MEPHOBARBITAL | Mebaral |
| MEPHOBARBITAL | mephobarbital |
| PENTOBARBITAL SODIUM | Nembutal Sodium |
| PENTOBARBITAL SODIUM | pentobarbital sodium |
| PENTOBARBITAL SODIUM | pentobarbital sodium (bulk) |
| PHENOBARBITAL | phenobarbital |
| PHENOBARBITAL SODIUM | Luminal |
| PHENOBARBITAL SODIUM | phenobarbital sodium |
| PHENOBARBITAL SODIUM IN 0.9 % SODIUM CHLORIDE | phenobarbital in 0.9 % sod chl |
| RAMELTEON | Rozerem |
| SECOBARBITAL SODIUM | Seconal |
| SECOBARBITAL SODIUM | Seconal Sodium |
| SUVOREXANT | Belsomra |
| TASIMELTEON | Hetlioz |

Appendix G. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

| Generic Name | Brand Name |
|-------------------|------------|
| ZALEPLON | Sonata |
| ZALEPLON | zaleplon |
| ZOLPIDEM TARTRATE | Ambien |
| ZOLPIDEM TARTRATE | Ambien CR |
| ZOLPIDEM TARTRATE | Edluar |
| ZOLPIDEM TARTRATE | Intermezzo |
| ZOLPIDEM TARTRATE | zolpidem |
| ZOLPIDEM TARTRATE | Zolpimist |

Appendix H. Specifications for Parameters for this Request

This request utilized the Cohort Identification and Descriptive Analysis (CIDA) tool, version 5.4.4 with custom code, to assess refill rates associated with initial opioid prescriptions following surgery in the Sentinel Distributed Database (SDD).

Query Period: October 1, 2009 - September 30, 2015

Pre-Exposure Enrollment Requirement: 365 days

Post-Exposure Enrollment Requirement: 111 days

Enrollment Gap: 0 days

Coverage Requirement: Medical and Drug

Age Groups: 18-40, 41-64, 65+ years

Sex: Male and female*

| Scenario | Exposure | Exposure | | | | Pre-existing Conditions | | | | Outcome | | | | | |
|----------|---------------|--------------------|----------------|--------------------------------|-------------------|--|-------------------|-----------|-------------------------|-------------|----------|---------|--------------------------------|----------------|------------------------|
| | | Incidence Criteria | Washout (days) | Intent to Treat-Surgery (days) | Cohort Definition | Censor due to Query End | Evidence of Death | Condition | Inclusion or Exclusion | Caresetting | Lookback | Outcome | Care Setting | Washout (days) | Blackout Period (days) |
| 1 | All surgeries | IP, AV | n/a | 0 | 7 | Include the first valid exposure per patient | No | Yes | Cancer | Exclude | Any | -365, 0 | Opioid dispensing (any opioid) | Any | 365 0 |
| | | | | | | | | | Substance abuse history | Exclude | Any | -365, 0 | | | |

Note: International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM), Current Procedural Terminology, Second Revision (CPT-II), Current Procedural Terminology, Fourth Edition (CPT-4), and Healthcare Common Procedure Coding System (HCPCS) codes are provided by Optum360. NDC codes are checked against First Data Bank's "National Drug Data File (NDDF®) Plus"

*The final groups for cesarean section and hysterectomy were restricted to females only

| Covariate | Evaluation | |
|--------------------------------|------------|-------------|
| | Window | Caresetting |
| Benzodiazepines | -30, 0 | |
| Gabapentinoids | -30, 0 | |
| Sedative Hypnotics | -30, 0 | |
| Comorbidity Score | -365, 0 | |
| IS encounter | -365, -1 | IS |
| IS encounter | 0, 7 | IS |
| Appendectomy (laparoscopic) | 0, 0 | IP*, AV* |
| Appendectomy (nonspecific) | 0, 0 | IP*, AV* |
| Bunionectomy | 0, 0 | IP*, AV* |
| Cesarean section | 0, 0 | IP*, AV* |
| Cholecystectomy (laparoscopic) | 0, 0 | IP*, AV* |
| Cholecystectomy (nonspecific) | 0, 0 | IP*, AV* |
| Coronary artery bypass graft | 0, 0 | IP*, AV* |
| Hip fracture treatment | 0, 0 | IP*, AV* |
| Hip replacement, total/partial | 0, 0 | IP*, AV* |

| Covariate | Evaluation | |
|---|---------------|-------------|
| | Window | Caresetting |
| Hysterectomy (abdominal/vaginal non-laparoscopic) | 0, 0 | IP*, AV* |
| Hysterectomy (laparoscopic) | 0, 0 | IP*, AV* |
| Knee arthroplasty | 0, 0 | IP*, AV* |
| Laminectomy, discectomy | 0, 0 | IP*, AV* |
| Spinal fusion (nonspecific) | 0, 0 | IP*, AV* |
| Spinal fusion (1-3 levels) | 0, 0 | IP*, AV* |
| Spinal fusion (4+ levels) | 0, 0 | IP*, AV* |
| Tooth extraction | 0, 0 | IP*, AV* |
| All surgeries | -365, -1 | IP*, AV* |
| Hospital LOS (implemented with custom code) | 0, 1, 2-5, 6+ | IP*, AV* |